American College of Allergy, Asthma & Immunology
2014 Annual Scientifi c Meeting
tla
A
gia
eor
G
nta
November 6-10 • PROGRAM GUIDE
acaai.org
le ump
b
a
l P
vai rless
A
w i
No 25g A
2
in a
A
M
M
I
X
E
Z
I
Visit
Visit www.epiceram-us.com
www.epiceram-us.com ffor
or full PI, samples
samples,, and mone
moneyy sa
saving
ving coupons
coupons..
, jg
( ),
Indicaations for Use
EpiCeram® Controlled Release Skin Barrier Emulsion is to be used to treat dry skin conditions and to manage and relieve the burning
and itching associated with various types of dermatoses, including atopic dermatitis, irritant contact dermatitis, and radiation
dermatitis. EpiCeram® helps to relieve dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the
healing process.
Contraindications
EpiCeram® Controlled Release Skin Barrier Emulsion is contraindicated in persons with known hypersensitivity to any of the
components of the formulation.
reach of children. Follo
o w directions for use. If condition does not improve within 10 to 14 days, consult a physician.
Instructions for Use
Apply in a thin layer to the affected skin areas two times per day (or as needed) and massage gently into the skin. If the skin is
broken, cover EpiCeram® Controlled Release Skin Barrier Emulsion with a dressing of choice.
How Supplied
EpiCeram® Controlled Release Skin Barrier Emulsion is supplied as follows:
NDC 51013-800-90: 90 gram tube
NDC 51013-800-36: 225 gram airless pump
Store at 15°C to 30°C (59°F to 86°F). Do not freeze.
Rx only — Prescription
cription Medicaal Device; Federral Law restricts this device to sale by or on the order of a physician.
Welcome
American College of
Allergy, Asthma & Immunology
Faces and Facets of
Allergy and Immunology
November 6-10
Georgia World Congress Center
Atlanta, Georgia
2013 – 2014 Officers and Board of Regents
Michael B. Foggs, MD, FACAAI
President . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2014
Richard W. Weber, MD, FACAAI
Immediate Past President. . . . . . . . . . . . . . . . 2014
James L. Sublett, MD, FACAAI
President-Elect . . . . . . . . . . . . . . . . . . . . . . . . . . 2014
Bryan L. Martin, DO, FACAAI
Vice-President . . . . . . . . . . . . . . . . . . . . . . . . . . 2014
Bradley E. Chipps, MD, FACAAI
Treasurer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2014
Stanley M. Fineman, MD, MBA, FACAAI
Past Immediate Past President . . . . . . . . . . . 2014
Leonard Bielory, MD, FACAAI . . . . . . . . . . . . . . . 2014
Warner W. Carr, MD, FACAAI . . . . . . . . . . . . . . . . 2014
Chitra Dinakar, MD, FACAAI . . . . . . . . . . . . . . . . . 2014
Gregory W. Bensch, MD, FACAAI . . . . . . . . . . . . 2015
Tao T. Le, MD, MHS, FACAAI . . . . . . . . . . . . . . . . . 2015
Maeve E. O’Connor, MD, FACAAI . . . . . . . . . . . . 2015
Curtis W. Hedberg, MD, FACAAI . . . . . . . . . . . . . 2016
Rohit K. Katial, MD, FACAAI . . . . . . . . . . . . . . . . . 2016
Christopher C. Randolph, MD, FACAAI . . . . . . 2016
FIT Representatives: Monica Bhagat, MD (’14), Andrew Nickels, MD (’15)
Speaker of the House: Kathleen R. May, MD, FACAAI (‘14)
Executive Medical Director: Bobby Q. Lanier, MD, FACAAI
Alliance President: Margaret Quel
1
ACAAI Premier Partners
The American College of Allergy, Asthma and Immunology recognizes the indispensable role that health care
companies play in furthering the mission of the College. ACAAI would like to thank the following companies for
their generous support of this year’s Annual Scientific Meeting.
DIAMOND
$500,000 and above
Teva Respiratory
PLATINUM
$300,000 – $499,999
Mylan Specialty L.P.
GOLD
$100,000 – $299,999
Baxter Healthcare
McNeil Consumer Healthcare
Meda Pharmaceuticals Inc.
Merck
Shire
Sunovion Pharmaceuticals Inc.
SILVER
$50,000 – $99,999
AstraZeneca
Genentech | Novartis
Salix Pharmaceuticals, Inc.
Sanofi US
OTHER CONTRIBUTORS
Aerocrine  ALK, Inc.  Allergy & Asthma Network
Boehringer Ingelheim Pharmaceuticals, Inc.  Boston Scientific  BR Surgical, LLC 
CSL Behring  European Academy of Allergy and Clinical Immunology  GlaxoSmithKline
GREER®  Lincoln Diagnostics, Inc.  Novartis Pharmaceuticals Corporation
PuraCap® Pharmaceutical LLC  SmartPractice
2
Table of Contents
Page
Page
Greetings From the Officers . . . . . . . . . . . . . . . . . . . . . . . . 5
Monday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . 61
Greetings From the Alliance . . . . . . . . . . . . . . . . . . . . . . . . 9
Monday Concurrent Sessions. . . . . . . . . . . . . . . . . . . . . . 63
Fundraiser . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Office Administrators Practice
Management Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Corporate Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Commercial Supporters . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Special Announcements . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Advanced Practice Health
Care Providers Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Allied Health Professionals Course. . . . . . . . . . . . . . . . . 71
Evaluation, Credit Claim and
Certificate System. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Poster Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Education Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Plenary and Symposia Faculty . . . . . . . . . . . . . . . . . . . . . 95
Maintenance of Certification . . . . . . . . . . . . . . . . . . . . . . 24
Faculty Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Daily Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
CME/CPD Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Committee Meetings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
Workshops. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Special Events . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Thursday Conference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
Named Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Friday Annual Literature Review . . . . . . . . . . . . . . . . . . . 40
ACAAI Past Presidents . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Friday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
Distinguished Fellows. . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Town Hall Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
ACAAI Foundation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Saturday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . 45
Alliance Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Saturday ACAAI Awards Ceremony and
President’s Welcome Reception . . . . . . . . . . . . . . . . . . . 50
Fellows-in-Training. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Sunday “Meet the Professor Breakfasts”. . . . . . . . . . . . 51
Product Theater . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
Sunday General Sessions . . . . . . . . . . . . . . . . . . . . . . . . . . 52
Exhibits. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Sunday Concurrent Sessions . . . . . . . . . . . . . . . . . . . . . . 55
Index of Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
Sunday Programs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Index of Exhibitors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 136
Monday “Meet the Professor Breakfasts” . . . . . . . . . . . 60
Exhibit Hall Map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 138
Monday Annual Business Meeting. . . . . . . . . . . . . . . . . 61
Georgia World Congress Center Maps . . . . . . . . . . . . 139
Travel Grant Recipients . . . . . . . . . . . . . . . . . . . . . . . . . . 111
This Conference is Paper-Lite
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai2014.conferencespot.org or snap the QR
code for a menu of online materials.
ONLINE
MATERIALS
➧
3
PLE AS E J O I N U S F O R A PR O D U CT TH E ATER LU N CH PR ES ENTATI O N AT TH E
2014 ACAAI Annual Scientific Meeting
THE LATEST INFORMATION
IN THERAPY FOR
Saturday
November 8, 2014
Asthma, COPD, and
Exercise-Induced
Bronchospasm
12:35
PM
– 1:30
PM
Georgia World Congress Center
Hall A1, Product Theater #1
Atlanta, Georgia
Gregory W. Bensch, MD
Assistant Professor
Allergy & Immunology Residency Program
Co-Partner of Bensch Research Associates
Stockton, California
A Complimentary Lunch Will Be Served
If you are licensed in any state or other jurisdiction
or are an employee or contractor of any organization or
governmental entity that limits or prohibits meals
from pharmaceutical companies, please identify
yourself so that you (and we) are able to comply with
such requirements. Your name, the value, and purpose
of any educational item, meal, or other items of value
you received may be reported as required by state or
federal law. Once reported, this information may be
publicly accessible.
Thank you for your cooperation.
This is a promotional event.
CME/CE credit will not be available for this session.
In compliance with PhRMA guidelines, spouses
or other guests are not permitted to attend
company-sponsored programs. This promotional
educational activity is brought to you by
Teva Respiratory and is not certified for continuing
medical education. The speakers are presenting
on behalf of Teva Respiratory and must present
information in compliance with FDA requirements
applicable to Teva Respiratory.
The Product Theater content and views expressed
therein do not necessarily reflect the views, policies
or position of the American College of Allergy,
Asthma & Immunology.
© Teva Respiratory 2014
Sponsored by
RESP-40359
General Information
Greetings From the Officers
Michael B. Foggs, MD, FACAAI
President
Over the past year, beginning with the theme of the 2013
Annual Scientific Meeting, New Frontiers in Allergy and
Immunology: From Bench to Clinic, I have
attempted to emphasize the value of our
specialty to the public and to stress the
importance of allergists stepping outside of
our comfort zones and beginning to
embrace more immunological disorders
that we have been already trained to diagDr. Foggs
nose and manage. New realities in the
medical marketplace make it necessary for us to better
demonstrate the breadth and depth of our training and
value within the new health care paradigm. The 2014
Annual Scientific Meeting will facilitate our being better
able to accomplish this goal.
During these tumultuous times, College leadership has seriously deliberated the future of the College and deeply contemplated how to make it a better organization so that it
can better serve its members and society. I am pleased to
announce that the College is moving forward. Within the
next year there will be growing evidence to substantiate
this fact. The dedication of the College officers, Board of
Regents and the College administration has resulted in
many hours devoted to revamping several facets of the
College’s infrastructure in a manner that will greatly benefit
its members. A number of initiatives will be rolled out over
the ensuing months that I think will make you proud to be
a College member. These innovations will make it easier for
allergists to overcome some of the growing pressures and
obstacles that now threaten the survival of the specialty of
Photo ©2014, Kevin C. Rose / AtlantaPhotos.com
allergy-immunology as we know it today. Vision 2020 will
usher in many of these changes and innovations. The Vision
2020 rubric has dual meaning, expressing the fact that the
College leadership has sharpened its vision regarding the
future and announcing that we plan to achieve many auspicious and laudable goals by the year 2020. Be sure to visit
the ACAAI booth to learn more about this initiative.
The College is fighting for the practicing allergist on all
fronts. The 2014 Annual Scientific Meeting is symbolic of
the College’s ongoing efforts to lead practicing allergists
into the future and remain the “go to” organization for the
practicing allergist. I know that you find this to be a very
worthwhile and meaningful meeting. President-Elect,
James Sublett, MD, FACAAI, has put together an outstanding meeting, focusing on the exciting theme Faces and
Facets of Allergy & Immunology. Don’t miss Thursday’s all-day
program, D-Day for Skin Deep Allergies, which will focus on
skin allergies and patch testing. The Symposia put together
by Bryan Martin, DO, FACAAI are outstanding. The Meet the
Professor programs put together by Bradley Chipps, MD,
FACAAI, are exciting as are the workshops assembled by
Luz Fonacier, MD, FACAAI. And don’t forget the famous FIT
Bowl. Much thought and work has been put into these
programs by these colleagues and their committees. You
will also find the entertainment at our annual Fundraising
Dinner both charming and exciting. This year’s dinner features the great seven-time Grammy winner, Al Jarreau.
Known as one of the greatest jazz singers alive, this is an
event you won’t want to miss. Welcome to Atlanta for a
wonderful experience!
5
Professional Education. Advocacy.
Public Education. Practice Parameters.
Publications and Annals. World-Class Events.
The College has a crystal clear
vision about where it’s headed
A set date by which it
plans to achieve its goals
General Information
Greetings From the Officers
James L. Sublett, MD, FACAAI
President-Elect and Program Chairman
Welcome to Atlanta for the 71st ACAAI Annual Scientific
Meeting. I am excited to present the focus of this year’s
meeting Faces and Facets of Allergy and
Immunology. We, the practicing allergists
and our staff, our patients and the
diseases we treat, serve as the muses for
this meeting.
As allergists/immunologists practicing in
the 21st century, we are truly holistic
specialists. Instead of focusing on one organ of the human
body, we focus on the entire immune system. Imagine if
you will a mirror ball. All of the facets on a mirror ball
reflect out like a prism to the different areas we are
involved in. We treat diseases ranging from the very common (allergic rhinitis and asthma) to the exceedingly rare
(primary immune deficiency) and a variety in between
(atopic and contact dermatitis, urticaria, food, stinging
insect and drug allergy), which include various organ
systems (respiratory tract, eyes, skin, gastrointestinal) in
patients from infancy to the elderly. Additionally, we are
faced with the changing health care delivery system and
challenges of the business side of running our clinics
and practices.
Dr. Sublett
The entire meeting is packed with valuable workshops,
symposia and plenaries addressing a wide array of topics
including COPD and asthma; overlap syndrome;
immunotherapy; climate change; emerging allergy treatments and the unique challenges we face in treating all
age demographics. All of the topics include compelling
clinical information and research that you can apply and
take back home to better treat your patients.
Thursday’s compelling full day conference, D-Day for
Skin Deep Allergies kicks-off our meeting. Experts will
discuss improved patch testing, consensus and controversies of guidelines, and treatment breakthroughs for
common allergies.
The Great Raft Debate: “The Allergy Epidemic – a Root
Cause Analysis” will be held on Saturday, moderated by
William K. Dolen, MD, FACAAI and Maeve E. O’Connor MD,
FACAAI. The five star line-up of debaters features: Stanley J.
Szefler, MD, FACAAI, Jay M. Portnoy, MD, FACAAI, Thomas
A.E. Platts-Mills, MD, FACAAI, Dennis Ownby, MD, FACAAI,
and David Peden, MD, FACAAI. You will not want to miss
this stimulating discussion, which is always a crowd pleaser.
New this year, are three special workshops presented by
scientists from the Atlanta-based Centers for Disease Control and Prevention (CDC).
We are saving some of the best for last this year, as the
meeting ends with a compelling presentation on Monday
from the world’s experts in food allergy. We will learn about
oral and sublingual immunotherapy for food allergy treatment and the use of allergen components in diagnosis.
If you visualize that mirror ball again, imagine how the
allergy specialty reflects out to business and clinical staff
and non-physician providers. This meeting has been
designed with you in mind too. Designated workshops
shed light on complex areas to educate you on the latest
so you too can better help patients.
I hope to see you on Saturday evening when we acknowledge the accomplishments of our fellow colleagues during
the awards ceremony, which will be followed by the
President’s Welcome Reception. The College will also be
inducting a record number of Fellows. We are thrilled to see
more than double the number of new Fellows than in the
previous years.
On Sunday, the legendary seven time Grammy Award
winner, Al Jarreau, will be headlining the Fundraising
Dinner. He is one of the few artists to win Grammys in three
different categories: jazz, pop and R&B and is sure to
entertain us.
This year’s meeting will provide you with the knowledge
and expertise you need to improve the faces and facets
of allergy and asthma in your practice. Again, welcome
to Atlanta.
7
8
Welcome to Alluring Atlanta!
Atlanta, the seat of the government for over 125 years,
has captivating historical homes which are enhanced by
this city’s cosmopolitan and modern
charm. Properties that housed Atlanta's
pioneers and Civil War heroes pass on some
important lessons of American history. Be
sure to visit these sites during your stay
and take time to savor the Southern culture
and hospitality.
Mrs. Quel
On this, the 60th anniversary of the Alliance of the
ACAAI, all of our efforts have been focused on presenting a
meeting filled with memorable moments. Don’t miss our
events as outlined below and we hope you have a wonderful time…
The Hospitality Suite will be housed in the charming glassenclosed Atrium of the Omni Hotel at CNN Center. Not only
will you be treated to a delicious daily breakfast, but each
morning you will also be entertained with a variety of
events: Friday a lecture regarding the Margaret Mitchell
House, especially important since this year marks the 75th
anniversary of the movie based on her famous novel,
Gone With The Wind. This event will be made unique with a
display of private GWTW memorabilia courtesy of Mrs.
Charlotte Meadows. The next program on Saturday will
highlight charming Chef Ticha and although it is early in
the day, she will tempt our palates with the preparation a
delicious dessert – most of us are always ready for dessert.
On Sunday, Mrs. Bonnie Miles, Virginia Master Naturalist
and former Alliance president, will provide us with an
important and fascinating environmental talk. The ACAAI
KIDS will be delighted by the Atlanta Zoo Mobile:
Saturday’s program will surely entertain and educate your
children about a variety of critters found in the wild.
All of the above events are listed by date and time in
the Program Guide and Pocket Pal, the mini program
provided to all spouses and guests. Please be sure to
review them both and carry the Pocket Pal so you don’t
miss any of the fun.
Annual Business Meeting & Luncheon
Gone With The Wind is not the only anniversary we are celebrating, as this month also marks the 60th anniversary of
the Alliance of the ACAAI. After a careful search, we found
a location near the Omni Hotel and arranged to have this
completely to ourselves. On Sunday, Nov. 9th not only will
we dine exclusively, but we will also be treated to charming
special guests. This is a luncheon not to be missed – please
be sure to purchase your luncheon ticket in advance as
seating is limited.
Photo Contest Grand Finale
This is the last chance to enter this wonderful event and
our sincere thanks to the efforts of Barbara Finegold and
Jeanne Zitt for creating such fun filled moments. It is the
last opportunity to see your favorite photos on display
throughout the meeting; these lovely images will be
eligible to become part of future fundraising activities.
Remember all proceeds benefit the Foundation of
the ACAAI.
Note-Worthy
During this meeting we will unveil a new item for sale
which displays a selection of your amazing photo entries:
A small spiral notebook, both colorful and practical, with a
selection of photos from past competitions on the outside
and blank pages on the inside for notes. This booklet is
attractive, useful and small enough to fit in a pocket or
purse. The notebook will be available for a nominal fee at
the Hospitality Suite as well as the ACAAI meeting registration desk and all proceeds will benefit the Foundation.
Perhaps a future version will reveal selections from the
2014 contest entries.
International Reception
Barbara Finegold and Jeanne Zitt, along with host of volunteers will once again present the International Reception. It
is an opportunity for our international guests to meet and
greet ACAAI and Alliance Board and International Committee members on a more personal level.
My thanks to President-Elect, Judy Fineman, the Alliance
Board of Directors and Committee Chairs, along with our
many volunteers and the College support staff who make
our programs possible.
Margaret Quel, Alliance President
9
General Information
Greetings From the Alliance
Sunday, November 9
Atlanta, Georgia
Known as one of the greatest jazz singers
alive, seven-time Grammy Award winner
Al Jarreau is one of the very few artists to
ever win a Grammy in three categories:
jazz, pop and R&B. Two of these were
German Grammys, showcasing the international following he has. With several hit
songs, such as We’re in this Love Together,
Mornin’, After All, Your Song and Tell Me
What I Gotta Do, he received his own star on
the "Hollywood Walk of Fame" in March 2001.
A singer since the age of four, Al Jarreau continues
to tour extensively worldwide. He will release his
23rd album, later this summer, nearly 40 years
after his first compilation debuted.
Net proceeds from the event will be
donated to the ACAAI Foundation to
support Fellows-in-Training Program
Relief Grants, Young Faculty Support
Awards and other Foundation programs.
7:00 pm: Reception
Physician Tickets: $250 each
9:30 pm: Performance
Corporate Tables: $10,000 each
8:00 pm: Plated Dinner
Physician Tables:
$2,300 each
ACAAI appreciates the following promotional contributions from its corporate supporters.
Aerocrine
Meda Pharmaceuticals Inc.
Supporter of a Product Theater.
Supporter of signage in the Omni hotel.
Supporter of a Non-CME Corporate Forum… hotel room
key… hotel restaurant and lounge promotion…
refreshment breaks… table at the fundraising dinner… and
the ACAAI Corporate Council.
AstraZeneca
Merck
Allergy & Asthma Network
Supporter of a table at the fundraising dinner…
and advertisements in the Final Program Guide.
Baxter Healthcare
Supporter of a Non-CME Corporate Forum… convention
center window clings… and hotel room mirror clings.
Boehringer Ingelheim
Pharmaceuticals, Inc.
Supporter of a Product Theater… advertisement in the
Final Program Guide… and AllergyWatch and its placement
on the ACAAI website.
Mylan Specialty L.P.
Supporter of the exhibit aisle markers… floor clings in the
convention center… hotel room door hangers… and the
Anaphylaxis Roundtable.
Novartis Pharmaceuticals Corporation
Supporter of the ACAAI Corporate Council.
Supporter of the ACAAI Corporate Council.
Boston Scientific
PuraCap® Pharmaceutical LLC
Supporter of the ACAAI Corporate Council.
Supporter of an advertisement in the Final Program Guide.
CSL Behring
Salix Pharmaceuticals, Inc.
Supporter of a Product Theater.
Supporter of the signage and video walls in the
convention center.
European Academy of Allergy and
Clinical Immunology
Supporter of an advertisement in the Final Program Guide.
Genentech | Novartis
Supporter of two tables at the fundraising dinner…
a Product Theater… and the ACAAI Corporate Council.
GlaxoSmithKline
Supporter of the ACAAI Corporate Council.
®
GREER
Supporter of Friday’s Fellows-in-Training Welcome Reception… and two Product Theaters.
Lincoln Diagnostics, Inc.
Supporter of two tables at the fundraising dinner.
McNeil Consumer Healthcare
Supporter of the Internet Café… and an advertisement in
the Final Program Guide.
Sanofi US
Supporter of the FIT Bowl… hotel tent card… and the
ACAAI Corporate Council.
Shire
Supporter of the Hereditary Angioedema Campaign…
and the Allergist Locator.
Sunovion Pharmaceuticals Inc.
Supporter of the President’s Private Dinner… Board of
Regents dinner… COPD Member Survey… and the ACAAI
Corporate Council.
Teva Respiratory
Supporter of the ACAAI Corporate Council… Nationwide
Asthma Screening Program… three Non-CME Corporate
Forums… a Product Theater… Mobile App… one table at
the fundraising dinner… electronic signage… escalator
clings… hand sanitizer stations… banners in the convention center… smartphone charging stations… WiFi in the
convention center… advertisements in the Final Program
Guide… and the ACAAI Member eNewsletter.
11
General Information
Corporate Supporters
Commercial Supporters
This activity is supported by independent educational grants from the following commercial supporters:
ALK, Inc.
Meda Pharmaceuticals Inc.
Supporter of FIT Travel Grants.
AstraZeneca
Supporter of the Friday Breakfast Symposium on Turbinates
to Terminal Bronchioles: The One Airway Concept and
Advancements in the Treatment of Asthmatics.
Supporter of Workshops W-5 – The Affordable Care Act and
Asthma Control… and W-10 – Severe Asthma.
Merck
Baxter Healthcare
Supporter of the Meet the Professor Breakfasts… and the
ACAAI Foundation Young Faculty Award.
Supporter of the Saturday symposium on Optimizing
Immunoglobulin Replacement Therapy… and a vodcast of
the symposium.
BR Surgical, LLC
In-kind support consisting of loaned durable equipment for
Workshop W-16 – Hands-On Session in Rhinolaryngoscopy.
Genentech | Novartis
Mylan Specialty L.P.
Supporter of the FIT Program… FIT Travel Grants… and
partial support of the Annual Literature Review.
Shire
Supporter of the Friday Symposium on Hereditary
Angioedema: Clinical Case Challenge.
Supporter of FIT Travel Grants.
SmartPractice
McNeil Consumer Healthcare
Partial support of the Thursday Conference on
Patch Testing.
Supporter of FIT Travel Grants.
Take Your Meeting Mobile
Target what you want to attend, learn and do at the ACAAI Annual
Meeting with the ACAAI mobile app – the app is free and the options
are endless!
View all the annual meeting info right at your fingertips:
 Schedule of events
 Exhibitor list and details
 Speakers, sponsors and more
Download the free app today and
maximize your time at the meeting.
To download the app:
 Go to annualmeeting/acaai.org
 Or, plug acaai.org/apps into your mobile device’s
browser. This link automatically detects your device
type and takes you to the right place.
 Or, snap the QR Code
Supported by Teva Respiratory
12
SYMBICORT 160/4.5 for the maintenance treatment of COPD
REV THE FEV
1
SYMBICORT offers something extra—sustained* control
with better breathing starting within 5 minutes each time 1-3
SYMBICORT is NOT a rescue medication and does NOT replace
fast-acting inhalers to treat acute symptoms
Mean percent change from baseline in FEV1 was measured at day
of randomization, months 6 and 123
FAST CONTROL
Majority of FEV1 improvement at 5 minutes each
time† in a subset of SUN Study patients taking
SYMBICORT 160/4.5 (n=121)1,4
SUSTAINED EFFECT
SYMBICORT 160/4.5 significantly improved 1-hour
postdose FEV1 at 1 month and end of treatment
compared to placebo, and improved predose FEV1
averaged over the course of the study compared to
placebo and formoterol, coprimary endpoints1
REASSURING SENSE
OF CONTROL
7KHPRVWFRPPRQDGYHUVHUHDFWLRQVŰUHSRUWHG
in COPD clinical trials included nasopharyngitis, oral
candidiasis, bronchitis, sinusitis, and upper respiratory
tract infection
*Sustained improvement in lung function was demonstrated in a
12-month efficacy and safety study.
†
In a serial spirometry subset of patients taking SYMBICORT 160/4.5
Q LQWKH6816WXG\RIKRXUSRVWGRVH)(91 improvement
RFFXUUHGDWPLQXWHVRQGD\RIUDQGRPL]DWLRQDWPRQWKDQG
DWHQGRIWUHDWPHQW
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
WARNING: Long-acting beta2-adrenergic agonists (LABA), such as
formoterol, one of the active ingredients in SYMBICORT, increase
the risk of asthma-related death. A placebo-controlled study with
another LABA (salmeterol) showed an increase in asthma-related
deaths in patients receiving salmeterol. This finding with salmeterol
is considered a class effect of LABA, including formoterol. Currently
available data are inadequate to determine whether concurrent
use of inhaled corticosteroids or other long-term asthma control
drugs mitigates the increased risk of asthma-related death from
LABA. Available data from controlled clinical trials suggest that
LABA increase the risk of asthma-related hospitalization in pediatric
and adolescent patients
When treating patients with asthma, prescribe SYMBICORT only for
patients not adequately controlled on a long-term asthma control
medication, such as an inhaled corticosteroid or whose disease
severity clearly warrants initiation of treatment with both an inhaled
corticosteroid and LABA. Once asthma control is achieved and
maintained, assess the patient at regular intervals and step down
therapy (eg, discontinue SYMBICORT) if possible without loss of
asthma control, and maintain the patient on a long-term asthma
control medication, such as an inhaled corticosteroid. Do not use
SYMBICORT for patients whose asthma is adequately controlled
on low or medium dose
inhaled corticosteroids
Please see additional Important Safety Information and Brief Summary of full Prescribing
Information, including Boxed WARNING, on following pages.
SUSTAINED EFFECT OVER 12 MONTHS
Improvement in 1-hour postdose FEV1 over the 12-month study4
250
SY
200
MBIC
O RT I S O
N
EXPRESS SCRIPTS®
NATIONAL PREFERRED
FORMULARY
150
Baseline* 0
2
4
6
Months
9
SUN: A 12-month efficacy and safety study
SYMBICORT 160/4.5 significantly improved 1-hour
postdose FEV1 at 1 month and end of treatment compared
to placebo, and improved predose FEV1 averaged over the
course of the study compared to placebo and formoterol,
coprimary endpoints1
12
5
B I
A P OTH N D I C AT E D AST N
P R COPD AND TIE
O P R I AT E P A
50
Day of
1
Randomization
H
TS MA
,
100
R
FO IN
Mean change from baseline in FEV1 (mL)
300
End of
Treatment†
COMPARATOR ARMS: Mean improvement in 1-hour postdose FEV1 (mL/%)
over 12 months. Month 1: SYMBICORT 160/4.5 mcg (220 mL/21%), formoterol
4.5 mcg (170 mL/17%), placebo (10 mL/1%). Month 6: SYMBICORT 160/4.5 mcg
(220 mL/21%), formoterol 4.5 mcg (190 mL/18%), placebo (30 mL/3%). End of
treatment: SYMBICORT 160/4.5 mcg (200 mL/20%), formoterol 4.5 mcg
(170 mL/17%), placebo (10 mL/1%). SYMBICORT 160/4.5 mcg‡ (n=494),
formoterol 4.5 mcg‡ (n=495), placebo‡ (n=479).
*Baseline is defined as the predose FEV1 value on the day of randomization.
†
Month 12, last observation carried forward.
‡
Administered as 2 inhalations twice daily.
SYMBICORT. Close monitoring is warranted in patients with
a change in vision or history of increased intraocular pressure,
glaucoma, or cataracts
In rare cases, patients on inhaled corticosteroids may present
with systemic eosinophilic conditions
SYMBICORT should be used with caution in patients with
convulsive disorders, thyrotoxicosis, diabetes mellitus,
ketoacidosis, and in patients who are unusually responsive
to sympathomimetic amines
Beta-adrenergic agonist medications may produce hypokalemia
and hyperglycemia in some patients
7KHPRVWFRPPRQDGYHUVHUHDFWLRQVŰUHSRUWHGLQDVWKPD
clinical trials included nasopharyngitis, headache, upper
respiratory tract infection, pharyngolaryngeal pain, sinusitis,
influenza, back pain, nasal congestion, stomach discomfort,
vomiting, and oral candidiasis
7KHPRVWFRPPRQDGYHUVHUHDFWLRQVŰUHSRUWHGLQ&23'
clinical trials included nasopharyngitis, oral candidiasis,
bronchitis, sinusitis, and upper respiratory tract infection
SYMBICORT should be administered with caution to patients
being treated with MAO inhibitors or tricyclic antidepressants,
or within 2 weeks of discontinuation of such agents
Beta-blockers may not only block the pulmonary effect of
beta-agonists, such as formoterol, but may produce severe
bronchospasm in patients with asthma
ECG changes and/or hypokalemia associated with
nonpotassium-sparing diuretics may worsen with concomitant
beta-agonists. Use caution with the coadministration of SYMBICORT
INDICATIONS
SYMBICORT is indicated for the treatment of asthma in patients
12 years and older (also see Boxed WARNING)
SYMBICORT 160/4.5 is indicated for the maintenance treatment
of airflow obstruction in patients with chronic obstructive
pulmonary disease (COPD), including chronic bronchitis
and emphysema
SYMBICORT is NOT indicated for the relief of acute bronchospasm
References: 1. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and
tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized
metered-dose inhaler in patients with chronic obstructive pulmonary
disease: results from a 1-year randomized controlled clinical trial. Drugs.
2009;69(5):549-565. 2. SYMBICORT [package insert]. Wilmington, DE:
AstraZeneca; 2012. 3. Data on File, 273071, AZPLP. 4. Data on File, 1084400,
AZPLP. 5. 2014 Express Scripts Preferred Drug List.
SYMBICORT is a
registered trademark of
the AstraZeneca group
of companies. ©2014
AstraZeneca. All rights
reserved. 3028625 9/14
15
SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients
postoperatively or during periods of stress for evidence of inadequate adrenal response.
It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis)
may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses
over prolonged periods of time. If such effects occur, the dosage of SYMBICORT should be reduced slowly, consistent with
accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.
Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors
Caution should be exercised when considering the coadministration of SYMBICORT with ketoconazole, and other known
strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir,
telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur [see DRUG
INTERACTIONS and CLINICAL PHARMACOLOGY in full Prescribing Information (12.3)].
Paradoxical Bronchospasm and Upper Airway Symptoms
As with other inhaled medications, SYMBICORT can produce paradoxical bronchospasm, which may be life threatening.
If paradoxical bronchospasm occurs following dosing with SYMBICORT, it should be treated immediately with an inhaled,
short-acting bronchodilator, SYMBICORT should be discontinued immediately, and alternative therapy should be instituted.
Immediate Hypersensitivity Reactions
Immediate hypersensitivity reactions may occur after administration of SYMBICORT, as demonstrated by cases of urticaria,
angioedema, rash, and bronchospasm.
Cardiovascular and Central Nervous System Effects
Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia
with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise,
and insomnia [see OVERDOSAGE]. Therefore, SYMBICORT, like all products containing sympathomimetic amines, should
be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias,
and hypertension.
Formoterol, a component of SYMBICORT, can produce a clinically significant cardiovascular effect in some patients as
measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of
formoterol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been
reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment
depression. The clinical significance of these findings is unknown. Fatalities have been reported in association with excessive
use of inhaled sympathomimetic drugs.
Reduction in Bone Mineral Density
Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled
corticosteroids. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is
unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family
history of osteoporosis, post menopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can
reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of
care. Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior
to initiating SYMBICORT and periodically thereafter. If significant reductions in BMD are seen and SYMBICORT is still
considered medically important for that patient’s COPD therapy, use of medication to treat or prevent osteoporosis should be
strongly considered.
Effects of treatment with SYMBICORT 160/4.5, SYMBICORT 80/4.5, formoterol 4.5, or placebo on BMD was evaluated in a
subset of 326 patients (females and males 41 to 88 years of age) with COPD in the 12-month study. BMD evaluations of the
hip and lumbar spine regions were conducted at baseline and 52 weeks using dual energy x-ray absorptiometry (DEXA)
scans. Mean changes in BMD from baseline to end of treatment were small (mean changes ranged from -0.01 - 0.01 g/cm2).
ANCOVA results for total spine and total hip BMD based on the end of treatment time point showed that all geometric LS Mean
ratios for the pairwise treatment group comparisons were close to 1, indicating that overall, bone mineral density for total hip
and total spine regions for the 12 month time point were stable over the entire treatment period.
Effect on Growth
Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Monitor the
growth of pediatric patients receiving SYMBICORT routinely (e.g., via stadiometry). To minimize the systemic effects of orally
inhaled corticosteroids, including SYMBICORT, titrate each patient’s dose to the lowest dosage that effectively controls his/her
symptoms [see DOSAGE AND ADMINISTRATION and USE IN SPECIFIC POPULATIONS].
Glaucoma and Cataracts
Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma and COPD following
the long-term administration of inhaled corticosteroids, including budesonide, a component of SYMBICORT. Therefore,
close monitoring is warranted in patients with a change in vision or with history of increased intraocular pressure, glaucoma,
and/or cataracts.
Effects of treatment with SYMBICORT 160/4.5, SYMBICORT 80/4.5, formoterol 4.5, or placebo on development of
cataracts or glaucoma were evaluated in a subset of 461 patients with COPD in the 12-month study. Ophthalmic examinations
were conducted at baseline, 24 weeks, and 52 weeks. There were 26 subjects (6%) with an increase in posterior subcapsular
score from baseline to maximum value (>0.7) during the randomized treatment period. Changes in posterior subcapsular
scores of >0.7 from baseline to treatment maximum occurred in 11 patients (9.0%) in the SYMBICORT 160/4.5 group,
4 patients (3.8%) in the SYMBICORT 80/4.5 group, 5 patients (4.2%) in the formoterol group, and 6 patients (5.2%) in the
placebo group.
Eosinophilic Conditions and Churg-Strauss Syndrome
In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions. Some of these patients
have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic
corticosteroid therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of
oral corticosteroid therapy following the introduction of inhaled corticosteroids. Physicians should be alert to eosinophilia,
vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients.
A causal relationship between budesonide and these underlying conditions has not been established.
Coexisting Conditions
SYMBICORT, like all medications containing sympathomimetic amines, should be used with caution in patients with
convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the
related beta2-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting
diabetes mellitus and ketoacidosis.
Hypokalemia and Hyperglycemia
Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular
shunting, which has the potential to produce adverse cardiovascular effects [see CLINICAL PHARMACOLOGY in full
Prescribing Information (12.2)]. The decrease in serum potassium is usually transient, not requiring supplementation.
Clinically significant changes in blood glucose and/or serum potassium were seen infrequently during clinical studies with
SYMBICORT at recommended doses.
ADVERSE REACTIONS
Long-acting beta2-adrenergic agonists, such as formoterol one of the active ingredients in SYMBICORT, increase the risk
of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA.
Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in
pediatric and adolescent patients. Data from a large placebo-controlled US study that compared the safety of another longacting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related
deaths in patients receiving salmeterol [see WARNINGS AND PRECAUTIONS].
Systemic and inhaled corticosteroid use may result in the following:
- Candida albicans infection [see WARNINGS AND PRECAUTIONS]
- Pneumonia or lower respiratory tract infections in patients with COPD [see WARNINGS AND PRECAUTIONS]
- Immunosuppression [see WARNINGS AND PRECAUTIONS]
- Hypercorticism and adrenal suppression [see WARNINGS AND PRECAUTIONS]
- Growth effects in pediatric patients [see WARNINGS AND PRECAUTIONS]
- Glaucoma and cataracts [see WARNINGS AND PRECAUTIONS]
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials
of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed
in practice.
2
Clinical Trials Experience in Asthma
Patients 12 years and older
The overall safety data in adults and adolescents are based upon 10 active- and placebo-controlled clinical trials in which
3393 patients ages 12 years and older (2052 females and 1341 males) with asthma of varying severity were treated with
SYMBICORT 80/4.5 or 160/4.5 mcg taken two inhalations once or twice daily for 12 to 52 weeks. In these trials, the patients
on SYMBICORT had a mean age of 38 years and were predominantly Caucasian (82%).
The incidence of common adverse events in Table 1 below is based upon pooled data from three 12-week, double-blind,
placebo-controlled clinical studies in which 401 adult and adolescent patients (148 males and 253 females) age 12 years and
older were treated with two inhalations of SYMBICORT 80/4.5 or SYMBICORT 160/4.5 twice daily. The SYMBICORT group
was composed of mostly Caucasian (84%) patients with a mean age of 38 years, and a mean percent predicted FEV1 at
baseline of 76 and 68 for the 80/4.5 mcg and 160/4.5 mcg treatment groups, respectively. Control arms for comparison
included two inhalations of budesonide HFA metered dose inhaler (MDI) 80 or 160 mcg, formoterol dry powder inhaler (DPI)
4.5 mcg, or placebo (MDI and DPI) twice daily. Table 1 includes all adverse events that occurred at an incidence of ≥3% in
any one SYMBICORT group and more commonly than in the placebo group with twice-daily dosing. In considering these data,
the increased average duration of patient exposure for SYMBICORT patients should be taken into account, as incidences are
not adjusted for an imbalance of treatment duration.
Table 1 Adverse reactions occurring at an incidence of ≥3% and more commonly than placebo in the SYMBICORT
groups: pooled data from three 12-week, double-blind, placebo-controlled clinical asthma trials in patients
12 years and older
Treatment*
SYMBICORT
Budesonide
Formoterol
Placebo
Adverse Event
80/4.5 mcg 160/4.5 mcg
80 mcg
160 mcg
4.5 mcg
N = 277
N =124
N =121
N = 109
N = 237
N = 400
%
%
%
%
%
%
Nasopharyngitis
10.5
9.7
14.0
11.0
10.1
9.0
Headache
6.5
11.3
11.6
12.8
8.9
6.5
Upper respiratory
tract infection
7.6
10.5
8.3
9.2
7.6
7.8
Pharyngolaryngeal pain
6.1
8.9
5.0
7.3
3.0
4.8
Sinusitis
5.8
4.8
5.8
2.8
6.3
4.8
Influenza
3.2
2.4
6.6
0.9
3.0
1.3
Back pain
3.2
1.6
2.5
5.5
2.1
0.8
Nasal congestion
2.5
3.2
2.5
3.7
1.3
1.0
Stomach discomfort
1.1
6.5
2.5
4.6
1.3
1.8
Vomiting
1.4
3.2
0.8
2.8
1.7
1.0
Oral Candidiasis
1.4
3.2
0
0
0
0.8
Average Duration of
Exposure (days)
77.7
73.8
77.0
71.4
62.4
55.9
* All treatments were administered as two inhalations twice daily.
Long-term safety - asthma clinical trials in patients 12 years and older
Long-term safety studies in adolescent and adult patients 12 years of age and older, treated for up to 1 year at doses up to
1280/36 mcg/day (640/18 mcg twice daily), revealed neither clinically important changes in the incidence nor new types of
adverse events emerging after longer periods of treatment. Similarly, no significant or unexpected patterns of abnormalities
were observed for up to 1 year in safety measures including chemistry, hematology, ECG, Holter monitor, and HPA-axis
assessments.
Clinical Trials Experience in Chronic Obstructive Pulmonary Disease
The incidence of common adverse events in Table 2 below is based upon pooled data from two double-blind, placebocontrolled clinical studies (6 and 12 months in duration) in which 771 adult COPD patients (496 males and 275 females)
40 years of age and older were treated with SYMBICORT 160/4.5, two inhalations twice daily. Of these patients 651 were
treated for 6 months and 366 were treated for 12 months. The SYMBICORT group was composed of mostly Caucasian (93%)
patients with a mean age of 63 years, and a mean percent predicted FEV1 at baseline of 33%. Control arms for comparison
included two inhalations of budesonide HFA (MDI) 160 mcg, formoterol (DPI) 4.5 mcg or placebo (MDI and DPI) twice daily.
Table 2 includes all adverse events that occurred at an incidence of ≥3% in the SYMBICORT group and more commonly than
in the placebo group. In considering these data, the increased average duration of patient exposure to SYMBICORT should be
taken into account, as incidences are not adjusted for an imbalance of treatment duration.
Table 2 Adverse reactions occurring at an incidence of ≥3% and more commonly than placebo in the
SYMBICORT group: pooled data from two double-blind, placebo-controlled clinical COPD trials
Treatment*
Adverse Event
Nasopharyngitis
Oral candidiasis
Bronchitis
Sinusitis
Upper respiratory tract
infection viral
Average Duration of
Exposure (days)
SYMBICORT
160/4.5 mcg
N = 771
%
7.3
6.0
5.4
3.5
Budesonide
160 mcg
N = 275
%
3.3
4.4
4.7
1.5
Formoterol
4.5 mcg
N = 779
%
5.8
1.2
4.5
3.1
Placebo
N = 781
%
4.9
1.8
3.5
1.8
3.5
1.8
3.6
2.7
255.2
157.1
240.3
223.7
* All treatments were administered as two inhalations twice daily.
Lung infections other than pneumonia (mostly bronchitis) occurred in a greater percentage of subjects treated with
SYMBICORT 160/4.5 compared with placebo (7.9% vs. 5.1%, respectively). There were no clinically important or unexpected
patterns of abnormalities observed for up to 1 year in chemistry, haematology, ECG, ECG (Holter) monitoring, HPA-axis, bone
mineral density and ophthalmology assessments.
Postmarketing Experience
The following adverse reactions have been reported during post-approval use of SYMBICORT. Because these reactions are
reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or
establish a causal relationship to drug exposure. Some of these adverse reactions may also have been observed in clinical
studies with SYMBICORT.
Cardiac disorders: angina pectoris, tachycardia, atrial and ventricular tachyarrhythmias, atrial fibrillation, extrasystoles,
palpitations
Endocrine disorders: hypercorticism, growth velocity reduction in pediatric patients
Eye disorders: cataract, glaucoma, increased intraocular pressure
Gastrointestinal disorders: oropharyngeal candidiasis, nausea
Immune system disorders: immediate and delayed hypersensitivity reactions, such as anaphylactic reaction, angioedema,
bronchospasm, urticaria, exanthema, dermatitis, pruritus
Metabolic and nutrition disorders: hyperglycemia, hypokalemia
Musculoskeletal, connective tissue, and bone disorders: muscle cramps
Nervous system disorders: tremor, dizziness
Psychiatric disorders: behavior disturbances, sleep disturbances, nervousness, agitation, depression, restlessness
Respiratory, thoracic, and mediastinal disorders: dysphonia, cough, throat irritation
Skin and subcutaneous tissue disorders: skin bruising
Vascular disorders: hypotension, hypertension
DRUG INTERACTIONS
In clinical studies, concurrent administration of SYMBICORT and other drugs, such as short-acting beta2-agonists, intranasal
corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. No formal
drug interaction studies have been performed with SYMBICORT.
ACAAI Booth
Capturing of NPI Numbers
Stop by the ACAAI booth, located on Level Four of the
Georgia World Congress Center, on Saturday and Sunday
from 9:00 am – 4:00 pm to learn more about ongoing
College programs and Vision 2020.
As part of the healthcare reform legislation signed into law
in March 2010, the Physician Payment Sunshine Act
requires medical device, biologic, and drug companies to
publicly disclose gifts and payments made to physicians,
beginning on August 1, 2013.
Admission by Badge Only
To help our 2014 ACAAI Annual Scientific Meeting
exhibitors and industry partners in fulfilling the mandatory
reporting provisions of the Sunshine Act, ACAAI is requesting U.S. healthcare provider attendees to supply their
10-digit NPI (National Provider Identifier) number when
registering for the 2014 Annual Scientific Meeting. The NPI
will be imbedded in the bar code data on the attendee’s
badge – it will NOT be printed on the badge. Exhibitors can
download the NPI information by scanning the badge
through a lead retrieval system so that they can record and
track any reportable transactions.
Admission to all meeting rooms and the exhibit area will be
by badge only. This rule will be strictly enforced by security
guards at all entrances. Note: Children under 12 are not
admitted to the Scientific Sessions or the exhibit area.
Alliance Hospitality Suite
The Alliance Hospitality Suite – located in the Atrium
Terrace (Atrium Terrace Level – South Tower) of the
Omni Hotel at CNN Center – will be open to registered
spouses and guests only from 8:00 – 10:30 am, Friday
through Monday.
Awards Ceremony and
President’s Welcome Reception
The College invites all registrants to the ACAAI Awards
Ceremony and President’s Welcome Reception on Saturday
at the Omni Hotel at CNN Center. The Awards Ceremony
will begin at 7:00 pm and will be held in the International
Ballroom Salons DE (Level M2 – North Tower). ACAAI will
recognize the 2014 Award recipients and formally welcome
our newly-approved Fellows. Award recipients include
ACAAI’s Distinguished Fellow, International Distinguished
Fellow, Distinguished Service, Woman in Allergy, Young
Faculty Support, and Clemens Von Pirquet awards. Finally,
we’ll introduce this year’s recipient of the College’s prestigious Gold Headed Cane Award.
The President’s Welcome Reception will be held in the
Grand Ballroom (Level M4 – North Tower) at the Omni
Hotel at CNN Center, from 7:45 – 9:00 pm. It’s the perfect
place to catch up with old friends, make new acquaintances and meet the ACAAI President, President-Elect and
the Alliance President.
Badge Designations
Blue
Member Physicians
Purple
Non–member Physicians
Green
Nurses/Allied Health
Lime
Fellows–in–Training/Residents
Orange
Non-Physicians
Red
Technical Exhibitors
Teal
Spouses/Guests
Lt Orange Press
Fuchsia
Staff
Replacement badges – $10.00 each
For more information on the capturing of the NPI number;
please visit www.acaai.org/annual_meeting/Pages/
2014Registration.aspx.
Child Care Services
Please contact the concierge at the hotel at which you are
staying for a list of bonded independent babysitters and
babysitting agencies. Note: Children under 12 are not
admitted to the Scientific Sessions or the exhibit area.
Coat & Baggage Check
A complimentary coat and baggage check is located in
Room A401 at the Georgia World Congress Center.
Hours:
7:30 am – 5:30 pm, Thursday
7:00 am – 6:30 pm, Friday
7:00 am – 7:30 pm, Saturday
6:00 am – 6:30 pm, Sunday
6:30 am – 5:30 pm, Monday
Disclaimer
The primary purpose of the ACAAI Annual Scientific Meeting is
educational. Information, as well as technologies, products
and/or services discussed, are intended to inform participants
about the knowledge, techniques and experiences of specialists who are willing to share such information with colleagues.
A diversity of professional opinions exists in the specialty and
the views of the ACAAI disclaim any and all liability for damages to any individual attending this conference and for all
claims which may result from the use of information, technologies, products and/or services discussed at the conference.
19
General Information
Special Announcements
Special Announcements
Doctors’ Job Fair
Looking for new opportunities, an associate for your group,
or a buyer for your practice? The Doctors’ Job Fair brings
together all interested parties seeking or offering professional opportunities.
This unique program is scheduled from 12:30 – 3:30 pm,
Sunday, in Hall A-1 of the Georgia World Congress Center.
Representatives of clinics, groups and physicians’ offices
looking for associates, will be among those conducting
interviews, which will be held in private, draped booths.
DVD-ROM
The Literature Review Course, Thursday Conference, and
selected Plenary Sessions and Symposia will be captured
and placed on an interactive DVD.
Visit the Conference Recordings sales desk located outside
the Sidney Marcus Auditorium (Level Four) of the Georgia
World Congress Center to learn more about this exciting
opportunity and order your copy at the special on-site
discounted rate. (Sorry, no personal audio or video recorders
will be allowed in the meeting rooms.)
Exhibit Hall
More than 85 technical and scientific exhibitors in 181
booths are displaying their latest products in Hall A-1 of the
Georgia World Congress Center during the convention.
ACAAI appreciates the support of its exhibitors and urges
all registrants to visit the displays. Exhibit hours are:
Hours: 3:00 pm – 6:00 pm, Friday
9:45 am – 4:00 pm, Saturday
9:45 am – 4:00 pm, Sunday
First Aid Office at
Georgia World Congress Center
A First Aid Station is located in Hall A-3 Lobby (behind
escalators) during the following hours:
Hours: 7:30 am – 5:30 pm, Wednesday
6:30 am – 6:30 pm, Thursday
6:30 am – 6:30 pm, Friday
5:30 am – 7:30 pm, Saturday
6:00 am – 10:00 pm, Sunday
6:00 am – 10:00 pm, Monday
Closest Hospitals
Crawford Long Hospital of Emory University (1.6 miles)
550 Peachtree Street, Atlanta, GA
Main 404 / 686-4411
ER 404 / 686-2435
Closest Walk-in Clinic
SmartCare Urgent Care (10.15 miles)
4400 Peachtree Rd NE, Atlanta, GA
404 / 348-8912
20
Closest Pharmacy
CVS Pharmacy (0.52 miles)
12 Broad Street SW, Atlanta, GA
404 / 681-1976
Foundation Display
The Foundation of the ACAAI is proud to recognize those
individuals who have generously contributed to the Foundation. A list of donors can be found on the Foundation
Honor Display in Building A on Level Three of the Georgia
World Congress Center.
Internet Café
Visit the “Internet Café” to access the internet and send and
retrieve email. The Internet Café is located in Building A,
Level Three Lobby of the Georgia World Congress Center
and is complimentary to all meeting registrants.
Supported by McNeil Consumer Healthcare
Mobile App
Maximize your time at the meeting
with the free ACAAI Annual Scientific
Meeting mobile app. To download, plug
www.acaai/apps into your mobile device’s
browser, scan the QR Code or search for ACAAI in your
app store.
Supported by Teva Respiratory
Networking Goes Viral
with #ACAAI
Be a part of the Annual Meeting conversation! Use
hashtag #ACAAI in your meeting-related tweets and follow
the College@ACAAI. Also, share Facebook posts from
facebook.com/TheACAAI.
Non-CME Corporate Forums
NOT FOR
CREDIT
Following the close of Friday and Saturday’s scientific session, all registrants are invited to attend the special Corporate Forums at the Omni Hotel at CNN Center.
Corporate Forums are non-CME promotional symposia
organized by industry and designed to enhance your educational experience.
Friday, November 7
Overview of HyQvia
6:00 – 7:30 pm
International Ballroom Salon F
Supported by Baxter Healthcare
Advances in Aerosol Therapy for
Patients with Asthma or Allergic Rhinitis
6:00 – 7:30 pm
International Ballroom Salon D
Supported by Teva Respiratory
Advances in Aerosol Therapy for
Patients with Allergic Rhinitis
8:00 – 9:30 pm
International Ballroom Salon D
Supported by Teva Respiratory
A Joint Presentation on Seasonal Allergic
Rhinitis and Maintenance Treatment of Asthma
8:00 – 9:30 pm
International Ballroom Salon E
Supported by Meda Pharmaceuticals Inc.
General Information
Special Announcements
Poster Presentations
All scientific posters will be on display in Hall A-1 of the
Georgia World Congress Center beginning Saturday
morning. Authors are requested to be at their poster to
discuss their work from 3:30 – 4:30 pm, Saturday and
7:30 – 8:30 am, Sunday.
Registration Desk Hours
(Subject to Change)
The Registration Desk is located in Building A Registration
Hall of the Georgia World Congress Center and will be open:
Hours: 7:00 am – 6:00 pm, Thursday
6:30 am – 6:00 pm, Friday
6:30 am – 4:00 pm, Saturday
6:30 am – 4:00 pm, Sunday
6:30 am – 4:00 pm, Monday
Speaker Ready Room
The Speaker Ready Room is located in Room A402 of the
Georgia World Congress Center and will be open:
Hours:
3:00 pm – 7:00 pm, Wednesday
7:00 am – 7:00 pm, Thursday
6:30 am – 7:00 pm, Friday
6:00 am – 6:00 pm, Saturday
6:00 am – 6:00 pm, Sunday
6:00 am – 5:00 pm, Monday
All presenters must check into the Speaker Ready Room
at least 6 hours before the start of their presentation.
Saturday, November 8
Wireless Internet
MD I Inhaler Technique: Optimizing
Patient Education and Outcomes
9:00 – 10:30 pm
International Ballroom Salons ABC
Free Wi-Fi is provided to all ACAAI attendees at the Georgia
World Congress Center (Building A – 3rd and 4th Floors
only). To access the free Wi-Fi simply:
• Open your wireless network connections
• Connect to the “ACAAI” wireless network
• Enter Password: acaai2014
Supported by Teva Respiratory
Photography/Video Recordings
By registering for this meeting, attendees acknowledge and
agree that ACAAI or its agents may take photographs during events and may freely use those photographs in any
media for ACAAI purposes, including but not limited to
news and promotional purposes.
Supported by Teva Respiratory
The presentations, slides, and materials provided in this
program are the property of ACAAI or used by permission.
Attendees may not photograph, videotape, audiotape or
otherwise record or reproduce any of the presentations
without express written permission from ACAAI. Any
attendee believed to be violating this restriction will be
removed from the session and may be prohibited from participating in further ACAAI meetings.
21
Evaluation, Credit Claim and Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2014 Annual Scientific
Meeting. This system will allow you to complete evaluations of the certified CME sessions that you attend which
are directly provided by ACAAI. Upon completion of the
Overall Evaluation, Session Evaluations and credit claiming
information, you will be able to immediately access, save
and/or print your certificate. Physicians will receive a certificate of credit and other healthcare professionals will
receive a certificate of attendance.
Locations to access the evaluations, claim credit, and obtain
certificates:
• Kiosks (near registration)
• Other available internet sources onsite
• Office or home computers (recommended)
as possible either onsite or following the meeting.
A checklist will be provided to help you track the
sessions you attend. The Evaluation site will close on
December 15, 2014. Up until then, you will be able to complete the evaluations, claim credit and obtain your certificates from your home or office computers.
For sessions attended, nurses and other healthcare professionals may receive a certificate of attendance via the
online system. Nurses may also use the online system to
obtain a CBRN certificate for the Allied Health and
Advanced Practice sessions.
Attendees of the jointly provided AACA activity will need to
complete the paper forms that will be available at this particular session in order to obtain credit. These must be
returned to the coordinator onsite.
Visit www.acaai.org for additional information.
Online access:
http://www.pswebsurvey.com/ACAAI
You will be asked to enter your Last Name and ID Number
in order to complete the evaluations. Your ID Number is
located on your Registration Card and Badge.
We encourage you to complete the appropriate evaluations, claim your credit, and obtain your certificates as soon
Snap the QR Code with your
mobile device to access the
evaluation site.
Photo provided by GWCC
22
This activity is supported by independent educational
grants from:
• ALK, Inc.
• AstraZeneca
• Baxter Healthcare
• Genentech | Novartis
• Recognize emerging trends in the prevalence of allergic
and immunologic disorders and discuss their impact on
public health
• Evaluate the impact of new diagnostic and therapeutic
strategies on healthcare costs and outcomes
• Discuss processes, tools and technologies for the efficient
allergy and immunology practice
• McNeil Consumer Healthcare
• Meda Pharmaceuticals Inc.
• Merck
• Mylan Specialty L.P.
• Shire
• SmartPractice
This activity is also supported by BR Surgical, LLC through
an independent educational grant consisting of loaned
durable equipment and disposable supplies.
Target Audience
• All practicing allergists/immunologists
• Fellows in allergy/immunology training programs
• Primary care physicians who care for allergy patients
• Allied health professionals in the field of allergy and
immunology
Overall Educational Objectives
Accreditation
The American College of Allergy, Asthma &
Immunology (ACAAI) is accredited by the
Accreditation Council for Continuing Medical
Education (ACCME) to provide continuing medical education for physicians.
The American College of Allergy, Asthma & Immunology
(ACAAI) designates this live activity for a maximum of
39 AMA PRA Category 1 Credits™. Physicians should claim
only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity has been
reviewed by the American Academy of Pediatrics and is
acceptable for a maximum of 39 AAP credits. These credits
can be applied toward the AAP CME/CPD Award available
to Fellows and Candidate Members of the American Academy of Pediatrics.
Special Needs
In compliance with the Americans with Disabilities ACT,
ACAAI requests that participants in need of special
accommodation submit a written request to ACAAI well
in advance.
At the conclusion of this activity, participants should be
able to:
• Identify major advances in key areas of cutting edge
research in immunologic mechanisms and allergic
responses, including anaphylaxis and pathophysiology of
the upper airways, lungs, eyes, skin and gastrointestinal
tract
• Demonstrate knowledge of basic processes linking
molecular and cellular biology and genetics with allergic
pathophysiology and immunodeficiency
• Translate emerging clinical science principles to clinical
practice in patients with allergic and immunologic
diseases
• Evaluate and implement state-of-the-art diagnostic and
therapeutic strategies for treating patients with allergic
and immunologic diseases
• Explain the impact of environmental exposures and
external influences on patients with allergic disorders
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2014 Annual
Scientific Meeting. This system will allow you to complete evaluations of the certified CME sessions that you
attend which are directly provided by ACAAI. Upon
completion of the Overall Evaluation, Session Evaluations and credit claiming information you will be able
to immediately access, save and/or print your certificate. Physicians will receive a certificate of credit and
other healthcare professionals will receive a certificate
of attendance for most sessions.
See page 22 for details.
23
General Information
Education Information
Maintenance of Certification
Through its responsibility to provide quality CME to its membership, the ACAAI continues its support of the ABAI, which
credentials and evaluates allergy and immunology specialists. Since 1977, ABAI has offered its Diplomates a recertification
process to demonstrate their efforts in continuing education. In 2009, ABAI transitioned to the more comprehensive Maintenance of Certification (ABMS MOC©) program.
Linking the education content of the ACAAI Annual Scientific Meetings to the MOC© program is one way ACAAI helps its
members provide ABAI with evidence of their commitment to lifelong learning. Ultimately, CME activities for which MOC©
credit is awarded may be cross-referenced to the ABAI examination content outline, available on the ABAI website:
www.abai.org. Members are encouraged to select areas of interest from the program, which will enhance their knowledge
of state-of-the-art allergy/immunology and improve the quality of patient care.
ACAAI will assist Allergy/Immunology Training Programs with additional curricular resources and assessment measures that
may be used to help meet their requirements for assessing competency in the six core areas as designed by the ACGME.
The six core competencies include:
1
Patient Care – the ability to provide patient care that is
compassionate, appropriate, and effective for the treatment of health problems and the promotion of health:
• data gathering
• history taking
• patient examination
• diagnosis
• interpretation/decision-making/assessment
• management/treatment plans
• preventive care
• procedures
2
Medical Knowledge – the knowledge about established and evolving biomedical, clinical, and cognate
sciences and the application of this knowledge to
patient care:
• general principles/concepts/theories
• applied basic sciences
• applied biomedical sciences
• applied clinical knowledge
• epidemiology and psychosocial behavioral sciences
• population-based medicine
3
Practice-based Learning and Improvement – the
ability to investigate and evaluate patient care practices,
appraise and assimilate scientific evidence, and improve
their patient care practices:
• benchmarks/best practices
• practice related quality improvement
• evidence-based practice/medicine
• continuing professional development/continuing
medical education
• practice self-assessment
• information technology/medical informatics
• teaching and learning and life-long learning
24
4
Interpersonal and Communication Skills – the ability to demonstrate interpersonal and communication
skills that result in effective information exchange and
collaboration with patients, their families, and other
health professionals:
• teaming and team leadership skills (inter-professional,
multi-disciplinary)
• effective communicator and listener
• caring, respectful behavior
• written and verbal communication skills
• educating/counseling patients and family members
• teaching skills
5
Professionalism – reflects a commitment to carrying
out professional responsibilities, adherence to
ethical principles, and sensitivity to a diverse
patient population:
• physician accountability
• humanistic qualities (respect, compassion, integrity)
• professional ethics
• socio-cultural factors (sensitivity to culture, diversity,
gender, age, disabilities)
• advocacy for and responsive to patient needs
• commitment to excellence and quality care
• mentorship and role-modeling
6
System-based Practice – an awareness of and responsiveness to the larger context and system of healthcare,
and the ability to call effectively on other resources in
the system to provide optimal health care:
• patient safety
• cost-effective care
• management of resources
• medical errors
• continuity of care
• healthcare delivery and systems of care models
• utilization issues
• risk management
• electronic record keeping
• management and leadership skills
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
7:00 am – 6:00 pm
7:00 am – 7:00 pm
7:30 am – 5:30 pm
7:45 am – 4:30 pm
8:00 am – noon
9:35 – 10:05 am
Noon – 1:00 pm
Noon – 1:00 pm
1:00 – 5:00 pm
2:35 – 3:05 pm
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Building A Registration Hall (Level Four)
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A402
Coat & Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A401
Board of Regents Meeting . . . . . . . . . . . . . . . . . . . . . . . . . .International AB (Omni / Level M2 – North Tower)
Thursday Conference: D-Day for Skin Deep Allergies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412
Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412 Foyer
Board of Regents Luncheon . . . . . . . . . . . . . . . . . . . . . . . . .International C (Omni / Level M2 – North Tower)
Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
Thursday Conference: Patch Testing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412
Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412 Foyer
Friday, November 7th
6:30 am – 6:00 pm
6:30 am – 7:00 pm
7:00 am – 6:30 pm
7:30 – 11:30 am
8:00 – 10:30 am
8:00 – 11:30 am
8:00 am – 12:30 pm
8:00 am – 3:00 pm
8:30 – 9:30 am
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Building A Registration Hall (Level Four)
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A402
Coat & Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A401
Literature Review: Part I – Morning Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412
Alliance Hospitality Suite . . . . . . . . . . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
Office Administrators Practice Management Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A305
Advanced Practice Health Care Providers Course: General Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A302
W-1 Identifying Particles in the Air We Breathe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A316
Alliance: The History of Atlanta – Margaret Mitchell &
Gone with the Wind . . . . . . . . . . . . . . . . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
8:30 – 10:30 am
Breakfast Symposium: Turbinates to Terminal Bronchioles:
The One Airway Concept and Advances in the Treatment of Asthmatics . . . . . . . . . .Hall A-2 (Level One)
9:30 – 9:45 am
Literature Review Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412 Foyer
9:45 – 10:00 am
Advanced Practice Health Care Providers Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A302 Foyer
9:45 – 10:00 am
Office Administrators Practice Mangement Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . .A305 Foyer
11:30 am – 12:30 pm Literature Review Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
11:30 am – 12:30 pm AACA Board of Directors Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A406
11:30 am – 1:00 pm Office Administrators Practice Management Course Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
11:30 am – 1:30 pm Luncheon Symposium: Hereditary Angioedema: Clinical Case Challenge . . . . . . . . . . .Hall A-2 (Level One)
Noon – 2:00 pm
Corporate Council Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
12:30 – 1:30 pm
Advanced Practice Health Care Providers Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
12:30 – 3:30 pm
Literature Review: Part II – Afternoon Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412
1:00 – 3:30 pm
Office Administrators Practice Management Course . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A305
1:30 – 3:00 pm
Advanced Practice Health Care Providers Interactive Concurrent Workshops
AP1 Dermatology Pearls: Case Studies –
Bring Your Interesting Cases . . . . . . . . . . . . . . . . . . . . .Dogwood A (Omni / Level M1 – North Tower)
AP2 Difficult to Manage Cases (PBL) . . . . . . . . . . . . . . . . . . .Dogwood B (Omni / Level M1 – North Tower)
AP3 What Patients Are Taking and What
Recommendations We Are Making . . . . . . . . . . . . . .Cottonwood (Omni / Level M1 – North Tower)
1:45 – 3:45 pm
Symposium: Asthma and COPD: What Is the Difference? . . . . . . .Sidney Marcus Auditorium (Level Four)
2:00 – 2:15 pm
Literature Review Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411-412 Foyer
2:00 – 4:00 pm
FIT Bowl Planning Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A407
25
Daily Events
Thursday, November 6th
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
Friday, November 7th
2:30 – 2:45 pm
3:00 – 3:15 pm
3:00 – 6:00 pm
3:15 – 4:45 pm
3:30 – 4:00 pm
3:30 – 5:30 pm
4:00 – 6:00 pm
4:00 – 6:00 pm
4:00 – 6:30 pm
5:30 – 6:30 pm
5:30 – 6:30 pm
6:00 – 7:30 pm
6:00 – 7:30 pm
6:00 – 9:30 pm
6:30 – 7:30 pm
8:00 – 9:30 pm
8:00 – 9:30 pm
(continued)
Office Administrators Practice Management Course Refreshment Break . . . . . . . . . . . . . . . . . . .A305 Foyer
Advanced Practice Health Care Providers
Refreshment Break . . . . . . . . . . . . . . . . .Cottonwood & Dogwood Foyers (Omni / Level M1 – North Tower)
Exhibit Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
Advanced Practice Health Care Providers Interactive Concurrent Workshops
AP4 Dermatology Pearls: Case Studies –
Bring Your Interesting Cases . . . . . . . . . . . . . . . . . . . . .Dogwood A (Omni / Level M1 – North Tower)
AP5 Difficult to Manage Cases (PBL) . . . . . . . . . . . . . . . . . . .Dogwood B (Omni / Level M1 – North Tower)
AP6 What Patients Are Taking and What
Recommendations We Are Making . . . . . . . . . . . . . .Cottonwood (Omni / Level M1 – North Tower)
Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
Fellows-in-Training Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A311-312
Workshops
W-2 Insect Allergy Update . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A302
W-3 When Work Makes You Sick . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A315
W-4 Food Challenges in Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A410
W-5 The Affordable Care Act and Asthma Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A404
W-6 Epinephrine and Asthma Treatment for Grandpa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A405
Alliance Pre-Board Meeting . . . . . . . . . . . . . . . . . . .Maple AB (Omni / Atrium Terrace Level – South Tower)
Town Hall Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
Fellows-in-Training General Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A311-312
Residents for Allergy Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Redwood (Omni / Level M1 – North Tower)
Non-CME Corporate Forum:
Teva Respiratory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .International D (Omni / Level M2 – North Tower)
Non-CME Corporate Forum:
Baxter Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .International F (Omni / Level M2 – North Tower)
American Association of Allergists and
Immunologists of Indian Origin (AAAII) . . . . . . . . .Grand Ballroom ABC (Omni / Level M4 – North Tower)
Fellows-in-Training Welcome Reception . . . . . . . . . .Grand Ballroom DE (Omni / Level M4 – North Tower)
Non-CME Corporate Forum:
Meda Pharmaceuticals Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . .International E (Omni / Level M2 – North Tower)
Non-CME Corporate Forum:
Teva Respiratory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .International D (Omni / Level M2 – North Tower)
Saturday, November 8th
6:00 am – 6:00 pm
6:30 – 7:45 am
6:30 am – 4:00 pm
7:00 am – 7:30 pm
26
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A402
Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A410
Adverse Reactions to Foods
Asthma & Respiratory Diseases
Insect Hypersensitivity
Membership Recruitment
Public Education and Outreach
Rhinitis / Sinusitis
Women’s Health
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Building A Registration Hall (Level Four)
Coat & Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A401
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
(continued)
8:00 – 8:30 am
8:00 – 10:30 am
8:00 am – noon
8:30 – 9:30 am
8:30 – 10:30 am
Opening Ceremony and Welcome Announcements . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
Alliance Hospitality Suite . . . . . . . . . . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
Allied Health Professionals Course: General Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
Alliance: Comidas de America Sur . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
Plenary Session: Unique Challenges for the
Allergist/Immunologist in COPD and Asthma . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
9:00 – 10:00 am
Task Force on Quality Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A406
9:00 am – 4:00 pm
ACAAI Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium Foyer (Level Four)
9:30 – 10:30 am
ACAAI KIDS: Zoo Atlanta Animal Encounters . . . . . . . .Pine (Omni / Atrium Terrace Level – South Tower)
9:45 am – 4:00 pm
Exhibit Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
9:45 am – 4:30 pm
Poster Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
9:55 – 10:10 am
Allied Health Professionals Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314 Foyer
10:30 – 11:00 am
Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
10:35 – 11:00 am
Product Theater 1: Aerocrine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
Product Theater 2: GREER® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
11:00 am – 12:30 pm Plenary Session: The Brave New World for the Allergist/
Immunologist in Immunotherapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
Noon – 1:30 pm
Allied Health Professionals Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
12:30 – 1:30 pm
Allergy / Immunology Program Directors Luncheon Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A408
12:30 – 1:30 pm
Immunotherapy and Diagnostics Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A406
12:30 – 1:30 pm
Lunch Concessions / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
12:35 – 1:30 pm
Product Theater 1: Teva Respiratory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
12:35 – 1:30 pm
Product Theater 2: Genentech | Novartis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
1:30 – 2:30 pm
ACAAI Foundation Board of Trustees Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A407
1:30 – 3:00 pm
Plenary Session: The Great Raft Debate on the
Allergy Epidemic: A Root Cause Analysis . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
1:30 – 3:00 pm
Allied Health Professionals Interactive Concurrent Workshops
SA1 Taking the Challenge Out of the Oral Food Challenges:
Bring Your Challenges . . . . . . . . . . . . . . . . . . . . . . . . . . .Dogwood A (Omni / Level M1 – North Tower)
SA2 Pulmonary Function Testing: Novice to Expert . . . .Dogwood B (Omni / Level M1 – North Tower)
SA3 Regulatory Update: What You Need to Know
Regarding Immunotherapy Compounding and
USP 797 Compliance . . . . . . . . . . . . . . . . . . . . . . . . . . . .Cottonwood (Omni / Level M1 – North Tower)
SA4 The Missing Piece: Applying Environmental
Health Parameters in Your Practice . . . . . . . . . . . .International A (Omni / Level M2 – North Tower)
SA5 Resources in Allergy and Asthma Management:
Making Nurses Aware of Available and Credible
Information in a Technological Age . . . . . . . . . . . .International B (Omni / Level M2 – North Tower)
SA6 Potpourri of Procedures Commonly Used in the
Clinical Setting (PCN Testing, Omalizumab
Administration, SLIT-SCIT Differences) . . . . . . . . .International C (Omni / Level M2 – North Tower)
3:00 – 3:15 pm
Allied Health Professionals Refreshment Break . . .International Foyer (Omni / Level M2 – North Tower)
3:00 – 3:30 pm
Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
3:00 – 5:00 pm
Annals Editorial Board Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
27
Daily Events
Saturday, November 8th
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
Saturday, November 8th
3:15 – 4:45 pm
3:30 – 4:30 pm
3:30 – 5:00 pm
3:30 – 5:30 pm
3:30 – 5:30 pm
5:00 – 7:00 pm
6:00 – 7:00 pm
7:00 – 7:45 pm
7:45 – 9:00 pm
9:00 – 10:30 pm
(continued)
Allied Health Professionals Interactive Concurrent Workshops
SA7 Taking the Challenge Out of the Oral Food Challenges:
Bring Your Challenges . . . . . . . . . . . . . . . . . . . . . . . . . . .Dogwood A (Omni / Level M1 – North Tower)
SA8 Pulmonary Function Testing: Novice to Expert . . . .Dogwood B (Omni / Level M1 – North Tower)
SA9 Regulatory Update: What You Need to Know
Regarding Immunotherapy Compounding and
USP 797 Compliance . . . . . . . . . . . . . . . . . . . . . . . . . . . .Cottonwood (Omni / Level M1 – North Tower)
SA10 The Missing Piece: Applying Environmental
Health Parameters in Your Practice . . . . . . . . . . . .International A (Omni / Level M2 – North Tower)
SA11 Resources in Allergy and Asthma Management:
Making Nurses Aware of Available and Credible
Information in a Technological Age . . . . . . . . . . . .International B (Omni / Level M2 – North Tower)
SA12 Potpourri of Procedures Commonly Used in the
Clinical Setting (PCN Testing, Omalizumab
Administration, SLIT-SCIT Differences) . . . . . . . . .International C (Omni / Level M2 – North Tower)
Poster Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
Investments Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A406
Symposium: Optimizing Immunoglobulin
Replacement Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
Workshops
W-7 Rhinitis: Novel Approaches to Diagnosis and Treatment:
An ENT and Allergist’s Perspective . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A404
W-8 Introductory Course in Rhinolaryngoscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A302
W-9 JCAAI 2014 Coding, Billing and Regulations: Part 1 of 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A305
W-10 Severe Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A410
W-11 Problem-Based Learning: An Interactive Case Discussion of a
Child With Recurrent Infections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A312
W-12 Competitive Swimming and Asthma: Good, Bad or Unrelated? . . . . . . . . . . . . . . . . . . . . . . . . . . .A315
W-13 Food Allergies: What’s New? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
W-14 Patch Me If You Can! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A405
W-15 Problem-Based Learning: An Interactive Case Discussion of a
Young Adult with Difficulty Swallowing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A311
23rd Annual FIT Bowl Competition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-2 (Level One)
Alliance International Reception . . . . . . . . . . . . . . . . . . . . .International F (Omni / Level M2 – North Tower)
Awards Ceremony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .International DE (Omni / Level M2 – North Tower)
ACAAI President’s Welcome Reception . . . . . . . . . . . . . .Grand Ballroom (Omni / Level M4 – North Tower)
Non-CME Corporate Forum: Teva Respiratory . . . . . .International ABC (Omni / Level M2 – North Tower)
Sunday, November 9th
6:00 am – 6:00 pm
6:00 am – 6:30 pm
6:30 – 8:15 am
6:30 – 8:15 am
28
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A402
Coat & Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A401
International Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
Committee Meetings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A410
Abstract Review
Drugs & Anaphylaxis
Environmental Allergy
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
Sunday, November 9th
(continued)
Committee Meetings (continued) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A410
Integrative Medicine
Medical Informatics
Sports Medicine
6:30 – 8:30 am
W-16 Hands-On Session in Rhinolaryngoscopy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A316
6:30 am – 4:00 pm
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Building A Registration Hall (Level Four)
7:00 – 8:15 am
Meet the Professor Breakfasts
S1
Severe Asthma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Dogwood A (Omni / Level M1 – North Tower)
S2
Practical Aspects of Sublingual Immunotherapy:
Dose/Duration/Specific Allergens/Geographic
Niches/Efficacy & Safety . . . . . . . . . . . . . . . . . . . . . . . . . .Dogwood B (Omni / Level M1 – North Tower)
S3
The Role of the Microbiome in
Allergic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Cottonwood (Omni / Level M1 – North Tower)
S4
Eosinophilic Gastrointestinal Disease . . . . . . . . . . . . . . .Redwood (Omni / Level M1 – North Tower)
S5
Tailoring Asthma Management:
Step-2 to Step-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .International A (Omni / Level M2 – North Tower)
S6
Rhinosinusitis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .International B (Omni / Level M2 – North Tower)
S7
Airway Inflammation Beyond
Th-1/Th-2 Mechanisms . . . . . . . . . . . . . . . . . . . . . . . .International C (Omni / Level M2 – North Tower)
S8
Mast Cell Activation Syndrome . . . . . . . . . .Maple AB (Omni / Atrium Terrace Level – South Tower)
S9
Aspirin Sensitivity Syndromes . . . . . . . . . . . . . . . .Pine (Omni / Atrium Terrace Level – South Tower)
S10 Novel Therapies for Chronic Urticaria
and Angioedema . . . . . . . . . . . . . . . . . . . . . . . . . . . .Birch (Omni / Atrium Terrace Level – South Tower)
7:00 am – noon
JCAAI Board of Directors Meeting . . . . . . . . . . . . . . . .Spruce (Omni / Atrium Terrace Level – South Tower)
7:30 – 8:30 am
Poster Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
8:00 – 9:30 am
Exhibitors Advisory Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A407
8:00 – 9:45 am
W-17 Technology (Tablets/Gadgets and Apps): An Integral Part of Patient Care . . . . . . . . . . . . . . . . .A315
8:00 – 10:30 am
Alliance Hospitality Suite . . . . . . . . . . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
8:00 am – noon
Allied Health Professionals Course: General Session . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
8:30 – 9:30 am
Alliance: Unusual Environmental
Helpers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
8:30 – 10:00 am
Plenary Session: Unique Challenges for the Allergist/
Immunologist in Our Aging Population . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
9:00 am – 4:00 pm
ACAAI Booth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium Foyer (Level Four)
9:45 am – 4:00 pm
Exhibit Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
9:45 am – 4:00 pm
Poster Hours . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
9:50 – 10:05 am
Allied Health Professionals Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314 Foyer
10:00 – 10:30 am
Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
10:05 – 10:30 am
Product Theater 1: CSL Behring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
10:30 – 11:00 am
Plenary Session: Bela Schick Lecture . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
11:00 am – 12:30 pm Plenary Session: Unique Challenges for the Allergist/
Immunologist in Children and Adolescents . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
12:30 – 1:30 pm
Lunch Concessions / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
12:30 – 1:30 pm
2015 Annual Meeting Program Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
12:30 – 1:30 pm
Meet the Professor Breakfasts Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
29
Daily Events
6:30 – 8:15 am
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
Sunday, November 9th
12:30 – 1:30 pm
12:30 – 1:30 pm
12:30 – 2:00 pm
12:30 – 3:00 pm
12:30 – 3:30 pm
12:35 – 1:30 pm
12:35 – 1:30 pm
1:30 – 3:30 pm
1:30 – 3:30 pm
1:30 – 3:30 pm
1:30 – 3:30 pm
1:30 – 3:30 pm
3:30 – 4:00 pm
4:00 – 6:00 pm
4:00 – 6:00 pm
4:00 – 6:00 pm
7:00 – 8:00 pm
8:00 – 10:30 pm
(continued)
Symposium Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
Workshop Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
Past Presidents’ Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A407
Alliance Annual Business Meeting and Luncheon . . . . . . . . . . . . . . . . . . .Off-Site (McCormick & Schmick’s)
Doctors’ Job Fair . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
Product Theater 1: Merck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
Product Theater 2: GREER® . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
WAO / ACAAI International Symposium: Emerging Approaches
Related to Allergy Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
Concurrent Session A: Adverse Food and Drug Reactions,
Insect Reactions, Anaphylaxis, Food Allergy, and Pharmacology/
Pharmacotherapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411
Concurrent Session B: Aerobiology, Allergens, Allergen Extracts
and Immunotherapy, Immunizations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A412
Concurrent Session C: Asthma and Other Lower Airway Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
Concurrent Session D: Basic Science Allergy and Immunology
and Clinical Immunology, Immunodeficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A305
Refreshment Break / Visit Exhibits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Hall A-1 (Level One)
SLAAI Program: Drug Allergy in Latin America . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A412
AACA Program: Chronic Urticaria – A Problem Based Learning Experience . . . . . . . . . . . . . . . . . . . . . . .A411
Workshops . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
W-18 JCAAI 2014 Coding, Billing and Regulations: Part 2 of 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A302
W-19 Climate Change, the Indoor Environment and Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A305
W-20 Food Allergy Prevention and Treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A311
W-21 Approach to Persistent Cough and Dyspnea in Children and Adults . . . . . . . . . . . . . . . . . . . . . . .A312
W-22 Laboratory Evaluation of the Immune System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A315
W-23 Atopic Dermatitis In-Depth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A316
W-24 Walk Through the Parameters of Chronic Urticaria . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A404
W-25 Allergies in Infants and Very Young Children (Asthma, Urticaria and
Eczema in Children 5 Years and Under) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A405
W-26 The Science Behind an Integrative Approach:
Herbs, Acupuncture, Yoga and More . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
Fundraiser Reception . . . . . . . . . . . . . . . . . . . . . . . . .Grand Ballroom Foyer (Omni / Level M4 – North Tower)
Fundraiser Dinner & Entertainment . . . . . . . . . . . . . . . . .Grand Ballroom (Omni / Level M4 – North Tower)
Monday, November 10th
6:00 am – 5:00 pm
6:30 am – 4:00 pm
6:30 am – 5:30 pm
7:00 – 8:15 am
30
Speaker Ready Room . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A402
Registration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Building A Registration Hall (Level Four)
Coat & Baggage Check . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A401
Meet the Professor Breakfasts
M1 Food Allergy: Controversies in Diagnosis . . . . . . . . .Dogwood A (Omni / Level M1 – North Tower)
M2 Vitamin D in Allergic and Immune Disorders . . . . . .Dogwood B (Omni / Level M1 – North Tower)
M3 Making Sense of the Literature in Food Allergy . . .Cottonwood (Omni / Level M1 – North Tower)
M4 Epigenetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Redwood (Omni / Level M1 – North Tower)
Daily Events
All programs held at the Georgia World Congress Center unless otherwise noted.
HOURS
ROOM
Monday, November 10th
(continued)
Meet the Professor Breakfasts (continued)
M5 Hereditary Angioedema . . . . . . . . . . . . . . . . . . . . . .International A (Omni / Level M2 – North Tower)
M6 Evaluation of Immunodeficiency . . . . . . . . . . . . . .International B (Omni / Level M2 – North Tower)
M7 Office Evaluation of Drug Allergy . . . . . . . . . . . . . .International C (Omni / Level M2 – North Tower)
M8 Exercise Induced Anaphylaxis and FoodDependent Exercise-Induced
Anaphylaxis . . . . . . . . . . . . . . . . . . . . . . . . . . . .Maple AB (Omni / Atrium Terrace Level – South Tower)
M9 Approaches to Patients Who Fail
Step 3 Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Pine (Omni / Atrium Terrace Level – South Tower)
M10 Cough in Children and Adults . . . . . . . . . . . . . . .Birch (Omni / Atrium Terrace Level – South Tower)
8:00 – 9:30 am
Plenary Session: My Patient Is Allergic to My Treatment:
Adverse and Allergic Responses to Allergy and
Asthma Medications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
8:00 – 9:45 am
W-27 Hands-On Skin Biopsy and Patch Testing:
Procedures and Interpretation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A315
8:00 – 10:30 am
Alliance Hospitality Suite . . . . . . . . . . . . . . . . .Atrium Terrace (Omni / Atrium Terrace Level – South Tower)
9:30 – 10:30 am
Annual Business Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
10:30 am – noon
Plenary Session: Healthy Homes and the
Allergist/Immunologist . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
10:30 am – noon
Alliance Post-Board Meeting . . . . . . . . . . . . . . . . . . .Maple AB (Omni / Atrium Terrace Level – South Tower)
10:30 am – 12:30 pm Continuing Medical Education /
Continuing Professional Development Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
Noon – 1:00 pm
Lunch Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .On Own
1:00 – 3:00 pm
Concurrent Session A: Allergy Testing, Clinical Laboratory
Immunology and Clinical Case Reports . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
1:00 – 3:00 pm
Concurrent Session B: Food Allergy, Rhinitis, Other Upper
Airway Disorders, Ocular Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A411
1:00 – 3:00 pm
Concurrent Session C: Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A412
1:00 – 3:00 pm
Concurrent Session D: Skin Disorders, Asthma, Other Lower
Airway Disorders and Clinical Immunology, Immunodeficiency . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A313-314
1:00 – 3:00 pm
Workshops
W-28 Diagnostic Approach to Eczemas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A404
W-29 Drug Allergies and Eruptions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A311
W-30 EMRs: Digitizing Your Practice for the Long Haul . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A315
W-31 Office Examination and Treatment for Tinnitus and Vertigo . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A312
W-32 Immunotherapy in 2014: The Nuts and Bolts of SCIT and SLIT
(Includes IT Prescription Writing) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A302
W-33 What Have We Learned About Asthma Using National Asthma
Surveillance Data? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A405
1:30 – 2:30 pm
Communications Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A406
1:30 – 2:30 pm
Professional Education Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A407
1:30 – 2:30 pm
Scientific Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A403
3:00 – 3:30 pm
Refreshment Break . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium Foyer (Level Four)
3:30 – 5:00 pm
Plenary Session: A New Era in the Diagnosis and
Treatment of Food Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .Sidney Marcus Auditorium (Level Four)
31
Daily Events
7:00 – 8:15 am
Committee Meetings
All meetings will be held at the Georgia World Congress Center unless otherwise noted.
A complimentary continental breakfast will be served at the following committee meetings.
Saturday, November 8
Sunday, November 9
Room A410
6:30 – 7:45 am
Room A410
6:30 – 8:15 am
Adverse Reactions to Foods
Asthma & Respiratory Diseases
Insect Hypersensitivity
Membership Recruitment
Public Education and Outreach
Rhinitus/Sinusitis
Women’s Health
Abstract Review
Drugs & Anaphylaxis
Environmental Allergy
Integrative Medicine
Medical Informatics
Sports Medicine
Other Committee Meetings
Friday, November 7
Sunday, November 9
Monday, November 10
FIT Bowl Planning Committee
2:00 – 4:00 pm
Room A407
International Committee
6:30 – 8:15 am
Room A403
Saturday, November 8
Exhibitors Advisory Meeting
8:00 – 9:30 am
Room A407
Continuing Medical Education/
Continuing Professional
Development Committee
10:30 am – 12:30 pm
Room A403
Task Force on Quality Measures
9:00 –10:00 am
Room A406
Allergy/Immunology Program
Directors Luncheon Meeting
12:30 – 1:30 pm
Room A408
Immunotherapy and
Diagnostics Committee
12:30 – 1:30 pm
Room A406
ACAAI Foundation
Board of Trustees Meeting
1:30 – 2:30 pm
Room A407
Annals Editorial Board
3:00 – 5:00 pm
Room A403
Investments Committee
3:30 – 5:00 pm
Room A406
32
Communications Council
1:30 – 2:30 pm
Room A406
2015 Annual Meeting
Program Committee
12:30 – 1:30 pm
Room A403
Meet the Professor
Breakfasts Committee
12:30 – 1:30 pm
Room A403
Symposium Committee
12:30 – 1:30 pm
Room A403
Workshop Committee
12:30 – 1:30 pm
Room A403
Past Presidents’ Council
12:30 – 2:00 pm
Room A407
Professional Education Council
1:30 – 2:30 pm
Room A407
Scientific Council
1:30 – 2:30 pm
Room A403
Workshops
Admission by ticket only • All Workshops will be held at the Georgia World Congress Center
The American Board of Allergy & Immunology (ABAI) will grant MOC Part II credits to Diplomates who complete any
of these eight selected workshops and are currently enrolled in ABAI’s Maintenance of Certification (MOC) program.
Special note regarding MOC/CME eligibility for selected workshops: To be eligible for MOC Part II credit, participants
must participate in the entire workshop and complete all necessary components, including: brief Pre-/Post Surveys and
Pre-/Post Tests online as well as the Evaluation online. Additionally, a link to a follow-up Outcomes Assessment regarding
application of the selected workshops to your practice will be emailed approximately 6-8 weeks later and must also be
promptly completed and submitted to ACAAI online. For each selected MOC/CME workshop completed, ABAI will recognize the 2 AMA PRA Category 1 Credits™ earned as 2 MOC Part II credits after you submit your ACAAI certificate of credit
from the Atlanta meeting to the ABAI portal and confirmation of eligibility for MOC credit is sent by ACAAI to ABAI. ABAI
will count each completed MOC/CME workshop toward 2 of the 8 self-assessment credits needed by physicians each
year for MOC Part II.
It is imperative that participants must participate in the entire workshop and complete all necessary components, as
partial credits will not be permitted for MOC eligibility related to this MOC/CME workshop. (Faculty are not eligible
for credit related to a workshop at which they teach.)
Please be sure to register for MOC/CME workshops prior to arriving in Atlanta. Registrants will receive an email
with a link to a brief ONLINE PreSurvey and PreTest to be completed before you attend the workshop. Please
ARRIVE PRIOR to the start of an MOC/CME workshop! On-time attendance will be monitored and badges scanned
at entrance and exit.
W-4
W-6
W-10
W-12
Food Challenges in Practice
Epinephrine and Asthma Treatment for Grandpa
Severe Asthma
Competitive Swimming and Asthma: Good, Bad
or Unrelated?
W-14 Patch Me If You Can
Friday
W-1
1 2 3 6 Y
Identifying Particles in the
Air We Breathe
8:00 am – 3:00 pm
Room A316
Fee: $100 (FITs $50) Lunch on own.
Estelle Levetin, PhD and Richard W. Weber, MD, FACAAI
Upon completion of this session, participants should be able to: set up
a sampling station to collect airborne pollen and fungal spores; and
recognize and discuss the most common types of pollen and fungal
spores found in the atmosphere.
W-2
Insect Allergy Update
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Theodore A. Freeman, MD, FACAAI and
David F. Graft, MD, FACAAI
1 2 3 4 5
Room A302
W-21 Approach to Persistent Cough and Dyspnea in
Children and Adults
W-24 Walk Through the Parameters of Chronic Urticaria
W-25 Allergies in Infants and Very Young Children
(Asthma, Urticaria and Eczema in Children 5
Years and Under)
1 2 3 5 6
W-3
When Work Makes You Sick
4:00 – 6:00 pm
Room A315
Fee: $60 (FITs $25)
D. Linn Holness, MD and Karin A. Pacheco, MD
Upon completion of this session, participants should be able to:
discuss the most common manifestation of work related illnesses such
as dermatitis, asthma, etc.; and develop a clinical approach to the
assessment of workers suspected of building-related symptoms.
W-4
MOC/CME
Food Challenges
in Practice
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Sami L. Bahna, MD, DrPH, FACAAI and
Anna Nowak-Wegrzyn, MD, FACAAI
1 2 3 4 5 6 Y
Room A410
Upon completion of this session, participants should be able to
describe how to perform an oral food challenge as well as review
indications and reasons for deferment.
Upon completion of this session, participants should be able to:
recognize the most common insects that cause reaction in humans
and the reactions these insects cause; and develop an evaluation and
treatment plan as well as evaluate how to work with local emergency
departments for aftercare of patients seen.
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
33
Workshops
MOC/CME Workshops
Workshops
Admission by ticket only • All Workshops will be held at the Georgia World Congress Center
Friday
W-8
(continued)
W-5
The Affordable Care Act and
Asthma Control
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Suzanne L. Beavers, MD and
Bradley E. Chipps, MD, FACAAI
1 2 3 4 5 6
Room A404
Upon completion of this session, participants should be able to: review
asthma statistics, current definitions of asthma control, and other
parameters of asthma care; and discuss Affordable Care Act health care
delivery models, high value, coordinated care networks and ABMS
initiated referral strategies.
Supported by an independent educational grant from
AstraZeneca
W-6
MOC/CME
Epinephrine and
Asthma Treatment for Grandpa
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Phillip L. Lieberman, MD, FACAAI and
Raymond G. Slavin, MD, FACAAI
1 2 3 4 5 6 Y
Room A405
Upon completion of this session, participants should be able to treat
anaphylaxis in the elderly.
Saturday
W-7
1 2 3 4 5 6
Rhinitis: Novel Approaches to
Diagnosis and Treatment:
An ENT and Allergist’s Perspective
3:30 – 5:30 pm
Room A404
Fee: $60 (FITs $25)
Peter S. Batra, MD and Stephen R. Durham, MD
Introductory Course in
Rhinolaryngoscopy
3:30 – 5:30 pm
Fee: $60 (FITs $25)
Seong H. Cho, MD and
Jerald W. Koepke, MD, FACAAI
1 2 3 4 5 6 Y
Room A302
Upon completion of this session, participants should be able to:
discuss the surgical anatomy of the upper airway and identify normal
and abnormal anatomy, as well as disease presentations and postoperative changes found with endoscopic examination; and identify
the indications for and the use of the fiber optic rhinoscope.
W-9
5 6 Y
JCAAI 2014 Coding, Billing and
Regulations: Part 1 of 2
3:30 – 5:30 pm
Room A305
Fee: $60 (FITs $25)
Donald W. Aaronson, MD, JD, MPH, FACAAI;
Gary N. Gross, MD, FACAAI; and J. Allen Meadows, MD
Upon completion of this session, participants should be able to:
develop good coding practices to obtain fair reimbursement and
discuss components of various codes, as established by
CPT/RUC/Allergy/parameters; avoid audits and coding errors by coding
correctly and doing what is right; and discuss changes in
reimbursement, coding and regulatory information for allergists.
MOC/CME 1 2 3 Y
W-10 Severe Asthma
3:30 – 5:30 pm
Room A410
Fee: $60 (FITs $25)
Leonard B. Bacharier, MD, FACAAI and
David M. Lang, MD, FACAAI
Upon completion of this session, participants should be able to:
describe how severe asthmatics are uniquely different and review the
evaluation/assessment of these patients, comparing pediatric and
adult; and develop a treatment plan for patients with severe asthma.
Supported by an independent educational grant from
AstraZeneca
Upon completion of this session, participants should be able to:
describe newer novel options in rhinitis diagnosis and management in
the office setting; and discuss other adjunctive methods for diagnosis
of rhinitis as well as studies that have shown promise for effective and
safe evidence-based treatment for this common condition.
1
34
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Workshops
Admission by ticket only • All Workshops will be held at the Georgia World Congress Center
W-11
(continued)
Problem-Based Learning:
An Interactive Case Discussion of a
Child With Recurrent Infections
3:30 – 5:30 pm
Fee: $60 (FITs $25)
Ray S. Davis, MD, MS, FACAAI and
Michael R. Nelson, MD, PhD, FACAAI
1 2 3 5 Y
Room A312
Upon completion of this session, participants should be able to:
properly identify patients who may be immunodeficient and require a
thorough immunological evaluation; discuss old and new forms of
immunodeficiency, appropriate testing and the interpretation of the
tests; and proficiently manage immunodeficient patients and refer
them to tertiary care centers, as needed.
W-12
MOC/CME 1 2 3
Competitive Swimming
and Asthma: Good, Bad or Unrelated?
3:30 – 5:30 pm
Room A315
Fee: $60 (FITs $25)
Charles J. Siegel, MD, FACAAI and
Stephen A. Tilles, MD, FACAAI
Upon completion of this session, participants should be able to:
compare the reasons for shortness of air in an athlete and judge the
value of pulmonary function testing in an athlete with this condition;
and explain the reasoning for natatorium induced respiratory
pathology in swimmers.
1 2 3 4 5 6
W-13 Food Allergies: What’s New?
3:30 – 5:30 pm
Rooms A313-314
Fee: $60 (FITs $25)
Alessandro Fiocchi, MD, FACAAI (SC) and
Robert A. Wood, MD
Upon completion of this session, participants should be able to:
diagnose the correct type of food allergy based on symptoms and
utilize diagnostic modalities, including the most recent IgE tests; and
apply knowledge of the natural history of food allergy to the
management of patients and advise patients regarding the utilization
of food allergen labeling.
W-14 Patch Me If You Can!
3:30 – 5:30 pm
Fee: $60 (FITs $25)
David I. Bernstein, MD, FACAAI and
Luz S. Fonacier, MD, FACAAI
MOC/CME
1 2 6
Room A405
Upon completion of this session, participants should be able to:
identify potential causes of allergic contact dermatitis based on clinical
history and location, determine indications for patch testing and
interpret patch test results; and recognize important contact allergens
in cosmetics, metals and other items and utilize appropriate patch
testing to these allergens.
W-15
1 2 3 4 5 6
Problem-Based Learning:
An Interactive Case Discussion of a
Young Adult with Difficulty Swallowing
3:30 – 5:30 pm
Room A311
Fee: $60 (FITs $25)
Mirna Chehade, MD and Mark Holbreich, MD, FACAAI
Upon completion of this session, participants should be able to:
discuss the differential diagnosis of eosinophils present in the
esophagus on biopsy; and initiate the appropriate allergy evaluation
for eosinophilic esophagitis, along with the appropriate medical and
dietary treatment for eosinophilic esophagitis.
Sunday
W-16
1 2 3 4 5
Hands-On Session
in Rhinolaryngoscopy
6:30 – 8:30 am
Room A316
SOLD OUT
Fee: $100 (FITs $50) Includes Continental Breakfast
Seong H. Cho, MD;
Jerald W. Koepke, MD, FACAAI;
Kevin R. Murphy, MD, FACAAI (SC);
Donald W. Pulver, MD, FACAAI;
Nathan Segall, MD, FACAAI and
C. Ross Westley, MD, FACAAI
Upon completion of this session, participants should be able to:
describe the major anatomical structures of the nasal, pharyngeal and
glottic areas as visualized during examination with the fiber-optic
rhinolaryngoscope; describe variations of normal seen when
participants examine one another in this hands-on session; and
demonstrate the proper handling and initial skills needed to perform a
comprehensive upper airway examination with a fiberoptic
endoscope.
This activity is supported by BR Surgical, LLC
through an independent educational grant
consisting of loaned durable equipment.
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
35
Workshops
Saturday
Workshops
Admission by ticket only • All Workshops will be held at the Georgia World Congress Center
Sunday
W-21
(continued)
W-17
1 2 3 4 5 6
Technology (Tablets/Gadgets
and Apps): An Integral Part of
Patient Care
8:00 – 9:45 am
Room A315
Fee: $60 (FITs $25)
Tao T. Le, MD, MHS, FACAAI and David R. Stukus, MD
Upon completion of this session, participants should be able to:
increase their utilization of new forms of technology; and recognize
the important aspects of mobile health applications and social media.
W-18
JCAAI 2014 Coding, Billing and
Regulations: Part 2 of 2
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Donald W. Aaronson, MD, JD, MPH, FACAAI;
Gary N. Gross, MD, FACAAI; and
J. Allen Meadows, MD, FACAAI
5 6
Room A302
Climate Change, the Indoor
Environment and Health
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Ginger L. Chew, ScD and
Stanley M. Fineman, MD, MBA, FACAAI
1 2
Room A305
Upon completion of this session, participants should be able to answer
questions about the effects of climate change on allergic diseases.
1 2 3
W-20 Food Allergy Prevention and Treatment
4:00 – 6:00 pm
Room A311
Fee: $60 (FITs $25)
Amal H. Assa’ad, MD, FACAAI and Ruby U. Pawankar, MD
Upon completion of this session, participants should be able to: utilize
current guidelines for the prevention of food allergy; and utilize
therapeutic strategies under investigation for food allergy.
1
36
2
3
4
5
6
Upon completion of this session, participants should be able to:
evaluate the patient with chronic cough and describe the differences
between a pediatric and an adult patient in this workup; and develop a
treatment plan for the cough.
W-22
Laboratory Evaluation of the
Immune System
4:00 – 6:00 pm
Fee: $60 (FITs $25)
Joseph A. Bellanti, MD, FACAAI and
Rohit K. Katial, MD, FACAAI
1 2 3 4 5
Room A315
Upon completion of this session, participants should be able to:
properly identify patients who require a thorough immunological
evaluation; and describe appropriate testing and interpretation and
where to access more sophisticated testing.
Upon completion of this session, participants should be able to discuss
changes in reimbursement, coding and regulatory information for
allergists.
W-19
MOC/CME 1 2 3
Approach to Persistent
Cough and Dyspnea in Children and Adults
4:00 – 6:00 pm
Room A312
Fee: $60 (FITs $25)
Alan B. Goldsobel, MD, FACAAI and Pramod S. Kelkar, MD
See page 24 for ACGME Competencies. •
1 2 3 4 5 6 Y
W-23 Atopic Dermatitis In-Depth
4:00 – 6:00 pm
Room A316
Fee: $60 (FITs $25)
Mark Boguniewicz, MD, FACAAI and Peter A. Lio, MD
Upon completion of this session, participants should be able to:
discuss indications for and limitations of allergy testing in children
with atopic dermatitis, especially as related to foods; and identify
common pitfalls in the treatment of eczema and describe the rationale
for an extended therapeutic ladder for patients refractory to standard
treatments.
W-24
MOC/CME 1 2 3 6
Walk Through the
Parameters of Chronic Urticaria
4:00 – 6:00 pm
Room A404
Fee: $60 (FITs $25)
Timothy J. Craig, DO, FACAAI and
Stephen C. Dreskin, MD, FACAAI
Upon completion of this session, participants should be able to:
discuss the differential diagnosis of angioedema without urticaria and
the evaluation of patients with urticaria and angioedema; and describe
the side effects of immunomodulatory agents as well as the new
therapeutic modalities for refractory chronic idiopathic/spontaneous
urticaria and angioedema.
Y
Sessions that may be of interest to young physicians.
Workshops
Admission by ticket only • All Workshops will be held at the Georgia World Congress Center
Monday
(continued)
W-25
W-27
Upon completion of this session, participants should be able to:
discuss new and current recommendations for diagnosis and
management of childhood asthma; and apply new and current
diagnostic and therapeutic options in respiratory allergies and other
conditions in pediatric patients.
Upon completion of this session, participants should be able to:
demonstrate the technique of performing a punch biopsy, list
materials needed, identify indications for, and ideal areas to effectively
biopsy a patient presenting with an undiagnosed pruritic skin disorder;
and obtain informed consent, discuss possible complications,
document punch biopsy procedures in medical chart, and allow punch
biopsies to be sent to a dermatopathologist for interpretation.
MOC/CME 1 2 3 4 5 6 Y
Allergies in Infants
and Very Young Children (Asthma, Urticaria and
Eczema in Children 5 Years and Under)
4:00 – 6:00 pm
Room A405
Fee: $60 (FITs $25)
Chitra Dinakar, MD, FACAAI and
Todd A. Mahr, MD, FACAAI
W-26
1 2 3 4 5 6
The Science Behind an
Integrative Approach: Herbs,
Acupuncture, Yoga and More
4:00 – 6:00 pm
Rooms A313-314
Fee: $60 (FITs $25)
William S. Silvers, MD, FACAAI and Julie Wang, MD
Upon completion of this session, participants should be able to:
explain evidence basis for Integrative/CAM modalities in the areas of
nutrition, exercise, stress reduction, supplements, and manipulation;
discuss Integrative/CAM modalities, in concert with traditional
environmental and pharmacologic recommendations, and address
effects, adverse effects, and CAM-drug interactions; and discuss the
immunodeficiency effects of Chinese herbal medicine for asthma and
food allergy.
1 2 3 5
Hands-On Skin Biopsy and Patch
Testing: Procedure and Interpretation
8:00 – 9:45 am
Room A315
Fee: $100 (FITs $50)
Marcella R. Aquino, MD, FACAAI and
David R. Weldon, MD, FACAAI
W-28 Diagnostic Approach to Eczemas 1 2 3 4 5 6
1:00 – 3:00 pm
Room A404
Fee: $60 (FITs $25)
Mark Boguniewicz, MD, FACAAI and Peter A. Lio, MD
Upon completion of this session, participants should be able to:
implement an approach to a patient with skin disease, utilize patch
testing and skin biopsy, and categorize the different morphologies of
skin lesions; and prescribe appropriate topical and systemic therapies
for common dermatologic diseases as well as discuss challenging
cases and identify different approaches to disease work-up.
1 2 3 6 Y
W-29 Drug Allergies and Eruptions
1:00 – 3:00 pm
Room A311
Fee: $60 (FITs $25)
Aleena Banerji, MD and David A. Khan, MD, FACAAI
Upon completion of this session, participants should be able to:
recognize clinical features of various drug hypersensitivity syndromes
and develop a systematic approach to evaluating patients with
multiple antibiotic allergies; and develop a rational approach to
graded dose challenges and induction of drug tolerance procedures.
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
37
Workshops
Sunday
Workshops
Admission by ticket only • All Workshops will be held at the Georgia World Congress Center
Monday
W-30
W-32
(continued)
EMRs: Digitizing Your Practice
for the Long Haul
1:00 – 3:00 pm
Fee: $60 (FITs $25)
A. Sean McKnight, MD, FACAAI and
David J. Shulan, MD, FACAAI
3 6
Room A315
Upon completion of this session, participants should be able to:
discuss the process for evaluating and selecting an EMR; identify
resources for implementing an EMR; and 3) explain strategies for long
term EMR optimization.
1 2 3 5 6
Immunotherapy in 2014:
The Nuts and Bolts of SCIT and
SLIT (Includes IT Prescription Writing)
1:00 – 3:00 pm
Room A302
Fee: $60 (FITs $25)
Bryan L. Martin, DO, FACAAI and
John J. Oppenheimer, MD, FACAAI
Upon completion of this session, participants should be able to:
explain the differences between standardized and non-standardized
extracts and compose a therapeutic mix for immunotherapy; and write
a prescription for immunotherapy that contains effective doses of each
component and use current guidelines to improve the safety and
effectiveness of immunotherapy in the office.
W-33
1 2 3 4 5 6
Office Examination and
Treatment for Tinnitus and Vertigo
1:00 – 3:00 pm
Room A312
Fee: $60 (FITs $25)
Richard K. Gurgel, MD and Robert M. Naclerio, MD
1 2 3 4 5 6
What Have We Learned
About Asthma Using National
Asthma Surveillance Data?
1:00 – 3:00 pm
Room A405
Fee: $60 (FITs $25)
Cathy Bailey, MS and Hatice Zahran, MD, MPH
Upon completion of this session, participants should be able to:
discuss the pathophysiology of balance disorders and tinnitus; and
determine the appropriate evaluation and initiate effective treatment
strategies for patients with these conditions.
Upon completion of this session, participants should be able to:
discuss the value of the National Asthma Surveillance Data; and
recognize the federal efforts to address asthma and how this
information may apply to practice.
W-31
1
38
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Thursday Conference
Rooms A411-412 • Georgia World Congress Center
Separate Registration Fee • Admission by Ticket Only
D-Day for Skin Deep Allergies
Upon completion of this session, participants should be able to: recognize the manifestations and differential diagnosis of eczema and pruritus,
including drug eruptions, mycosis fungoides, and immunodeficiency; discuss use of a practical approach for the diagnosis and treatment of
difficult to control atopic dermatitis (AD), including topical corticosteroid, calcineurin inhibitors, supportive care such as wet wraps, bleach baths,
proactive treatment and Vitamin D; discuss some highlights of the new parameters in urticaria and compare the European and US published
guidelines; and discuss diagnosis and management of mucous membrane disorders in the allergy practice, such as apthous ulcers, herpes simplex,
the burning mouth syndrome, lichenoid contact dermatitis and stomatitis, oral lichen planus, geographic tongue, dry mouth, dental metal allergy
and oral involvement in immune mediated mucosal lesions (bullous pemphigoid, pemphigus vulgaris, Bechets).
Moderator: Luz S. Fonacier, MD, FACAAI
Registration
8:00 am
Welcome and Introductions
Luz S. Fonacier, MD, FACAAI
8:10 am
Itching for a Reason: Eczema
and Pruritus – When It Is Not
Atopic Dermatitis
Lisa A. Beck, MD
8:50 am
Difficult Atopic Dermatitis: When
Corticosteroids Are Not Enough
Mark Boguniewicz, MD, FACAAI
9:35 am
1 2 3 4 5 6
1 2 3 4 5
10:05 am
Urticaria Guidelines: European
and American – Comparing,
Consensus and Controversies
David A. Khan, MD, FACAAI
10:50 am
Mucocutaneous Immunity
and Disease
Alison Bruce, MD
11:35 am
Questions and Discussion
Noon
Lunch (on own – concessions open on Level Four)
1 2 3 4
1 2 3
Refreshment Break (A411-412 Foyer)
Patch Testing
Upon completion of this session, participants should be able to: discuss the pathophysiology of allergic contact dermatitis and the use of patch
testing in an allergists’ office; discuss the diagnosis and differential diagnosis of contact dermatitis and other highlights of the parameters on
contact dermatitis; discuss the most common (clinically relevant) fragrance and preservative allergens in cosmetic products, common metal
allergens and implant considerations as well as steroid allergy; and describe patch test application methods, patch test reading and interpretation
as well as patient counseling and management tools.
Supported in part by an independent educational grant from SmartPractice
Moderator: Marcella R. Aquino, MD, FACAAI
1:00 pm
Welcome and Introductions
Marcella R. Aquino, MD, FACAAI
1:05 pm
Patch Test: An Allergist’s Tool
Sharon D. Jacob, MD
1:50 pm
1
Common Allergen Review: Metals,
Fragrances, Preservatives, Steroids
Joseph F. Fowler, Jr., MD
3:50 pm
The Patch Test: Patient Presentation
Matthew J. Zirwas, MD
4:35 pm
Questions and Discussion
5:00 pm
Adjourn
1 2 3 4 5 6
Highlights From the Parameters
on Contact Dermatitis
Luz S. Fonacier, MD, FACAAI
2:35 pm
3:05 pm
1 2 3
1 2 3 6
1 2
Refreshment Break (A411-412 Foyer)
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
39
Thursday Conference
7:00 am
Friday Annual Literature Review
Rooms A411-412 • Georgia World Congress Center
Everything You Should Have Read Last Year, But Didn’t!
Separate Registration Fee • Admission by Ticket Only
Upon completion of this session, participants should be able to: 1) discuss recent developments in basic immunology and genetics in relation to
allergic disorders; 2) recognize the present role for prebiotic and probiotic supplementation in the prevention of allergic disease, identify the
relationship between post-vaccination antibody titer and protection against disease, the role of herd immunity post-vaccination in protecting
against specific infectious disease, as well the opportunity for selected use of vaccination in certain immunodeficiencies, identify the role for co-viral
and bacterial infection in asthma exacerbation, and recognize the relationship between reported drug allergy status, health care utilization, and rates
of serious infection; and identify potential protective association between H. pylori infection in infancy and development of allergic disease;
3) specifically name the types of organisms and spectrum of infections associated with gain of function mutations in STAT1; 4) better diagnose and
manage asthma and COPD; 5) discuss important scientific and clinical advances in the pathophysiology and treatment of urticaria, angioedema, and
atopic dermatitis; 6) apply practical lessons learned from recent literature in pediatric allergy, asthma and immunology; 7) identify new concepts in
anaphylaxis, insect and drug allergy and utilize clinically relevant findings in these areas; 8) discuss the changes in types of CD-4 T cells and their
cytokines that follow successful injection immunotherapy; 9) describe current diagnostic and treatment options in patients with food allergy;
10) better counsel patients on environmental factors that may impact respiratory and allergic disease, and to better recognize, diagnose and manage
occupational allergic diseases; 11) identify a rhinitis patient with local allergic rhinitis, asymptomatic lower airway involvement and/or in whom the
risk of driving is lessened; and 12) apply practical lessons learned from recent literature in allergic diseases and asthma.
Supported in part by an independent educational grant from Mylan Specialty L.P.
Chair: Mark T. O’Hollaren, MD, FACAAI
Part I – Morning Session
Part II – Afternoon Session
Moderator: James T. Li, MD, PhD, FACAAI
Moderator: Mark T. O’Hollaren, MD, FACAAI
7:30 am
Basic Immunology and Genetics
for the Allergist
David A. Khan, MD, FACAAI
1 2 3 Y
8:00 am
Update on Infectious Diseases,
Antimicrobials, and Vaccines
Matthew Greenhawt, MD, MBA, MSc
1 2 3 Y
8:30 am
Update in Clinical Immunology
John M. Routes, MD, FACAAI
1 2 Y
9:00 am
Asthma and Lower Respiratory
Diseases
James T. Li, MD, FACAAI
1 2 Y
9:30 am
Refreshment Break (A411-412 Foyer)
9:45 am
Update on Skin Diseases:
Urticaria, Angioedema and
Other Skin Disorders
Marc A. Riedl, MD, MS
1 2 3 5 Y
10:15 am
Update in Pediatric Allergy
John M. Kelso, MD, FACAAI
1 2 5 Y
10:45 am
Anaphylaxis, Drug Allergy and
Stinging Insect Hypersensitivity
Anthony Montanaro, MD, FACAAI
11:15 am
Questions and Discussion
11:30 am
Lunch (on own)
1
40
2
3
4
5
6
12:30 pm
Immunotherapy
Harold S. Nelson, MD, FACAAI
1:00 pm
Food and Additives Allergy
Vivian Hernandez-Trujillo, MD, FACAAI
1:30 pm
Occupational and
Environmental Allergy
Mark S. Dykewicz, MD, FACAAI
2:00 pm
Refreshment Break (A411-412 Foyer)
2:15 pm
Rhinitis and Sinusitis
Richard A. Nicklas, MD, FACAAI
2:45 pm
The Ten Best Articles in the Specialty
of Allergy
Mark T. O’Hollaren, MD, FACAAI
3:15 pm
Questions and Discussion
3:30 pm
Adjourn
1 2 3 Y
1 2 Y
1 2 3 Y
1 2 3 4 5 6 Y
1 2 Y
1 2 3 6 Y
See page 24 for ACGME Competencies. •
3:00 – 6:00 pm
Visit Exhibits
Y
Sessions that may be of interest to young physicians.
Friday Symposia
Breakfast Symposium • Hall A-2 • Georgia World Congress Center
Turbinates to Terminal Bronchioles: The One Airway
Concept and Advances in the Treatment of Asthmatics
Upon completion of this session, participants should be able to: compare and contrast the effects of allergic and non-allergic rhinitis on the
asthmatic patient; describe the guideline-based treatment for allergic and non-allergic rhinitis and its potential affect on the asthmatic patient; and
discuss the independent contribution of the small airways to asthmatic symptoms.
Supported by an independent educational grant from Meda Pharmaceuticals Inc.
Moderator: Warner W. Carr, MD, FACAAI
8:30 am
Welcome and Introductions
Warner W. Carr, MD, FACAAI
8:35 am
Allergy and Adult Asthma
Timothy J. Craig, DO, FACAAI
9:05 am
9:35 am
1
The Importance of the
Small Airway in Asthma
Kevin R. Murphy, MD, FACAAI (SC)
10:05 am
Questions and Discussion
10:30 am
Adjourn
1 2 3 6
Non-Allergic Rhinitis and Asthma
Jonathan A. Bernstein, MD, FACAAI
1 2 3 4 5
2 3 4 5 6
Luncheon Symposium • Hall A-2 • Georgia World Congress Center
Hereditary Angioedema: Clinical Case Challenge
Upon completion of this sessions, participants should be able to: implement strategies for the efficient and accurate diagnosis of hereditary
angioedema (HAE); identify the enzymatic pathways involved in HAE and describe the mechanisms that underlie effective treatment options;
identify evidence-based strategies for the acute treatment of HAE; and implement strategies to initiate prophylactic treatment plans for patients
with HAE who are appropriate candidates.
Supported by an independent educational grant from Shire
Moderator: Richard G. Gower, MD, FACAAI
Welcome and Introductions
Richard G. Gower, MD, FACAAI
11:35 am
Overview of Hereditary
Angioedema
Aleena Banerji, MD
Noon
1
Management of Pediatric
Hereditary Angioedema
Richard G. Gower, MD, FACAAI
2
3
4
5
6
12:25 pm
Management of Adult
Hereditary Angioedema
Marc A. Riedl, MD
12:50 pm
Questions and Panel Discussion
1:30 pm
Adjourn
1 2 3 6
1 2 3 5 6
Friday
11:30 am
1 2 3 5 6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
41
Friday Symposia
Sidney Marcus Auditorium • Georgia World Congress Center
Asthma and COPD: What Is the Difference?
Upon completion of this session, participants should be able to: compare and contrast the distinct and shared immunologic and physiologic
characteristics that define asthma and COPD; define the appropriate diagnostic tests to characterize patients and predict response to therapy; and
define the therapeutic options that may be applied to both diseases.
Moderator: Bradley E. Chipps, MD, FACAAI
1:45 pm
Welcome and Introductions
Bradley E. Chipps, MD, FACAAI
1:50 pm
1 2 3 4 5
Immunologic and Physiologic
Assessment of Chronic Airway Obstruction
Reynold A. Panettieri, MD
2:20 pm
2:50 pm
Pharmacologic Interventions
Shared With Asthma and COPD
Stephen P. Peters, MD
3:20 pm
Questions and Discussion
3:45 pm
Adjourn
6
1 2 3 4 6
Diagnostic Tests That Help
Define Response to Therapy
Donald P. Tashkin, MD
3:00 – 6:00 pm
Visit Exhibits
3:30 – 4:30 pm
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
Take Your Meeting Mobile
Target what you want to attend, learn and do at the ACAAI Annual
Meeting with the ACAAI mobile app – the app is free and the options
are endless!
View all the annual meeting info right at your fingertips:
 Schedule of events
 Exhibitor list and details
 Speakers, sponsors and more
Download the free app today and
maximize your time at the meeting.
To download the app:
 Go to annualmeeting/acaai.org
 Or, plug acaai.org/apps into your mobile device’s
browser. This link automatically detects your device
type and takes you to the right place.
 Or, snap the QR Code
Supported by Teva Respiratory
1
42
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Town Hall Meeting
4:00 – 6:30 pm
Rooms A313-314 • Georgia World Congress Center
NOT FOR
CREDIT
Town Hall Meeting
All Meeting Attendees are Welcome!
Refreshments to be Served: Beer, Wine & Cheese
The Town Hall Meeting, brought to you by the ACAAI House of Delegates, has been redesigned with you in
mind. It will begin with an informal networking session, giving you the opportunity to discuss issues with
colleagues, Delegates and the ACAAI leadership followed by the HOD Business Meeting and important information on state compounding and socioeconomic issues impacting the allergist.
4:15 pm
Important Communication
• Welcome and Call to Order
• Update from the JCAAI
J. Allen Meadows, MD, FACAAI
JCAAI President
Kathleen R. May, MD, FACAAI
Speaker, House of Delegates
• Affordable Care Act Impact on
the Allergist
J. Allen Meadows, MD, FACAAI
Michael B. Foggs, MD, FACAAI
ACAAI President
James L. Sublett, MD, FACAAI
ACAAI President-Elect
• State Compounding Legislation:
Overview & Update
Kathleen R. May, MD, FACAAI
• Business Meeting
Approve 2013 HOD Minutes
• ACAAI Support for the
Practicing Allergist
James L. Sublett, MD, FACAAI
ACAAI President-Elect
Quorum Call
Election of Officers &
Super-delegates/By Acclamation
Resolutions
6:30 pm
Adjourn
Friday
Meeting Agenda
43
Friday Program
Annual Meeting and Dinner Symposium • 6:00 – 9:30 pm
Grand Ballroom Salons ABC (Level M4 – North Tower) • Omni Hotel
American Association of Allergists and
Immunologists of Indian Origin (AAAII)
NOT FOR
CREDIT
Learning Objectives: Upon completion of this session, participants should be able to: identify patients appropriate for
drug allergy skin testing; identify patients appropriate for drug challenges and desensitizations; recognize the severe
asthmatic and describe the unique phenotypes; explain that “control” of symptoms is not the endpoint of therapy; and
implement new forms of adult education to the MOC and CME process.
Moderator: Mauli Desai, MD, President, AAAII
6:00 pm
Drug Allergy: Separating the Wheat
from the Chaff
David A. Khan, MD, FACAAI
9:30 pm
Adjourn
Severe Asthma: Is “Control” the Endpoint?
Bobby Q. Lanier, MD, FACAAI
*Please visit www.aaaii.org for the latest information and
for pre-registration
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai2014.conferencespot.org or snap the QR
code for a menu of online materials.
44
➧
ONLINE
MATERIALS
Saturday General Sessions
Opening Ceremony and Welcome Announcements
8:00 – 8:30 am • Sidney Marcus Auditorium • Georgia World Congress Center
Michael B. Foggs, MD, FACAAI
President
James L. Sublett, MD, FACAAI
Program Chair and President-Elect
Mrs. Margaret Quel
Alliance President
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
Unique Challenges for the
Allergist/Immunologist in COPD and Asthma
Upon completion of this session, participants should be able to: recognize the comorbidities that occur in patients with COPD and be able to
manage them; recognize that asthma, like COPD, can be an irreversible lung disease in both children and adults and be able to institute
appropriate measures to reverse this decline; and manage exacerbations in patients with both severe asthma and COPD, and assess when, and if,
such patients should be referred to another specialist for further care.
Moderators: Michael B. Foggs, MD, FACAAI and Rohit A. Katial, MD, FACAAI
8:30 am
Welcome and Introductions
Michael B. Foggs, MD, FACAAI and
Rohit A. Katial, MD, FACAAI
8:35 am
Systemic Manifestations and
Comorbidities of COPD
Reynold A. Panettieri, MD
9:05 am
1 2 3 4 5 6
9:35 am
Severe Asthma vs. COPD:
Therapeutic Dilemmas
William W. Busse, MD, FACAAI
10:05 am
Questions and Discussion
10:30 am
Adjourn
1 2 3 5 6
John P. McGovern Lecture
10:30 – 11:00 am
Saturday
1 2 3
Asthma as COPD:
Pulmonary Remodeling –
A Phenomenon of Children
and Adults
Phillip L. Lieberman, MD, FACAAI
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
45
Saturday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
The Brave New World for the
Allergist/Immunologist in Immunotherapy
Upon completion of this session, participants should be able to: describe how to use SLIT as well as rush and cluster SCIT in allergy patients; decide
where the use of SLIT oral tablets may be appropriate in the management of children and adults with allergic rhinitis; and explain how emerging
types of immunotherapy and how immunomodulatory agents in conjunction with immunotherapy may benefit the outcomes of patients needing
immunotherapy.
Moderators: Tao T. Le, MD, MHS, FACAAI and Bryan L. Martin, DO, FACAAI
11:00 am
Welcome and Introductions
Tao T. Le, MD, MHS, FACAAI and
Bryan L. Martin, DO, FACAAI
11:05 am
1
Is It Time to “Retire” Conventional
SCIT? SLIT Drops, Rush and Cluster SCIT
Harold S. Nelson, MD, FACAAI
11:30 am
SLIT Tablets: Why Should
the Allergist Embrace Their Use?
Stephen R. Durham, MD
46
2
3
4
5
6
Emerging Immunotherapy Treatments:
Will We “Cure” Allergies?
David I. Bernstein, MD, FACAAI
12:20 pm
Questions and Discussion
12:30 pm
Adjourn
1 2
1 2 3 4 5 6
12:30 – 1:30 pm
1
2 3 4
11:55 am
Visit Exhibits
Lunch on own
(Concessions Open in Exhibit Hall)
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Saturday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
The Great Raft Debate on the Allergy Epidemic:
A Root Cause Analysis
Upon completion of this session, participants should be able to: describe the “hygiene hypothesis” and the role of the microbiome in the increasing
incidence of allergic disease; identify the role of environmental tobacco smoke, indoor allergens, and air pollution as causative factors in the
increasing incidence of allergic disease; apply to patient care the understanding that human behavior (obesity, lack of exercise, and diet) is an
important contributing factor in the increasing incidence of allergic disease; critique the role of climate change in both triggering and causing
progression of allergic disorders; and evaluate the risk/benefit of the use of acetaminophen and other drugs in children or adults as related to the
development of asthma and/or allergic disorders.
Moderators: William K. Dolen, MD, FACAAI and Maeve E. O’Connor, MD, FACAAI
1:30 pm
Welcome and Introductions
William K. Dolen, MD, FACAAI and
Maeve E. O’Connor, MD, FACAAI
Climate Change
Jay M. Portnoy, MD, FACAAI
Hygiene Hypothesis and the Microbiome
Dennis R. Ownby, MD, FACAAI
Acetaminophen
Stanley J. Szefler, MD, FACAAI
2
Smoking, Air Pollution, Indoor Triggers
David B. Peden, MD, FACAAI
2
2:45 pm
Questions and Discussion
3:00 pm
Adjourn
Human Behavior: Obesity, Lack of
Exercise, Diet
Thomas A.E. Platts-Mills, MD, PhD, FACAAI
3:00 – 3:30 pm
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
Poster Session (Hall A-1)
Saturday
3:30 – 4:30 pm
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
47
Saturday General Sessions
Symposium • Sidney Marcus Auditorium • Georgia World Congress Center
Optimizing Immunoglobulin Replacement Therapy
Upon completion of this session, participants should be able to: provide appropriate monitoring for patients on immunoglobulin replacement
therapy; recognize and manage side effects and adverse events to immunoglobulin replacement therapy; and discuss risks and benefits of the
various routes of administration of immunoglobulin replacement therapy.
Supported by an independent educational grant from Baxter Healthcare Corporation
Moderator: Richard L. Wasserman, MD, PhD, FACAAI
3:30 pm
Welcome and Introductions
Richard L. Wasserman, MD, PhD, FACAAI
4:35 pm
3:35 pm
Immunoglobulin Therapy:
What Is the Right Dose?
Vincent R. Bonagura, MD
Pros and Cons of Possible Routes of
Administration: IV, SC and Hy
Richard L. Wasserman, MD, FACAAI
4:55 pm
Panel Discussion
5:05 pm
Full Faculty Panel Discussion
5:30 pm
Adjourn
3:55 pm
Panel Discussion
4:05 pm
Managing Patients With Side
Effects and Adverse Events to
Immunoglobulin Therapy
Mark R. Stein, MD, FACAAI
4:25 pm
Panel Discussion
1 2 3 5
1 2 3
1 2 3 4 5 6
The above symposium will be featured on the ACAAI website.
1
48
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Gold Headed Cane
Dr. Peter Boggs to Receive Gold Headed Cane Award
Dr.Boggs
The College is proud to honor Peter B.
Boggs, MD, FACAAI, as this year’s recipient
of the ACAAI Gold Headed Cane Award. The
Award will be presented during the ACAAI
Awards Ceremony scheduled at 7:00 pm,
Saturday, in the International Ballroom
Salons DE (Level M2 – North Tower) of the
Omni Hotel at CNN Center.
Aside from his ACAAI activities, Dr. Boggs has served as an
active faculty member of the LSUHSC-Shreveport School of
Medicine Allergy & Immunology Program, a Mentor for
Fellows-in-Training, a member of the group writing the
Guidelines for the Use of FeNO in Asthma (American
Thoracic Society), and facilitating the acquisition and
availability of EpiPens Auto-Injectors in all public schools in
Caddo and Bossier Parishes.
The ACAAI Gold Headed Cane Award is presented annually
to an allergist who has demonstrated the highest standards
of scientific excellence and integrity while serving as a Fellow
of the College for at least 20 years. It is designed to serve as
an inspiration to younger doctors and encourage them in
their family, social, civil, religious and professional lives.
Dr. Boggs received his medical degree from Louisiana
State University Medical School. He completed pediatric
training, as well as allergy and immunology training at
Baylor College of Medicine. Dr. Boggs is certified by the
American Board of Pediatrics and the American Board of
Allergy and Immunology.
A long-standing Fellow of the College, Dr. Peter Boggs
served as ACAAI president from 1986 to 1987, and has
been a Fellow for 43 years, beginning when the College
was known as The American College of Allergists.
“One of my most memorable experiences in the College
includes being a member of the small group who in the
late 1970’s, committed to creating a new shared vision for
The American College of Allergists from a small ‘good old
boys club’ to a serious professional organization,” said Dr.
Boggs. “That commitment continued and the result is The
American College of Allergy, Asthma and Immunology that
we enjoy today. Just being a part of that process and experiencing the power that shared vision can have on an
organization was truly a lesson that I shall treasure and will
never forget.”
During his presidency, Dr. Boggs developed the first Fellowin-Training Section to enable young physicians to have a
role in the activities and direction of the College, as well as
the first National Media Awards program.
The Literature Review for ABAI Certification and the Annual
Literature Review (Everything You Should Have Read Last
Year, But Didn’t) courses were created and brought to
fruition by Dr. Boggs, for which he was honored with special awards. He also received the ACAAI 1987 Distinguished
Fellow Award, Master in Allergy and was honored as a Bella
Schick lecturer.
Dr. Boggs has also served as ACAAI Program Chairman,
member of the Board of Regents, as well as chair and member of the Nominating Committee. He was also a member
of the Ethics, Planning, Recertification, and Board Review
committees.
Other special College memories Dr. Boggs shares with his
wife, Mary, are the close and lasting friendships with many
ACAAI members, who have become members of their
extended family. Dr. Boggs and his wife have two daughters and four grandchildren. They enjoy visiting their
children and grandchildren, and are involved in Bible
study groups. Dr. Boggs also enjoys shooting sporting
clays and skeet.
Gold Headed Cane Recipients
2006
Phillip L. Lieberman, MD
2007
Betty B. Wray, MD
2008
Donald W. Aaronson, MD, JD, MPH
2009
Emil J. Bardana, Jr., MD
2010
Raymond Slavin, MD
2011
Ira Finegold, MD
2012
Rufus E. Lee, Jr., MD
2013
Michael S. Blaiss, MD
2014
Peter B. Boggs, MD
Saturday
2001
Harold S. Nelson, MD
2002
Joseph A. Bellanti, MD
2003
Edward J. O’Connell, MD
2004
Elliot F. Ellis, MD
2005
John C. Selner, MD
49
Saturday Awards Ceremony &
President’s Welcome Reception
Awards Ceremony
7:00 – 7:45 pm
International Ballroom Salons DE (Level M2 – North Tower) • Omni Hotel
The College invites all registrants to the ACAAI Awards Ceremony where we will recognize our 2014 Award recipients
and formally welcome our newly-approved Fellows.
The event will begin at 7:00 pm with our new Fellows being honored for their accomplishments. We will also recognize
the recipients of the ACAAI’s Distinguished Fellow, International Distinguished Fellow, Distinguished Service, Clemens
von Pirquet, Woman in Allergy and Photography Contest awards.
Finally, we’ll introduce this year’s recipient of the College’s prestigious Gold Headed Cane Award.
I.
Welcome
Michael B. Foggs, MD, FACAAI
ACAAI President
VII.
Young Faculty Support Awards
Suellyn S. Rossman, MD, FACAAI
ACAAI Foundation President
II.
Recognition of Newly-Elected Fellows
James L. Sublett, MD, FACAAI
ACAAI President-Elect
VIII.
Clemens von Pirquet Awards
Mrs. Margaret Quel
ACAAI Alliance President
III.
Distinguished Fellow Award
Michael B. Foggs, MD, FACAAI
ACAAI President
IX.
Photography Contest Awards
Mrs. Margaret Quel
ACAAI Alliance President
IV.
International Distinguished Fellow Award
Michael B. Foggs, MD, FACAAI
ACAAI President
X.
V.
Distinguished Service Award
Michael B. Foggs, MD, FACAAI
ACAAI President
Gold Headed Cane Award
Michael B. Foggs, MD, FACAAI
ACAAI President, and
Bobby Q. Lanier, MD, FACAAI
ACAAI Executive Medical Director
VI.
Woman in Allergy Award
Michael B. Foggs, MD, FACAAI
ACAAI President
President’s Welcome Reception
7:45 – 9:00 pm
Grand Ballroom (Level M4 – North Tower) • Omni Hotel
The College invites all registrants to the ACAAI President’s Welcome Reception, which will immediately follow the Awards
Ceremony. It’s the perfect place to catch up with old friends, make new acquaintances and meet the ACAAI President,
President-Elect and the Alliance President.
50
Sunday MTP Breakfasts
Meet the Professor Breakfasts
Omni Hotel at CNN Center
7:00 – 8:15 am • Admission by ticket only • Fee $40 (FITs $20) • Limit: 30
Supported by an independent educational grant from Merck
Sunday
Upon completion of this session, participants should be able to: describe the evaluation of a patient with symptoms for severe asthma;
differentiate severe asthma from difficult-to-control asthma; define severe asthma that manifests as irreversible airway obstruction, bronchodilatorunresponsive and, in part, steroid-insensitive; summarize why novel anti-inflammatory agents and bronchodilators are necessary to meet the
therapeutic needs of patients with severe persistent asthma; discuss evidence-based data on the safety and therapeutic efficacy of sublingual
immunotherapy (SLIT); choose allergens, dosing and length of treatment based on published study data and clinical observations; properly advise
patients and parents of pediatric patients on the roles microbiomes may play in allergic disease; discuss how some environmental exposures may
alter human microbiomes; determine the diagnostic criteria for varied phenotypic expression of childhood asthma; describe predictors of response
to Step Care 2-5; examine the implication for treatment given the varied immunopathologic and phenotypic expressions; discuss the principles of
stepping up and stepping down asthma therapy to reduce asthma impairment and to minimize risk in an overall attempt to control asthma; list the
relative and absolute indications for endoscopic sinus surgery; describe the pathophysiology of sinus disease and state-of-the-art treatment of
chronic rhinosinusitis; describe several mechanisms that drive airway inflammation and do not involve Th1 or Th2 cells; describe the mechanisms
leading to Th17 driven inflammation and the impact that Th17 cells have on airway diseases such as asthma; recognize the symptoms of mast cell
activation and identify the right diagnostic tools for clonal mast cell activation disease; establish prognostic factors for mast cell activation
syndromes (MCAS) and discuss management options for MCAS; distinguish mast cell activation syndrome from non-mast cell-mediated disorders;
identify patients with a history of past adverse reaction to aspirin who warrant aspirin therapy for indications, such as primary or secondary
cardioprotection, and are likely to tolerate aspirin challenge without untoward reaction; list the minimum criteria for performing safe and
successful aspirin desensitization for AERD; discuss therapeutic options for antihistamine-resistant chronic urticaria, including the use of
omalizumab in the treatment paradigm; and discuss pathogenesis of chronic urticaria.
S1
1 2
Severe Asthma
Dogwood A (Level M1 – North Tower)
Leonard B. Bacharier, MD, FACAAI and
Reynold Panettieri, MD
3 4 5 6
S2
1 2 3 4
Practical Aspects of Sublingual
Immunotherapy: Dose/Duration/Specific
Allergens/Geographic Niches/Efficacy & Safety
Dogwood B (Level M1 – North Tower)
OUT Peter S. Creticos, MD and
SOLD
Stephen R. Durham, MD
S3
The Role of the Microbiome in
Allergic Disease
Cottonwood (Level M1 – North Tower)
Elizabeth Matsui, MD and
Dennis R. Ownby, MD, FACAAI
S4
Eosinophilic Gastrointestinal Disease
Redwood (Level M1 – North Tower)
UT Amal H. Assa’ad, MD, FACAAI and
O
SOLD
Karen A. Freedle, MD, MPH, FACAAI
S5
1
Tailoring Asthma Management:
Step-2 to Step-4
International A (Level M2 – North Tower)
Bradley E. Chipps, MD, FACAAI and
Stanley J. Szefler, MD, FACAAI
1 2 3
1 2 3
2
3
4
5
6
Rhinosinusitis
International B (Level M2 – North Tower)
Robert M. Naclerio, MD and
Talal Nsouli, MD, FACAAI
S7
Airway Inflammation Beyond
Th-1/Th-2 Mechanisms
International C (Level M2 – North Tower)
Mitchell H. Grayson, MD, FACAAI and
R. Stokes Peebles, MD, FACAAI
2 3 4 5 6
1 2 3 6
2 3
S8
1 2 3 4 5 6
S9
1 2 3 4 5 6
Mast Cell Activation Syndrome
Maple AB (Atrium Level – South Tower)
Mariana Castells, MD, PhD and
OUT
SOLD
Fred H. Hsieh, MD
Aspirin Sensitivity Syndromes
Pine (Atrium Level – South Tower)
David A. Lang, MD, FACAAI and
OUT
SOLD
Andrew A. White, MD
S10
7:30 – 8:30 am
1
5 6
S6
Novel Therapies for Chronic Urticaria
and Angioedema
Birch (Atrium Level – South Tower)
Thomas B. Casale, MD, FACAAI and
OUT
SOLD
Sheldon L. Spector, MD, FACAAI
1 2 3 4 6
Poster Session (Hall A-1)
Coffee and tea will be provided
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
51
Sunday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
Unique Challenges for the
Allergist/Immunologist in Our Aging Population
Upon completion of this session, participants should be able to: identify the unique challenges of allergy testing and immunotherapy in senior
citizens; recognize the diagnostic difficulties in differentiating COPD from asthma in the aging patient; and identify the challenges of drug therapy
in the elderly with allergy and/or asthma.
Moderators: William E. Berger, MD, MBA, FACAAI and Sandra M. Gawchik, DO, FACAAI
8:30 am
Welcome and Introductions
William E. Berger, MD, MBA, FACAAI and
Sandra M. Gawchik, DO, FACAAI
9:25 am
1
Challenges of Allergy and
Asthma Drug Therapies in Seniors
Gailen D. Marshall, MD, PhD, FACAAI
8:35 am
1 2
Allergy Testing and
Immunotherapy in the Senior Citizen
John J. Oppenheimer, MD, FACAAI
9:50 am
Questions and Discussion
10:00 am
Adjourn
9:00 am
Is It COPD or Undiagnosed
Asthma in the Aging Patient?
Stephen P. Peters, MD
3 4 5 6
2 3 4 5 6
1 2 3 4 6
10:00 – 10:30 am
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2014 Annual
Scientific Meeting. This system will allow you to complete evaluations of the certified CME sessions that you
attend which are directly provided by ACAAI. Upon
completion of the Overall Evaluation, Session Evaluations and credit claiming information you will be able to
immediately access, save and/or print your certificate.
Physicians will receive a certificate of credit and other
healthcare professionals will receive a certificate of
attendance for most sessions.
See page 22 for details.
1
52
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Sunday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
Moderator: James L. Sublett, MD, FACAAI
10:30 am
Bela Schick Lecture
Sunday
1 2 3 4 5 6
If You Don’t
Know Where You Are Going, You
May End Up Somewhere Else
Bradley E. Chipps, MD, FACAAI
Unique Challenges for the
Allergist/Immunologist in Children and Adolescents
Upon completion of this session, participants should be able to: diagnose and manage food protein-induced enterocolitis syndrome (FPIES), oral
allergy syndrome (OAS) and eosinophilic esophagitis (EoE); recognize the emerging role of probiotics in the prevention of allergy; and prescribe
appropriate therapeutic options to manage home exacerbations of asthma.
Moderators: Bradley E. Chipps, MD, FACAAI and Stanley M. Fineman, MD, MBA, FACAAI
11:00 am
Welcome and Introductions
Bradley E. Chipps, MD, FACAAI and
Stanley M. Fineman, MD, MBA, FACAAI
11:05 am
FPIES, OAS and EE: An Alphabet Soup
of Food-Related Disorders
Anna H. Nowak-Wegrzyn, MD, FACAAI
11:30 am
11:55 am
Management of Home
Exacerbations of Asthma:
Yellow Zone Interventions
Chitra Dinakar, MD, FACAAI
12:20 pm
Questions and Discussion
12:30 pm
Adjourn
1 2
1 2 3 4 5 6
Daniel Goodman Lecture
1 2 3 4 5 6
Probiotics in
Prevention of Allergy
Alessandro Fiocchi, MD, FACAAI
(SC)
12:30 – 1:30 pm
Visit Exhibits
Lunch On Own
(Concessions Open in Exhibit Hall)
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
12:30 – 3:30 pm
Doctors’ Job Fair
Hall A-1
Y
1:30 – 3:30 pm
Concurrent Sessions
(See pages 55-58)
Sessions that may be of interest to young physicians.
53
Sunday General Sessions
WAO/ACAAI International Symposium • Sidney Marcus Auditorium • Georgia World Congress Center
Emerging Approaches Related to Allergy Treatment
Upon completion of this session, participants should be able to: discuss molecular-based allergy as a new and rapidly evolving evidence available
for diagnostics; evaluate new aspects of sublingual immunotherapy (SLIT), such as the new schedules; and apply evidence-based
recommendations accurately for the management of chronic urticaria in simulated patient encounters
Moderators: Michael B. Foggs, MD, FACAAI and Lanny Rosenwasser, MD, FACAAI
1:30 pm
Welcome and Introductions
Michael B. Foggs, MD, FACAAI and
Lanny Rosenwasser, MD, FACAAI
1:35 pm
Molecular Diagnosis
Ignacio J. Ansotegui, MD
1 2 3 4 5 6
2:05 pm
Urticaria
Mario Sanchez-Borges, MD
1 2 3 4 5 6
3:30 – 4:00 pm
2:35 pm
WAO SLIT Guidelines Update
Ruby U. Pawankar, MD, PhD
3:05 pm
Questions and Discussion
3:30 pm
Adjourn
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2014 Annual
Scientific Meeting. This system will allow you to complete evaluations of the certified CME sessions that you
attend which are directly provided by ACAAI. Upon
completion of the Overall Evaluation, Session Evaluations and credit claiming information you will be able to
immediately access, save and/or print your certificate.
Physicians will receive a certificate of credit and other
healthcare professionals will receive a certificate of
attendance for most sessions.
See page 22 for details.
1
54
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Sunday Concurrent Sessions
Room A411 • Georgia World Congress Center
Upon completion of this session, participants should be able to: 1) identify different mechanisms resulting in delayed and atypical hypersensitivity
reaction to bee stings; 2) discuss the usefulness of a systematic, prospective evaluation of cow’s milk sensitization to modulate the dietary work-up
in patients with short bowel syndrome, as well, as address the need for caution when using early massive exposure to food allergens in reducing
the incidence of food allergy; 3) discuss the use of penicillin allergy skin testing in the preoperative setting to improve surgical antibiotic choice;
4) differentiate between pollen-food allergy syndrome and anaphylaxis; 5) promptly recognize FPIES and the potential for this condition to
manifest at a very early age as well as discuss how to better manage this condition from a dietary perspective; 6) examine the effects of form factor
of commercially available auto-injectors on the maximum applied force capability of adults and the effects of the device design and instruction on
force production and orientation of an auto-injector; 7) discuss the risk for developing pneumonia with chronic inhaled corticosteroid (ICS) use, as
well as, the diference in grade and confidence between randomized controlled trials (RCTs) and observational studies; and 8) illustrate the efficacy
of recombinant human C1 INH in treating severe swelling attacks of hereditary angioedema (HAE).
Moderators: Karen A. Freedle, MD, FACAAI and Joseph S. Yusin, MD, FACAAI
1:30 pm
1 – Atypical Presentation of Honey Bee Sting
Hypersensitivity
S. Melethil*, S. Ho, R.S. Mehta, Galveston, TX.
1:45 pm
2 – Cow’s Milk Allergy in Short Bowel
Syndrome
A. Diamanti, A. Fiocchi, L. Dahdah*, O. Mazzina,
F. Bellucci, T. Capriati, Rome, Holy See (Vatican
City State).
2:00 pm
3 – Improving Surgical Antibiotic Options With
Penicillin Allergy Testing
T. Pongdee, A. Thethi*, E. Rodrigues, J. Irizarry
Alvardo, Jacksonville, FL.
2:15 pm
4 – A Case of Near Fatal Anaphylaxis to Orange
in a Toddler
S.B. Sindher*, S.P. DaVeiga, Philadelphia, PA.
2:30 pm
5 – Food Protein-Induced Enterocolitis
Syndrome of Difficult Management
A. Fiocchi*1, L. Dahdah2, O. Mazzina1, S. Corrente2,
C. Riccardi1, S. Salvatore3, 1. Rome, Holy See
(Vatican City State); 2. Rome, Italy; 3. Varese, Italy.
3:30 – 4:00 pm
2:45 pm
6 – Effect of Device and Form Factor on Autoinjector Application Force and Efficiency
A. Barbir*1, M. Janelli1, M. Lin1, R.A. Wolf2,
J. Dennerlein1, 1. Boston, MA; 2. Plantation, FL.
3:00 pm
7 – Inhaled Corticosteroids and Incident
Pneumonia in Patients With Asthma: Systematic Review and Meta-Analysis
V. Bansal, M. Mangi*, E. Festic, Jacksonville, FL.
3:15 pm
8 – Efficacy of Recombinant Human C1
Inhibitor for the Treatment of Hereditary
Angioedema Patients With Severe Attacks
H. Li*1, A. Reshef2, H. Farkas3, J. Baker4,
G. Porebski5, D. McNeil6, A. Relan7, A. Zanichelli8,
1. Chevy Chase, MD; 2. Tel Hashomer, Israel;
3. Budapest, Hungary; 4. Lake Oswego, OR;
5. Krakow, Poland; 6. Columbus, OH; 7. Leiden,
Netherlands; 8. Milan, Italy.
3:30 pm
Adjourn
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
55
Sunday
Session A – Adverse Food and Drug Reactions,
Insect Reactions, Anaphylaxis, Food Allergy,
and Pharmacology/Pharmacotherapeutics
Sunday Concurrent Sessions
Room A412 • Georgia World Congress Center
Session B – Aerobiology, Allergens, Allergen
Extracts and Immunotherapy, Immunizations
Upon completion of this session, participants should be able to: 9) discuss the difficulty of predicting pollen levels; 10) determine the allergenicity
of cyanobacteria in chronic rhinitis patients as well as describe the effect of cyanotoxins on cyanobacteria allergenicity; 11) identify common
fungal spores seen indoors as well as outdoors and identify areas in the home at risk for fungal growth; 12) discuss how climate change induced
warming impacts ragweed pollination in Ukraine; 13) discuss the role of tryptase an an adjunctive marker in anaphylaxis and the differences in
systemic reactions after SCIT; 14) discuss potential benefits of SLIT-T in patients over the age of 50; 15) discuss the duration and time of recurrence
for local allergic reactions associated with SLIT-T; and 16) describe the features of "Conventional" JTF-recommended immunotherapy and discuss
the expected treatment outcomes for compliant patients.
Moderators: Leonard Bielory, MD, FACAAI and Janna M. Tuck, MD, FACAAI
1:30 pm
9 – The Predicted Tree Pollen Burst of 2014 Was
a “Bust”
J.J. Anderson*, P. Pityn, London, ON, Canada.
1:45 pm
10 – The Allergenicity of the Cyanobacteria
Specie Microcystis Aeruginosa Is Dependent on
Its Microcystin Production
E. Geh, D. Ghosh, J.A. Bernstein*, Cincinnati, OH.
2:00 pm
11 – Comparison of Outdoor and Indoor
Fungal Spore Count in Kansas City
D.A. Jara*, C.S. Barnes, J. Portnoy, M. Dhar, Kansas
City, MO.
2:15 pm
12 – Climate Change Induced Warming Impacts
Ragweed Pollination in Ukraine
V. Rodinkova1, A. Prikhodko2, A. Maleeva2,
O. Palamarchuk1, I. Motruk1, L. Kremenska1,
K. Musatova1, L.M. DuBuske*3, 1. Vinnitsa, Ukraine;
2. Zaporizhzhia, Ukraine; 3. Gardner, MA.
2:30 pm
13 – The Evaluation of Serum Tryptase Levels
After Subcutaneous Immunotherapyassociated Systemic Reactions
P.H. Wong*1, H.C. Crisp2, T.S. Rans3, 1. San Antonio,
TX; 2. Andrews AFB, MD; 3. Lackland AFB, TX.
3:30 – 4:00 pm
2:45 pm
14 – Efficacy, Immunologic Response, and
Safety of Rapidly-dissolving Sublingual
Immunotherapy Tablets in Subjects Over 50
Years of Age With Allergic Rhinitis
P. Creticos*1, D.I. Bernstein2, R. Weber3, N.J. Amar4,
Z. Li5, A. Kaur5, J. Maloney5, H. Nolte5,
1. Baltimore, MD; 2. Cincinnati, OH; 3. Denver, CO;
4. Waco, TX; 5. Whitehouse Station, NJ.
3:00 pm
15 – Occurrence and Duration of Local Allergic
Reactions is Similar for Ragweed, Grass, and
House Dust Mite Sublingual Immunotherapy
Tablets and Consistent With an Immediate IgEMediated Reaction
H.S. Nelson*1, J. Maloney2, M.A. Calderon3,
J.A. Bardelas4, A. Kaur2, H. Nolte2, 1. Denver, CO;
2. Whitehouse Station, NJ; 3. London, United
Kingdom; 4. High Point, NC.
3:15 pm
16 – JTF Practice Parameter-Compliant
Subcutaneous Immunotherapy for Allergic
Rhinitis Due to Mountain Cedar Induces Skin
Test Anergy and Long-Term Clinical Remissions
M.P. Vaughn*, San Antonio, TX.
3:30 pm
Adjourn
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
56
Sunday Concurrent Sessions
Rooms A313-314 • Georgia World Congress Center
Upon completion of this session, participants should be able to: 17) critically appraise the educational quality of information regarding asthma on a
popular internet site; 18) identify the impact of dose adjustment due to conservative management of local reactions during administration of
aeroallergen immunotherapy; 19) discuss which administrative asthma quality measures best associate with asthma outcomes; 20) discuss whether
or not allergy immunotherapy rush treatment impacts adherence; 21) recognize that there are numerous factors, in addition to the Asthma Control
Test, that play a role when assessing asthma control and subsequently managing asthma; 22) discuss the significance of high attenuating mucus
(HAM) and other radiologic findings (ORF) in patients of allergic bronchopulmonary aspergillosis; 23) discuss the importance of environmental
triggers exacerbating asthma and allergy events; and 24) recognize that asthma medication non-adherence is a major problem in newly diagnosed
persistent asthmatics and utilize a question from the Pediatric Asthma Adherence Tool to screen patients for possible medication non-adherence.
Moderators: Mitchell H. Grayson, MD, FACAAI and Talal M. Nsouli, MD, FACAAI
1:30 pm
17 – Popular on YouTube: A Critical Appraisal of
the Educational Quality of Information Regarding Asthma
A. Gonzalez-Estrada*, L. Cuervo Pardo, B. Ghosh,
F. Pazheri, M. Smith, K. Zell, X. Wang, D.M. Lang,
Cleveland, OH.
1:45 pm
18 – Local Reactions During Immunotherapy
and Their Impact on Dose Adjustment
Q. Kamili*, A.C. Gavino, R. Rossen, F. Orson,
A. Casillas, Houston, TX.
2:00 pm
19 – The HEDIS Medication Management for
People With Asthma Measure Does Not
Correlate With Improved Asthma Outcomes
A. Crans Yoon*1, W. Crawford1, J. Sheikh1,
A. Gong1, R. Nakahiro2, M. Schatz2, 1. Los Angeles,
CA; 2. San Diego, CA.
2:15 pm
20 – Allergy Immunotherapy Adherence: Does
Rush Make a Difference?
S.P. Raschal, J.M. Holcombe, B.G. Carlton*,
Chattanooga, TN.
2:30 pm
2:45 pm
22 – Utility of High Attenuating Mucus and
Other Radiologic Features in Diagnosed Cases
of Allergic Bronchopulmonary Aspergillosis
P. Agarwal*, A. Chowdhary, S. Gaur, Delhi, India.
3:00 pm
23 – Asthma Ally: Taking Advantage of the
Cloud to Understand Environmental Triggers of
Asthma and Allergies
R. Lucas*1, J. Dees2, R. Reynolds2, B. Rhodes3,
N. Allen3, R.W. Hendershot4, 1. Phoenix, AZ; 2. Salt
Lake City, UT; 3. Provo, UT; 4. North Salt Lake, UT.
3:15 pm
24 –The Pediatric Asthma Adherence Test
(PAAT): A Survey for Pediatric Patient Propensity to Adhere to Controller Medications
B.T. Kelly*1, W. An1, C. Bauer2, H. Zafra1,
L. Gimenez1, L. Crandall1, P. Simpson1,
M. Nugent1, P. Vargas2, K.J. Kelly3,1. Milwaukee, WI;
2. Phoenix, AZ; 3. Chapel Hill, NC.
3:30 pm
Adjourn
21 – Assessing Subjective Measures of
Asthma Control in an Inner City Pediatric and
Adolescent Population
P.J. Patel*1, N. Abou Baker2, R. Travis2, A. Tentler2,
E. Montalvo Stanton2, 1. North Brunswick, NJ;
2. Newark, NJ.
3:30 – 4:00 pm
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
57
Sunday
Session C – Asthma and Other Lower Airway Disorders
Sunday Concurrent Sessions
Room A305 • Georgia World Congress Center
Session D – Basic Science Allergy and
Immunology and Clinical Immunology, Immunodeficiency
Upon completion of this session, participants should be able to: 25) identify an association between mouse and cockroach skin prick test, serum
specific IgE, environmental exposure and asthma morbidity in atopic children <4 years of age in the Bronx, New York; 26) identify the genetic
defect in X-linked Hyper-IgM, pitfalls in current therapy, and benefits of gene therapy for this disease; 27) discuss possible immunomodulatory
effects of the monoclonal IgG antibody omalizumab in macrophages; 28) analyze VDR polymorphism associations with pediatric asthma and atopy
found in this admixed population of the Caribbean area and compare the results with other studies done in differents ethnic goups suggesting
that VDR influences asthma and allergy susceptibility in spite of the load and the genetic structure of the populations studied; 29) discuss possible
etiologies to steroid resistance in obese asthmatics; 30) discuss the long-term progression of common variable immunodeficiency (CVID) interstitial
lung disease (ILD); 31) recognize that multiple heterozygous defects, although not previously reported as related, together can present as a
primary immunodeficiency (PID); and 32) discuss novel data collection acquisition of PIDD in the home infusion setting.
Moderators: Marianne Frieri, MD, PhD, FACAAI and Maeve E. O’Connor, MD, FACAAI
25 – Association Between Mouse and
Cockroach Skin Prick Test, Serum Specific IgE,
Environmental Exposure and Asthma Morbidity
in Atopic Children <4 Years of Age in the Bronx,
New York
A.L. Richler*1, Y. Jorge2, Y. Pichardo2, P. Polanco3,
K. Achar2, R. Nazari4, G. de Vos2, 1. Brooklyn, NY;
2. Bronx, NY; 3. San Juan, Puerto Rico;
4. Philadelphia, PA.
2:30 pm
29 – M1 Macrophages: A Potential Role in the
Development of Steroid Resistant Asthma in
Obese Mice
J.M. Diaz*1, X. Xue2, M. Solanki2, M. Gupta2,
P. Chatterjee2, V.R. Bonagura2, C. Metz2, 1. North
Bellmore, NY; 2. Manhasset, NY.
2:45 pm
30 – Longitudinal Study of CVID ILD
P.J. Maglione*, C. Cunningham-Rundles,
New York, NY.
1:45 pm
26 – Targeted Gene Therapy in the Treatment
of X-Linked Hyper-IgM Syndrome
C.Y. Kuo*1, M.D. Hoban1, A.V. Joglekar2,
D.B. Kohn1, 1. Los Angeles, CA; 2. Pasadena, CA. 3:00 pm
31 – Multiple Unrelated Heterozygous
Gene Defects Presenting As a Primary
Immunodeficiency
P. Abghari*, E. Secord, P. Poowuttikul, Detroit, MI.
2:00 pm
27 – Macrophage Phenotype Shift Toward M1
After IgG Stimulation With Omalizumab in an
IgE Free System
R. Steele*, M. Littlefield, I. Voloshyna,
M. Davis-Lorton, M. Aquino, L. Fonacier, A. Reiss,
Mineola, NY.
3:15 pm
32 – Novel Clinical Data Acquisition Technology
for Monitoring of Home IG Infusion for PIDD
T. Walton1, J. Ney2, D. Schaefer1, B. Geng*3,
1. Lenexa, KS; 2. Boston, MA; 3. Los Angeles, CA.
3:30 pm
Adjourn
1:30 pm
2:15 pm
28 – Association of VDR Genetic Variants
to Pediatric Asthma: A Case Control Study
in a Poor Community of the Colombian
Caribbean Area
E. Egea1, G. Garavito de Egea*1, L. Visbal1,
N. Lecompte1, G.E. Egea1, M. Sanchez Borja2,
L. Fang3, 1. Barranquilla, Colombia; 2. Caracas,
Bolivarian Republic of Venezuela; 3. Cartagena,
Colombia.
3:30 – 4:00 pm
Refreshment Break in Exhibit Hall
Supported by Meda Pharmaceuticals Inc.
58
Sunday Programs
Room A411 • Georgia World Congress Center
Chronic Urticaria – A Problem Based Learning Experience
Jointly Provided by the American Association of Certified Allergists-Immunologists and
the American College of Allergy, Asthma and Immunology
Sunday
Upon completion of this session, participants should be able to: outline the impact on Quality of Life and burden of disease attributable to
chronic urticaria, discuss the pathophysiology of chronic urticaria, describe the role of autoantibodies and inflammatory cells in chronic
urticaria, describe a step care approach for management of chronic urticaria/angioedema as recommended in the 2014 Practice Parameter
Update; discuss the rationale and efficacy of alternative therapies for chronic urticaria; and relate an evicence-based approach to diagnostic
evaluation of patients with chronic urticaria/angioedema.
Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council
for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and
American Association of Certified Allergists-Immunologists (AACA). The American College of Allergy, Asthma and Immunology (ACAAI) is
accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 2 AMA PRA
Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Moderator: Russell A. Settipane, MD, President, American Association of Certified Allergists-Immunologists
4:00 pm
Problem Based Learning: A Case of Chronic
Urticaria
Ray S. Davis, MD, MS, FACAAI
5:00 pm
Chronic Urticaria Burden of Illness
David R. Weldon, MD, FACAAI
5:10 pm
Chronic Urticaria Pathophysiology
Thomas B. Casale, MD, FACAAI
5:20 pm
Chronic Urticaria Laboratory Evaluation
David M. Lang, MD, FACAAI
5:30 pm
Chronic Urticaria Treatment
David A. Khan, MD, FACAAI
5:40 pm
Questions and Panel Discussion
6:00 pm
Adjourn
Room A412 • Georgia World Congress Center
Sociedad Latinoamericana de Alergia, Asma e Inmunología (SLAAI)
NOT FOR
CREDIT
Drug Allergy in Latin America
Moderators: Alfonso Mario Cepeda, MD, SLAAI President, and Miguel Medina, MD, CMICA President
4:00 pm
Welcome and Introductions
Alfonso Mario Cepeda, MD, SLAAI President,
and Miguel Medina, MD
5:05 pm
Severe Drug Allergic Reactions in
Latin America
Carlos Serrano, MD
4:05 pm
Drug-Induced Anaphylaxis in Latin America
Edgardo Jares, MD
5:35 pm
Questions and Discussion
6:00 pm
Adjourn
4:35 pm
Hypersensitivity to Aspirin and NSAIDs in
Latin America
Mario Sanchez-Borges, MD
59
Meet the Professor Breakfasts
Omni Hotel at CNN Center
7:00 – 8:15 am • Admission by ticket only • Fee $40 (FITs $20) • Limit: 30
Supported by an independent educational grant from Merck
Monday
Upon completion of this session, participants should be able to: describe the use of the different diagnostic tests for food allergy; recognize that
insufficient Vitamin D levels are associated with risks for atopic disease; discuss epigenetics in the context of its applicability to clinical allergy and
immunology; discuss the clinical presentation, diagnosis and treatment options available for patients with hereditary angioedema with and
without C1 inhibitor deficiency; describe the diagnostic and management challenges for hereditary angioedema (HAE); discuss differential
diagnosis and key diagnostic and treatment approaches for HAE and related conditions; discuss the approach to evaluation of recurrent infections
in adults and children; review recently described immune deficiencies, testing available for assessment and therapeutic interventions;
appropriately determine when and in whom to perform drug allergy testing, graded challenge, and/or desensitization; recognize patients whose
presentation is consistent with exercise-induced anaphylaxis or food-dependent exercise-induced anaphylaxis; distinguish exercise-induced
anaphylaxis from cholinergic urticaria and describe management of patients with exercise-induced anaphylaxis syndromes; explore the literature
and apply it to the care of patients who fail Step 3 treatment of asthma; utilize an evidence-based approach to improve asthma care in this subpopulation; select a reasonable treatment approach for patients who fail Step 3 asthma therapy; and differentiate the common causes of chronic
cough in children and adults.
M1
SOLD
Food Allergy: Controversies
in Diagnosis
Dogwood A (Level M1 – North Tower)
A. Wesley Burks, MD, FACAAI
OUT
1 2 3 6
1 2 3 Y
1 2 3
M9
1
Approaches to Patients Who Fail
Step 3 Therapy
Pine (Atrium Level – South Tower)
John J. Oppenheimer, MD, FACAAI and
Stephen P. Peters, MD
2 3 4 6
2 3 5
M10 Cough in Children and Adults
1 2 3
M3
Making Sense of the Literature in
Food Allergy
Cottonwood (Level M1 – North Tower)
Hugh A. Sampson, MD, FACAAI and
Robert A. Wood, MD
M4
Epigenetics
Redwood (Level M1 – North Tower)
Mitchell H. Grayson, MD, FACAAI and
Gailen D. Marshall, MD, PhD, FACAAI
M6
Evaluation of Immunodeficiency
International B (Level M2 – North Tower)
Mark A. Ballow, MD, FACAAI and
I. Celine Hanson, MD, FACAAI
1
60
2
3
4
5
6
1 2 3 Y
Exercise-Induced Anaphylaxis
and Food-Dependent Exercise-Induced
Anaphylaxis
Maple AB (Atrium Level – South Tower)
David M. Lang, MD, FACAAI and
Roxana L. Siles, MD
Vitamin D in Allergic and
Immune Disorders
Dogwood B (Level M1 – North Tower)
Michael B. Foggs, MD, FACAAI and
Mitchell R. Lester, MD, FACAAI
1 2
Hereditary Angioedema
International A (Level M2 – North Tower)
Aleena Banerji, MD and
H. Henry Li, MD, PhD, FACAAI
Office Evaluation of Drug Allergy
International C (Level M2 – North Tower)
UT David A. Khan, MD, FACAAI and
O
SOLD
Stephen A. Tilles, MD, FACAAI
M8
M2
M5
M7
1 2 3 5 Y
Birch (Atrium Level – South Tower)
Alan B. Goldsobel, MD, FACAAI
3 4 5 6 Y
1 2 3 6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Monday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
My Patient Is Allergic to My Treatment: Adverse and
Allergic Responses to Allergy and Asthma Medications
Upon completion of this session, participants should be able to: diagnose various types of hypersensitivities or adverse responses to topical
dermatological preparations; identify patients who are having paradoxical or hypersensitivity responses to antihistamines used in the treatment of
allergic diseases; and recognize hypersensitivity responses to various drugs and biologicals used in the treatment of asthma.
Moderators: Richard G. Gower, MD, FACAAI and Charles J. Siegel, MD, FACAAI
Welcome and Introductions
Richard G. Gower, MD, FACAAI and
Charles J. Siegel, MD, FACAAI
8:05 am
Hypersensitivities to Dermatologic
Preparations
Luz S. Fonacier, MD, FACAAI
8:30 am
Hypersensitivities to
Antihistamines
Sami L. Bahna, MD, DrPH, FACAAI
1 2
8:55 am
Hypersensitivities to Systemic and Inhaled
Asthma Medications
Mariana Castells, MD, PhD, FACAAI
9:20 am
Questions and Discussion
9:30 am
Adjourn
Monday
8:00 am
1 2 3 4
Sidney Marcus Auditorium • Georgia World Congress Center
Annual Business Meeting
9:30 – 10:30 am
All Registrants Invited • Refreshments will be provided
Michael B. Foggs, MD, FACAAI Presiding
Agenda
I.
Call to Order
Michael B. Foggs, MD, FACAAI
IX.
Recognition of Outgoing Editor – AllergyWatch
Michael B. Foggs, MD, FACAAI
II.
Approval of 2013 Minutes and Standing Rules
Michael B. Foggs, MD, FACAAI
X.
III.
Historian’s Report
Joseph A. Bellanti, MD, FACAAI
Nominating Committee Report and
Election of Officers
Stanley M. Fineman, MD, MBA, FACAAI
XI.
IV.
Bylaws Committee Report
TBD
Presentation of New Officers and Regents
Michael B. Foggs, MD, FACAAI
XII.
Installation of New President
Michael B. Foggs, MD, FACAAI
V.
Alliance President’s Address – Mrs. Margaret Quel
VI.
State of the College
Michael B. Foggs, MD, FACAAI
XIII.
President’s Acceptance
James L. Sublett, MD, FACAAI
VII.
Vision 2020 Report
Bobby Q. Lanier, MD, FACAAI
XIV.
Presentation to Outgoing President
James L. Sublett, MD, FACAAI
VIII.
Recognition of Outgoing Regents
Michael B. Foggs, MD, FACAAI
XV.
New Business – James L. Sublett, MD, FACAAI
XVI.
Adjournment – James L. Sublett, MD, FACAAI
61
Monday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
Healthy Homes and the Allergist/Immunologist
Upon completion of this session, participants should be able to: advise patients to implement specific interventions that have been shown to
reduce contaminant exposure; identify facilitative factors, sources and reservoirs as they relate to furry animals, rodents, cockroaches, dust mites
and fungi; and work effectively with an indoor environmental professional (IEP) to develop a hypothesis for home assessment and to interpret and
use the report generated as a result.
Moderator: Janna M. Tuck, MD, FACAAI
10:30 am
Welcome and Introductions
Janna M. Tuck, MD, FACAAI
10:35 am
Practice Parameters for
Environmental Contaminants
Wanda Phipatanakul, MD, MS, FACAAI
Noon – 1:00 pm
1
62
2
Provider-Facilitated
Home Assessment
Kevin Kennedy, MPH, CIEC
11:50 am
Questions and Discussion
Noon
Adjourn
Bernard Berman Memorial Lecture
Overview of
Environmental Assessment
and Exposure Control
Jay M. Portnoy, MD, FACAAI
11:00 am
11:25 am
3
4
1 2
1 2 3
Lunch On Own
(Concessions open on Level Four)
5
6
1 2 3 4 5 6
See page 24 for ACGME Competencies. •
1:00 – 3:00 pm
Y
Concurrent Sessions (See pages 63-66)
Sessions that may be of interest to young physicians.
Monday Concurrent Sessions
Sidney Marcus Auditorium • Georgia World Congress Center
Session A – Allergy Testing, Clinical Laboratory
Immunology and Clinical Case Reports
Upon completion of this session, participants should be able to: 33) discuss penicillin skin testing to reduce the use of high cost broad spectrum
antibiotics in patients with previously documented unclear penicillin allergy; 34) discuss the more common adverse effects of the MMR
vaccination, as well as recognize the potential for rarer side effects, specifically idiopathic thrombocytopenia (ITP) associated with hemorrhagic
complications post MMR-vaccination; 35) identify clinical presentations consistent with granulomatous interstitial lung diesase and the specific
results of B-Cell Immunophenotyping that correlate with this subset of patients; 36) recognize that rituximab antibodies can transfer from mother
to infant; 37) identify and discuss different presentations of primary immunodeficiency; 38) identify extra respiratory manifestations of aspirin
exacerbated respiratory disease; 39) discuss the use of omalizumab as an option to manage solar urticaria that is refractory to standard therapy
with anti-histamines and sunscreen; and 40) identify signs of IgG4-related disease in patients who present with atopic clinical features.
Moderators: Jay M. Portnoy, MD, FACAAI and James L. Sublett, MD, FACAAI
33 – Impact of Penicillin Skin Testing (PST) on
Antibiotic (ABX) Use in Patients With a Penicillin Allergy (PA)
S. Challa*1, E. King2, K. Patel2, S. Anghel2,
J. Brensilver2, L. Bielory2, 1. Springfield, NJ;
2. Summit, NJ.
1:15 pm
34 – Severe Thrombocytopenia With Upper GI
Bleed After MMR Vaccination
K. Winkler*, T. Abramowitz Saadia, J. Moallem,
New York, NY.
1:30 pm
35 – B-Cell Immunophenotyping in Patients
With GI-ILD (Granulomatous Interstitial Lung
Disease) Associated With CVID (Common
Variable Immune Deficiency)
E. Willits*, A. Joshi, Rochester, MN.
1:45 pm
36 – In Utero Rituximab: Detection of
Rituximab in an Infant at 4 Months of Age
J. Jin*, J. Mills, E. Conboy, M. Snyder, D. Murray,
U. Specks, A. Joshi, Rochester, MN.
3:00 – 3:30 pm
2:00 pm
37 – Diagnostic Dilemma: Primary
Immunodeficiency in a 3 Year-Old Patient
With Guillain-Barré Syndrome
S. Rogers*1, L. Potter2, 1. Kailua, HI;
2. Portsmouth, VA.
2:15 pm
38 – Resolution of Alcohol-induced Respiratory
Reaction for Aspirin Exacerbated Respiratory
Disease Following Aspirin Desensitization
C.J. Calais*, Rockville, MD.
2:30 pm
39 – A Successful Treatment of Solar Urticaria
With Omalizumab
M. Chong*, M. Aquino, M. Davis-Lorton,
L. Fonacier, Mineola, NY.
2:45 pm
40 – IgG4-Related Disease in a Patient With
Allergic Rhinitis, Eosinophilia and Chronic
Urticaria
V. Bundy*, B. Geng, R. Kachru, M. Garcia-Lloret,
Los Angeles, CA.
3:00 pm
Adjourn
Monday
1:00 pm
Refreshment Break in the Sidney Marcus Auditorium Foyer
Supported by Meda Pharmaceutials Inc.
63
Monday Concurrent Sessions
Room A411 • Georgia World Congress Center
Session B – Food Allergy, Rhinitis,
Other Upper Airway Disorders, Ocular Disorders
Upon completion of this session, participants should be able to: 41) describe the role of food allergy in EoE and the need of an allergy evaluation in
EoE patients for appropriate and succinct management; 42) report approximate prevalence of pediatric food allergy in Kansas City in the context of
nationally reported prevalence ranges; 43) identify appropriate assays for detection of specific IgE relevant to the characterization and diagnosis of
the various food allergy syndromes discussed; 44) explain how Chicago Public Schools (CPS) became the first large, urban school district in the US
to stock emergency epinephrine in its 600+ schools and describe Year 1 outcomes of the CPS initiative as well as strategies for successful
implementation of similar initiatives nationwide; 45) discuss the available evidence on the occupational and environmental risk factors for chronic
rhinosinusitis; 46) describe the effect of upper airways allergic inflammatory disorders on quality of life and quality of sleep; 47) treat vernal
keratoconjunctivitis as a systemic disease; and discuss whether periostin is a potential biomarker for allergic rhinitis.
Moderators: Sami L. Bahna, MD, DrPH, FACAAI and Chitra Dinakar, MD
1:00 pm
41 – Eosinophilic Esophagitis: Is There a Food
Allergy Connection?
T.M. Nsouli*1, F.H. Al-Kawas2, N.Z. Diliberto2,
C.M. Davis2, S.T. Nsouli2, J.A. Bellanti2, 1. Burke, VA;
2. Washington, DC.
2:15 pm
46 – Effect of Nasal Polyposis on Nocturnal
Sleep Disturbances, Daytime Sleepiness, and
Sleep Specific Quality of Life Disturbances in
Patients Presenting With Allergic Rhinitis
K. Kumar*, A. Shah, Delhi, India.
1:15 pm
42 – The Prevalence of Pediatric Food Allergy
in Urban Kansas City
A.L. Humphrey*, M. Reddy, J. Shroba, C. Ciaccio,
Kansas City, MO.
2:30 pm
47 – Vernal Keratoconjunctivitis As a Systemic
Disease
M. Duse*, A. Zicari, M. Nebbioso, F. Occasi,
L. Leonardi, A. Zicari, Rome, Italy.
1:30 pm
43 – Challenges With Measurement of IgE
Antibodies in Eosinophilic Esophagitis, Peanut
Allergy and Mammalian Meat Allergy
A. Tripathi*1, L.J. Workman1, S.P. Commins1,
R. Hamilton2, E.A. Erwin3, T.A. Platts-Mills1,
1. Charlottesville, VA; 2. Baltimore, MD;
3. Columbus, OH.
2:45 pm
48 – Periostin Tissue Expression and Its
Potential Value As a Serum Biomarker in
Allergic Rhinitis
R. Patel*1, P. Howarth1, E. Beattie2, R. Modeste2,
A. Salapatek2, 1. Southampton, United Kingdom;
2. Mississauga, ON, Canada.
3:00 pm
Adjourn
1:45 pm
44 – Emergency Epinephrine Use for Food
Allergy Reactions in Chicago Public Schools
R. Gupta*1, L. DeSantiago-Cardenas2, V. Rivkina1,
1. Chicago, IL; 2. Phoenix, AZ.
2:00 pm
45 – Occupational and Environmental Risk
Factors for Chronic Rhinosinusitis: A Systematic
Review
A. Sundaresan*1, A. Hirsch1, M. Storm1,
B. Schwartz2, 1. Danville, PA; 2. Baltimore, MD.
3:00 – 3:30 pm
Refreshment Break in the Sidney Marcus Auditorium Foyer
Supported by Meda Pharmaceutials Inc.
64
Monday Concurrent Sessions
Room A412 • Georgia World Congress Center
Session C – Other
Upon completion of this session, participants should be able to: discuss the associations between vitamin D and eosinophilic esophagitis;
50) discuss several substantial knowledge gaps in regards to common allergy/immunology conditions among physicians at academic medical
centers; 51) identify the potential overlap between ocular allergy and dry eye disorders, as well as, discuss the potential value of measuring tear
osmolarity as a meaningful tool in assisting the allergy specialist in an office- based practice; 52) more accurately estimate nicotine exposure in
smoking and non-smoking households; 53) discuss the utility of using urinary 3-BrTyr as a marker of inflammation in eosinophilic esophagitis;
54) identify resources released by the Center for Medicare and Medicaid Services (CMS) regarding Medicare utilization data and compare their
practice patterns to the national data found within the Provider Utilization and Payment Data: Physician and Other Supplier Public Use File (PUF);
55) discuss potential effects of prenatal smoking, maternal atopy, early-life second-hand smoke, breastfeeding and pets on the risk of childhood
allergy; and 56) describe the effect of indoor air pollution on human health.
Moderators: Andrew S. Nickels, MD and James W. Sublett, MD, FACAAI
49 – Serum 25-Hydroxyvitamin D Levels in
Patients With Eosinophilic Esophagitis
M. Slack*1, P.U. Ogbogu1, T.A. Platts-Mills2,
E.A. Erwin1, 1. Columbus, OH; 2. Charlottesville, VA.
2:15 pm
54 – Analysis of the 2012 US Medicare
Reimbursement Data: Putting Allergy/
Immunology Data Into Context
A.S. Nickels*, G. Volcheck, Rochester, MN.
1:15 pm
50 – Allergy Misconceptions Among Physicians
at Academic Medical Centers
K.J. Wada*1, S. Montandon2, T. Green2, D. Stukus1,
1. Columbus, OH; 2. Pittsburgh, PA.
2:30 pm
1:30 pm
51 – Increased Comorbidity of Anterior
Segment Disease in an Allergic Population
B.P. Bielory*1, J. Pepose2, E. Donnenfeld3,
M. McDonald3, K. Nichols4, L. Bielory5, 1. Valhalla,
NY; 2. St Louis, MO; 3. Lynbrook, NY; 4. Houston, TX;
5. Springfield, NJ.
55 – Prenatal and Early Life Determinants of
Atopy: Preliminary Findings of the Kingston
Allergy Birth Cohort
M.L. North, J. Thiele, V. Omana, M. Soliman,
A.K. Ellis*, Kingston, ON, Canada.
2:45 pm
56 – The Association of Household Air Pollution
With Allergic Respiratory Diseases in Children
R. Kumar*, K. Singh, U. Mehto, S. Nagar, R. Prasad,
Delhi, India.
3:00 pm
Adjourn
1:45 pm
52 – Correlation of House Dust Nicotine With
Reported Smoking History
C.S. Barnes*, F. Pacheco, R. Allenbrand, L. Gard,
C. Ciaccio, Kansas City, MO.
2:00 pm
53 – Development of a Noninvasive Screening
Assay for Eosinophilic Esophagitis
K.M. Maples*, T.C. Burch, A.M. Perkins,
K.M. Cunnion, N.K. Krishna, H. Minto, L.K. Willis,
J.O. Nyalwidhe, Norfolk, VA.
3:00 – 3:30 pm
Monday
1:00 pm
Refreshment Break in the Sidney Marcus Auditorium Foyer
Supported by Meda Pharmaceutials Inc.
65
Monday Concurrent Sessions
Rooms A313-314 • Georgia World Congress Center
Session D – Skin Disorders, Asthma, Other Lower
Airway Disorders and Clinical Immunology, Immunodeficiency
Upon completion of this session, participants should be able to: 57) discuss how quickly CIU/CSU patients respond to omalizumab treatment and
how long their response tends to last; 58) discuss factors influencing health literacy in rural adolescents and how this information might guide the
type of asthma education provided to these patients; 59) visualize the care pathway and cost relational system among providers in the Medicaid
system and target interventions to reduce redundant cost; 60) discuss the epidemiological trends of asthma in a key Latin American country;
61) discuss the efficacy of reslizumab on patient reported outcomes and the tolerability of reslizumab in patients with uncontrolled asthma and
elevated blood eosinophils; 62) discuss this risk stratification tool for future asthma related acute care visits; 63) discuss population based screening
for SCID and other T-cell lymphopenic disorders; and 64) discuss the importance of TREC NBS in early identification of SCID and the effects of early
SCID identification on morbidity and cost.
Moderators: David I. Bernstein, MD, FACAAI and H. James Wedner, MD, FACAAI
1:00 pm
57 – Patterns of Response in Chronic
Idiopathic/Spontaneous Urticaria (CIU/CSU)
Patients Treated With Omalizumab in Two
Randomized Double-Blind Placebo-Controlled
Clinical Trials (Asteria I and Asteria II)
A. Kaplan*1, E. Antonova2, B. Trzaskoma2,
K. Raimundo2, S. Khalil3, T. Omachi2, J. Zazzali2,
1. Charleston, SC; 2. South San Francisco, CA;
3. Basel, Switzerland.
1:15 pm
58 – Do Parents Influence Health Literacy and
Impact Asthma Self-Management in Rural
Georgia High School Students?
J.S. Bush*, J.L. Waller, D.R. Ownby, M.S. Tingen,
Augusta, GA.
1:30 pm
59 – Profiling and Visualizing Utilization and
Cost for Pediatric Asthma Care in the Medicaid
System
R.P. Hilton1, N. Serban1, Y. Zheng*2, 1. Atlanta, GA;
2. Smyrna, GA.
1:45 pm
60 – Trends of Attention of Asthma at the
Instituto Mexicano Del Seguro Social
2007-2012
M. Nunez*, M. Becerril-Angeles, V.H. BorjaAburto, A. Rascon-Pacheco, U. Angeles-Garay,
M. Vargas-Becerra, Mexico City, DF, Mexico.
3:00 – 3:30 pm
2:00 pm
61 – A Randomized Phase 3 Study Assessing
Patient-Reported Outcomes and Safety of
Reslizumab in Patients With Asthma With
Elevated Eosinophils
J. Maspero*1, L. Bjermer2, C. Lemiere3, M. Ciesielska4, C. O’Brien4, J. Zangrilli4, 1. Buenos Aires,
Argentina; 2. Lund, Sweden; 3. Montreal, Canada;
4. Frazer, PA.
2:15 pm
62 – Developing a Risk Stratification Model to
Allocate Limited Asthma Resources
J. Hanson*, H. Murphy, D. Williams, B. Lee,
M. Reddy, Kansas City, MO.
2:30 pm
63 – Newborn Screening for Severe Combined
Immunodeficiency in Iowa: Results of a One
Year Pilot Study
S. Aleem*1, E. Phillips1, T. Henry1, C. Johnson2,
P. Ferguson2, S. Rumelhart2, C. Kremer2, K. Piper2,
M. Fasano2, 1. Iowa City, IA; 2. Des Moines, IA.
2:45 pm
64 – Financial and Morbidity Impact of Adding
TRECS to NBS
S.E. Henrickson*1, J. Heimall2, S. Jyonouchi2,
1. Haddonfield, NJ; 2. Philadelphia, PA.
3:00 pm
Adjourn
Refreshment Break in the Sidney Marcus Auditorium Foyer
Supported by Meda Pharmaceutials Inc.
66
Monday General Sessions
Plenary Session • Sidney Marcus Auditorium • Georgia World Congress Center
A New Era in the Diagnosis and
Treatment of Food Allergy
Upon completion of this session, participants should be able to: state how component resolved food allergy diagnosis should be utilized in clinical
practice; recognize the risks and benefits associated with oral and sublingual food immunotherapy; and discuss the future types of food allergy
treatment that are currently being studied.
Moderator: Dana V. Wallace, MD, FACAAI
Welcome and Introductions
Dana V. Wallace, MD, FACAAI
3:35 pm
Use of Allergen Components in the
Diagnosis of Food Allergy
Robert A. Wood, MD
1 2 3 6
Oral and Sublingual Immunotherapy
for Food Allergy
A. Wesley Burks, MD, FACAAI
1 2 3 6
4:00 pm
4:25 pm
Future Approaches in the Treatment
of Food Allergy
Hugh A. Sampson, MD, FACAAI
4:50 pm
Questions and Discussion
5:00 pm
Adjourn
1 2 3 6
Monday
3:30 pm
5:00 pm Meeting Adjourns
Plan to attend the
ACAAI 2015
Annual Scientific Meeting
San Antonio
November 5 – 9, 2015
Texas
67
Office Administrators Practice Management Course
Room A305 • Georgia World Congress Center
NOT FOR
CREDIT
Separate Registration Fee • Admission by ticket only
Friday
Target Audience: Office managers, administrators and others involved in the administration of an allergy/immunology/asthma office practice.
Upon completion of this session participants should be able to: describe important changes at the national level that impact practice
management; discuss future changes occurring within the allergy landscape, including the positives and the negatives; describe the various social
media platforms and how use of these may help in managing a practice; recognize the differences between Generation X and Generation Y and
creating work place harmony; describe an alternate organizational structure (holocracy) to motivate and retain staff; examine the basic keys to
running a financially and operationally successful allergy practice; and utilize an open platform to share ideas, discuss challenges, provide
resources, and help each other strengthen our organizations.
Moderator: Kay Tyler, BS, BA, MBA
8:00 am
Welcome and Introductions
James L. Sublett, MD, FACAAI and
Kay Tyler, BS, BA, MBA
8:15 am
CMS, ICD-10, Coding, MUE –
JCAAI Update
J. Allen Meadows, MD, FACAAI
9:00 am
11:30 am
Lunch (on own – concessions open on Level Four)
1:00 pm
Strategies for Employee
Engagement and Staff Retention
Jason Biddy, MBA
1:45 pm
1
Basics and Must-Haves to be
a Top Notch Practice
Stanley M. Fineman, MD, MBA, FACAAI
2:30 pm
Refreshment Break (A305 Foyer)
2:45 pm
Town Hall Discussion
James L. Sublett, MD and
Kay Tyler, BS, BA, MBA
3:30 pm
Adjourn
4 5 6
1 3 4 5
Futuristic View for Allergy
Specialty; Telemedicine, ACO’s, Rural Health
Models, Retail Partnerships
Maeve E. O’Connor, MD, FACAAI
6
9:45 am
Refreshment Break (A305 Foyer)
10:00 am
4 5
Marketing your Practice
Robin Panethere and Michael Tanoury, BA, MA
10:45 am
Generation X vs. Generation Y Employees
Bryan L. Martin, DO, FACAAI
In an effort to be
environmentally responsible,
ACAAI is reducing the amount of paper we use at our
annual meeting. Electronic program materials and online
materials will replace paper and will be accessible online
before, during and after the program.
Visit acaai2014.conferencespot.org or snap the QR
code for a menu of online materials.
1
68
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
3 4 5
3 4 5 6
1 3 4 5 6
ONLINE
MATERIALS
➧
Sessions that may be of interest to young physicians.
Advanced Practice Health Care Providers Course
Room A302 • Georgia World Congress Center
Separate Registration Fee • Admission by ticket only
Friday General Session
Target Audience: Nurse practitioners, physician assistants, allergy/immunology nurses, other health care providers with extensive experience
and physicians.
Nursing Accreditation: Provider approved by the California Board of Registered Nursing, Provider Number 14486 for 8.7 contact hours.
Upon completion of this session, participants should be able to: evaluate select recent literature in pediatric allergy, asthma and immunology for
important developments with practical application in management including patient education; describe how allergy fits into the Accountable
Care Organization framework; discuss implication of the Affordable Care Act on the specialty of allergy and ways we can impact population health
quality measures; discuss the efficacy, safety and status of Sublingual Immunotherapy (SLIT); describe the main differences and similarities
between SCIT AND SLIT; describe the modulating effect each has as an adjuvant for allergic rhinitis and asthma; describe the presenting signs and
symptoms of acute and chronic urticaria; discuss treatment options for the treatment of chronic urticaria, including anti-histamines, immune
modulators and omalizumab; differentiate clinical presentations of IgE-mediated food allergy, from immunologic and non-immunologic
gastrointestinal disorders related to foods; and discuss the diagnostic approach to evaluating patients with various immunologic and nonimmunologic reactions to food.
8:00 am
Moderator: Deidra H. Sanders, MSN, APRN, FNP-BC
Welcome and Introduction
Deidra H. Sanders, MSN, APRN, FNP-BC
10:00 am
Changing Lives with
Immunotherapy Options of
SLIT vs SCIT
Michael R. Nelson, MD, PhD
1 2 3
10:50 am
1 2 3
Chronic Idiopathic Urticaria
New Indications
Mary Lou Hayden, MSN, APRN, CPNP-PC,
FNP-BC, AE-C
4 5 6
11:40 am
The Gut Check: Differential
Diagnosis of GI Complaints
Maria G. Crain, CPNP, AE-C
12:20 pm
Questions and Discussion
12:30 pm
Lunch (on own – concessions open on Level Four)
An Update in Allergic Diseases
8:05 am
What’s Cooking: A Food
Allergy Update
Jodi A. Shroba, MSN, APRN, CPNP
8:20 am
Burden of Allergic Rhinitis
Deidra H. Sanders, MSN, APRN, FNP-BC
1 2 3
8:35 am
What’s New with Asthma in
Children and Adults
Karen S. Rance, DNP, APRN, CPNP, AE-C
1 2 3
8:55 am
Responding to the Changing
Health Care Landscape
Gary N. Gross, MD, FACAAI
9:45 am
Refreshment Break (A302 Foyer)
1
2
3
4
5
6
1 3
See page 24 for ACGME Competencies. •
Y
1 2 3 4 5 6
Sessions that may be of interest to young physicians.
69
Health Care Providers
Moderator: Charlotte M. Jacobsen, MSN, RN
Advanced Practice Health Care Providers Course
Omni Hotel at CNN Center
Separate Registration Fee • Admission by ticket only
Friday Interactive Concurrent Workshops
Upon completion of this session, participants should be able to: describe the evaluation and management of the patient with skin disease
including patch testing and biopsy; outline topical and systemic therapies for common dermatological diseases; engage participants in problem
solving some interesting cases from their practices; discuss pertinent history, physical findings and diagnostic studies in the patient with difficult to
control asthma; use presented history, physical exam and diagnostic studies to create a list of possible differential diagnosis and determine the
most likely diagnosis for a pediatric and adult patient with difficult to control asthma; formulate a treatment plan for a pediatric and adult patient
with difficult to control asthma; describe the non-prescription treatment of asthma and allergy: complementary and alternative medicine (CAM),
dietary influences on the microbiome, probiotics, OTC, Vitamin D; and discuss approaches to taking a CAM history and its integration into
traditional medically prescribed treatment plans.
1:30 – 3:00 pm
3:15 – 4:45 pm
AP1
1 2
Dermatology Pearls: Case Studies –
Bring Your Interesting Cases
Dogwood A (Level M1 – North Tower)
Luz S. Fonacier, MD, FACAAI
AP4
1 2
Dermatology Pearls: Case Studies –
Bring Your Interesting Cases
Dogwood A (Level M1 – North Tower)
Luz S. Fonacier, MD, FACAAI
AP2
Difficult to Manage Cases (PBL) 1 2 3 4 5 6
Dogwood B (Level M1 – North Tower)
Gwen Carlton, DNP, FNPI
AP5
Difficult to Manage Cases (PBL) 1 2 3 4 5 6
Dogwood B (Level M1 – North Tower)
Gwen Carlton, DNP, FNP
AP3
1 2 3 4 5 6
What Patients Are Taking
and What Recommendations
We Are Making
Cottonwood (Level M1 – North Tower)
Maureen George, PhD, RN, AE-C, FAAN and
William S. Silvers, MD, FACAAI
AP6
1 2 3 4 5 6
What Patients Are Taking
and What Recommendations
We Are Making
Cottonwood (Level M1 – North Tower)
Maureen George, PhD, RN, AE-C, FAAN and
William S. Silvers, MD, FACAAI
3:00 pm
Refreshment Break
Cottonwood & Dogwood Foyers
4:45 pm
Adjourn
1
70
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
Allied Health Professionals Course
Rooms A313-314 • Georgia World Congress Center
Separate Registration Fee • Admission by ticket only
Saturday General Session
Target Audience: Health professionals including, but not limited to, RNs, LPNs, MAs, PAs, NPs, MDs/DOs.
Accreditation: Provider approved by the California Board of Registered Nursing, Provider #CEP 14486, for 12.0 contact hours.
Upon completion of this session, participants should be able to: identify components of the innate and adaptive immune system where
deficiency leads to clinical manifestations; describe the usefulness of lab evaluation and vaccines in determining appropriate immune
responsiveness; interpret the specific antibody responses to pneumococcal polysaccharide vaccination; explain how age specific considerations,
such as childhood, pregnancy, or older adulthood, effects an asthma diagnosis; discuss asthma treatment options for children and adults; discuss
the signs and symptoms of anaphylaxis and risk factors for occurrence; describe the appropriate equipment needs for treating mild to severe cases
of anaphylaxis; present case scenarios of patients presenting with anaphylaxis; recognize the most common insects which cause reactions in
humans; identify the most common types of reactions involving stinging insects; and develop an evaluation and management plan for stinging
insect allergy.
8:00 am
Welcome and Introductions
David A. Khan, MD, FACAAI and
Deidra H. Sanders, MSN, APRN, FNP-BC
8:05 am
The Competent Immune System:
How Do We Know?
Christina E. Ciaccio, MD, FACAAI
9:00 am
10:10 am
1 2 3 4
Asthma Management Across
the Lifespan: Age-specific Considerations
for Diagnosis and Treatment
Karen S. Rance, DNP, APRN, CPNP, AE-C
11:05 am
Stinging Insects: Let’s Talk
Venom IT
Theodore M. Freeman, MD, FACAAI
11:50 am
Questions and Discussion
Noon
Lunch (on own – concessions open in Exhibit Hall)
1 2 3 4
1 2 3
Anaphylaxis: Are We Up
to Speed?
Kimberly G. Clay, MN, APRN, FNP-BC and
Stanley M. Fineman, MD, MBA, FACAAI
9:55 am
1
Moderator:
Mary Lou Hayden, MSN, APRN, CNP-PC, FNP-BC, AE-C
4 5 6
5 6
1 2 3
Refreshment Break (A313-314 Foyer)
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
71
Health Care Providers
Moderator:
Jodi A. Shroba, MSN, APRN, CPNP
Allied Health Professionals Course
Omni Hotel at CNN Center
Saturday Interactive Concurrent Workshops
Upon completion of this session, participants should be able to: discuss how to perform an oral challenge in the clinical office setting; describe
when and how do we utilize pulmonary function testing in light of clinical symptoms and diagnoses; list key features that the patient and
performer must insure to make PFT interpretation valid; recognize abnormal measurements and their likely clinical interpretation; describe the
compliance requirements for allergen extract preparation according to the USP chapter 797, immunotherapy practice guidelines third edition
update and the Compounding Bill of November 27, 2013; identify practical approaches for implementation of the guidelines; describe questions
regarding the environmental asthma/allergy triggers that should be included when obtaining a medical health history; compare allergy/asthma
triggers in various patient environments, such as home, school, daycare, work, etc.; explain ways of modifying a patient’s environment to limit or
eliminate the burden on their asthma/allergies; examine the range of available resources for children, adults, low-literacy populations; apply
accepted evaluation criteria to websites and apps; discuss the indications for, procedure and patient/family education associated with FENO,
bronchial challenge testing (methacholine, mannitol), penicillin skin testing and Omalizumab administration; and discuss indications for and
patient/family education regarding pre/post vaccine titers.
1:30 – 3:00 pm
3:15 – 4:45 pm
SA1
1
Taking the Challenge Out of the
Oral Food Challenge: Bring Your Challenges
Dogwood A (Level M1 – North Tower)
Jodi A. Shroba, MSN, APRN, CPNP
SA7
1
Taking the Challenge Out of the
Oral Food Challenge: Bring Your Challenges
Dogwood A (Level M1 – North Tower)
Jodi A. Shroba, MSN, APRN, CPNP
SA2
1 2 3
Pulmonary Function Testing:
Novice to Expert
Dogwood B (Level M1 – North Tower)
Concettina Tolomeo, DNP, APRN, FNP-BC, AE-C
SA8
1 2 3
Pulmonary Function Testing:
Novice to Expert
Dogwood B (Level M1 – North Tower)
Concettina Tolomeo, DNP, APRN, FNP-BC, AE-C
SA3
1 2 3 4 5 6
Regulatory Update: What You
Need to Know Regarding Immunotherapy
Compounding and USP 797 Compliance
Cottonwood (Level M1 – North Tower)
Cheryl K. Bernstein, BSN, RN, CCRC
SA9
1 2 3 4 5 6
Regulatory Update: What You
Need to Know Regarding Immunotherapy
Compounding and USP 797 Compliance
Cottonwood (Level M1 – North Tower)
Cheryl K. Bernstein, BSN, RN, CCRC
SA4
1 2 3 4 5 6
The Missing Piece: Applying
Environmental Health Parameters in Your Practice
International A (Level M2 – North Tower)
Charlotte M. Jacobsen, MSN, RN and
Kristen K. Welborn, MSN, APRN, FNP-BC
SA10 The Missing Piece: Applying
1 2 3 4
Resources in Allergy and Asthma
Management: Making Nurses Aware of Available
and Credible Information in a Technological Age
International B (Level M2 – North Tower)
Maureen George, PhD, RN, AE-C
SA11 Resources in Allergy and Asthma
1 2 3 4 5 6
Potpourri of Procedures
Commonly Used in the Clinical Setting
(PCN Testing, Omalizumab Administration,
SLIT-SCIT Differences)
International C (Level M2 – North Tower)
Mary Lou Hayden, MSN, APRN, CPNP-FC, FNP-BC, AE-C
and Christine W. Wagner, MSN, APRN, CPNP
SA12 Potpourri of Procedures
SA5
SA6
3:00 pm Refreshment Break
International Foyer (Level M2 – North Tower)
1
72
2
3
4
5
6
See page 24 for ACGME Competencies. •
1 2 3 4 5 6
Environmental Health Parameters in Your Practice
International A (Level M2 – North Tower)
Charlotte M. Jacobsen, MSN, RN and
Kristen K. Welborn, MSN, APRN, FNP-BC
1 2 3 4
Management: Making Nurses Aware of Available
and Credible Information in a Technological Age
International B (Level M2 – North Tower)
Maureen George, PhD, RN, AE-C
1 2 3 4 5 6
Commonly Used in the Clinical Setting
(PCN Testing, Omalizumab Administration,
SLIT-SCIT Differences)
International C (Level M2 – North Tower)
Mary Lou Hayden, MSN, APRN, CPNP-FC, FNP-BC, AE-C
and Christine W. Wagner, MSN, APRN, CPNP
4:45 pm Adjourn
Y
Sessions that may be of interest to young physicians.
Allied Health Professionals Course
Rooms A313-314 • Georgia World Congress Center
Sunday General Session
Upon completion of this session, participants should be able to: recognize the signs and symptoms of common ocular disorders such as vernal,
giant papillary, conjunctivitis, and episcleritis; discuss treatment modalities for various ocular disorders seen in allergy; discuss the current use of
over the counter medications in controlling allergic rhinitis and implications of inadequate management; describe the multifactorial elements of
chronic rhinosinusitis (CRS); evaluate the most recent evidence in supportive therapies for CRS; identify the alternatives to tobacco cigarettes that
patients might be using; describe smoking cessation programs available to patients; discuss current data on the safety of alternatives to tobacco
cigarettes; review indications and limitations on allergy testing of children with atopic dermatitis; discuss issues that interfere with adherence to
recommended therapy; and review the most current literature on novel therapies for the treatment of atopic dermatitis.
8:00 am
“Eye” Have a Problem
Leonard Bielory, MD, FACAAI
8:55 am
Upper Airway Disease: Mechanisms
and Complicating Factors
Sheldon L. Spector, MD, FACAAI
9:50 am
Moderator: Deidra H. Sanders, MSN, APRN, FNP-BC
1 2 3 4 5 6
10:05 am
1 2 3
Insults to the Airways: Patient
Advocacy Issues Related to Cigarettes,
E-cigarettes, Hookahs, Marijuana
Christine W. Wagner, MSN, APRN, CPNP
11:00 am
1 2 3 4
Wrap It Up! Treating
Atopic Dermatitis
Noreen H. Nicol, PhD, APRN, CPNC-PC, FNP,
NEA-BC
11:55 am
Questions and Discussion
Noon
Adjourn
1 2 3 6
Refreshment Break (A313-314 Foyer)
4 5 6
5 6
Health Care Providers
Moderator: Gwen Carlton, DNP, FNP
Online Evaluation, Credit Claim and
Certificate System
ACAAI will utilize a convenient online evaluation, credit
claim and certificate system for the 2014 Annual
Scientific Meeting. This system will allow you to complete evaluations of the certified CME sessions that you
attend which are directly provided by ACAAI. Upon
completion of the Overall Evaluation, Session Evaluations and credit claiming information you will be able to
immediately access, save and/or print your certificate.
Physicians will receive a certificate of credit and other
healthcare professionals will receive a certificate of
attendance for most sessions.
See page 22 for details.
1
2
3
4
5
6
See page 24 for ACGME Competencies. •
Y
Sessions that may be of interest to young physicians.
73
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
All Scientific Posters will be on display in Hall A-1 beginning Saturday morning. Authors of these posters are requested
to be at their posters to discuss their work from 3:30 – 4:30 pm, Saturday and from 7:30 – 8:30 am, Sunday.
Adverse Food and Drug Reactions,
Insect Reactions, Anaphylaxis
P12
Catamenial Anaphylaxis: A Rare Case
N. Kharod*1, M. Sands2, 1. Orchard Park, NY;
2. Buffalo, NY.
P13
Tree Nut Allergy and Anaphylaxis: A Case of
Delayed Diagnosis
S. Joychan*1, K. Dass2, 1. Kalamazoo, MI; 2. Chicago,
IL.
P14
Positive Patch Test to Lamotrigine in a Pediatric
Patient With DRESS Syndrome
J.A. Mendez*, C. Acantilado, S. Nazario, San Juan,
Puerto Rico.
P15
Treatment of Drug Reaction With Eosinophilia and
Systemic Symptoms (DRESS) With Mycophenolate
Mofetil as a Steroid-Sparing Agent
M. Mortezavi*, J.M. Lomas, R.J. Looney, Rochester,
NY.
P16
Prevalence of Allergy to Hymenoptera Sting
Among Schoolchildren in Monterrey, Mexico
H. Hernandez-Sanchez*, A. Arias Cruz, S.N. Gonzalez
Díaz, L. Leal Villarreal, M. Hernandez Robles,
J.A. Buenfil Lopez, I.V. Yanez Perez, Monterrey, NL,
Mexico.
P1
A Case of Successful Desensitization to
Alglucosidase Alfa in a 7 Week-Old With InfantileOnset Pompe Disease
C. Adkins*1, C.M. Makris2, S. Kankirawatana2,
1. Hoover, AL; 2. Birmingham, AL.
P2
Food Protein Induced Enterocolitis Syndrome
(FPIES) to Sweet Potato in a Highly Atopic Child
B.J. Lanser*, N. Rabinovitch, Denver, CO.
P3
Enzyme Replacement Therapy: A Case of
Successful Elosulfase Alfa Desensitization in a
Morquio A Syndrome Patient
A. CaJacob*1, C. Adkins2, M. Descartes1, C. Allen1,
J. Anderson1, 1. Birmingham, AL; 2. Hoover, AL.
P4
First Study of Pattern of Epinephrine Auto Injector
Prescriptions for Anaphylaxis in a Large Tertiary
Care Hospital in Saudi Arabia
S. Al Gazlan*, R. Amin, A. Khaliq, T. Al Otaibi,
S. Alhashim, F. Sheikh, Riyadh, Saudi Arabia.
P5
Phenytoin Induced DRESS Presenting With
Laryngeal Edema Requiring Intubation
H.N. Hartman*, L. Gimenez, Milwaukee, WI.
P17
Peanut IgE Threshold for Reflex Peanut
Component Testing
M. Altrich*1, H.D. Wells1, J.C. Thompson2, 1. Lee’s
Summit, MO; 2. Atlanta, GA.
Successful Meropenem Challenge in a Patient
With Fulminant Piperacillin-Induced Immune
Hemolytic Anemia
B. Prince*, A. Peters, Chicago, IL.
P18
NSAIDs Are the Most Common Cause of Drug
Induced Anaphylaxis at a Vilnius University
Hospital
A. Blaziene1, N. Buterleviciute1, V. Paltarackiene1,
K. Linauskiene1, L.M. DuBuske*2, 1. Vilnius, Lithuania;
2. Gardner, MA.
P19
Treatment of Beta Blocker-Induced Cutaneous
Reaction and Angioedema With Systemic
Cyclosporine
M. Imran*, Y. Zgherea, S. Gierer, J. Martinez,
1. Kansas City, MO.
P20
In Vitro Characterization of a Delayed
Hypersensitivity Reaction to Docetaxel Using
Gene Expression Profiling in a Patient With Stage
3 Breast Cancer
T. Kelbel*, F. Ishmael, Hershey, PA.
P21
Drug Induced Hypersensitivity With Use of
Amlodipine
P. Oza*, Ann Arbor, MI.
P6
P7
Utility of Patch Testing in Fixed Drug Eruption
D.A. Cariño Cartagena*, A.A. Velasco-Medina,
J.C. Fernández de Córdova-Aguirre, S. GonzálezFlores, M.E. Arroyo-Cruz, G. Velázquez-Samano,
Mexico City, DF, Mexico.
P8
Unusual Severe Rash Caused by Adalimumab
A.A. Mourad*, S.L. Bahna, Shreveport, LA.
P9
An Unusual Presentation of DRESS Syndrome in a
Post-Transplant Patient: A Case Report
S.B. Sindher*, J. Heimall, Philadelphia, PA.
P10
Successful Mycophenolate Mofetil
Desensitization in a Double Heart-Kidney
Transplant Recipient
M.A. Smith*1, A. Gonzalez-Estrada2, E. Glancy2,
D. Fernandez2, A. Subramanian2, 1. South Euclid, OH;
2. Cleveland, OH.
P11
74
Amphotericin Desensitization
A. Ravi*, D. Maddox, Rochester, MN.
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Recurrent Drug Reaction With Eosinophilia and
Systemic Symptoms (DRESS) Triggered by a
Structurally Unrelated Drug
S. Spriet*, T. Banks, T. Love, Bethesda, MD.
P23
Bacitracin Irrigations as a Cause of Anaphylaxis
and Rash
S.E. Chiarella*, D. Nayak, N. Fenny, C. Saltoun,
Chicago, IL.
P24
DRESS in a Pediatric Patient to Mexiletine
C. Collins*1, J. Sherr2, A. Liu2, 1. Cupertino, CA;
2. Palo Alto, CA.
P25
Suspected Methylprednisolone Succinate
Anaphylaxis Confirmed With Skin Testing
L.M. Cristiano*, J.W. Caldwell, Winston Salem, NC.
P26
Anaphylactic Reactions to Murine Bites: A Case
Report and Review of the Literature for
Management Guidelines
L.M. Cristiano*, G. Krishnaswamy, Winston Salem,
NC.
Upon completion of this session, participants should be able to:
P1) recognize the importance of enzyme replacement therapy with
alglucosidase alfa, especially in patients with infantile-onset Pompe
disease and discuss an effective protocol for desensitization in patients
who have experienced a prior systemic allergic reaction to this drug;
P2) distinguish FPIES from IgE mediated reactions and discuss the
management differences, as well as, the unique management
challenges posed by a patient with both FPIES and IgE mediated food
allergy; P3) discuss the risks of drug allergy and therapeutic
desensitization to elosulfase alfa enzyme replacement therapy;
P4) recognize the patterns of anaphylaxis and epinephrine
autoinjector use in Saudi Arabia; P5) describe the causes and
presentation of DRESS as well as discuss a novel presentation;
P6) evaluate the lower limit of peanut IgE when component testing
will be complete; P7) discuss the usefullnes of skin patch test in drug
fixed erythema; P8) evaluate patients with severe rashes and
suspected multiple medications; P9) discuss the difficulties associated
with the diagnosis and management of DRESS syndrome;
P10) successfully desensitize a transplant recipient to mycophenolate
mofetil; P11) discuss amphotericin desensitizations; P12) identify,
diagnose, and treat possible cases of catamenial anaphylaxis, which is
a rare and possibly underdiagnosed condition; P13) discuss the
importance of taking a detailed allergy history and performing a
thorough examination when presented with a case of anaphylaxisl;
P14) discuss the utility of patch testing in the evaluation of patients
with lamotrigine-induced delayed hypersensitivity reactions;
P14) discuss the clinical and laboratory abnormalities in DRESS and the
necessity to consider steroid sparing medications in the treatment of
this condition; P16) identify the prevalence of allergy to hymenoptera
in a schoolchildren population; P17) discuss drug-induced immune
hemolytic anemia and identify the most common causal drugs;
P18) discuss NSAIDs as the most common cause of drug induced
anaphylaxis at a Vilnius University Hospital; P19) describe the use of
cyclosporine to prevent a drug-induced skin reaction; P20) discuss a
novel approach to diagnosing type IV hypersensitivity reactions to
chemotherapuetic medications; P21) identify drug hypersensitivity
reaction secondary to amlodipine use; P22) recognize the signs and
symptoms of recurrent DRESS and thereby be able to manage this
condition sooner; P23) identify bacitracin irrigations as a cause of
anaphylaxis and rash; P24) identify diagnostic criteria and features of
DRESS; P25) recognize corticosteroids as an important cause of
perioperative anaphylaxis and the utility of the electronic medical
record as a tool for diagnosis of anaphylaxis and to guide drug
testing; and P26) recognize murine bites as an important cause of
workplace anaphylaxis as well as the employment implications for
affected patients.
Aerobiology, Allergens,
Allergen Extracts
P27
Compatibility of Short Ragweed Extracts in
Concentrated Mixtures With High-Protease and
Low-Protease Glycerinated Extracts at
Refrigeration or Ambient Temperatures
T.J. Grier*, D. Hall, E. Duncan, T. Coyne, Lenoir, NC.
P28
Stabilization of Labile Grass-Fungal and GrassInsect Extract Mixtures During Storage at
Sub-Zero (Conventional Freezer) Temperatures
T.J. Grier*, D. Hall, E. Duncan, T. Coyne, Lenoir, NC.
P29
Correlation of Pollen Count With New Allergy and
Asthma Visits
J. Turbyville*1, R. Arora2, P. Hall3, S. Pollard3, 1. Fort
Knox, KY; 2. Lexington, KY; 3. Louisville, KY.
P30
High Cedar Elm Pollen Counts in the Fall in
Atlanta, Georgia: 2009-2013
M.R. Shams*1, S. Fineman2, 1. Atlanta, GA;
2. Marietta, GA.
P31
Anaphylaxis From Compression Bandage PostDialysis
K. Chotikanatis*, A. Mathew, R. Barth, R. Joks,
Brooklyn, NY.
P32
Relationship Between Pollen Counts and
Emergency Department Visits for Asthma
O. Gourgy-Hacohen*, J. Jacobs, Walnut Creek, CA.
P33
Allergen Extract Stability: Non-Standardized
Expiration Dating
G. Plunkett*, B. Mire, Round Rock, TX.
P34
A Qualitative Analysis of a New Rotorod System
Utilizing Microcontrollers and Optical Sensor
Technology in the Environmental Exposure Unit
(EEU)
T.J. Walker*, L.M. Steacy, B. Hobsbawn, A.K. Ellis,
Kingston, ON, Canada.
P35
Occupational Allergy to Peach (Prunus
Persica) Pollen and Cross-Reactivity Between
Rosaceae Family Pollens
N. Jiang*, L. Wen, J. Yin, Beijing, China.
75
Posters
P22
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P36
Unique Allergy and Asthma Smartphone App
S. Kagen*, Appleton, WI.
P37
Grass Pollination Occurs Earlier and Is More
Abundant in Central Ukraine Likely Due to
Climate Change
V.V. Rodinkova1, O.O. Palamarchuk1, I.I. Motruk1,
L.V. Kremenska1, K.V. Musatova1, L.M. DuBuske*2,
1. Vinnitsa, Ukraine; 2. Gardner, MA.
P38
Influences of Early Pet Exposure On Cytokine
Levels in Later Childhood
H. Nguyen*, J.M. Biagini Myers, U. Sivaprasad,
G.K. LeMasters, D.I. Bernstein, T. Reponen, P.H. Ryan,
G.K. Hershey, Cincinnati, OH.
Upon completion of this session, participants should be able to:
P27) recognize the favorable stability of major short ragweed allergen
Amb a 1 in diverse mixtures with other high-protease and lowprotease extracts and summarize the effects of 50% glycerin on short
ragweed allergen recoveries in these mixtures and controls;
P28) discuss the relationships between glycerin content, freezing point
temperatures, and allergen recoveries in extract mixtures that possess
limited compatibilities at 2-8°C and recognize the potential of freezer
storage of certain product-glycerin combinations to provide viable
alternatives for patient treatment regimens; P29) discuss the
correlation between pollen counts and new visits for allergic rhinitis
and asthma; P30) discuss the clinical relevance of annual and seasonal
fluctuations in local aerobiology and recognize Cedar Elm pollen as a
dominant Fall aeroallergen in the southeastern United States;
P31) describe allergic reactions caused by alginate; P32) recognize the
correlation between specific pollen types and emergency department
visits for asthma in Contra Costa County, California; P33) discuss
methods to characterize allergen extracts for potency and stability, as
well as, the determination of expiration dating for the extracts;
P34) discuss local advancements in rotorod technology in a research
setting; P35) identify peach pollen as a potential cause of IgE mediated
occupational respiratory disease and discuss the extensive cross
reactivity among Rosaceae pollens; P36) describe the connection
between the environment and your health; P37) discuss grass
pollination, which occurs early and abundantly in Central Ukraine,
perhaps due to climate change; and P38) discuss the relationship
between early pet allergen exposure and cytokine levels.
Allergy Testing, Clinical
Laboratory Immunology
P39
The Correlation of Body Mass Index (BMI) to
Allergen Skin Testing and Serum Specific IgE
M.Z. Braunstein*, R. Joks, Brooklyn, NY.
P40
The Association Between Serum IgE, Eosinophil
Levels and Cancer, NHANES 2005-2006
S. Nagarajan*1, Q. Meng1, L. Bielory2, 1. Piscataway,
NJ; 2. Springfield, NH.
76
P41
Contact Sensitivity to Metal and Acrylates in
Patients Undergoing Joint Replacement
M. Goebel, J. Tan*, D. Bernstein*, Cincinnati, OH.
P42
Hepatitis C Virus-Associated Cryoglobulinemia
Presenting as Chronic Urticaria
S. Bantz*, M. Rodenas*, New Haven, CT.
Upon completion of this session, participants should be able to:
P39) describe the associations of BMI with skin prick tests and serum
specific IgE; P40) describe the association between markers of allergy,
as measured by serum IgE and eosinophil % levels, and cancer (overall
vs. type specific); P41) discuss which patients may benefit from metal
and acrylate patch testing prior to joint replacement surgery; and
P42) discuss different types of cryoglobulinemia, including diagnosis,
treatment, and the varying clinical presentations which warrant
evaluation of cryoglobulins.
Asthma and Other
Lower Airway Disorders
P43
Impact of Weight Loss on Markers of Systemic
Inflammation in Obese
Saudi Children With Asthma
O.H. Al Jiffri*, Jeddah, Saudi Arabia.
P44
The Usefulness of Serum High Sensitivity CReactive Protein as a Marker of Airway
Inflammation in Bronchial Asthma
T. Shimoda*1, Y. Obase2, M. Imaoka1, R. Kishikawa1,
T. Iwanaga1, 1. Fukuoka, Japan; 2. Nagasaki, Japan.
P45
Asthma Severity and Increased Risk of
Cardiovascular and Cerebrovascular Outcomes in
Patients With Moderate-to-Severe Persistent
Asthma
T.A. Omachi*1, T. Haselkorn1, D.P. Miller2, M. Shah2,
M.D. Eisner1, H. Chen2, C. Iribarren3, 1. South San
Francisco, CA; 2. San Francisco, CA; 3. Oakland, CA.
P46
Longitudinal Change in Asthma Symptom Control
in Patients Who Continued Vs. Discontinued
Omalizumab: Results From the XPORT Study
J. Antonova, B. Trzaskoma, K. Raimundo, P. Solari*,
J. Zazzali, South San Francisco, CA.
P47
Asthma Knowledge and Disease Control
M. Stevens*1, J. Stokes1, A. Bewtra1, M. Fasano2,
1. Omaha, NE; 2. Iowa City, IA.
P48
The Association of Blood Eosinophil Levels and
Severe Asthma Defined by New Guidelines
J. Casciano*1, J. Krishnan2, M. Buatti Small3,
S. Bajpai1, C. Li4, Z. Dotiwala1, 1. White Plains, NY;
2. Chicago, IL; 3. Frazer, PA; 4. Little Rock, AR.
Poster Session
P49
Reducing Bedside Education Time By Expanding
Parental Access to An Inpatient Asthma Class
H. Murphy*, D. Williams, J. Wolverton, M. Reddy,
Kansas City, MO.
P50
Effects of Budesonide/Formoterol on Fixed
Airflow Obstruction Status and Early Study
Withdrawal Due to Predefined Asthma Events in
Patients With Moderate to Severe Asthma
B.E. Chipps*1, D.P. Tashkin2, M. DePietro3,
F. Trudo3, 1. Sacramento, CA; 2. Los Angeles, CA;
3. Wilmington, DE.
P51
Effect of Fixed Airflow Obstruction Status on Peak
Expiratory Flow and Rescue Medication Use in
Response to Budesonide/Formoterol Treatment in
Patients With Moderate to Severe Asthma
B.E. Chipps*1, D. Tashkin2, M. DePietro3,
F. Trudo3, 1. Sacramento, CA; 2. Los Angeles, CA;
3. Wilmington, DE.
P52
A Persistent Asthmatic Patient After Lovebird
Contact: Case Report
S. Kaygusuz, M. Nursoy*, A. Gedik, S. Uzuner,
E. Cakir, Istanbul, Turkey.
P53
Poorly Controlled Asthma: New Therapeutic
Options
J. Fernandez de Cordova Aguirre*, A. VelascoMedina, D. Carino-Cartagena, M.E. Arroyo-Cruz,
S. Gonzalez Flores, G. Velazquez-Samano, Mexico
City, DF, Mexico.
P54
P55
Chronic Cough With Restrictive Changes on
Spirometry Diagosed as Hypersensitivity
Pneumonitis From Exposure to Nymphicus
Hollandicus (Cockatiel)
R. Harris*, Beverly Hills, CA.
Pharmacokinetics, Safety, and Tolerability of
Fluticasone Propionate Multidose Dry Powder
Inhaler and Fluticasone Diskus® Administered in
Healthy Subjects: An Open-Label, Randomized,
Three-Period Crossover, Single-Dose Study
A.B. Vutikullird1, M. Gillespie2, S. Song2, J. Steinfeld*2,
1. Cypress, CA; 2. Frazer, PA.
P56
A Novel Albuterol Multidose Dry Powder
Inhaler in Adult and Adolescent Patients With
Exercise-Induced Bronchoconstriction: A SingleDose Study
N. Ostrom*1, H. Taveras2, H. Iverson2, D. Pearlman3,
1. San Diego, CA; 2. Miami, FL; 3. Denver, CO.
P57
Results From Two Trials Evaluating the Potential
Effects of Flunisolide HFA (Aerospan) on
Growth in Pediatric Patients With Mild-toModerate Asthma
G. Bensch*1, L. Greos2, N. Ruiz3, J. Karafilidis3,
1. Stockton, CA; 2. Centennial, CO; 3. Somerset, NJ.
P58
Inhaler-Device Satisfaction, Smoking History,
Allergic Rhinitis and Adherence in Us Adult
Asthma Patients: Relationship to HealthRelated Outcomes
D. Price1, B. Harrow*2, L. Gever*2, J. Pike3, M. Small3,
V. Higgins3, 1. Aberdeen, Scotland, United Kingdom;
2. Somerset, NJ; 3. Macclesfield, United Kingdom.
P59
Evaluation of Recurrent Respiratory Infections in
Patients With Allergic Rhinitis, Asthma, and/or
COPD Pre- and Post-Treatment With Bacterial
Lysate Vaccines
A.M. Koatz*, Buenos Aires, Argentina.
P60
Childhood Obesity in Difficult to Control
Pediatric Asthma Patients in a Tertiary Pediatric
Subspecialty Clinic
Y. Hamzavi Abedi*, A.M. Perkins, M.B. Morales,
Norfolk, VA.
P61
Inhaled Mometasone Furoate-Induced Adrenal
Suppression in an Adolescent
M. Hanna*1, D.P. Mack2, 1. Oakville, ON, Canada;
2. Burlington, ON, Canada.
P62
Efficacy of Flunisolide HFA (Aerospan) in Adult
and Adolescent Patients 12 Years and Older With
Asthma by Baseline Inhaled Steroid
L. Greos*1, J. Corren2, N. Ruiz3, J. Karafilidis3,
1. Centennial, CO; 2. Los Angeles, CA; 3. Somerset, NJ.
P63
Peanut Aspiration in an Adult With Allergic
Asthma
A.P. Nguyen*, K.G. Clay, S.M. Fineman, Atlanta, GA.
P64
Eye Symptoms Correlate With Asthma Severity
M. Chen*1, E. Rael2, 1. State College, PA; 2. Hershey, PA.
P65
Serum Levels of Vitamin D and IgE Immune
Response to Allergens in Pediatric Asthmatic
Children: Controversial Results From a Poor
Caribbean Colombian Community
E. Egea*1, G. Garavito de Egea1, L. Fang1, G. Egea1,
L. Visbal1, N. Lecompte1, J. Escamilla2, 1. Barranquilla,
Colombia; 2. Cartagena, Colombia.
P66
Identifying Risk Factors Associated With Elevated
Blood Eosinophil Counts in Patients With Asthma
From Primary Care Clinical Records
D.B. Price*1, E.R. Bleecker2, J.D. Campbell3,
C.J. Corrigan4, I.D. Pavord5, A. Rigazio6, A. Burden6,
J. von Ziegenweidt6, V.L. Ashton6, G.H. Gopalan7,
M. Buatti Small7, 1. Aberdeen, United Kingdom;
2. Winston-Salem, NC; 3. Denver, CO; 4. London,
United Kingdom; 5. Oxford, United Kingdom;
6. Cambridge, United Kingdom; 7. Frazer, PA.
77
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P67
Correlation Between Gastroesophageal Reflux
Disease and Asthma Symptoms
A. DeWaters*1, M.P. Henao2, E. Rael2,
1. Hummelstown, PA; 2. Hershey, PA.
P68
Association Between Asthma Control and Body
Mass Index in Asthmatics
P.K. Gleeson*, E. Rael, Hershey, PA.
P69
Improving Documentation of the Asthma Control
Test™ Using Patient/Caregiver Electronic Entry
H. Murphy*, L. Harte, J. Parker, M. Reddy,
Kansas City, MO.
P70
Trends in the Use of Asthma Medications in
Mexico
M. Becerril-Angeles*, M. Vargas-Becerra, J.L. EstradaAguilar, V. Borja-Aburto, Mexico City, DF, Mexico.
P71
Asthma Baseline for Children in the Georgia and
North Carolina Medicaid Program
K.E. Johnson*, J. Swann, N. Serban, Atlanta, GA.
P72
Short-Term Improvement of Asthma Knowledge
in Asthmatic Children Following Asthma Camp
Attendance
J. Olsen*, M. Stevens, P. Foster, R. Hopp, Omaha, NE.
P73
Albuterol Multidose Dry Powder Inhaler in
Patients 12 Years and Older With Persistent
Asthma: 12 and 52 Week Safety
C. LaForce*1, D. Miller2, H. Taveras3, H. Iverson3,
C. O’Brien4, G. Raphael5, 1. Raleigh, NC; 2. North
Dartmouth, MA; 3. Miami, FL; 4. Frazer, PA;
5. Bethesda, MD.
P74
Efficacy of Albuterol Multidose Dry Powder
Inhaler Versus Placebo in Subjects 12 Years of Age
and Older With Persistent Asthma
G. Raphael*1, H. Taveras2, H. Iverson2, C. O’Brien3,
D. Miller4, 1. Bethesda, MD; 2. Miami, FL; 3. Frazer, PA;
4. North Dartmouth, MA.
P75
Impact of Obesity on Pulmonary Function:
Prospective Study in Young Adults
S. Melendez*, B. Del Río, J. Del Río, E. Navarrete,
Mexico City, DF, Mexico.
P76
Cumulative Dose Comparison of the Efficacy and
Safety of Albuterol-Multidose Dry Powder Inhaler
and Albuterol-Hydrofluoroalkane Metered Dose
Inhaler in Adults With Asthma
D. Miller1, D. Wayne2, H. Taveras2, H. Iverson2,
T. Ferro*3 , 1. North Dartmouth, MA; 2. Miami, FL;
3. Frazer, PA.
78
P77
Polymorphism in the Cd14 Promoter (CD14C159T) in Crimean Adults With Early and
Late-Onset Asthma
Y. Bisyuk1, V. Beloglazov1, A. Dubovyi1,
L.M. DuBuske*2, 1. Simferopol, Ukraine; 2. Gardner,
MA.
P78
Clinical Features of Allergic Rhinitis in
Intermittent and Mild Persistent Allergic Asthma
V. Tsybulkina1, N. Kurmaeva1, N. Tsybulkin1,
L.M. DuBuske*2, 1. Kazan, Russian Federation;
2. Gardner, MA.
P79
Correlation Between Atmospheric Pollutants,
Clime and Asthma Exacerbations in Children Over
a Five Year Period in Mexico City
C. Hernandez-Ramirez*, J. Vidal-Guzman,
U. Angeles-Garay, A. Ortega-Gonzalez, M. BecerrilAngeles, Mexico City, DF, Mexico.
P80
Lapses in Asthma Control in Patients Who
Continued Vs. Discontinued Omalizumab in a
Real-World Setting
G. Sun1, E. Antonova2, E. Chang1, M. Broder1,
P. Solari2, J. Zazzali*2, 1. Beverly Hills, CA; 2. South San
Francisco, CA.
Upon completion of this session, participants should be able to:
P43) summarize the effects of weight loss on markers of systemic
inflammation in obese children with bronchial asthma; P44) discuss
available markers of estimating airway inflammation in patients with
bronchial asthma; P45) describe the association between asthma
severity and increased risk of cardiovascular and cerebrovascular
outcomes in patients with moderate-to-severe persistent asthma;
P46) describe the longitudinal impact of discontinuing omalizumab on
patient asthma symptom control; P47) identify possible correlations
between asthma knowledge and disease control; P48) describe the
association between elevated EOS and asthma severity as defined by
new ERS/ATS guidelines and discuss the underlying implications ;
P49) discuss the effect of an inpatient asthma class on education time
spent at the bedside; P50) discuss the effects of treatment with the
individual components or combination of budesonide and formoterol
on predefined asthma worsenings in patients with or without fixed
airflow obstruction; P51) discuss the effects of treatment with the
individual components or combination of budesonide and formoterol
on lung function and rescue medication use in asthma patients with or
without fixed airflow obstruction; P52) discuss how differential
diagnosis of asthma-like symptoms could be made; P53) discuss
alternate options for the treatment of difficult to control asthma;
P54) recognize that cockatiel protein can cause hypersensitivity
pneumonitis; P55) discuss the differences in systemic exposures of
fluticasone multidose dry powder inhaler and fluticasone DISKUS for
the treatment of subjects with persistent asthma; P56) discuss the
efficacy and safety of albuterol multidose dry powder inhaler for the
prevention of exercise-induced bronchoconstriction; P57) discuss the
effect of flunisolide HFA on growth velocity in pediatric patients with
mild-to-moderate asthma; P58) identify the relationship between
inhaler-device satisfaction, adherence, smoking history and allergic
rhinitis to health-related outcomes; P59) describe the mechanism of
action of the bacterians vaccines in the protection of recurrent
Poster Session
infections of the mentioned pathologies; P60) recognize the
association between childhood obesity and difficult to control asthma;
P61) recognize the risk of adrenal suppression with the use of high
dose inhaled corticosteroids as well as screen for adrenal suppression
in at risk patients; P62) discuss the relative efficacy of different
flunisolide HFA and CFC formulations based on the intranasal
corticosteroids patients were taking prior to study entry; P63) discuss
the evaluation of foreign body aspiration in an adult; P64) observe a
correlation between eye symptoms and asthmatic severity;
P65) discuss serum levels of Vitamin D and IgE immune response to
allergens in asthmatic children and the unexpected study results;
P66) identify clinical and demographic factors predicting elevated and
low blood eosinophil counts in adolescent and adult patients with
asthma, as well as, describe how these factors influence asthma
outcomes prospectively and may be used to direct therapy;
P67) discuss the relationship between gastroesophageal reflux disease
and asthma; P68) discuss the correlation between BMI and asthma
control in asthmatics; P69) identify quality improvement methods that
increase documentation of the Asthma Control Test; P70) describe the
epidemiological trends of asthma in one of the key Latin American
countries; P71) identify problem areas for pediatric asthma care in
Georgia and North Carolina, both geographically and over time;
P72) discuss the utility of using an asthma survey or questionnaire to
test patients' knowledge or understanding of asthma; P73) discuss the
safety profile of albuterol multidose dry powder inhaler for the
treatment of subjects with persistent asthma; P74) discuss the
pulmonary efficacy and time to onset of albuterol multidose dry
powder inhaler for the treatment of subjects with persistent asthma;
P75) discuss weight and BMI in asthmatic patients as well as the
importance of tracking; P76) discuss the efficacy, pharmacokinetics,
pharmacodynamics and tolerability of albuterol multidose dry powder
inhaler versus albuterol hydrofluoroalkane metered dose inhaler for
the treatment of adolescents and adults with persistent asthma;
P77) discuss polymorphism in the CD14 Promoter (CD14-C159T) in
Crimean adults with early and late-onset asthma; P78) describe the
role of allergic rhinitis in asthma exacerbations; P79) assess the
correlation of atmospheric pollutants and some climatic factors with
the number of cases of asthma exacerbations in children; and
P80) discuss differences in lapses in asthma control in patients who
continued vs. discontinued omalizumab in a real world setting.
Basic Science Allergy and Immunology
P81
Inhibitory Effects of Salidroside On Inflammatory
Responses in Rat Alveolar Macrophages
X. Hu*, Hangzhou, China.
P82
Regulation of Airway Eosinophilia in a Model of
Feline Allergic Asthma by KTN0158, a Humanized
Anti-KIT Monoclonal Antibody
E.M. Mandel*1, C.R. Reinero2, R.W. Gedrich1,
C. Chang2, J. Trzil2, J. Dodam2, L.A. Cohn2,
C. Lubeski1, Y. Hadari1, T. LaVallee1, 1. New Haven, CT;
2. Columbia, MO.
P84
Evaluation of Genes Involved in Transition
FromAutoimmune Disease to Lymphoma
R. Anand*1, E. George2, M. Yu2, J.L. Ambrus2, L. Shen2,
1. Getzville, NY; 2. Buffalo, NY.
P85
Cutaneous Non-Tuberculous Mycobacterial
Infection in a Patient With Severe T-Cell
Lymphopenia and Selective IgM Deficiency
A. Gharib*1, A. Gupta Louis2, S. Agrawal2, S. Gupta2,
1. Los Angeles, CA; 2. Irvine, CA.
P86
Complement Deficiency Presenting as Group A
Streptococcal (GAS) Sepsis With Toxic Shock
Syndrome and Escherichia Coli Urosepsis in
Infancy
L. Helfner*, A.M. Jongco, Great Neck, NY.
P87
Guanylyl Cyclase-CGMP Pathway Mediates
Mitogenesis Inhibition By Natriuretic Peptides
and Sodium Nitroprusside in Rat Airway Smooth
Muscle Cells
F.A. Placeres-Uray*, R. Gonzalez de Alfonzo, I. Lippo
de Becemberg, M. Alfonzo, Caracas, Bolivarian
Republic of Venezuela.
P88
Cytidine Deaminase and Adenosine Deaminase
are Highly Sensitive Enzymatic Regulators of
Immune Response Intensity and Specificity
L. Titov1, K. Pavlov1, A. Hancharou1, O. Yanovitch1,
S. Javoronok1, L.M. DuBuske*2, 1. Minsk, Belarus;
2. Gardner, MA.
P89
Assessment of Select Serum Cytokines in Oral
Lichen Planus Patients
G. Drannik1, A. Kurchenko1, R. Rehuretska1,
L.M. DuBuske*2, 1. Kiev, Ukraine; 2. Gardner, MA.
P90
Immunosupressive Properties of Human
Olfactory Epithelium-Derived Ectomesenchymal
Stem Cells Cultured Ex Vivo
A. Hancharou1, N. Antonevich1, V. Chekan1,
L.M. DuBuske*2, 1. Minsk, Belarus; 2. Gardner, MA.
P91
Alterations in Minor Subsets of Peripheral Blood
Leukocytes in Infectious Mononucleosis Patients
A. Hancharou1, G. Davidovich1, I. Ramanava1,
E. Duzh1, L.M. DuBuske*2, 1. Minsk, Belarus;
2. Gardner, MA.
P92
The Effect of Gender on the Peripheral Blood B
Cells Maturation
A. Khojah*1, A. Bukhari1, O. Alpan2, 1. Chicago, IL;
2. Vienna, VA.
P93
CREST Syndrome in an 8 Year Old African
American Girl
I. Katayeva*1, K. Chotikanatis2, S. Glick3, J. Moallem2,
1. Forest Hills, NY; 2. Brooklyn, NY; 3. New York, NY.
Upon completion of this session, participants should be able to:
P81) discuss the new progress in the treatment of inflammation
related diseases; P82) discuss the effects of an anti-KIT antibody in
feline allergic asthma; P83) identify allergic screening test and
immunotherapy to formulate better allergy treatment; P84) identify
potential genetic mechanisms behind development of lymphoma in
autoimmune disease using an IL-14-alpha transgenic mouse model of
79
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Sjogren's syndrome; P85) discuss an extensive immunological analysis
of cell mediated immune deficiency in a patient with cutaneous nontuberculous Mycobacterial infection, as well as, identify and
investigate this condition appropriately in a clinical setting;
P86) recognize the clinical presentation, evaluation and management
of complement deficiency; P87) discuss the evaluation of the
proliferative response to ANP, CNP and sodium nitroprusside (NO
donator; SNP) in ASMC from rats and the pathway that mediates its
effects; P88) recognize cytidine deaminase and adenosine deaminase
as the highly sensitive enzymatic regulators of immune response
intensity and specificity; P89) summarize the assessment of select
serum cytokines in oral lichen planus patients; P90) discuss the
immunosupressive properties of human olfactory epithelium-derived
ectomesenchymal stem cells cultured ex vivo; P91) summarize the
alterations in minor subsets of peripheral blood leukocytes in
infectious mononucleosis patients; P92) describe the effect of gender
on the peripheral blood B cell maturation and the importance of
having gender-specific reference ranges, especially in the adolescent
age group; P93) discuss and identify the clinical presentation of
CREST syndrome.
Clinical Case Reports
P94
Aseptic Meningitis With Intravenous
Gammaglobuln Administration
C.C. Randolph*, D.H. Dreyfus, Waterbury, CT.
P95
Hemophagocytic Lymphohistiocytosis: Making a
Challenging Diagnosis
A. Mathur*, L. Yao, Phoenix, AZ.
P96
A Case of Eosinophilic Esophagitis in a Patient
With Strongyloides Stercoralis
A. Ali*, M. Segal, Philadelphia, PA.
P97
Combined Immunodeficiency in Wolf-Hirschhorn
Syndrome
S. Galowitz*, M. DeFelice, Wilmington, DE.
P98
IgE-Mediated Allergy to Bacitracin: Key Concepts
Illustrated Via a Case Series
E. Glancy*, C. Radojicic, Cleveland, OH.
P99
IgG4-Related Dacryoadenitis in Young Male
V. Reddy*, T. Craig, Hershey, PA.
P100
Common Variable Immunodeficiency in a Patient
With Systemic Lupus Erythematosus: Case Report
E. Sandoval*1, C. Quezada-Chalita1, C. CunninghamRundles2, S. Enciso-Pelaez1, M. Gutiérrez-Ceniceros1,
1. Mexico City, DF, Mexico; 2. New York, NY.
P101
Case Report: Successful Bronchial Thermoplasty
in a Case of Severe Persistent Atopic Asthma
C. Lee-Kim*1, S. Patel2, 1. Buffalo, NY; 2. Los Angeles,
CA.
80
P102
A Case of Irbesartan-Induced Angioedema With
Severe Laryngeal Edema
R. Rishi*1, S. Ringwala1, S. Fatteh2, 1. Fort Lauderdale,
FL; 2. Plantation, FL.
P103
Black Rubber and P-Phenylenediamine Contact
Dermatitis
C. Lin*, M. Frieri, East Meadow, NY.
P104
Successful Monoclonal Antibody Desensitization
in a Pediatric Patient With Hypersensitivity to
Rituximab
S. Logsdon*, L. Schneider, Boston, MA.
P105
Clearing the Aire
C. Lundberg*1, T. Banks2, 1. Silver Spring, MD;
2. Bethesda, MD.
P106
Refractory Hypotension in a Patient With Systemic
Mastocytosis Uncovered After Acute Myeloid
Leukemia Treatment
D. Ferastraoaru*, M. Janakiram, G. Hudes, Bronx, NY.
P107
Seed Allergy: When Natural Colors Are Dangerous
K. Tuano*, C. Hanson, K. Dillard, Houston, TX.
P108
Extraovarian Primary Peritoneal Carcinoma and
Abdominal Cocoon Syndrome Initially Presented
as Dermatomyositis: A Case Report
N.F. Morgal*, M. Patrimonio, S. Sonza, A. Jesena,
M. Tupas, V. Gasataya, Iloilo, Philippines.
P109
A Case of a Hypersensitivity Reaction Secondary
to Seabather’s Eruption
S. Ringwala*1, R. Rishi1, S. Fatteh2, 1. Fort Lauderdale,
FL; 2. Plantation, FL.
P110
Utility of a Website Based Database of Drug
Allergy: American Impressions
N.P. Joshi*1, T. Pun2, V. Jain3, M. Sidhu4, L. Miller1,
1. St. John’s, NF, Canada; 2. Toronto, ON, Canada;
3. Winnipeg, MB, Canada; 4. London, ON, Canada.
P111
Olive Oil Sensitivity and Desensitization: A NonIgE Mediated Mechanism
M. Karam*1, T. Franxman2, M. McMorris1, J. Baldwin1,
1. Ann Arbor, MI; 2. Lexington, KY.
P112
Longitudinal Multimodal Therapy in a Patient
With Mast Cell Activation Syndrome
A.S. Chau*1, L. Helfner2, V.R. Bonagura2,
A.M. Jongco2, 1. Mineola, NY; 2. Great Neck, NY.
P113
A Rare Case of Breastfeeding Anaphylaxis
A. Speck*, M. McMorris, Ann Arbor, MI.
P114
Cross-Reactivity to Balsalazide in a Mesalamine
Hypersensitive Patient
R. Rishi*1, H. Nasir2, S. Ringwala1, S. Fatteh3, 1. Fort
Lauderdale, FL; 2. Miami, FL; 3. Plantation, FL.
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
A Case of Tongue Swelling Caused By
Endotracheal Tube-Induced Vascular Obstruction
M. Saifi*, J.A. Bird, Dallas, TX.
P129
Terminal Ileum Perforation in a Patient With
Hyper IgE Syndrome
J. Jiao*, C.C. Horner, A.L. Kau, St Louis, MO.
P116
Hypersensitivity Reaction to Subcutaneous
Immunoglobulin
Q. Rashid*, A. Grant, 1. Galveston, TX.
P130
P117
Eosinophilic Cholecystitis in An Aspirin
Exacerbated Respiratory Disease (AERD) Patient
L. Finkas*, R. Katial, Denver, CO.
First Reported Case of Anaphylaxis Induced by
Pogonomyrmex SPP Bite in Mexico
J. Fernandez de Cordova Aguirre*, A. VelascoMedina, M.E. Arroyo-Cruz, S. Gonzalez Flores,
D. Cariño-Cartagena, G. Velazquez-Samano, Mexico
City, DF, Mexico.
P118
Diagnosis of Cystic Fibrosis in 59-Year-Old Woman
Referred for Immune Deficiency
C. Dutmer*, E. Gelfand, Denver, CO.
P131
The Diagnosis is in the History: A Case of DRESS in
a Pediatric Patient
B.J. Buelow*1, H.T. Zafra2, 1. Menomonee Falls, WI;
2. Milwaukee, WI.
P119
Protracted Angioedema in a 9-Year-Old Girl:
Propofol and Food Allergy
S.K. Lin*, T.B. Fausnight, Hershey, PA.
P132
P120
Management of Hypogammaglobulinemia
During Measles and Mumps Outbreak in Patients
Transitioning Off Immunoglobulin Replacement
K. Strothman*, R. Scherzer, Columbus, OH.
Cryptococcus Meningitis as the First
Manifestation of Idiopathic CD4
Lymphocytopenia
J. Brooks*1, G. Ghaffari2, 1. Lititz, PA; 2. Hershey, PA.
P133
Successful Treatment of Acute Urticaria With
Omalizumab
K. Patel*, R. Ten-Boquera, K. Gundling,
San Francisco, CA.
P134
A Rare Case of Acute Compartment Syndrome
Secondary to Insect Bite
F. Farri*1, T. Akande2, S. Baghian2, Y.K. Persaud2,
1. Ossining, NY; 2. Bronx, NY.
P135
A Young Immunocompetent Female With Asthma
and Allergic Rhinitis Found to Have Rare Fungal
Rhinosinusitis With Skull Erosion, Schizophyllum
Radiatum
R. Gupta*1, M. Segal2, 1. Vernon Hills, IL;
2. Philadelphia, PA.
P136
Treatment of Granulomatous-Lymphocytic
Interstitial Lung Disease (GLILD) in CVID With
Rituximab and Mycophenolate
J.M. Lomas*, M. Mortezavi, R.J. Looney,
Rochester, NY.
P137
Mastocytic Enterocolitis: Chronic Intractable
Diarrhea, Abdominal Pain,
With Increased Mucosal Mast Cells
A.C. Netterville*, A. Ochoa, New Orleans, LA.
P138
Cow’s Milk Protein Allergy Presenting With
Hypereosinophilia and Elevated Brain Natriuretic
Peptide
C. Parrish*, A.K. Wong, S. Thobani, M. Li, L. Scott,
Los Angeles, CA.
P139
Rash Associated With Angioimmunoblastic T-Cell
Lymphoma Mistaken for DRESS
A.K. Wong*, C. Parrish, S. Thobani, M. Li, L. Scott,
Los Angeles, CA.
P121
Mustard Seed Anaphylaxis
L. Cuervo-Pardo*, A. Gonzalez-Estrada, J. Fernandez,
Cleveland, OH.
P122
Allergic Rhinitis: Unassuming Until Meningitis
Recurred
P. Uong*, R. Casper, Phoenix, AZ.
P123
Omalizumab May Prevent Perfume Triggered
Laryngeal Angioedema
R.M. Young*, P. Ciminera, East Meadow, NY.
P124
Uncontrolled Asthma in a Primary Ciliary
Dyskinesia Patient Treated Successfully With
Omalizumab
J.X. Lee*, A. Rafi, W.B. Klaustermeyer, J.S. Yusin,
Los Angeles, CA.
P125
P126
P127
P128
A Rare Case of Food Induced Anaphylaxis to
Beetroot
F. Pazheri*1, B. Schroer2, 1. Shaker Heights, OH;
2. Cleveland, OH.
Drug Reaction With Eosinophilia and Systemic
Symptoms (DRESS) Presenting in An HIV Patient
Treated With Interferon and Anti-retrovirals
S. Hamadani*, A. Wong, C. Parrish, S. Thobani,
L. Scott, M. Li, Los Angeles, CA.
Persistent High Immunglobulin E Levels and
Tuberculosis: A Case Report
M. Yuksel, M. Nursoy*, A. Gedik, E. Cakir, Istanbul,
Turkey.
Evaluation of Eosinophilia: Hypereosinophilic
Syndrome
G. Rosner*1, D.W. Rosenthal2, 1. New York, NY;
2. Great Neck, NY.
Posters
P115
81
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P140
Dyshidrotic Eczema Induced by Gamunex
Intravenous Immunoglobulin That Resolved With
Gammagard in a Patient With Myasthenia Gravis
M. Shtessel*, D. Ferastraoaru, J. Graber, G. Hudes,
Bronx, NY.
P141
Löffler Syndrome in an Eight-Year-Old Pig Farmer
H. Shah*1, K. Gipson2, L. Wall2, 1. Yorba Linda, CA;
2. New Orleans, LA.
P142
An Atypical Presentation of Giant Cell Arteritis
J.R. Zaragoza*, N. Vernon, G. Ghaffari, Hershey, PA.
P143
Adult Female With Serum Sickness Secondary to
Mupirocin
A. Asawa*1, R. Bonds2, 1. Sugar Land, TX; 2. Galveston,
TX.
P153
Successful Desensitization to Antithymocyte
Globulin in An Adult Patient With Aplastic Anemia
K. Lindgren*1, K. Conner2, B. Yu2, 1. Elmhurst, IL;
2. Chicago, IL.
P154
Intranasal Mometasone as an Alternative to
Fluticasone in an HIV Patient on Ritonavir
S. Deol*, D.A. Khan, Dallas, TX.
P155
The Potential Effects of Allergy Immunotherapy
on Eosinophilic Esophagitis
V. Miller*, E. Lanford, J. Kurz, S. Shah, G. Patel, Dublin,
OH.
P156
Functional Abdominal Pain or Mast Cell GI
Disorder: A Stain Away
K. Anthony*, L. Wild, New Orleans, LA.
P144
When Wheeze is More Than Asthma: A Case
Report
M. Gupta*, S.P. DaVeiga, Philadelphia, PA.
P157
Anaphylaxis to a Life-Saving Remedy
P. Uong*1, K. Christine1, D. Wong2, 1. Phoenix, AZ;
2. Mesa, AZ.
P145
Unusual Case of Acquired Angioedema
Presenting Initially as Hereditary Angioedema
M. Joseph*, Saginaw, MI.
P158
A Navajo Infant With SCID Presents With Hypoxia,
Severe Neutropenia and a Normal Igg Level
P. Uong*1, N. Jain2, 1. Phoenix, AZ; 2. Gilbert, AZ.
P146
Orofacial Granulomatosis in a Patient With
Hereditary Angioedema
S.P. Brady*1, H.J. Wedner2, 1. Clayton, MO; 2. St. Louis,
MO.
P159
Metal Hypersensitivity as a Cause of Recurrent
Infections After Joint Replacement
D. Hirsch*, V. Bonagura, Great Neck, NY.
P160
P147
Treatment of Post-Transplant Acute Rejection
With Subcutaneous Immunoglobulin
Replacement
Z. Pirani, MD*, J. Shih, MD, Atlanta, GA.
Use of IVIG in Patients With Shwachman-Diamond
Syndrome
J.M. Zibert*1, M. Scotten2, S. Gierer2, 1. Kansas City,
MO; 2. Kansas City, KS.
P161
P148
Atypical Case of Kabuki Syndrome With
Indeterminate Immunodeficiency, Low B Cells and
Autoimmune Enteropathy
M. Gogna*, Glenshaw, PA.
Steroid Refractive Angioedema Associated With
Mild Mast Cell Activation and Histaminemia
J. Dara*1, A. Rubinstein2, 1. New York, NY; 2. Bronx, NY.
P162
Use of Rituximab Treatments for Acquired
Deficiency of C1 Esterase Inhibitor
T. Lee*, P. Busse, New York, NY.
P163
West Nile Virus Encephalitis in GATA2 Deficiency:
Clinical Improvement After IVIG and Interferon
Alfa-2b Therapy
J.S. Rosa*1, S. Kappagoda1, A. Hsu2, S. Holland2,
A.Y. Liu1, 1. Stanford, CA; 2. Bethesda, MD.
Evaluating the Use of Icatibant Injections
(FIRAZYR®) With C1 Esterase Inhibitors (Cinryze®
and Berinert®) During Pregnancy of a Type III
Hereditary Angioedema Patient
F.F. Ansary*1, T.J. Craig2, 1. Hummelstown, PA;
2. Hershey, PA.
P164
Epoetin Alfa Hypersensitivity Reaction and
Successful Desensitization in a Child
J.S. Rosa*, A.Y. Liu, Stanford, CA.
The Perplexing Nature and Clinical Progression of
Eosinophilic Granulomatosis With Polyangitis in a
Previously Healthy Elite Athlete
T. Ocampo*, T. Rans, San Antonio, TX.
P165
Eosinophilic Granulomatosis With Polyangiitis
Precipitated by Corticosteroid Withdrawal
J.L. Hill*, S. Patel, D. Sudano, T.F. Carr, Tucson, AZ.
P149
P150
P151
P152
82
A Case of Hashimoto’s Encephalopathy Treated
With Immunomodulation and Thyroidectomy
With Incidental Finding of Thyroid Cancer
J.A. Quirt*1, O. Perlov2, D.A. Haaland1, 1. Hamilton,
ON, Canada; 2. Barrie, ON, Canada.
Nickel and Cobalt Allergy: The Importance of
Patient History
P. Naik*, R. Steele, M. Aquino, L. Fonacier, Mineola,
NY.
Poster Session
P166
Treatment of Refractory Macrophage Activation
Syndrome in Systemic Juvenile Idiopathic
Arthritis With High Dose Anakinra
J. Kwong1, T. Peng*2, A. Mohiuddin1, P.F. Weiss3,
R.Q. Cron4, D. Chefitz1, V. Craig1, D. Weissmann1,
J. Andujar-DeLaCruz1, L.N. Moorthy1, 1. New
Brunswick, NJ; 2. Edison, NJ; 3. Philadelphia, PA;
4. Birmingham, AL.
P167
Priming of Anaphylaxis With Sequential Allergen
Exposure in a 35 Year-Old Male
R.S. Paul1, L. Anderson2, A. Rafi2, J. Yusin*2, 1. San
Francisco, CA; 2. Los Angeles, CA.
P168
Pancytopenia in a Patient With Good’s Syndrome
J. Regan*, W. Stevens, B. Stein, P. Avila, Chicago, IL.
P169
Minocycline-Induced Anaphylaxis in an
Adolescent Female
T. Peng*1, A. Ettinger2, C. Maccia2, A. Weller2,
L. Moorthy2, 1. Edison, NJ; 2. New Brunswick, NJ.
P178
Aspirin Exacerbated Respiratory Disease
(AERD) and Cerebrospinal Fluid Rhinorrhea: Case
Report
D.A. Carino Cartagena*, A.A. Velasco-Medina,
J.C. Fernandez de Cordova-Aguirre, M.E. ArroyoCruz, S. Gonzalez-Flores, G. Velazquez-Samano,
Mexico City, DF, Mexico.
P179
Successful Approach to a Patient With Multiple
Drug Reactions (Including Serum Sickness) to
Rituximab
J.K. Kim*1, S. Deol1, C. Wysocki1, D.A. Khan2, 1. Dallas,
TX; 2. Grapevine, TX.
P180
An Unusual Case of Recurrent Abdominal Pain
Simulating Angioedema
L. Rampur, A. Rubinstein, Z. Ren*, Bronx, NY.
P181
A Case of Multiple Myeloma Manifesting as LifeThreatening Angioedema
S. Bose*, D. Nayak, C. Saltoun, Chicago, IL.
P182
Fatal Aseptic Meningitis Due to Coxsackie B3 Virus
Infection in a Patient With Acquired
Hypogammaglobulinemia
T.V. Palacios*, M. Lawrence, L. Borish,
Charlottesville, VA.
P170
DRESS Following PRES
S.M. May*, N.L. Ott, A. Joshi, M. Hartz, Rochester, MN.
P171
Anticonvulsant Hypersensitivity Syndrome
Associated With a Symptom Free Period
S. Patel*1, E. Nwaobasi-Iwuh2, A. Wolff3, 1. Summit,
NJ; 2. Morristown, NJ; 3. Newark, NJ.
P183
Food Protein Induced Enterocolitis Syndrome
(FPIES) in a Patient With Prior IgE Mediated Food
Allergy
J. Giacinto Lawrence*1, P. Ponda2, 1. Roslyn, NY;
2. Manhasset, NY.
Prevention of Kounis Syndrome Episodes Using a
Combination of Ketotifen and Non-Sedating
Antihistamines
J. McCracken*1, C. Schlegel2, S. Sur2, 1. League City,
TX; 2. Galveston, TX.
P184
Recurrent Perioperative Anaphylaxis in a 24 Year
Old Female With Untreated Asthma
J. Kannan, J. Bernstein*, Cincinnati, OH.
P185
Lymphopenia and Agammaglobulinemia of
Unclear Etiology
L. Bornstein*1, R. Herzog2, 1. New York, NY; 2. New
York City, NY.
P186
Prolactinoma Mimicking Refractory Rhinitis
M.S. Motosue*, Rochester, MN.
P172
P173
P174
An Atypical Presentation of Chronic Eosinophilic
Pneumonia
A. Yang*, R. Ganim, J. Mueller, P. Gurung,
Springfield, MA.
IgM Deficiency Presenting as Strongyloides
Hyperinfection
J.G. Ghably*1, A. Kapila1, G. Shaw1, T. Roy1, R. Byrd1,
K. Guha2, 1. Johnson City, TN; 2. Winston-Salem, NC.
P175
A Case of Hypereosinophilic Syndrome Presenting
With Myocarditis
N. Fenny*, K. McGrath, A. Peters, Chicago, IL.
P187
Case of Hypogammaglobulinemia Following
Rituximab Therapy
M. Egan*, C. Cunningham-Rundles, New York, NY.
P176
Emerging Trend of Henna Tattoos Causing a
Clinical Contact Dermatitis
P. Buddiga*, Fresno, CA.
P188
P177
Granulomatous Disease Associated With
Immunodeficiency
D. Shah*, T. Truong, Denver, CO.
Use of Rituximab in Hemophilia B Patients With
Anaphylaxis and Factor IX Inhibitor
J. Kiehm*1, N. Qamar2, S. Acharya3, B. Kaplan1,
1. Great Neck, NY; 2. Manhasset, NY; 3. New Hyde
Park, NY.
P189
A Common Skin Eruption With an Uncommon
Cause
J.T. Abraham*, J. Fernandez, Cleveland, OH.
83
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P190
IgE Mediated Allergic Reaction to Methimazole in
a Pediatric Patient With Subsequent Successful
Desensitization
E. Akl*, B. Ward, A. Kumar, W. Zhao, Richmond, VA.
P191
Was Trauma the Cause? A Case of Hereditary
Angioedema
M.B. Reddy*, Denver, CO.
P192
A Curious Cough
C. Caruthers*, J. Vitale, M. Warrier, St. Louis, MO.
P193
Non-Tuberculous Mycobacteria (NTM) Infection
Presenting as Difficult-to-Control Asthma
J.M. Rodrigues*, A. Katta, R. Nayak, R. Slavin,
St Louis, MO.
P194
An Early Presentation of Drug Reaction With
Eosinophilia and Systemic Symptoms
S. Waqar*1, S. Farzan2, 1. Dix Hills, NY; 2. Great
Neck, NY.
P195
Diagnosis of Oral Erythema Multiforme in a
Patient With Mycoplasma Pneumonia
K.R. Brown*1, D. Eisen2, J. Li2, A. Assa’ad2, 1. Lakeside
Park, KY; 2. Cincinnati, OH.
P196
A Successful Pre-Medication Protocol for a Patient
With Anaphylatoid Reaction to Intravenous
Radiocontrast Media in Spite of Standard PreMedication Protocol
M.H. Chong*, S.L. Mawhirt, J. Sher, M. Aquino,
M. Davis-Lorton, L. Fonacier, Mineola, NY.
P197
Post-Infusion Myocardial Infarction in a Patient
Receiving IVIG
S. Draikiwicz*1, S. Arakali2, E. Capitle3, 1. Scotch
Plains, NJ; 2. New Brunswick; 3. Newark, NJ.
P198
Granulomatosis With Polyangitis in An
Adolescent Boy
S. Burke-Mcgovern*, Middle Village, NY.
P199
Case Report: A Patient With Acquired C1-INH
Deficiency (ACID) and Hypogammaglobulina
E. Schussler*, P. Busse, New York, NY.
P200
A Delayed Presentation of Severe Combined
Immunodeficiency
J. Bergerson*, B. Pelz, B. Prince, R. Fuleihan,
Chicago, IL.
P201
G6PC3 Deficiency and Poland Syndrome in a
Three Year Old
G. Coscia*, M. Foca, K. Anyane-Yeboa, K. Ender,
Y. Demirdag, New York, NY.
P202
Recrudescent Exanthem Secondary to
Streptococcus Pyogenes Pharyngitis
G. Imperato*1, A. Khokhar2, S. LaBarba1, P. Ponda1,
1. Great Neck, NY; 2. Manhasset, NY.
84
P203
Delayed Hypersensitivity Reactions to ADHD
Medications: A Case Series
S. LaBarba*, P. Ponda, Great Neck, NY.
P204
Eosinophilic Cystitis: A Rare Cause of Dysuria and
Hematuria in Children
I.R. Bachove*, Philadelphia, PA.
P205
Case Report: Cashew as an Inciting Food for FPIES
E.J. Feuille*, New York, NY.
P206
Hypersensitivity Reaction During Hemodialysis
Z. Li*, J. Celestin, M. Pasha, Albany, NY.
P207
Infection as the Culprit in Angioedema
M.L. Curtiss*, J.T. Anderson, T. Hwangpo,
Birmingham, AL.
Upon completion of this session, participants should be able to:
P94) discuss aseptic meningitis as a delayed adverse outcome of IVIG;
P95) identify the challenges encountered in making a diagnosis of
hemophagocytic lymphohistiocytosis; P96) associate parasitic
infections with systemic eosinophilia and eosinophilic esophagitis;
P97) evaluate and appropriately treat for immunodeficiency in patients
with Wolf-Hirschhorn Syndrome; P98) identify the variable routes of
topical antibiotic exposure causing allergic reactions, identify
bacitracin as equally important as neomycin in allergic reactions, and
discuss the utility of skin prick testing to confirm topical antibiotic
components as allergens; P99) identify important information
necessary to diagnose IgG4-related disease; P100) recognize the
relation between immunodeficiency and autoimmunity; P101) discuss
the merits and pitfalls of bronchial thermoplasty in the treatment of
severe persistent asthma; P102) identify the potential risks of
angiotensin II receptor blockers in causing angioedema, as well as,
possible mechanisms by which these risks are increased; P103) identify
p-Phenylenediamine (hair dye) contact dermatitis, confirm the
diagnosis and provide appropriate care; P104) discuss desensitization
protocols and how to modify them for pediatric patients with drug
hypersensitivity to monoclonal antibodies; P105) identify and treat
chronic idiopathic urticaria in APECED patients; P106) suspect
coexistence of systemic mastocytosis in patients with hematological
malignancies since proper treatment significantly improves symptoms
secondary to mediators release; P107) recognize adverse reactions to
food additives and advocate for FDA certification as well as specific
labeling for all natural flavors and coloring; P108) discuss the
relationship of dermatomyositis and malignancy; P109) identify the
history and physical exam findings of seabather's eruption and
formulate proper strategies for supportive care; P110) identify the
opinions of American allergists and immunologists with regard to both
the utility of a database of adverse drug reactions as well as how the
majority inform their clinical practice regarding desensitization
therapies; P111) identify the mechanism of olive oil sensitivity;
P112) discuss the current diagnostic criteria and treatment of mast cell
activation syndrome; P113) identify cases of breastfeeding anaphylaxis
and develop potential treatment strategies for women with this
diagnosis who desire to continue breastfeeding; P114) utilize an
outpatient provocative balsalazide challenge procedure in IBD patients
who are hypersensitive to mesalamine and discuss the use of
provocative drug challenging prior to initiating a medication with
potential cross-reactivity; P115) identify mechanical obstruction of
venous drainage as an etiology of prolonged tongue swelling in
intubated individuals; P116) discuss adverse reactions caused by
Poster Session
immunoglobulin infusions and management of patients with
hypersensitivity reactions to immunoglobulin infusion; P117) identify
that eosinophilic cholecystitis may be a possible complication in
aspirin exacerbated respiratory disease patients with eosinophilia;
P118) identify when cystic fibrosis should be suspected and evaluated,
even in the face of atypical age of symptom-onset and lack of classic
phenotypic features; P119) identify the food allergy contraindications
to propofol use and discuss the clinical relevance of the
contraindications; P120) discuss the management and treatment
options of patients with hypogammaglobulinemia during outbreaks of
vaccine-preventable illness; P121) identify mustard seed anaphylaxis;
P122) have high suspicion for cerebral spinal fluid (CSF) leak in
patients with allergic rhinitis with other co-morbid history such as
meningitis, stroke, or neurological signs; P123) discuss similar cases
such as this one and discuss the possibility of expanding the uses of
omalizumab for angioedema due to indoor pollutants such as
perfume; P124) discuss uncontrolled asthma and use of omalizumab
even in patients with advanced lung disease; P125) discuss the
potential for anaphylaxis to beetroot ; P126) identify abacavir as a
potential cause of DRESS, a severe life threatening drug reaction that
requires early detection and treatment; P127) discuss differential
diagnosis of hyperimmunglobulin E; P128) review the differential
diagnosis regarding hypereosinophilia; P129) establish the diagnosis
of gastrointestinal histoplasmosis in HIES and initiate appropriate
antifungal therapy; P130) discuss insects that can be related to severe
allergic reactions; P131) summarize the clinical and laboratory
characteristics of patients with DRESS as well as available treatment
options; P132) state the diagnostic criteria and discuss the workup and
treatment options for idiopathic CD4 lymphocytopenia; P133) discuss
available treatments for acute urticaria; P134) identify the different
manifestations of insect hypersensitivity, recognize that insect bite
hypersensitivity can rarely present as acute compartment syndrome
and that severe complications can occur from non-allergic insect bites
that require immediate care; P135) describe medical complications of
fungal sinusitis and be wary of healthy hosts who may be harboring
such infections; P136) discuss combination chemotherapy treatment
options for granulomatous and lymphocytic interstitial lung disease
(GLILD) in CVID; P137) evaluate and treat paients with mastocytic
enterocolitis; P138) recognize that cow’s milk protein allergic
proctocolitis can be associated with significant eosinophilia;
P139) recognize that the presentation of angioimmunoblastic T-cell
lymphoma may mimic that of DRESS syndrome; P140) identify
dyshidrotic eczema as a drug reaction of IVIG therapy; P141) identify
and diagnose rare but serious conditions such as Loeffler's syndrome;
P142) consider giant cell arteritis as a differential diagnosis in an
atypical presentation where tongue swelling is the main symptom
presented in an elderly patient; P143) recognize features of serum
sickness; P144) recognize bronchiectasis in patients with asthma and
formulate a management plan; P145) distinguish between hereditary
and acquired angioedema and be aware of pitfalls in laboratory data
interpretation; P146) recognize the presentation of orofacial
granulomatosis; P147) discuss the use of subcutaneous
immunoglobulin as a potential treatment for post-transplant acute
antibody mediated rejection; P148) identify and manage
immunodeficiency in a patient with Kabuki syndrome; P149) discuss
the clinical presentation, diagnosis and treatment options for
Hashimoto's encephalopathy, a rare immune mediated neurologic
syndrome; P150) evaluate for GATA2 deficiency for patients who
present with recurrent/severe viral, mycobacterial infections or
leukemia; P151) create a slow desensitization protocol for a child with
delayed type hypersensitivity reaction to erythropoietin; P152) discuss
the importance of history and physical exam in the evaluation of
dermatitis; P153) discuss a successful desensitization with
antithymocyte globulin; P154) discuss the interaction between
ritonavir and fluticasone and provide alternative intranasal steroid
therapies to patients with rhinitis on ritonavir; P155) discuss the
potential effects of allergy immunotherapy on eosinophilic
esophagitis; P156) recognize mast cell gastrointestinal disorders in
patients with chronic abdominal pain and bowel dysfunction, as well
as, evaluate patients for gastrointestinal mast cell disease;
P157) discuss some of the complications related to hemophilia B and
recognize the risk of anaphylaxis with exogenous blood products,
especially one that is needed to be replaced periodically;
P158) diagnose SCID in children with severe neutropenia and normal
immunoglobulin levels, especially in the presence of lymphopenia;
P159) discuss the different reasons for joint replacement failure and
recognize metal hypersensitivity as an increasingly important
challenge to orthopedic procedures; P160) discuss immunodeficiency
in Schwachman Diamond Syndrome and the potential use of IVIg to
reduce the rate of infections; P161) manage a patient with
angioedema unresponsive to traditional therapies; P162) discuss
available treatments for acquired deficiency of C1 esterase inhibitor;
P163) discuss the future use of icatibant as a treatment during
pregnancy for type III hereditary angioedema patient; P164) identify
the variable clinical features and lab findings supportive of the
diagnosis of eosinophilic granulomatosis with polyangitis (EGPA);
P165) identify the clinical presentation of eosinophilic granulomatosis
with polyangiitis and its possible precipitants, including corticosteroid
tapering and withdrawal; P166) describe macrophage activation
syndrome (MAS) and treatment options; P167) conceptualize
anaphylaxis as a continuous and dynamic process rather than a chain
of discrete molecular and cellular events; P168) identify characteristics
of Good Syndrome; P169) identify anaphylaxis as a potential adverse
effect of minocycline; P170) identify causal agents, including atypical
medications and risk factors for the development of drug related
eosinophilia with systemic symptoms (DRESS); P171) recognize one
variable presentation of anticonvulsant hypersensitivity syndrome as
well as discuss the inclusion of drug hypersensitivity reactions in the
differential diagnosis of sepsis; P172) develop an increased awareness
of non-IgE-mediated reactions when diagnosing or challenging a
patient with prior IgE-mediated food allergy; P173) identify the criteria
for diagnosis of chronic eosinophilic pneumonia; P174) identify
strogyloides hyperinfection; P175) discuss the differential diagnosis
and diagnostic evaluation of hypereosinophilia; P176) discuss henna
as a potential trigger causing a contact dermatitis; P177) identify
immune component of granulomatous disease; P178) describe the
comprehensive management of a complex case with rhinopathy
causes; P179) discuss a successful management strategy for a patient
with a serum sickness-like reaction to rituximab; P180) identify other
abdominal conditions, such as, eosinophilic enteritis in patients
presenting with symptoms of abdominal visceral angioedema;
P181) recognize that lymphoproliferative disorders can cause acquired
angioedema; P182) discuss potential side effects of rituximab, such as
secondary B cell and antibody deficiency and potential susceptibility
to enteroviral meningeal infections; P183) discuss effective treatment
regimens for the prevention of Kounis syndrome episodes;
P184) recognize the contribution of poorly controlled asthma to
anaphylaxis and the serious consequences it could have in the
perioperative period; P185) diagnose newborns presenting with
lymphopenia and severe immune deficiency of unknown etiology;
P186) discuss the differential and work up for persistent rhinorhea;
P187) discuss screening of patients who previously received
85
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
rituximabab therapy presenting with frequent infections for
hypogammaglobulinemia; P188) recognize that patients inhibitor
antibodies can play a part in the development of anaphylaxis to
biologic agents and rituximab can be used to eliminate the inhibitor
antibodies; P189) identify the clinical presentation and work up of
autoimmune progesterone dermatitis; P190) discuss treatment options
for hyperthyroidism in patients with allergic reaction to methimazole
who are not tolerating PTU; P191) identify the causes of hereditary
angioedema and discuss the role of trauma in inciting an attack of
hereditary angioedema; P192) identify other causes of persistent
asthma, cough and rhinorrhea such as complications from lap-band
surgery; P193) identify the risk factors and treatment measures for
difficult-to-control asthma with superimposed non- tuberculous
mycobacteria infection; P194) recognize and manage early-onset drug
reaction with eosinophilia and systemic symptoms (DRESS);
P195) identify characteristics of oral erythema multiforme in a patient
presenting with mycoplasma pneumonia; P196) discuss current and
potential pre-medication protocol options for patients requiring
subsequent diagnostic or therapeutic studies utilizing radiocontrast
media in order to prevent repeat breakthrough reactions, especially if
with symptoms that may be life-threatening; P197) describe the
pathophysiology of IVIG in development of thromboembolic events
and the association between IVIG therapy and post-therapy
myocardial infarction; P198) discuss ANCA positive vasculitides in
children and aldolescents, especially in the minority patient poulation;
P199) discuss previously unidentified associations in ACID;
P200) discuss genetic causes of SCID syndromes with delayed
presentation; P201) discuss the clinical spectrum of G6PC3 Deficiency
as well as Poland Syndrome; P202) summarize the evaluation and
diagnosis of exanthems secondary to streptococcal pharyngitis;
P203) discuss ADHD medications as a possible source of delayed
hypersensitivity reactions; P204) discuss the presenting signs and
symptoms, causes, diagnosis and treatment of eosinophilic
esophagitis; P205) describe classic presentation of FPIES as well as
potential inciting foods; P206) recognize immediate allergic reactions
during hemodialysis and how to treat them; P207) discuss the
contributing effects of sinus, nasal, and lip infection on orofacial
swelling, and the possible confusion this may cause with swelling from
medication-induced angioedema.
P211
Are Patients With Primary Immunodeficiency
(PID) at Greater Risk of Infection After
Cardiopulmonary Bypass for Heart Valve
Replacement?
M. Stein1, R. Price2, A. Koterba*1, W. Tuer3, 1. North
Palm Beach, FL; 2. Palm Beach Gardens, FL; 3. West
Palm Beach, FL.
P212
Mowat-Wilson Syndrome (MWS) With Asplenia
and Low Immunoglobulin Levels
S. Wu*1, C.M. Bollard2, B.S. Vartabedian1, K. Paull3,
B.P. Chumpitazi1, I.C. Hanson1, 1. Houston, TX;
2. Washington, DC; 3. Bryan, TX.
P213
Balancing Inflammation and Infection in a Patient
With Common Variable Immunodeficiency
(CVID) and Chronic Giardiasis
D.A. Andreae*, C. Cunningham-Rundles,
New York, NY.
P214
Tsukamurella Species Infection Prompting
Diagnosis of Chronic Granulomatous Disease in a
17 Year Old Male
C.D. Kubiak*, J.R. Trotter, J.K. Potthast, A. Petrovic,
J.W. Leiding, St. Petersburg, FL.
P215
Renal Complication of Common Variable
Immunodeficiency
H.M. Tartibi*, S.L. Bahna, Shreveport, LA.
P216
Sarcoidosis Without Granuloma Presenting as
Lymphopenia
A. Kleva*, A. Jongco, Great Neck, NY.
P217
Identification of GATA2 Mutation in
Asymptomatic Patient
M.R. Shams*, L. Kobrynski, Atlanta, GA.
P218
Effective Use of 20% Subcutaneous Immunoglobulin Therapy in an Adult Male With
Pre-Existing Thrombi
C.M. Duff*1, M. Sher2, J. Leiding2, 1. Parrish, FL;
2. St. Petersburg, FL.
Clinical Immunology, Immunodeficiency
P208
Anterior Uveitis in a Patient With Underlying
Immunodeficiency
R. Kreiner*1, R. Rosenbaum1, A. Rubinstein2, 1. New
York, NY; 2. Bronx, NY.
P219
Divergent Phenotypes in Siblings With
X-Linked CGD
F. Alkhatib*1, D.M. Robertson2, 1. Holyoke, MA;
2. Hadley, MA.
P209
The Immunoglobulin Diagnosis, Evaluation, and
Key Learnings (IDEAL) Patient Registry: Results
From Our Primary Immune Deficiency Population
Treated in Alternate Sites of Care
S. Kearns*1, L. Kristofek1, B. Bolgar1, L. Seidu2,
1. Denver, CO; 2. Atlanta, GA.
P220
Newborn TREC Screening Identified an Infant
With NHEJ1 Heterozygous Mutation Leading to
the Diagnosis of Atypical Radiosensitive SCID
H. Bhatti*, P. Poowuttikul, E. Secord, Detroit, MI.
P221
STAT3 Mutation in Good Syndrome
L. Buyantseva*, T. Craig, Hershey, PA.
Frequencies of Autoimmune Diseases Associated
Polymorphisms in Mexican Population
B. Esquivel*, Mexico City, DF, Mexico.
P222
Mannose Binding Lectin Deficiency With a
Concurrent Esophageal Candidiasis and Recurrent
Herpes Gingivalis
K. Achar*1, D. Ferastraoaru2, D.L. Rosenstreich2,
1. New York, NY; 2. Bronx, NY.
P210
86
Poster Session
P223
Risk Factors Related to Mortality in Children With
Haemophagocytic Lymphohistiocytosis in a
Children’s Hospital From Mexico City
L.I. Calderon*, A. Partida, B.E. Del Rio, O. Saucedo,
C. Cicero, Mexico City, DF, Mexico.
P224
Neutropenia: A Clue for the Diagnosis of X-Linked
Agammaglobulinemia
M. Tallar*1, M. Hintermeyer1, H.N. Hartman2,
J. Verbsky1, J. Casper1, J. Routes1, 1. Wauwatosa, WI;
2. Milwaukee, WI.
P225
Long-Term Prophylactic Treatment of Hereditary
Angioedema: Findings From an International
Hereditary Angioedema Expert Survey
B. Zuraw1, T. Craig*2, J.A. Bernstein3, H. Farkas4,
I. Boccon-Gibod5, L. Bouillet5, M. Cicardi6,
M. Cancian7, A. Reshef8, M. Stobiecki9,
P. Nordenfelt10, H. Longhurst11, M. Guilarte12,
T. Caballero13, M.B. Ferreira14, K. Bork15, M. Magerl16,
I. Martinez-Saguer17, E. Aygören-Pürsün18,
A. Bygum19, 1. La Jolla, CA; 2. Hershey, PA;
3. Cincinnati, OH; 4. Budapest, Hungary; 5. Grenoble,
France; 6. Milan, Italy; 7. Padova, Italy; 8. Tel
Hashomer, Israel; 9. Cracow, Poland; 10. Jönköping,
Sweden; 11. London, United Kingdom; 12. Barcelona,
Spain; 13. Madrid, Spain; 14. Lisbon, Portugal;
15. Mainz, Germany; 16. Berlin, Germany;
17. Frankfurt- Mörfelden, Germany; 18. Frankfurt,
Germany; 19. Odense, Denmark.
P226
A Case of GATA2 Mutation Presenting With
Cryptococcal Meningitis
K. Welch*, New York, NY.
P227
Recombinant Human Hyaluronidase [rHuPH20]Facilitated Subcutaneous (SC) Infusion of
Immunoglobulin G (IgG) (Hyqvia; IGHy) in
Patients Aged ≥16 Years With Primary
Immunodeficiencies (PI): Long Term Safety,
Efficacy, and Tolerability
R.L. Wasserman1, M. Stein2, I. Melamed3,
L. Kobrynski4, J.A. Grant5, S. Gupta6, W. Engl7,
H. Leibl7, L. Yel*8, R.I. Schiff8, 1. Dallas, TX; 2. North
Palm Beach, FL; 3. Centennial, CO; 4. Atlanta, GA;
5. Galveston, TX; 6. Irvine, CA; 7. Vienna, Austria;
8. Westlake Village, CA.
P228
P229
New Complex Chromosome Abnormality in a
Partial DiGeorge Patient Associated With Late
Presentation of Immune Alterations
V. Cavero Chavez*, S.A. Schwartz, Buffalo, NY.
IgG4-Related Disease Presenting as Abdominal
Pain With Mass
L. Zhou*, G.D. Marshall, Jackson, MS.
P230
Outcomes of Splenectomy in CVID: A Survey of
44 Patients
J.M. Camacho*, C. Cunningham-Rundles,
New York, NY.
P231
Optic Neuritis in a 29-Year-Old With Common
Variable Immunodeficiency Treated With
Infliximab
M. Mortezavi*, E. Weis, R.J. Looney, Rochester, NY.
P232
Topical GM-CSF for Wound-Healing in
Lymphopenic Patient Without Known
Neutrophilic Dysfunction
B. Geng*, M. Breslin, M. Garcia-Lloret, R. Roberts,
Los Angeles, CA.
P233
Cytokine and SLPI Levels in Blood and Urine of
Patients With Chronic Cystitis and Pyelonephritis
G. Drannik1, F. Gaisenyuk1, V. Driyanska1,
N. Stepanova1, L.M. DuBuske*2, 1. Kiev, Ukraine;
2. Gardner, MA.
P234
Interrelation of Antiendotoxin and Humoral
Immunity in Patients With Systemic Lupus
Erythematosus
D.V. Shaduro1, V.A. Beloglazov2, A.I. Gordienko2,
L.M. DuBuske*3, 1. Minsk, Belarus; 2. Simferopol,
Ukraine; 3. Gardner, MA.
P235
Interaction Between Sperm and Mucosal
Immunity as Assessed by Reactive Oxygen
Species Generation in Seminal Fluid of Chronic
Abacterial Prostatitis Patients
G.N. Drannik1, T.V. Poroshina1, V.S. Savchenko2,
K.R. Nyrimanov1, L.M. DuBuske*2, 1. Kiev, Ukraine;
2. Gardner, MA.
P236
Concentration of Tgf-β1 in Urine of Children With
Obstructive and Refluxing Megaureter
G.N. Drannik1, N.A. Kalinina1, V.F. Peterburgskiy1,
T.V. Poroshina1, V.S. Savchenko1, L.A. Mygal1,
L.M. DuBuske*2, 1. Kiev, Ukraine; 2. Gardner, MA.
P237
Recurrent Lung Abscesses
L. Bornstein, R. Herzog*, New York, NY.
P238
Noncaseating Granulomatous Disease With
Eosinophilic Spongiosis Associated With Potential
Common Variable Immunodeficiency (CVID)
B. Patel*, A.S. Nickels, G.W. Volcheck, A.Y. Joshi,
Rochester, MN.
P239
Anti-Neutrophil Antibody Positivity in Severe
Congenital Neutropenia
S.E. Henrickson*1, S. Jyonouchi2, 1. Haddonfield, NJ;
2. Philadelphia, PA.
P240
A Case of Idiopathic CD4 Lymphopenia With
Cutaneous HPV Infection
J. Toh*1, J. Dara1, A. Rubinstein2, 1. New York, NY;
2. Bronx, NY.
87
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P241
Early Onset of Marked Lymphopenia,
Neutropenia and Mild Thrombocytopenia in An
African-American Girl
L.E. Moore*1, L. Zhou2, A.B. Yates2, 1. Navarre, FL;
2. Jackson, MS.
P242
Severe and Early Presentation of NEMO/IKBKG
Deficiency
V. Nayima*, P. Atkinson, Birmingham, AL.
Upon completion of this session, participants should be able to:
P208) discuss possible underlying immunodeficiency in patients
presenting with uveitis; P209) discuss factors involved in identifying
primary immune deficiency patients and using immunoglobulin
replacement therapy in alternate sites of care; P210) identify genetic
variants in Mexican population that have more penetrance in the
phenotype; P211) anticipate risks of infection due to dropping IgG
levels in patients with PID who are undergoing cardiopulmonary
bypass surgery for heart valve replacement whether they are receiving
or have not yet started to receive immune globulin therapy;
P212) discuss asplenia risk and possible immune abnormalities,
specifically B cell defects, in patients with Mowat-Wilson syndrome;
P213) discuss treatment options for chronic giardia infections in
patients with CVID; P214) recognize pathogens associated with
chronic granulomatous disease; P215) recognize the importance of
early diagnosis and treatment of primary immunodeficiencies and of
monitoring for potential complications; P216) recognize the
differential diagnosis of peripheral lymphopenia; P217) discuss the
implications of Whole Exome Sequencing used as a screening
modality and identify the varied manifestations associated with GATA2
mutation; P218) identify the benefits and risks associated with the use
of immunoglobulin replacement therapy in a patient with pre-existing
thrombi; P219) discuss variability in clinical presentations in siblings
with X-linked CGD due to the same mutation; P220) describe an
unusual form of radiosensitive SCID; P221) identify Good syndrome as
a rare cause of combined immune deficiency that occurs in association
with thymoma as well as the association of STAT3 mutation with Good
syndrome; P222) identify and keep a high suspicion of MBL deficiency
in challenging cases with repeated episodes of infections that are
ruled negative of HIV; P223) identify clinical or laboratory parameters
associated with death in patients with haemophagocytic
lymphohistiocytosis; P224) identify neutropenia as a presenting
manifestation of X-linked agammaglobulinemia; P225) discuss the use
of attenuated androgens for HAE prophylaxis and identify barriers that
may prevent physicians/patients switching to other treatment
modalities; P226) identify characteristics of MonoMAC syndrome and
when to consider this in the differential diagnosis of recurrent
infections; P227) discuss the efficacy, safety and tolerability of
recombinant human hyaluronidase-facilitated subcutaneous Infusion
of immunoglobulin G (IGHy; HyQvia) in patients with primary
immunodeficiencies who were treated for up to 3 years; P228) initiate
immunological work up in a partial DiGeorge syndrome patient with
new onset of infections; P229) recognize the IgG-related disease in
different clinical presentation and pathological findings;
P230) summarize the possible outcomes and complications of
splenectomy in patients with common variable immunodeficiency
(CVID); P231) discuss treatment of granulomatous disease in patients
with common variable immunodeficiency (CVID); P232) discuss the
role of GM-CSF in the process of wound healing and particularly its
potential for the immunodeficient patient who does not have any
primary neutrophilic defects; P233) discuss cytokine and SLPI levels in
88
blood and urine of patients with chronic cystitis and pyelonephritis;
P234) describe the association of cellular anti-endotoxin immunity as
represented by the CD14 receptor with humoral immunity (IgA, CIC) in
patients with SLE; P235) describe the role of reactive oxygen species in
ejaculate of men with abacterial prostatitis associated with infertility;
P236) describe the role of TGF Beta levels in obstructive megaureter in
children; P237) discuss the clinical manifestations of autoinflammatory
disorders as well as the differential diagnosis of recurrent lung
abscesses; P238) state the diagnostic criteria for CVID and identify an
association between CVID and granulomatous disease; P239) discuss
the diagnosis of severe combined neutropenia and the roles of genetic
and antibody testing in that diagnosis; P240) identify the features of
idiopathic CD4 lymphopenia and characteristics of increased
morbidity in this condition; P241) discuss the diagnostic evaluation
and management strategies for patients with lymphopenia in the
absence of an underlying diagnosis; and P242) discuss the inclusion of
early and severe presentation of NEMO deficiency in the differential
diagnosis for a patient suspected of having an immunodeficiency.
Food Allergy
P243
Eosinophilic Esophagitis Secondary to Fresh
Cilantro Ingestion
K. Cook*, Orange, CA.
P244
An Unusual Case of Asparagus Allergy
K.M. White1, P.H. Wong*2, R.A. Gomez1, M.H. Tucker3,
1. Lackland AFB, TX; 2. San Antonio, TX; 3. Bonita, CA.
P245
Pineapple Anaphylaxis
K.E. Bruner*1, R. Gomez2, J. Freiler2, K. White2,
A. White3, 1. Lackland AFB, TX; 2. San Antonio, TX;
3. San Diego, CA.
P246
A Case of FPIES to Sweet Potato
B. Navetta*, Manhasset, NY.
P247
Anaphylaxis Due to Topical Pramoxine
S.J. Kim*, C.K. Lin, B.J. Goldberg, Los Angeles, CA.
P249
Characteristics of Food Allergy in An Adult
Population
T. Shankar*, A. Petrov, M. Fajt, Pittsburgh, PA.
P250
Rituximab and Food Allergy in a Pediatric Liver
Transplant Patient
W.M. Rassbach*, J. Wang, New York, NY.
P251
Frequency of Sensitization to Foods Rich in Lipid
Transfer Proteins and Profilin in Patients of the
National Institute of Respiratory Diseases
R.D. Ruiz Morales*, M.D. García Cruz,
V.A. Maldonado Ríos, F. Ramírez Jiménez, G.F. Pavon
Romero, M. Molina Macip, N. Camacho Ordonez,
P. Sanchez de la Vega Reynoso, Z. Perez Estrella,
L.M. Teran Juarez, Mexico City, DF, Mexico.
Poster Session
P252
Differences in Common Food Allergens, Food
Allergy Severity and Thresholds in 16 Countries
R. Gupta*1, J. Blumenstock1, L. Bilaver2, L. Harada3,
M. Marchisotto4, 1. Chicago, IL; 2. DeKalb, IL;
3. Toronto, ON, Canada; 4. New York, NY.
P253
Food Protein-Induced Enterocolitis Syndrome
(FPIES) Caused By Avocado
A. Doshi*, S. Leonard, San Diego, CA.
P254
Severe Sequellae of Dehydration in a Food
Protein-Induced Enterocolitis Patient
M.A. Ruffner*1, J. Fiedler2, 1. Rutledge, PA;
2. Philadelphia, PA.
P255
A Spoonful of Sugar Helps Budesonide Go Down
J. Lee*, M.M. Shuker, T.F. Brown-Whitehorn,
A. Cianferoni, L.M. Gober, C.A. Liacouras, R. Verma,
J.M. Spergel, Philadelphia, PA.
P256
When IgE Crashes the Party: A Case of Beer
Allergy
J.D. Waldram*1, K.M. Woessner2, 1. La Jolla, CA;
2. San Diego, CA.
Upon completion of this session, participants should be able to:
P243) discuss options in evaluating food allergy secondary to fresh
food intake; P244) discuss asparagus allergy and peculiarities
regarding laboratory testing; P245) discuss available modalities for
testing a patient for pineapple allergy; P246) diagnose FPIES;
P247) identify that topical pramoxine may give rise to life-threatening
anaphylaxis, especially if the skin barrier is compromised;
P249) identify clinical characteristics of adult food allergy;
P250) describe the evaluation and management of food allergy in the
setting of rituximab-induced B cell depletion; P251) discuss food
allergy; P252) discuss food allergen threshold levels in 16 countries
around the world; P253) describe the clinical symptoms of Food
Protein Induced Enterocolitis Syndrome (FPIES) and identify common
and uncommon triggers for the syndrome; P254) recognize potential
for severe dehydration in food protein induced enterocolitis patients;
P255) identify various delivery vehicles available for swallowed
budesonide in the treatment of patients with eosinophilic esophagitis;
and P256) recognize that beer allergy exists and should be considered
in the differential diagnosis.
Immunotherapy, Immunizations
P257
Quantitative Benefit and Risk Assessment of
Timothy Grass and Short Ragweed Sublingual
Immunotherapy Tablets in the Treatment of
Allergic Rhinitis
A. Kaur1, G. Koch2, S. Durham3, J.M. Portnoy4, Z. Li1,
J. Maloney1, H. Nolte*1, 1. Whitehouse Station, NJ;
2. Chapel Hill, NC; 3. London, United Kingdom;
4. Kansas City, MO.
P258
Analysis of Dust Mite Immunotherapy
Maintenance Goal Achievement
N. Khoiny*1, J. Chase2, J. Sheikh2, M. Kaplan2,
1. Long Beach, CA; 2. Los Angeles, CA.
P259
Gastrointestinal Adverse Events in Subjects
Receiving Rapidly Dissolving Timothy Grass or
Short Ragweed Sublingual Immunotherapy
Tablets
J. Maloney*1, D. Skoner2, G. Berman3, B.Q. Lanier4,
A. Kaur1, H. Nolte1, 1. Whitehouse Station, NJ;
2. Pittsburgh, PA; 3. Minneapolis, MN;
4. Fort Worth, TX.
P260
Immunomodulatory Therapy of Recurrent and
Recalcitrant Warts: Efficacy Using Candida
Albicans Antigens
T.M. Nsouli*1, L.E. Firestone2, N.Z. Diliberto2,
S.T. Nsouli2, J.A. Bellanti2, 1. Burke, VA;
2. Washington, DC.
P261
The Efficacy of the United Allergy Services SelfAdministered Immunotherapy Protocol
F.M. Schaffer*1, L. Garner1, M. Ebeling2, T. Hulsey2,
A. Naples1, 1. San Antonio, TX; 2. Charleston, SC.
P263
Safety of Subcutaneous Specific Allergic
Immunotherapy in Patients With Allergic Rhinitis
From the National Institute of Respiratory
Diseases From 2005 to 2014
G.F. Pavon Romero, J.I. Rodríguez Gaspar*,
M.E. Cervantes Malagon, F. Ramírez Jimenez,
M.H. García Cruz, L.M. Teran Juarez, Mexico City, DF,
Mexico.
P264
Safety of the 5-Grass Pollen Sublingual Tablet in
Adult and Pediatric Populations With Grass
Pollen-Induced Allergic Rhinoconjunctivitis
R.K. Zeldin*1, Y. Amistani1, L. Paolozzi1, U. Wahn2,
1. Antony, France; 2. Berlin, Germany.
P265
Safety of the 5-Grass Pollen Sublingual Tablet in
Mono- and Poly-Sensitized Patients With Grass
Pollen-Induced Allergic Rhinoconjunctivitis
D.B. Golden*1, K. Abiteboul2, R.K. Zeldin2,
1. Baltimore, MD; 2. Antony, France.
P266
Efficacy of House Dust Mite Sublingual
Immunotherapy Tablet on Ocular Symptoms
Using an Environmental Exposure Chamber
H. Nolte*1, J. Maloney1, H.S. Nelson2, D.I. Bernstein3,
Z. Li1, R. Zieglmayer4, P. Zieglmayer4, P. Lemell4,
F. Horak4, 1. Whitehouse Station, NJ; 2. Denver, CO;
3. Cincinnati, OH; 4. Vienna, Austria.
89
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P267
P268
P269
P270
Safety of the Sublingual Tablet of House Dust
Mite Allergen Extracts in An Environmental
Exposure Chamber Study: Focus On AsthmaRelated Symptoms
M. Roux1, W.H. Yang2, P. Devillier3, R.K. Zeldin*1,
1. Antony, France; 2. Ottawa, ON, Canada;
3. Suresnes, France.
Allergy Immunotherapy Adherence: Does Rush
Make a Difference?
S.P. Raschal, J.M. Holcombe, B.G. Carlton*,
Chattanooga, TN.
Efficacy of Subcutaneous Immunotherapy in
Patients Polysensitized Compared to Patients
Monosensitized With Allergic Rhinitis and Asthma
D. Rivero Yeverino, M. Molina Macip*, M.H. García
Cruz, G. Pavon Romero, F. Ramírez Jimenez, L. Teran
Juarez, Mexico City, DF, Mexico.
Safety of Subcutaneous Specific Allergic
Immunotherapy in Patients With Allergic Rhinitis
From the National Institute of Respiratory
Diseases From 2005 to 2014
G. Pavon, I. Rodriguez*, M. Cervantes, F. Ramirez,
M. Garcia, L. Teran, Mexico City, DF, Mexico.
Upon completion of this session, participants should be able to:
P257) discuss the benefit-risk ratios of grass and ragweed SLIT-T in
terms of number needed to treat and number needed to harm;
P258) identify patients who are at high risk of not achieving
maintenance goal for dust mite immunotherapy; P259) discuss the
gastrointestinal events associated with SLIT-T that are distal to the
mouth and throat; P260) discuss the efficacy of immunomodulatory
therapy of recurrent and recalcitrant warts; P261) discuss the SCIT
efficacy assessment tools, application and results in reference to
relevant clinical trials; P262) identify the impact of dose adjustment
due to conservative management of local reactions during
administration of aeroallergen immunotherapy; P263) identify the
different elements that affect immunotherapy in Mexican population;
P264) discuss the safety of 5-grass pollen sublingual tablet in the adult
and pediatric population; P265) discuss the safety of the 5-grass pollen
sublingual tablet in mono-sensitized and poly-sensitized patients;
P266) discuss the effect of HDM SLIT-T on ocular symptoms associated
with HDM-induced allergic rhinitis; P267) discuss the safety of the
sublingual tablet of house dust mite allergen extracts during allergen
challenges in an environmental exposure chamber study;
P268) discuss allergy immunotherapy rush treatment and impact on
adherence; P269) recognize that immunotherapy is an effective
treatment for patients polysensitized and monosensitized; and
P270) identify the different elements that affect immunotherapy in
Mexican population.
Other
P271
90
Gastroesophageal Reflux Disease (GERD) Therapy
Dosing Misses the Mark
J.L. Mutnick*, Morris, MN.
P272
Inpatient Consultations to the Allergy and
Immunology Service at a Tertiary Care Pediatric
Referral Center
E.E. Kempe*1, D. Stukus1, K. Strothman2, R. Scherzer1,
1. Columbus, OH; 2. Dublin, OH.
P273
Assessing Epipen® Proficiency Among Internal
Medicine Interns
S. Bodner*, S. Akbar, R. Sejour, S. Chaudhry,
M. Tamuz, A.M. Jongco, Manhasset, NY.
P274
Successful Switch From Long-Term Prophylaxis
With Danazol to Acute Treatment With C1 Esterase
Inhibitor Concentrate (Berinert) in a Patient With
Hereditary Angioedema
I. Martinez-Saguer*, W. Kreuz, Moerfelden-Walldorf,
Germany.
P275
The Practical Use of a Real World Data Base in
Clinical Practice
G. Steven*, Milwaukee, WI.
P276
Reconciliation of Health Records Following
Penicillin Allergy Testing of Hospitalized Patients
R. Pratt*1, A. Romanova2, J. Greenbaum3, M. Cyr3,
1. Stoney Creek, ON, Canada; 2. Ottawa, ON, Canada;
3. Hamilton, ON, Canada.
P277
Use of a Private Practice Allergy Specialty Health
Care Data Base in Identification of Patients That
May Benefit From New Therapies
G. Steven*, Greenfield, WI.
P278
Allergic Diseases and Correlated Risk Factors in
Preschool Children
M. Duse*, G. Forastiere, D. Porta, T. Melengu, A. Di
Coste, L. Indinnimeo, Rome, Italy.
P279
Effects of Delivery and Feeding on Incidence of
Atopic Disorders
M. Hauk1, B.A. McGoey2, M. Michelis*2, 1. Mahwah,
NJ; 2. Hackensack, NJ.
P280
Temporomandibular Joint Disease and Its
Relationship to Sleep Hygiene and Sleep
Deprivation
C. DiMaio*1, P. Henao2, E. Rael2, 1. Palmyra, PA;
2. Hershey, PA.
P281
The Associations of Allergy Skin Test, Ocular and
Nasal Symptoms and Asthma During Nhanes II (NII) and Nhanes III (N-III)
Q. Meng*1, S. Nagarajan1, L. Bielory2, 1. Piscataway,
NJ; 2. Springfield, NJ.
P282
Pediatric Allergy and Gi Combined Care
Improves Eosinophilic Esophagitis Symptom
Control in Children
M. Hogan*1, A. Wonnaparhown2, R. Scherr2,
N. Wilson2, 1. Reno, NV; 2. Las Vegas, NV.
Poster Session
P283
Hypersensitivity Course: Empowering Fellows to
Design/Conduct Their Own Effective Allergy
Curriculum
A.C. Gavino*, Q. Kamili, Z. Maskatia, N. Chokshi,
D. Bayer, K. Tuano, S. Wu, S. Hasan, M. Garcia Buheis,
L.M. Noroski, Houston, TX.
P284
Evaluation of An Electronic Daily Diary for
Measuring Symptoms and Impact of Chronic
Obstructive Pulmonary Disease
K. Kulich1, B. Tiplady*2, D. Banerji3, 1. Basel,
Switzerland; 2. Peterborough, United Kingdom;
3. East Hanover, NJ.
Upon completion of this session, participants should be able to:
P271) further individualize and tailor more appropriate GERD therapy
to many allergy and asthma patients presenting with chronic cough
and/or GERD; P272) discuss the primary reasons for pediatric inpatient
allergy and immunology consultations at a tertiary pediatric referral
center, as well as patterns in patient demographics and follow-up;
P273) recognize the key components in an effective training module
for teaching residents how to use epinephrine autoinjectors and
identify a reliable scoring method to assess epinephrine autoinjector
(EpiPen®) proficiency in residents; P274) recognize how to switch from
long-term prophylaxis with danazol to acute treatment with C1-INH
concentrate in patients with hereditary angioedema; P275) describe
how real world data base is useful in daily clinical practice;
P276) discuss allergy reconciliation and communication of allergy
status; P277) discuss the utility of a private practice Allergy Specialty
Health Care Data Base in identification of patients that may benefit
from new therapies; P278) discuss with parents the risk for allergic
diseases in their children; P279) discuss the incidence of atopic
diseases in both breastfed and bottle fed children; P280) discuss the
clinical manifestations of TMJ disease, as well as, its epidemiology;
P281) discuss the associations of allergy skin test, ocular and nasal
symptoms, and asthma across a 20-year course from NHANES II to
NHANES III; P282) discuss advantages of comprehensive GI and
allergy/immunology care for pediatric eosinophilic esophagitis
patients; P283) identify a model of an effective fellows-implementedcourse curriculum; and P284) learn development and validation of an
eDiary for assessing impact of symptoms on patients with COPD.
Pharmacology and
Pharmacotherapeutics
P285
The Characterization of RPC4046, a Novel AntiIL13 Monoclonal Antibody That Blocks Binding to
IL-13 Receptor α1 and α2 in Development for
Eosinophilic Esophagitis: Results of a First-inHuman Study
C. Tripp*1, A. Campbell2, B. Hendrickson2, C. Cuff1,
R. Miller1, C. Wu1, K. Kim3, 1. Worcester, MA; 2. North
Chicago, IL; 3. Cypress, CA.
P286
Efficacy of Sulfasalazine, An Anti-Inflammatory
Agent, for the Treatment of Severe Chronic
Idiopathic Urticaria Patients Not Controlled on
Oral Antihistamines
S. Nsouli*, Danville, CA.
P287
Patient Acceptance and Preference for the
Warming Sensation Accompanying Flavour
Agent 316282 in an Over-the-Counter Cough
and Cold Syrup
R. Furcha1, A. Amin*2, 1. Nyon, Switzerland;
2. Parsippany, NJ.
P288
Once-Daily Tiotropium Respimat® Add-on to
Maintenance Therapy Improves Lung Function
in Patients With Moderate or Severe Symptomatic
Asthma, Independent of T Helper 2 Inflammatory
Status
M.L. Vandewalker*1, J. Karpel2, G. Bensch3, L. Ford4,
M. Engel5, R. Sigmund5, P. Moroni-Zentgraf5,
H. Kerstjens6, 1. Columbia, MO; 2. New York, NY;
3. Stockton, CA; 4. Bellevue, NE; 5. Ingelheim am Rhein,
Germany; 6. Groningen, Netherlands.
P289
Pharmacologic Modeling to Guide the DX-2930
Dosing Regimen in Investigating Long-Term
Prophylaxis of Hereditary Angioedema
Y. Chyung*, D. Sexton, C. TenHoor, J. Kenniston,
R. Faucette, R. Iarrobino, J. Biedenkapp, B. Adelman,
Burlington, MA.
P290
Review of Histamine Receptor (H1, H2, and
H3) Antagonist Binding Affinities Yields Three
Trends of Binding Properties
J. Maik*1, L. Bielory2, 1. New York, NY;
2. Springfield, NJ.
P291
Treatment With Recombinant Human C1 Inhibitor
Shortens Duration of Hereditary Angioedema
Attack Symptoms
M. Riedl*1, D. Moldovan2, W. Yang3, H. Wedner4,
M. Stobiecki5, A. Relan6, M. Cicardi7, 1. San Diego, CA;
2. Tirgu-Mures, Romania; 3. Ottawa, ON, Canada;
4. St. Louis, MO; 5. Krakow, Poland; 6. Leiden,
Netherlands; 7. Milan, Italy.
P292
Global Availability of Hereditary Angioedema
Drugs
N. Onyango*, K. Karikari, T. Craig, Hershey, PA.
P293
Safety Evaluation of Olopatadine Hcl Ophthalmic
Solution 0.77%, a Topical Ocular Anti-Allergic
Agent, in Asymptomatic Subjects
E.J. Meier*, Mason, OH.
91
Posters
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P294
P295
Once-Daily Tiotropium Respimat® Add-On to
Inhaled Corticosteroids ± Long-Acting β2Agonists Improves Lung Function and Asthma
Control and Reduces Risk of Asthma Worsening in
Patients With Moderate or Severe Asthma
K. Murphy*1, G. Bensch2, W.E. Berger3, M. Engel4,
H. Schmidt5, P. Moroni-Zentgraf4, H.A. Kerstjens6,
1. Boys Town, NE; 2. Stockton, CA; 3. Mission Viejo, CA;
4. Ingelheim Am Rhein, Germany; 5. Biberach an der
Riss, Germany; 6. Groningen, Netherlands.
24-Hour Lung Function Response to Tiotropium
Respimat® Add-On to Maintenance Therapy in
Symptomatic Patients With Moderate Persistent
Asthma
T. Casale*1, W.W. Carr2, L. Greos3, M. Engel4, L.J. Bour5,
P. Moroni-Zentgraf4, H.A. Kerstjens6, 1. Tampa, FL;
2. Mission Viejo, CA; 3. Centennial, CO; 4. Ingelheim am
Rhein, Germany; 5. Biberach an der Riss, Germany;
6. Groningen, Netherlands.
Upon completion of this session, participants should be able to:
P285) identify the pharmacokinetic and safety profile of RPC4046, an
anti–IL-13 antibody, in patients with asthma and in healthy volunteers;
P286) use as treatment a pharmacological agent that is safe and also
provide an alternative successful treatment option for patients
suffering from a chronic skin disorder, rather than the use of more
toxic pharmacological agents, such as systemic corticosteroids or
immunosuppressant drugs; P287) identify positive properties of
warming sensation from product ingredients that may enhance use of
over-the-counter medicines for the short-term treatment of symptoms
of upper respiratory infections; P288) discuss how the use of
tiotropium Respimat® add-on to at least medium dose ICS ± LABA has
the potential to improve lung function in patients with moderate to
severe symptomatic asthma independent of TH2 inflammatory status;
P289) discuss the role of plasma kallikrein in hereditary angioedema
(HAE) as well as the scientific rationale supporting continuous plasma
kallikrein inhibition as a potential therapeutic approach for the
prevention of HAE attacks; P290) discuss different ligand affinity
patterns of histamine receptor agonists; P291) discuss the efficacy of
recombinant C1INH in shortening hereditary angioedema symptoms;
P292) identify current therapies used in the treatment of hereditary
angioedema and their availability in different regions of the world;
P293) discuss the safety of olopatadine 0.77% in adult and pediatric
patients; P294) discuss how the use of once-daily tiotropium
Respimat® add-on to at least medium-dose ICS ± LABA has the
potential to provide significant and sustained improvements in lung
function, improved asthma control, and reduced risk of asthma
worsening in adults with moderate or severe symptomatic asthma;
and P295) discuss how once-daily tiotropium Respimat® 5 µg and 2.5
µg add-on therapy has potential to improve lung function throughout
the 24-hour dosing interval in patients with moderate persistent
asthma who are symptomatic despite receiving maintenance therapy
with medium ICS+LABA.
92
Rhinitis, Other Upper Airway
and Ocular Disorders
P296
Cetirizine-Pseudoephedrine Combination
Effectively Relieves Both Ocular and Nasal
Allergy Symptoms in Subjects With Seasonal
Allergic Rhinitis
E.R. Urdaneta*1, X. Tian2, M. Wu3, Q. Du2,
K.B. Franklin1, M.K. Patel1, 1. Fort Washington, PA;
2. Shanghai, China; 3. Morris Plains, NJ.
P297
Cetirizine-Pseudoephedrine Combination
Effectively Relieves Ocular Allergy Symptoms in
Subjects With Seasonal Allergic Rhinitis
M.K. Patel*1, E.R. Urdaneta1, K.B. Franklin1, X. Tian2,
M. Wu3, Q. Du2, 1. Fort Washington, PA; 2. Shanghai,
China; 3. Morris Plains, NJ.
P298
Allergic Rhinitis in the Elderly: A Pilot Study of
Vitamin D Supplementation
M. Columbo*, A. Rohr, Bryn Mawr, PA.
P299
Deposition Characteristics of Dymista Nasal Spray
(Azelastine Hcl 137 µG / Fluticasone Propionate
50 µG) in An Anatomical Model of the Human
Nasal Cavity
A. D’Addio*1, N. Ruiz1, M. Mayer2, L. Gever1,
E.O. Meltzer3, 1. Somerset, NJ; 2. Baltimore, MD;
3. San Diego, CA.
P300
Randomized, Double-Blind, Placebo-Controlled
Trial of the Safety and Efficacy of Astepro
(Azelastine 0.15% Solution and 0.10% Solution) in Children Ages ≥6 to <12 With Perennial
Allergic Rhinitis
J.A. Bernstein*1, S. Meltzer2, L. Gever3, N. Ruiz3,
J. Blessing-Moore4, 1. Cincinnati, OH; 2. Long Beach,
CA; 3. Somerset, NJ; 4. Palo Alto, CA.
P301
Randomized Trial of the Safety of Dymista Nasal
Spray Compared With Fluticasone Propionate
Nasal Spray in Children Ages ≥4 Years to <12 Years
With Allergic Rhinitis
W. Berger*1, P. Ratner2, D. Soteres3, L. Gever4,
N. Ruiz4, 1. Mission Viejo, CA; 2. San Antonio, TX;
3. Colorado Springs, CO; 4. Somerset, NJ.
P302
Efficacy of Azelastine HCL and Fluticasone
Propionate in a Single Nasal Spray (Dymista) in
Treating Ocular Symptoms of Seasonal Allergic
Rhinitis
B. Stanaland*1, R. Settipane2, S. Gawchik3, N. Ruiz4,
F. Hampel5, 1. Naples, FL; 2. Providence, RI; 3. Upland,
PA; 4. Somerset, NJ; 5. New Braunfels, TX.
P303
Assessment of Symptom Severities of Allergic
Rhinitis Patients Sensitive to Multiple Allergens
Compared to Single Allergen in Mast
B. Yu*1, J. Lee2, D. Lee2, 1. Uijeongbu, Republic of
Korea; 2. Daejeon, Republic of Korea.
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
The Efficacy of a Nasal Antihistamine
Azelastine Hydrochloride and Corticosteroid
Fluticasone Propionate for the Treatment of
Serous Otitis Media
S. Nsouli*, Danville, CA.
P305
Efficacy and Safety of Beclomethasone
Dipropionate Nasal Aerosol in Children
(4-11 Years of Age) With Perennial Allergic Rhinitis
W. Berger*1, R. Jacobs2, N. Amar3, S. Tantry4, J. Li4,
C. Small4, 1. Mission Viejo, CA; 2. San Antonio, TX;
3. Waco, TX; 4. Frazer, PA.
P306
Complementary Therapy for Treatment of
Allergic Rhintis
J. Kern*1, L. Bielory2, S. Luster2, 1. Newark, NJ;
2. Springfield, NJ.
P307
Prevalence of Mold Sensitization in Chronic
Rhinosinusitis Patients Requiring Surgery
R. Gawlik1, E. Czecior1, W. Scierski1, L.M. DuBuske*2,
1. Katowice, Poland; 2. Gardner, MA.
P308
Epidemiology of Allergy in Various Children of
Various Age Groups in Western Hungary From
2002 to 2005 and From 2006 to 2009
L. Soti1, Z. Petz1, L.M. DuBuske*2, 1. Szombathely,
Hungary; 2. Gardner, MA.
P309
Cerebrospinal Fluid (CSF) Rhinorrhea Presenting
Three Years After Head Trauma
M. Shum*1, K. Chotikanatis2, T.A. Saadia2, R. Joks2,
1. New York, NY; 2. Brooklyn, NY.
P310
Challenges of Chronic Cough
V. Ta*1, K. Woessner2, 1. Redondo Beach, CA;
2. San Diego, CA.
Upon completion of this session, participants should be able to:
P296) discuss the relief of both ocular and nasal allergy symptoms in
patients with seasonal allergic rhinitis; P297) discuss the relief of both
ocular and nasal allergy symptoms in patients with seasonal allergic
rhinitis; P298) discuss the role of vitamin D supplementation in elderly
subjects with allergic rhinitis; P299) identify differences in deposition
characteristics of nasal sprays for treatment of allergic rhinitis
depending on the amount of spray delivered and the sequence of
administration; P300) evaluate and discuss the efficacy and safety of
intranasally administered azelastine in children 6 to 11 years of age
with allergic rhinitis; P301) evaluate and discuss the efficacy and safety
of combination nasal spray therapy with azelastine HCl and fluticasone
propionate (Dymista) in pediatric patients 4 to 11 years of age;
P302) evaluate and discuss the efficacy and safety of intranasal therapy
with azelastine and fluticasone propionate in a single nasal spray for
treatment of ocular symptoms of SAR; P303) identify relationship
between clinical symptoms and number of allergens that allergic
rhinitis patient is sensitive to; P304) use a combination treatment that
is successful, safer and shorten the therapy of systemic antibiotics,
given the safety issues with long-term use of systemic antibiotics;
P305) discuss the favorable efficacy profile of beclomethasone
dipropionate nasal aerosol for management of perennial allergic
rhinitis in children; P306) discuss available complementary therapies
including the utilization of traditional Chinese medicine, acupuncture
and herbal/homeopathy therapies with their patients; P307) discuss
the prevalence of mold sensitization in chronic rhinosinusitis patients
requiring surgery; P308) discuss the epidemiology of allergy in various
children of various age groups in Western Hungary from 2002 to 2005
and from 2006 to 2009; P309) identify risk factors for CSF rhinorrhea as
a differential diagnosis for rhinorrhea; and P310) diagnose and identify
symptoms associated with supraesophageal reflux disease.
Skin Disorders
P311
Evidence of Autoimmunity in Patients With
Spontaneous Chronic Urticaria (SCU)
M.I. Rojo-Gutierrez, C.N. Flores Ruvalcaba*,
J. Mellado Abrego, G. Castillo Narvaez, P. Ramirez
Rojo, Mexico City, DF, Mexico.
P312
A Retrospective Review of Chronic Urticaria and
Body Mass Index (BMI) in a Hispanic Cohort
M. Rodríguez-Roa*, C.M. Pimentel, B.K. Di Giorgi,
J. Méndez, I. Malinow, C. Ramos, S. Nazario, San
Juan, Puerto Rico.
P313
Efficacy of Anti-IgE Monoclonal Antibodies at a
Dose of 150 to 300mg in Patients With Chronic
Urticaria Spontaneous (CUS) With Failure in the
Efficacy of Antihistamine
M.I. Rojo-Gutierrez*, C.N. Flores Ruvalcaba,
J. Mellado Abrego, G. Castillo Narvaez, M. Gonzalez
ibarra, Mexico City, DF, Mexico.
P314
Severe Atopic Dermatitis Exacerbated by
Staphylococcus Intermedius
V. Bozoghlanian*, D. Levy, R. Gutta, Irvine, CA.
P315
Why Is It Important to Know About Sweet
Syndrome?
A. Hamad*, Madison Heights, MI.
P316
Atopic Dermatitis in Children: Cost-Effectiveness
Comparative Estimation of Various Immunotropic
Therapy Programmes
T. Slavyanskaya*1, V. Derkach2, B. Sangidorj1,
1. Moscow, Russian Federation; 2. Vladivostok, Russian
Federation.
P317
Chronic Idiopathic/Spontaneous Urticaria: Patient
Characteristics and Resource Use
G. Sun1, K. Raimundo2, E. Antonova3, E. Chang1,
M. Broder*1, 1. Beverly Hills, CA; 2. South San
Francisco, CA; 3. San Francisco, CA.
P318
Treatment of Chronic Urticaria With
Immunosupressors: Case Report
M.E. Arroyo-Cruz, A.A. Velasco-Medina,
S. Gonzalez-Flores, J.C. Fernandez-Cordova*,
D.A. Cariño-Cartajena, G. Velazquez-Samano,
Mexico City, DF, Mexico.
93
Posters
P304
Poster Session
3:30 – 4:30 pm, Saturday and 7:30 – 8:30 am, Sunday
Hall A-1 • Georgia World Congress Center
P319
An Unusual Presentation of Toxic Epidermal
Necrolysis in a Patient With Systemic Lupus
Erythematosus
R. Patel MD*1, G. Jyothirmayi PA-C2, E. Capitle MD2,
1. Long Island City, NY; 2. Newark, NJ.
P320
Improvement of Sleep in Patients With Chronic
Idiopathic/Spontaneous Urticaria
(CIU/CSU) Treated With Omalizumab: Results of a
Randomized, Double-Blind, Placebo-Controlled
Clinical Trial (Glacial)
J. Antonova, K. Raimundo*, B. Trzaskoma, P. Solari,
T. Omachi, J. Zazzali, South San Francisco, CA.
P321
Allergic Contact Dermatitis to Henna Hair Dye
Q. Kamili*, Q.L. Nguyen, R. Katta, J. Schmidt,
Houston, TX.
P322
Usefulness of a Purine Biosynthesis Inhibitor in
Atopic Dermatitis
J. Fernandez de Cordova Aguirre*, A. VelascoMedina, M.E. Arroyo-Cruz, S. Gonzalez Flores,
D. Cariño-Cartagena, G. Velazquez-Samano, Mexico
City, DF, Mexico. P323
Psoriasiform Spongiotic Dermatitis and
Autoimmune Disease
S. Sran, M. Taborga*, M. Frieri, 1. East Meadow, NY.
P324
The Hazards of Henna: An Evaluation of
Commercially Available Henna Hair Dyes
Q. Kamili*, R. Katta, Q.L. Nguyen, Houston, TX.
P325
A Challenging Case of Acute Generalized
Exanthematous Pustulosis
A. Kim*, San Diego, CA.
P326
Acquired Acrodermatitis Enteropathica and
Hypothyroidism in a Severely Atopic Infant
N.N. Shah*, K. Paris, New Orleans, LA.
P327
Overlapping Urticaric Skin Manifestation in Food
Allergy and Gluten-Sensitive Enteropathy
J. Baik*, A.B. Kim, Los Angeles, CA.
P328
A Novel Human-Derived Probiotic Extract With
Filaggrin Promoting Therapeutic Effect
B. Subhadra*, S. Shastri, M. Henson, J. Krier,
N. Monsul, E. Berkes, Sarasota, FL.
P329
A Novel Human-Derived Probiotic Extract With
Anti-Methicillin Resistant Staphylococcus Aureus
(MRSA) Biofilm Therapeutic Effect
E. Berkes, B. Subhadra*, M. Henson, J. Krier,
N. Monsul, Sarasota, FL.
P330
Delayed Diagnosis of Erythropoietic
Protoporphyria: A 36 Year Old Hispanic Female
With Sun-Induced Angioedema
M. Rodríguez-Roa*1, S. Nazario2, 1. San Juan, Puerto
Rico; 2. Hato Rey, Puerto Rico.
94
P331
Elephantiasis Nostras of the Lip
K. Dass*, A. Ditto, Chicago, IL.
Upon completion of this session, participants should be able to:
P311) discuss evidence of autoimmunity in patients with spontaneous
chronic urticaria (SCU); P312) discuss the association of obesity and
low grade chronic inflammation and describe the effect of body mass
index on chronic urticaria; P313) determine the effectiveness of
omalizumab in patients with chronic urticaria spontaneous (CUS) in
whom it was not enough to use antihistamines; P314) investigate for
Staphylococcus intermedius colonization or infection in patients with
severe atopic dermatitis refractory to first and second-line therapies;
P315) identify Sweet Syndrome as a possible cause of acute skin
eruptions which is a very common skin complaint in daily practice;
P316) discuss available techniques of estimating the effectiveness of
different therapy programs in children with atopic dermatitis;
P317) discuss the healthcare resource use and costs that are incurred
by patients with chronic idiopathic/spontaneous urticaria;
P318) consider alternative treatment for urticaria; P319) identify Toxic
Epidermal Necrolysis vs Steven Johnsons Syndrome as well as the
Severity of Illness Score for TEN (SCORTEN) and its criteria;
P320) discuss how patients with CIU/CSU that experience sleep
problems can be impacted by omalizumab therapy; P321) identify the
risk of contact dermatitis with use of henna hair dyes in patients with
allergy to PPDA; P322) review other therapies for patients with atopic
dermatitis; P323) identify the link between spongiosis and
autoimmune conditions; P324) discuss the presence of pphenylenediamine in some of the commercially available ‘natural’
henna hair dye products; P325) discuss the clinical features of acute
generalized exanthematous pustulosis; P326) identify the
dermatologic manifestations of zinc deficiency and recommend
nutritionally appropriate elimination diets for children with atopic
dermatitis; P327) evaluate urticaria as a form of combined disease;
P328) discuss the role of filaggrin in skin barrier integrity; P329) discuss
the role of MRSA biofilms in atopic dermatitis; P330) suspect EPP in
patients presenting with non-blistering photosensitivity and/or
angioedema, especially when it is prolonged and beginning in early
childhood, as well as, recognize that delay in diagnosis and treatment
is fairly common and could be associated with life-threatening
complications; and P331) differentiate elephantiasis nostras from other
causes of lip swelling.
Plenary & Symposia Faculty
Sami L. Bahna, MD, DrPH, FACAAI
Professor of Pediatrics & Medicine,
Chief of Allergy & Immunology
Section, Director of Allergy &
Immunology Training Program, YK
Reddy Professor of Allergy &
Immunology, Louisiana State
University Health Sciences Center,
Shreveport, LA
Aleena Banerji, MD
Assistant Training Program Director,
Massachusetts General Hospital,
Assistant Professor of Medicine,
Harvard University, Boston, MA
Lisa A. Beck, MD
Professor of Dermatology, University
of Rochester, Rochester, NY
David I. Bernstein, MD, FACAAI
Professor of Medicine and
Environmental Health, Division of
Immunology, Allergy and
Rheumatology, University of Cincinnati
College of Medicine, Cincinnati, OH
Jonathan A. Bernstein, MD, FACAAI
Professor of Medicine, University of
Cincinnati College of Medicine,
Department of Internal Medicine,
Division of Immunology/Allergy
Section, Director of Clinical Research,
Cincinnati, OH
Mark Boguniewicz, MD, FACAAI
Professor, Department of Pediatrics,
National Jewish Health and University
of Colorado School of Medicine,
Denver, CO
Vincent R. Bonagura, MD
Chief, Allergy and Immunology, Jack
Hausman Professor of Pediatrics,
Microbiology & Immunology, North
Shore/Long Island Jewish Health
System, Steven & Alexandra Cohen
Children's Medical Center of New York,
New York, NY
Alison Bruce, MD
Associate Professor of Dermatology,
Mayo Clinic College of Medicine,
Rochester, MN
A. Wesley Burks, MD, FACAAI
Curnen Distinguished Professor and
Chair, Physician in Chief, North
Carolina Children's Hospital, The
University of North Carolina, Chapel
Hill, NC
Luz S. Fonacier, MD, FACAAI
Professor of Clinical Medicine, State
University of New York at Stony Brook;
Head of Allergy & Training Program
Director, Winthrop University Hospital,
Mineola, NY
William W. Busse, MD, FACAAI
Univ of Wisconsin School of Medicine
and Public Health Professor of
Medicine, Allergy, Pulmonary, and
Critical Care Medicine, University of
Wisconsin School of Medicine and
Public Health, Madison, WI
Joseph F. Fowler, Jr., MD
Clinical Professor of Dermatology,
University of Louisville, Louisville, KY
Mariana Castells, MD, PhD, FACAAI
Associate Physician, Brigham &
Women's Hospital, Department of
Medicine, Rheumatology,
Immunology; Associate Professor of
Medicine, Harvard Medical School,
Boston, MA
Bradley E. Chipps, MD, FACAAI
Capital Allergy & Respiratory Disease
Center, Sacramento, CA
Timothy J. Craig, DO, FACAAI
Professor of Medicine and Pediatrics,
Division of Pulmonary, Allergy and
Critical Care, Penn State University
Milton S. Hershey Medical Center,
Hershey, PA
Chitra Dinakar, MD, FACAAI
Professor of Pediatrics, University of
Missouri-Kansas City; Staff Physician,
Division of Allergy, Asthma and
Immunology, Children's Mercy
Hospital & Clinics, Kansas City, MO
Stephen R. Durham, MD
Imperial College London; Professor of
Allergy & Respiratory Medicine and
Head, Section of Allergy and Clinical
Immunology, Imperial College at
National Heart & Lung Institute; Head,
Section of Allergy and Clinical
Immunology, Imperial College,
London, United Kingdom
Mark S. Dykewicz, MD, FACAAI
Raymond and Alberta Slavin Professor
of Medicine; Chief, Section of Allergy
and Immunology, St. Louis University
School of Medicine, St. Louis, MO
Alessandro Fiocchi, MD, FSCI
Director of Allergy, Pediatric Hospital
Bambino Gesu, Vatican City, Italy
Richard G. Gower, MD, FACAAI
Marycliff Allergy Specialists,
Spokane, WA
Matthew Greenhawt, MD, MBA, MSc
Assistant Professor, Division of Allergy
and Clinical Immunology, University of
Michigan Food Allergy Center, Division
of General Pediatrics, Child Health
Evaluation and Research Unit,
University of Michigan Health System,
University of Michigan Medical School,
Ann Arbor, MI
Vivian P. Hernandez-Trujillo, MD,
FACAAI
Director, Division of Allergy and Clinical
Immunology, Miami Children’s Hospital;
Clinical Assistant Professor, Herbert
Wertheim School of Medicine, Florida
International University, Miami, FL
Sharon E. Jacob, MD
Associate Professor of Dermatology
and Director of the Contact Dermatitis
Clinic, Loma Linda University Health
System, Department of Dermatology,
Loma Linda, CA; University of
California, San Diego, CA
John M. Kelso, MD, FACAAI
Division of Allergy, Asthma and
Immunology, Scripps Clinic; Clinical
Professor of Pediatrics and Internal
Medicine, University of California,
San Diego, School of Medicine,
San Diego, CA
Kevin Kennedy, MPH, CIEC
Environmental Hygienist and
Managing Director, Center for
Environmental Health, Children’s
Mercy Hospital, Kansas City, MO
David A. Khan, MD, FACAAI
Professor of Medicine, University of
Texas Southwestern Medical Center,
Dallas, TX
95
Faculty
Marcella R. Aquino, MD, FACAAI
Assistant Program Director, Fellowship
Program Winthrop University Hospital,
Mineola, NY
Plenary & Symposia Faculty
James T. Li, MD, PhD, FACAAI
Professor of Medicine, Director of
Allergy and Immunology Training
Program, Mayo Clinic, Rochester, MN
Phillip L. Lieberman, MD, FACAAI
Clinical Professor Pediatrics and
Medicine, University of Tennessee
College of Medicine, Memphis, TN
Gailen D. Marshall, MD, PhD, FACAAI
The R Faser Triplett Sr. MD Chair in
Allergy and Immunology; Professor of
Medicine and Pediatrics; Vice
Chairman for Research, Department of
Medicine; Director, Division of Clinical
Immunology and Allergy; Chief,
Laboratory of Behavioral Immunology
Research, The University of Mississippi
Medical Center, Jackson, MS
Bryan L. Martin, DO, FACAAI
Program Director, Allergy Immunology
Fellowship, The Ohio State University,
Columbus, OH
Anthony Montanaro, MD, FACAAI
Professor of Medicine, Department of
Medicine; Chief, Division of Allergy and
Clinical Immunology, Oregon Health
and Science University, Portland, OR
Kevin R. Murphy, MD, FSCI
Director of Allergy, Asthma and Pulmonary Research, Boys Town National
Research Hospital, Boys Town, NE
Harold S. Nelson, MD, FACAAI
Professor of Medicine, Department of
Medicine, National Jewish Health
Center, Denver, CO
Richard A. Nicklas, MD, FACAAI
Clinical Professor of Medicine, George
Washington Medical Center,
Washington DC; Adjunct Clinical
Professor of Medicine, Uniform
Services University of Health Sciences;
Bethesda, MD
Anna H. Nowak-Wegrzyn, MD, FACAAI
Associate Professor of Pediatrics,
Icahn School of Medicine at Mount
Sinai; Jaffe Food Allergy Institute,
New York, NY
Mark T. O'Hollaren, MD, FACAAI
Professor of Medicine, VP, Strategic
Outreach, Oregon Health & Science
University, Portland, OR
John J. Oppenheimer, MD, FACAAI
Clinical Professor of Medicine, RutgersNJ Medical School, Newark, NJ
96
Dennis R. Ownby, MD, FACAAI
Professor of Pediatrics, Division of
Allergy, Immunology and
Rheumatology, Medical College of
Georgia, Augusta, GA
Reynold A. Panettieri, Jr., MD
University of Pennsylvania/
Pulmonary/ABI, Philadelphia, PA
David B. Peden, MD, MS, FACAAI
Andrews Distinguished Professor of
Pediatrics; Senior Associate Dean for
Translational Research; Director, The
Center for Environmental Medicine,
Asthma and Lung Biology; and Chief,
Division of Allergy, Immunology &
Rheumatology, Department. of
Pediatrics, The School of Medicine, The
University of North Carolina at Chapel
Hill, Chapel Hill, NC
Stephen P Peters, MD, PhD
Thomas H Davis Chair in Pulmonary
Medicine; Chief, Section on Pulmonary,
Critical Care, Allergy, and Immunologic
Diseases; Professor of Internal
Medicine, Pediatrics and Translational
Science; Associate Director, Center for
Genomics and Personalized Medicine
Research; Executive Director,
Respiratory Service Line Wake Forest
Baptist Health, Wake Forest School of
Medicine, Winston-Salem, NC
Wanda Phipatanakul, MD, MS, FACAAI
Associate Professor, Pediatrics,
Children's Hospital, Harvard Medical
School, Boston, MA
Thomas A.E. Platts-Mills, MD, PhD,
FACAAI
Professor of Medicine and Head,
Division of Allergy and Immunology,
University of Virginia, Charlottesville,
VA
Jay M. Portnoy, MD, FACAAI
Director, Division of Allergy, Asthma &
Immunology, Children's Mercy
Hospital & Clinics, Kansas City, MO
Marc A. Riedl, MD, MS
Associate Professor of Medicine,
Clinical Director, US HAEA
Angioedema Center, Division of
Rheumatology, Allergy & Immunology,
University of California, San Diego, La
Jolla, CA
John M. Routes, MD, FACAAI
Chief, Section of Allergy and Clinical
Immunology; Professor of Pediatrics,
Medicine, Microbiology and Molecular
Genetics, Department of Pediatrics,
Children's Hospital of Wisconsin
Medical College of Wisconsin,
Milwaukee, WI
Hugh A. Sampson, MD, FACAAI
Dean for Translational Biomedical
Sciences, Kurt Hirschhorn Professor of
Pediatrics, Department of Pediatrics/
Allergy & Immunology; Director, Jaffe
Food Allergy Institute Icahn School of
Medicine, New York, NY
Mark R. Stein, MD, FACAAI
Medical Director, Allergy Associates of
the Palm Beaches; Chief, Section of
Allergy at Good Samaritan Medical
Center, West Palm Beach, Fl
James L. Sublett, MD, FACAAI
Managing Partner, Family Allergy &
Asthma, Louisville, KY; Clinical
Professor and Chief, Section of
Pediatric Allergy, University of
Louisville, Louisville, KY
Stanley J. Szefler, MD, FACAAI
Director, Pediatric Asthma Research
at Children's Hospital Colorado,
Denver, CO
Donald P. Tashkin, MD
Professor of Medicine, David Geffen
School of Medicine at UCLA,
Los Angeles, CA
Richard Wasserman, MD, PhD, FACAAI
Clinical Professor, Department of
Pediatrics, University of Texas
Southwestern Medical School,
Dallas, TX
Robert A. Wood, MD, FACAAI
Chief of Pediatric Allergy and
Immunology, Johns Hopkins Hospital,
Baltimore, MD
Matthew Zirwas, MD
Director, Contact and Occupational
Dermatitis Center, Division of
Dermatology, Ohio State University,
Columbus, OH
Aaronson, D. . . . . . . . . . . . . . .34, 36, 106
Clay, K. . . . . . . . . . . . . . . . . . . . . . . . . . . . .71
Jacobsen, C. . . . . . . . . . . . . . . . . . . .69, 72
Ansotegui, I. . . . . . . . . . . . . . . . . . . . . . . .54
Craig, T. . . . . . . . . . . . . . . . . . . . . . . . .36, 41
Katial, R. . . . . . . . . . . . . . . . . . . . . . . .36. 45
Aquino, M. . . . . . . . . . . . . . . . . . . . . .37, 39
Crain, M. . . . . . . . . . . . . . . . . . . . . . . . . . .69
Kelkar, P. . . . . . . . . . . . . . . . . . . . . . . . . . . .36
Assa'ad, A. . . . . . . . . . . . . . . . . . . . . .36, 51
Creticos, P. . . . . . . . . . . . . . . . . . . . . . . . . .51
Kelso, J. . . . . . . . . . . . . . . . . . . . . . . . . . . .40
Bacharier, L. . . . . . . . . . . . . . . . . . . . .34, 51
Davis, R. . . . . . . . . . . . . . . . . . . . . . . . . . . .35
Kennedy, K. . . . . . . . . . . . . . . . . . . . . . . .62
Bahna, S. . . . . . . . . . . . . . . . . . . . . . .33, 61
Dinakar, C. . . . . . . . . . . . . . . . . . . . . .37, 53
Khan, D. . . . . . . . . . . . . . . . .37, 39, 40, 60
Bailey, C. . . . . . . . . . . . . . . . . . . . . . . . . . .38
Dolen, W. . . . . . . . . . . . . . . . . . . . . . . . . . .47
Koepke, J. . . . . . . . . . . . . . . . . . . . . . .34, 35
Ballow, M. . . . . . . . . . . . . . . . . . . . . . . . . .60
Dreskin, S. . . . . . . . . . . . . . . . . . . . . . . . . .36
Lang, D. . . . . . . . . . . . . . . . . . . . .34, 51, 60
Banerji, A. . . . . . . . . . . . . . . . . . . .37, 41, 60
Durham, S. . . . . . . . . . . . . . . . . .34, 46, 51
Le, T. . . . . . . . . . . . . . . . . . . . . . . . . . . .36, 46
Batra, P. . . . . . . . . . . . . . . . . . . . . . . . . . . . .34
Dykewicz, M. . . . . . . . . . . . . . . . . . . . . . .40
Lester, M. . . . . . . . . . . . . . . . . . . . . . . . . . .60
Beavers, S. . . . . . . . . . . . . . . . . . . . . . . . . .34
Fineman, S. . . . . .36, 53, 68, 70, 71, 106
Levetin, E. . . . . . . . . . . . . . . . . . . . . . . . . .33
Beck, L. . . . . . . . . . . . . . . . . . . . . . . . . . . . .39
Fiocchi, A. . . . . . . . . . . . . . . . . . . . . .35, 53
Li, H. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .60
Bellanti, J. . . . . . . . . . . . . . . . . . . . . . . . . .36
Foggs, M. . . . . . . . . . . . . . . . . . . .45, 54, 60
Li, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .40
Berger, W. . . . . . . . . . . . . . . . . . . . . . . . . . .52
Fonacier, L. . . . . . . . . . . . . . .35, 39, 61, 70
Lieberman, P. . . . . . . . . . . . . . . . . . . . . . .45
Bernstein, C. . . . . . . . . . . . . . . . . . . . . . . .72
Fowler, J. . . . . . . . . . . . . . . . . . . . . . . . . . .39
Lio, P. . . . . . . . . . . . . . . . . . . . . . . . . . .36, 37
Bernstein, D. . . . . . . . . . . . . . . . . . . .35, 46
Freedle, K. . . . . . . . . . . . . . . . . . . . . . . . . .51
Mahr, T. . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Bernstein, J. . . . . . . . . . . . . . . . . . . . . . . .41
Freeman, T. . . . . . . . . . . . . . . . . . . . .33, 71
Marshall, G. . . . . . . . . . . . . . . . . . . . .52, 60
Biddy, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . .68
Gawchik, S. . . . . . . . . . . . . . . . . . . . . . . . .52
Martin, B. . . . . . . . . . . . . . . . . . .38, 46, 68
Bielory, L. . . . . . . . . . . . . . . . . . . . . . . . . . .73
George, M. . . . . . . . . . . . . . . . . . . . . .70, 72
Matsui, E. . . . . . . . . . . . . . . . . . . . . . . . . . .51
Boguniewicz, M. . . . . . . . . . . . .36, 37, 39
Goldsobel, A. . . . . . . . . . . . . . . . . . .36, 60
McKnight, A. S. . . . . . . . . . . . . . . . . . . . .38
Bonagura, V. . . . . . . . . . . . . . . . . . . . . . . .48
Gower, R. . . . . . . . . . . . . . . . . . . . . . .41, 61
Meadows, J. A. . . . . . . . . . . . . .34, 36, 68
Bruce, A. . . . . . . . . . . . . . . . . . . . . . . . . . . .39
Graft, D. . . . . . . . . . . . . . . . . . . . . . . . . . . .33
Montanaro, A. . . . . . . . . . . . . . . . . . . . . .40
Burks, A.W. . . . . . . . . . . . . . . . . . . . . .60, 67
Grayson, M. . . . . . . . . . . . . . . . . . . . .51, 60
Murphy, K. . . . . . . . . . . . . . . . . . . . . .35, 41
Busse, W. . . . . . . . . . . . . . . . . . . . . . . . . . .45
Greenhawt, M. . . . . . . . . . . . . . . . . . . . . .40
Naclerio, R. . . . . . . . . . . . . . . . . . . . .38, 51
Carlton, G. . . . . . . . . . . . . . . . . . . . . . . . . .70
Gross, G. . . . . . . . . . . . . . .34, 36, 69, 106
Nelson, H. . . . . . . . . . . . . . . . . . . . . .40, 46
Carr, W. . . . . . . . . . . . . . . . . . . . . . . . . . . . .41
Gurgel, R. . . . . . . . . . . . . . . . . . . . . . . . . .38
Nelson, M. . . . . . . . . . . . . . . . . . . . . .35, 69
Casale, T. . . . . . . . . . . . . . . . . . . . . . . . . . .51
Hanson, I.C. . . . . . . . . . . . . . . . . . . . . . . .60
Nicklas, R. . . . . . . . . . . . . . . . . . . . . . . . . .40
Castells, M. . . . . . . . . . . . . . . . . . . . .51, 61
Hayden, M. . . . . . . . . . . . . . . . . .69, 71, 72
Nicol, N. . . . . . . . . . . . . . . . . . . . . . . . . . . .73
Chehade, M. . . . . . . . . . . . . . . . . . . . . . . .35
Hernandez-Trujillo, V. . . . . . . . . . . . . . .40
Nowak-Wegrzyn, A. . . . . . . . . . . . .33, 53
Chew, G. . . . . . . . . . . . . . . . . . . . . . . . . . . .36
Holbreich, M. . . . . . . . . . . . . . . . . . . . . . .35
Nsouli, T. . . . . . . . . . . . . . . . . . . . . . . . . . . .51
Chipps, B. . . . . . . . . . . . . . . .34, 42, 51, 53
Holness, D. L. . . . . . . . . . . . . . . . . . . . . . . .33
O'Connor, M. . . . . . . . . . . . . . . . . . . .47, 68
Cho, S. . . . . . . . . . . . . . . . . . . . . . . . . .34, 35
Hsieh, F. . . . . . . . . . . . . . . . . . . . . . . . . . . .51
O'Hollaren, M. . . . . . . . . . . . . . . . . . . . . .40
Ciaccio, C. . . . . . . . . . . . . . . . . . . . . . . . . .71
Jacob, S. . . . . . . . . . . . . . . . . . . . . . . . . . . .39
Oppenheimer, J. . . . . . . . . . . . .38, 52, 60
97
Faculty
Faculty Index
Faculty Index
Ownby, D. . . . . . . . . . . . . . . . . . . . . .47, 51
Sampson, H. . . . . . . . . . . . . . . . . . . .60, 67
Tilles, S. . . . . . . . . . . . . . . . . . . . . . . . .35, 60
Pacheco, K. . . . . . . . . . . . . . . . . . . . . . . . .33
Sanchez Borges, M. . . . . . . . . . . . . . . . .54
Tolomeo, C. . . . . . . . . . . . . . . . . . . . . . . . .72
Panethere, R. . . . . . . . . . . . . . . . . . . . . . .68
Sanders, D. . . . . . . . . . . . . . . . . . . . . . . . .69
Tuck, J. . . . . . . . . . . . . . . . . . . . . . . . . . . . .62
Panettieri, R. . . . . . . . . . . . . . . .42, 45, 51
Segall, N. . . . . . . . . . . . . . . . . . . . . . . . . . .35
Tyler, K. . . . . . . . . . . . . . . . . . . . . . . . . . . .68
Pawankar, R. . . . . . . . . . . . . . . . . . . .36, 54
Shroba, J. . . . . . . . . . . . . . . . . . .69, 71, 72
Wagner, C. . . . . . . . . . . . . . . . . . . . . .72, 73
Peden, D. . . . . . . . . . . . . . . . . . . . . . . . . . .47
Shulan, D. . . . . . . . . . . . . . . . . . . . . . . . . .38
Wallace, D. . . . . . . . . . . . . . . . . . . . . . . . .67
Peebles, R.S. . . . . . . . . . . . . . . . . . . . . . . .51
Siegel, C. . . . . . . . . . . . . . . . . . . . . . . .35, 61
Wang, J. . . . . . . . . . . . . . . . . . . . . . . . . . . .37
Peters, S. . . . . . . . . . . . . . . . . . . .42, 52, 60
Siles, R. . . . . . . . . . . . . . . . . . . . . . . . . . . . .60
Wasserman, R. . . . . . . . . . . . . . . . . . . . . .48
Phipatanakul, W. . . . . . . . . . . . . . . . . . . .62
Silvers, W. . . . . . . . . . . . . . . . . . . . . . .37, 70
Weber, R. . . . . . . . . . . . . . . . . . . . . . . . . . .33
Platts-Mills, T. . . . . . . . . . . . . . . . . . . . . . .47
Spector, S. . . . . . . . . . . . . . . . . . . . . .51, 73
Welborn, K. . . . . . . . . . . . . . . . . . . . . . . . .72
Portnoy, J. . . . . . . . . . . . . . . . . . . . . .47, 62
Stein, M. . . . . . . . . . . . . . . . . . . . . . . . . . . .48
Weldon, D. . . . . . . . . . . . . . . . . . . . . . . . .37
Pulver, D. . . . . . . . . . . . . . . . . . . . . . . . . . .35
Stukus, D. . . . . . . . . . . . . . . . . . . . . . . . . .36
Westley, C.R. . . . . . . . . . . . . . . . . . . . . . . .35
Rance, K. . . . . . . . . . . . . . . . . . . . . . . .69, 71
Sublett, J. . . . . . . . . . . . . . . . . . . . . . .53. 68
White, A. . . . . . . . . . . . . . . . . . . . . . . . . . .51
Riedl, M. . . . . . . . . . . . . . . . . . . . . . . .40, 41
Szefler, S. . . . . . . . . . . . . . . . . . . . . . .47, 51
Wood, R. . . . . . . . . . . . . . . . . . . .35, 60, 67
Rosenwasser, L. . . . . . . . . . . . . . . . . . . . .54
Tanoury, M. . . . . . . . . . . . . . . . . . . . . . . . .68
Zahran, H. . . . . . . . . . . . . . . . . . . . . . . . . .38
Routes, J. . . . . . . . . . . . . . . . . . . . . . . . . . .40
Tashkin, D. . . . . . . . . . . . . . . . . . . . . . . . . .42
Zirwas, M. . . . . . . . . . . . . . . . . . . . . . . . . .39
CME/CPD Committee
Chair: Charles Siegel, MD, FACAAI
Noga Askenazi, MD, FACAAI
Amal H. Assa’ad, MD, FACAAI
Leonard Bielory, MD, FACAAI
Don A. Bukstein, MD, FACAAI
Adrian M. Casillas, MD, FACAAI
Christina E. Ciaccio, MD, FACAAI
Peter S. Creticos, MD
Vesselin Dimov, MD
Karen A. Freedle, MD, FACAAI
Pinkus Goldberg, MD, FACAAI
Curtis L. Hedberg, MD, FACAAI
Vivian P. Hernandez-Trujillo, MD, FACAAI
Vice Chair: Gerald B. Lee, MD
Lewis J. Kanter, MD, FACAAI
Tao T. Le, MD, MHS, FACAAI
Todd A. Mahr, MD, FACAAI
Lyndon E. Mansfield, MD, FACAAI
Bryan L. Martin, DO, FACAAI
Michael R. Nelson, MD, PhD, FACAAI
Myngoc T. Nguyen, MD, FACAAI
Joram S. Seggev, MD, FACAAI
Brett E. Stanaland, MD, FACAAI
Gary C. Steven, MD, PhD, FACAAI
David R. Weldon, MD, FACAAI
Please see Disclosures section for additional information.
98
Disclosures
Disclosures
ACAAI 2014 Annual Scientific Meeting
November 6-10, 2014, Atlanta, Georgia
Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American
College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators,
authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all
relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified
conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and
appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of
the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed
in an educational activity or included in related materials. Disclosure in no way implies that the information presented is
biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program
contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.
All identified conflicts of interest have been resolved.
Ignacio J. Ansotegui, MD, PhD
Consultant/Advisory Board: Bial, Faes Farma;
Speaker: Bial, Faes Farma, Pfizer, Sanofi
§Marcella R. Aquino, MD, FACAAI
Research Grant: Genentech, Merck
 Noga Askenazi MD, FACAAI
Stock Ownership: Johnson & Johnson
 Amal H. Assa'ad, MD, FACAAI
Research Grant: Cephalon, DBV Technologies,
GlaxoSmithKline
Leonard B. Bacharier, MD, FACAAI
Consultant/Advisory Board: Boehringer
Ingelheim, DBV Technologies,
GlaxoSmithKline, Merck, Teva; Speaker:
GlaxoSmithKline, Merck, Teva
Mark A. Ballow, MD, FACAAI
Consultant/Advisory Board, Honorarium:
Baxter, CSL Behring; Speaker: Baxter, CSL
Behring, Grifols; DSMB: Kedrion; Research
Grant: CSL Behring
Aleena Banerji, MD
Consultant/Advisory Board: Biocryst, CSL
Behring, Dyax, Salix, Shire; Research Grant: CSL
Behring, Dyax, Shire
Peter S. Batra, MD
Consultant/Advisory Board: Medtronic, Merck
Lisa A. Beck, MD
Consultant/Advisory Board: Celgene,
MedImmune, Novartis, Regeneron;
Honorarium: Array BioPharma, Sanofi; Stock:
Wyeth
Gregory W. Bensch, MD, FACAAI
Research Grant: Meda
§William E. Berger, MD, MBA, FACAAI
Consultant/Advisory Board: AstraZeneca,
Genentech, GlaxoSmithKline, Meda, Merck,
Novartis, Sanofi, Teva; Speaker: Alcon, Allergen,
AstraZeneca, Circassia, Genentech, McNeil,
Meda, Mylan, Teva; Honorarium: Alcon,
Allergen, AstraZeneca, Genentech,
GlaxoSmithKline, Meda, Merck, Mylan,
Novartis, Ono Pharma, Sanofi, Sunovion, Teva
 Cheryl K. Bernstein, RN, BSN, CCRC
Research Grant: Amgen, AstraZeneca,
Boehringer Ingelheim, Circassia, Forest
Research, GlaxoSmithKline, MedImmune,
Merck, Pfizer, Quintiles, Teva
David I. Bernstein, MD, FACAAI
Consultant/Advisory Board: Circassia,
Genentech, Merck; Speaker: Merck;
Honorarium: Circassia, Merck; Research Grant:
Boehringer Ingelheim, Circassia, Genentech,
GlaxoSmithKline, Janssen, Merck, Pfizer, Sanofi,
Teva
Jonathan A. Bernstein, MD, FACAAI
Consultant/Advisory Board: Flint Hills
Resources, Genentech, Meda, Novartis;
Speaker: Genentech, Meda, Novartis, Teva;
Honorarium: Genentech, Meda, Novartis;
Research Grant: AstraZeneca, Meda,
Genentech, Novartis, Teva
Brett Bielory, MD
Stock: TearLab
 Leonard Bielory, MD, FACAAI
Consultant/Advisory Board: Allergan, Bausch &
Lomb, Merck, Pharmacal; Speaker/
Honorarium: Allergan, Bausch & Lomb, Merck;
Research Grant: Allergan, EPA; Stock:
STARxTech
Mark Boguniewicz, MD, FACAAI
Consultant/Advisory Board: Celgene, Unilever;
Research Grant: Anacor, Merck
 = Planner
Vincent Bonagura, MD
Consultant/Advisory Board, Speaker,
Honorarium: Baxter, CSL Behring
 Don A. Bukstein, MD, FACAAI
Consultant/Advisory Board: Circassia, Novartis;
Speaker: Alcon, AstraZeneca, Genentech,
Meda, Merck, Novartis; Research Grant:
Circassia
A. Wesley Burks, MD, FACAAI
Consultant/Advisory Board: DOW Agro
Sciences, Dynavax Technologies, Genalyte,
GLG Research, Hycor Biomedical, Medline
Industries, Merck, Nordic Biotech Advisors,
Nutricia North America, Perrigo, Regeneron,
Perosphere; Honorarium: Mylan Specialty;
Research Grant: Hycor Biomedical; Stock:
Allertein Therapeutics, Mast Cell
Pharmaceuticals
William W. Busse, MD, FACAAI
Consultant/Advisory Board: Genentech,
GlaxoSmithKline, Novartis, Roche; DSMB:
Boston Scientific, Genentech, Icon
§B. Gwen Carlton, DNP, APRN, FNP-BC
Speaker, Honorarium: Genentech
§Warner W. Carr, MD, FACAAI
Consultant/Advisory Board: Aerocrine, Alcon,
Allergan, AstraZeneca, Meda, Merck, Mylan,
Teva; Speaker: Aerocrine, Allergan,
AstraZeneca, Meda, Mylan, Teva; Honorarium:
Aerocrine, Alcon, Allergan, AstraZeneca, Meda,
Mylan, Teva; Clinical Research: Merck, Novartis,
Novum, Sanofi
Thomas B. Casale, MD, FACAAI
Consultant/Advisory Board, Research Grant:
Genentech, Novartis
Mariana C. Castells, MD, PhD, FACAAI
Consultant/Advisory Board: Merck, Sanofi;
Research Grant: National Institutes of Health
(NIH)
§= Moderator
99
Disclosures
§Bradley E. Chipps, MD, FACAAI
Consultant/Advisory Board, Honorarium:
AstraZeneca, Genentech, GlaxoSmithKline,
Meda, Merck, Mylan Specialty, Novartis,
Sunovion; Speaker: AstraZeneca, Genentech,
GlaxoSmithKline, Meda, Merck, Novartis,
Sunovion
§Timothy J. Craig, DO, FACAAI
Consultant/Advisory Board: Genentech, Merck:
Research Grant: Genentech, GlaxoSmithKline,
Merck, Novartis
 Peter S. Creticos, MD
Consultant/Advisory Board: Circassia, Greer;
Speaker: Merck; Honorarium, Research Grant:
Circassia, Greer, Merck
Ray S. Davis, MD, FACAAI
Consultant/Advisory Board: Alcon, AstraZeneca,
Meda, Merck, Mylan, Sunovion, Teva; Speaker,
Honorarium: Alcon, AstraZeneca, Meda, Merck,
Mylan, Teva
 Chitra Dinakar, MD, FACAAI
Speaker, Honorarium: Aerocrine,
GlaxoSmithKline, Teva
Stephen C. Dreskin, MD, FACAAI
Consultant/Advisory Board: Clinical
Immunization and Safety Assessment (CISA),
Pfizer; Honorarium/Compensation: CISA,
Division of Vaccine Injury Compensation (DVIC)
Department of Health and Human Services,
Pfizer; Research Grant: Genentech, National
Institutes of Health (NIH)
Stephen R. Durham, MD
Consultant/Advisory Board: Circassia, Leti,
Merck; Research Grant: ALK
Mark S. Dykewicz, MD, FACAAI
Consultant/Advisory Board, Honorarium: Merck;
Research Grant: Novartis
Anne K. Ellis, MD, FRCPC
Consultant/Advisory Board: Merck, Novartis,
Sanofi; Speaker: AstraZeneca, Merck, Novartis,
Pfizer; Research Grant: Circassia,
GlaxoSmithKline, Sun Pharma
§Stanley M. Fineman, MD, MBA, FACAAI
Consultant/Advisory Board: Mylan; Speaker:
Aerocrine, AstraZeneca, Genentech, Meda,
Mylan, Novartis; Research Grant: Genentech,
Mylan, Novartis
Alessandro Fiocchi, MD, FACAAI (SC)
Consultant/Advisory Board: Boehringer
Ingelheim, Chiesi Farmaceutici, Stallergenes;
Research Grant: Danone, Valeas
§Michael B. Foggs, MD, FACAAI
Consultant/Advisory Board: AstraZeneca,
Boehringer Ingelheim, Boston Scientific,
GlaxoSmithKline, Hycor, Meda, Merck, Mylan,
Sunovion; Speaker: AstraZeneca, Boston
Scientific, GlaxoSmithKline, Merck; Honorarium:
AstraZeneca, Boehringer Ingelheim,
GlaxoSmithKline, Hycor, Meda
100
§Luz S. Fonacier, MD, FACAAI
Speaker: Baxter; Honorarium: Genentech;
Research Grant: Baxter, Dyax, Genentech, Merck
Joseph W. Fowler, MD, Jr., FACAAI
Consultant/Advisory Board, Speaker, Research
Grant: SmartPractice
§Sandra M. Gawchik, DO, FACAAI
Consultant/Advisory Board: AstraZeneca,
Genentech, Meda, Merck; Speaker: AstraZeneca,
Genentech, Merck; Honorarium: AstraZeneca,
Genentech, Meda, Merck, Novartis; Research
Grant: AstraZeneca, Genentech, Sanofi,
Sunovion, Teva; Stock: AstraZeneca, Merck, Teva
Bob Geng, MD
Consultant/Advisory Board: Baxter
 Maureen George, PhD, RN, AE-C, FAAN
Consultant/Advisory Board, Speaker,
Honorarium: Teva
Pinkus Goldberg, MD
Consultant/Advisory Board: Allergan; Speaker:
Genentech, Meda, Merck, Mylan, Novartis;
Research Grant: Circassia, Genentech,
GlaxoSmithKline, Meda, Merck, Novartis, Teva
Alan B. Goldsobel, MD, FACAAI
Speaker: Merck, Teva; Research Grant: Alvine,
Amgen, AstraZeneca, Array, Cerecor, Cytos,
KaloBios, Meda, Merck, Mylan, Novartis,
Pulmagen, Rigel, Sanofi, Teva, Vectura
§Richard G. Gower, MD, FACAAI
Consultant/Advisory Board: CSL Behring, Dyax,
Genentech, HollisterStier, Mylan, Novartis,
Roche, Shire, Teva; Speaker: CSL Behring, Mylan,
Shire, Teva; Honorarium: CSL Behring,
Genentech, Mylan, Novartis, Roche, Shire, Teva;
Research Grant: AstraZeneca, Circassia, CSL
Behring, Eli Lilly, Genentech, GlaxoSmithKline,
Mylan, Novartis, Pearl, Roche, Shire, Teva
David F. Graft, MD, FACAAI
Speaker: Merck
Mitchell H. Grayson, MD, FACAAI
Research Grant: Merck, Polyphor
Matthew Greenhawt, MD, MBA, MSc
Consultant/Advisory Board: BioStrategies,
Deerfield Industires, Huron Consulting, Nutricia;
Speaker: Nutricia; Research Grant: National
Institutes of Health (NIH), University of
Michigan Food Allergy Center
 Gary N. Gross, MD, FACAAI
Consultant/Advisory Board, Honorarium: Merck;
Speaker: AstraZeneca, Merck; Research Grant:
AstraZeneca, Amgen, Genentech, Johnson &
Johnson, Merck, Sanofi, Teva
I. Celine Hanson, MD, FACAAI
Consultant/Advisory Board: Baxter
§Mary Lou Hayden, MSN, APRN, CPNP-FC, FNPBC, AE-C
Consultant/Advisory Board: Mylan, Novartis,
Teva; Speaker, Honorarium: Genentech, Teva
 Curtis L. Hedberg, MD, FACAAI
Stock Ownership: US Healthrecords
 Vivian Hernandez-Trujillo, MD, FACAAI
Consultant/Advisory Board, Speaker: Baxter,
CSL Behring, Merck, Sanofi;
Fred H. Hsieh, MD
Research Grant: Howard Hughes Medical
Institute (HHMI)
Sharon E. Jacob, MD
Consultant/Advisory Board: Johnson &
Johnson; Research Grant: SmartPractice USA
 Lewis J. Kanter, MD, FACAAI
Speaker: Alcon, AstraZeneca, Teva
§Rohit K. Katial, MD, FACAAI
Consultant/Advisory Board, Speaker,
Honorarium: Teva
 David A. Khan, MD, FACAAI
Speaker, Honorarium: Baxter, Genentech
David M. Lang, MD, FACAAI
Consultant/Advisory Board: Genentech,
GlaxoSmithKline, Hycor, Merck, Novartis, Quest;
Speaker, Honorarium, Research Grant:
Genentech, Merck, Novartis
Estelle Levetin, PhD
Consultant/Advisory Board: Greer
H. Henry Li, MD, PhD, FACAAI
Consultant/Advisory Board: CSL Behring, Dyax,
Pharming, Salix, Shire; Speaker: CSL Behring,
Dyax, Shire; Honorarium: Shire; Research Grant:
CSL Behring, Dyax, Shire
Phillip L. Lieberman, MD, FACAAI
Consultant/Advisory Board: Genentech, Merck;
Speaker: Genentech, Meda, Merck, Teva
Peter A. Lio, MD
Consultant/Advisory Board: Anacor, Galderma,
Johnson & Johnson, Pierre Fabre Derm;
Speaker: Galderma, Mission Pharmacal, Pierre
Fabre Derm; Honorarium: Anacor, Galderma,
Johnson & Johnson, Mission Pharmacal, Pierre
Fabre Derm; Research Grant: Atopic Derm
Foundation
 Todd A. Mahr, MD, FACAAI
Consultant/Advisory Board: Meda, Mylan,
Sanofi, Teva; Speaker, Honorarium: Aerocrine,
Genentech, GlaxoSmithKline, Meda, Mylan,
Sanofi, Teva; Research Grant: Genentech,
GlaxoSmithKline
 Lyndon Mansfield, MD, FACAAI
Consultant/Advisory Board: Genentech
Speaker: Sunovion, Teva
 Gailen D. Marshall, MD, PhD, FACAAI
Research Grant: Amgen, AstraZeneca, National
Institutes of Health (NIH)
A. Sean McKnight, MD, FACAAI
Speaker: Mylan
§J. Allen Meadows, MD, FACAAI
Speaker: GlaxoSmithKline, Meda
Anthony Montanaro, MD, FACAAI
Research Grant: Circassia, Genentech,
GlaxoSmithKline, Merck, Novartis, Pulmagen
Therapeutics, Teva
Kevin R. Murphy, MD, FACAAI (SC)
Consultant/Advisory Board, Honorarium:
Aerocrine, AstraZeneca, Genentech, Greer,
Meda, Mylan, Novartis, Teva; Speaker: Aerocrine
AstraZeneca, Genentech, Mylan, Novartis, Teva;
Research Grant: Teva
 Robert M. Naclerio, MD
Consultant/Advisory Board: Meda, Merck,
Mylan, Teva; Speaker: Merck, Teva; Research
Grant: Meda, Teva
Harold S. Nelson, MD, FACAAI
Consultant/Advisory Board: Circassia, Merck;
Research Grant: Circassia; DSMB: Pearl
Anna H. Nowak-Wegrzyn, MD, FACAAI
Consultant/Advisory Board: Merck, Nestle,
Stallergenes; Speaker: Merck, Thermo Fisher
Scientific; Research Grant: Food Allergy
Research and Education (FARE), National
Institute of Allergy and Infectious
Diseases/Immune Tolerance Network
(NIAID/ITN), Nutricia
Talal M. Nsouli, MD, FACAAI
Consultant/Advisory Board, Speaker: Aerocrine,
Sunovion, Teva, Thermo Fisher Scientific
§Maeve E. O'Connor, MD, FACP, FACAAI
Consultant/Advisory Board: Greer, Meda, Merck,
Mylan, Sunovion, Teva; Speaker: Greer, Meda,
Merck, Mylan, Sunovion, Thermo Fisher
Scientific, Teva
§Mark T. O'Hollaren, MD, FACAAI
WebMD
John J. Oppenheimer, MD, FACAAI
Consultant/Advisory Board: AstraZeneca,
GlaxoSmithKline, Meda, Mylan, Teva; Research
Grant: AstraZeneca, Boehringer Ingelheim,
Genentech, GlaxoSmithKline, MedImmune
Reynold A. Panettieri, Jr., MD
Consultant/Advisory Board: AstraZeneca,
Gilead, Johnson & Johnson, Merck, Teva;
Research Grant: AstraZeneca, Gilead, Johnson &
Johnson, Merck, Roche, Sanofi
David B. Peden, MD, FACAAI
Consultant/Advisory Board/Editor-in-Chief:
Current Asthma & Allergy Reports
Stephen P. Peters, MD
Consultant/Advisory Board: Aerocrine, Airsonett
AB, Array Biopharma, AstraZeneca, Boehringer
Ingelheim, Experts in Asthma, GlaxoSmithKline,
Merck, Ono, Pfizer, PPD Development, Quintiles,
Saatchi & Saatchi, Sunovion, Targacept, Teva;
Speaker: Merck; Research/Research Grants:
NHLBI, American Lung Association; Actelion,
Amgen, AstraZeneca, Boehringer Ingelheim,
Centocor, Genentech, GlaxoSmithKline, Forest,
MedImmune, Novartis, Sanofi, Teva
Jay M. Portnoy, MD, FACAAI
Speaker, Honorarium: Mylan, Thermo Fisher
Scientific
Karen S. Rance, DNP, APRN, CPNP, AE-C
Consultant/Advisory Board: Genentech, Meda,
Merck
Marc A. Riedl, MD, MS
Consultant/Advisory Board: Baxter, BioCryst,
CSL Behring, Dyax, Salix, Shire; Speaker: Baxter,
CSL Behring, Dyax, Shire; Research Grant:
Biocryst, CSL Behring, Dyax, Salix, Shire
§Lanny J. Rosenwasser, MD, FACAAI
Consultant/Advisory Board: National Heart
Lung Blood Institute (NHLBI AsthmaNet),
Circassia, Regeneron, Sanofi
John M. Routes, MD, FACAAI
Research Grant: Baxter
Hugh A. Sampson, MD, FACAAI
Consultant/Advisory Board: Allertein
Therapeutics, Danone, MedImmune,
Regeneron; Stock: Allertein Therapeutics;
Stock/Ownership Interest: Herbs Spring
Mario Sanchez-Borges, MD
Consultant/Advisory Board: Genentech,
Novartis; Speaker: FAES Farma
§Deidra H. Sanders, MSN, APRN, FNP-BC
Stock: AllergyZone
David J. Shulan, MD, FACAAI
Stock: General Electric
§Charles J. Siegel, MD, FACAAI
Consultant/Advisory Board: Meda, Teva;
Speaker, Honorarium: Alcon, Meda, Teva
William S. Silvers, MD, FACAAI
Speaker: Teva
Sheldon L. Spector, MD, FACAAI
Consultant/Advisory Board: Stallergenes;
Speaker: AstraZeneca, Genentech, Merck;
Research Grant: Amgen, Genentech,
GlaxoSmithKline, Mylan, Novartis, Sunovion,
Teva
 Brett E. Stanaland, MD
Speaker: Meda
Mark R. Stein, MD
Consultant/Advisory Board, Speaker,
Honorarium: Baxter, CSL Behring; Investigator:
ADMA Biologics, Baxter, Bio Products Lab (BPL),
CSL Behring, Green Cross, Kedrion
 Gary C. Steven, MD, PhD, FACAAI
Speaker: Merck, Novartis, Teva; Research Grant:
Merck, AstraZeneca, Circassia, Genentech,
Mylan, Novartis, Novum, Optinose, Concentric,
Pulmagen, GlaxoSmithKline, Teva
§James L. Sublett, MD, FACAAI
Consultant/Advisory Board: Aerocrine,
Asthmapolis, Genentech, GlaxoSmithKline,
Meda, Merck, Sunovion, Teva; Speaker:
GlaxoSmithKline, Merck, Sunovion, Teva;
Honorarium: Aerocrine, GlaxoSmithKline, Meda,
Merck, Sunovion, Teva; Research Grant:
Asthmapolis, AstraZeneca, Forest, Genentech;
Stock: AllergyZone
Stanley J. Szefler, MD, FACAAI
Consultant/Advisory Board: Aerocrine,
Boehringer Ingelheim, GlaxoSmithKline, Roche;
Honorarium: Genentech; Research Grant:
GlaxoSmithKline
Michael Tanoury, MA
Employee: Family Allergy and Asthma
Donald P. Tashkin, MD
Consultant/Advisory Board: AstraZeneca,
Boehringer Ingelheim, Novartis, Teva; Speaker,
Honorarium: AstraZeneca, Boehringer
Ingelheim, Meda, Novartis, Teva; Research
Grant: Boehringer Ingelheim, Novartis
Stephen A. Tilles, MD, FACAAI
Consultant/Advisory Board: Genentech, Greer,
Hycor, Sunovion, Teva; Research Grant: Amgen,
Astellas, AstraZeneca, DVB Technologies,
Genentech, Merck, Mylan, Novartis, Pulmagen,
Teva, National Institutes of Health (NIH)
Immune Tolerance Network (ITN), Perrigo
§Janna M. Tuck, MD, FACAAI
Stock Ownership: Advanced Tech, Alrstar, CELSCI, ContraVir, InvenSense, Synergy
Christine W. Wagner, MSN, APRN, CPNP
Consultant/Advisory Board, Speaker,
Honorarium: Teva
§Dana V. Wallace, MD, FACAAI
Consultant/Advisory Board: Mylan, Sanofi;
Speaker: Meda, Mylan, Sanofi, Sunovion, Teva
Julie Wang, MD
Consultant/Advisory Board: Merck; Stock
Option: Journal of Ocular Pharmacology
Therapeutics
 = Planner
§= Moderator
101
Disclosures
Disclosures
Disclosures
§Richard L. Wasserman, MD, PhD, FACAAI
Consultant/Advisory Board: ADMA Biologics,
Baxter, CSL Behring, Therapure; Speaker: Alcon,
Baxter, CSL Behring, GlaxoSmithKline;
Honorarium: ADMA Biologics, Alcon, Baxter, CSL
Behring, GlaxoSmithKline; Research Grant:
ADMA Biologics, Baxter, Bioplasma Labs, CSL
Behring, Kedrion, Green Cross
 Richard W. Weber, MD, FACAAI
Speaker: Merck; Research Grant:
GlaxoSmithKline
Matthew J. Zirwas, MD
Consultant/Advisory Board: SmartPractice, Sun
Products, Valeant
The following have no relevant financial relationships to disclose:
Donald W. Aaronson, MD, JD, MPH, FACAAI
Mark Holbreich, MD, FACAAI
Wanda Phipatanakul, MD, MS, FACAAI
Sohaib Aleem, MD
Linn Holness, MD
Thomas A.E. Platts-Mills, MD, PhD, FACAAI
James Anderson
Alison L. Humphrey, MD
Donald W. Pulver, MD, FACAAI
Sami L. Bahna, MD, DrPH, FACAAI
§Charlotte M. Jacobsen, RN, MSN
Virginia K. Rensel, RN
Cathy Bailey, MS
Jay Jin
Charles S. Barnes, PhD
Steve Kagen, MD
Suzanne F. Beavers, MD
Pramod S. Kelkar, MD
Joseph A. Bellanti, MD, FACAAI
Brian T. Kelly, MD, MA
Roxana I. Siles, MD
Jason L. Biddy, MBA
John M. Kelso, MD, FACAAI
Raymond G. Slavin, MD, MS, FACAAI
Alison Bruce, MD
Kevin Kennedy, MPH, CIEC
Ryan Steele, DO
Jeana Bush, MD
Charles Calais
Sridevi Challa
Mirna Chehade, MD, MPH
Ginger L. Chew, ScD
Seong H. Cho, MD
 Christina E. Ciaccio, MD, FACAAI
Kimberly G. Clay, MN, APRN, FNP-BC
Maria G. Crain, NP, CPNP, AE-C
 Vesselin Dimov, MD
§Jerald W. Koepke, MD, FACAAI
§Tao T. Le, MD, MHS, FACAAI
 Gerald B. Lee, MD
Mitchell R. Lester, MD, FACAAI
§James T. Li, MD, PhD, FACAAI
Paul J. Maglione, MD, PhD
§Bryan L. Martin, DO, FACAAI
Elizabeth Matsui, MD
 Michael R. Nelson, MD, PhD, FACAAI
 Myngoc T. Nguyen, MD, FACAAI
Nathan Segall, MD, FACAAI
 Joram S. Seggev, MD, FACAAI
§Jodi Shroba, MSN, RN, CPNP
David R. Stukus, MD
Agnes S. Sundaresan, MD, MPH
Concettina Tolomeo, DNP, APRN, FNP-BC, AE-C
§Kay Tyler, MBA
Michael P. Vaughn, MD, PhD
Kara J. Wada, MD
Kristen K. Welborn, MSN, FNP-BC, APRN
 David R. Weldon, MD, FACAAI
Charles R. Westley, MD, FACAAI
Andrew A. White, MD, FACAAI
Richard A. Nicklas, MD, FACAAI
Erin Willits, MD
Noreen H. Nicol, PhD, RN, FNP, NEA-BC
Karyn Winkler, MD
Grant C. Olson, MD, FACAAI
Priscilla Wong, MD
Theodore M. Freeman, MD, FACAAI
Dennis R. Ownby, MD, FACAAI
Robert A. Wood, MD
Alexel Gonzalez-Estrada, MD
Karin A. Pacheco, MD
Angela Crans Yoon, MD
Richard K. Gurgel, MD
Ruby U. Pawankar, MD, PhD, FRCP
Hatice S. Zahran, MD, MPH
Sarah Henrickson, MD, PhD
R. Stokes Peebles, MD, FACAAI
§William K. Dolen, MD, FACAAI
Eduardo Egea, MD
 Karen A. Freedle, MD, MPH, FACAAI
 = Planner
102
§ = Moderator
Special Events
23rd Annual FIT Bowl Competition
NOT FOR
CREDIT
5:00 – 7:00 pm, Saturday
Hall A-2 • Georgia World Congress Center
General Information
Test your knowledge, sharpen your wits and join in the fun at the dynamic, fast-paced FIT Bowl!
Participating teams from training programs around the country will compete to answer a
variety of serious (and not so serious) questions posed by an expert panel. In 2013, thirty-five
teams from the US and Mexico participated at this popular game show.
Supported by Sanofi US
Alliance International Reception
6:00 – 7:00 pm, Saturday
International Ballroom Salon F (Level M2 – North Tower) • Omni Hotel
International attendees are cordially invited to attend the
International Reception hosted by the ACAAI Alliance.
Awards Ceremony
7:00 – 7:45 pm, Saturday
International Ballroom Salons DE (Level M2 – North Tower) • Omni Hotel
The College invites all registrants to the ACAAI Awards Ceremony on Saturday
at the Omni Hotel at CNN Center. ACAAI will recognize the 2014 Award recipients and
formally welcome our newly-approved Fellows. We will also recognize the recipients of the
ACAAI’s Distinguished Fellow, International Distinguished Fellow, Distinguished Service, and
Woman in Allergy awards. Finally, we’ll introduce this year’s winner of the
College’s prestigious Gold Headed Cane Award, Dr. Peter Boggs.
President’s Welcome Reception
7:45 – 9:00 pm, Saturday
Grand Ballroom (Level M4 – North Tower) • Omni Hotel
The College invites all registrants to the ACAAI President’s Welcome Reception held in the
Grand Ballroom (Level M4 – North Tower) at the Omni Hotel at CNN Center, from 7:45 – 9:00 pm.
It’s the perfect place to catch up with old friends, make new acquaintances and meet the
ACAAI President, President-Elect and the Alliance President.
103
2014 Named Lectures
Each year, the American College of Allergy, Asthma & Immunology presents several named lectures during its annual scientific meeting. The “Bela Schick”, “John P. McGovern” and “Bernard Berman” lectures are presented annually. The “Daniel J.
Goodman” and “Lester Mittelstaedt” lectures are presented in alternate years.
The allergists selected to present named lectures embody the high standards and achievements of the physicians for whom
the lectures are named. The College is proud to present the following named lectures at its 2014 Annual Scientific Meeting.
John P. McGovern Lecture
Bela Schick Lecture
Saturday, November 8, 9:05 am
Sidney Marcus Auditorium
Georgia World Congress Center
Asthma as COPD: Pulmonary
Remodeling – A Phenomenon of
Children and Adults
Phillip L. Lieberman, MD, FACAAI
Memphis, TN
Sunday, November 9, 10:30 am
Sidney Marcus Auditorium
Georgia World Congress Center
If You Don’t Know Where
You Are Going, You May End Up
Somewhere Else
Bradley E. Chipps, MD, FACAAI
Sacramento, CA
This annual lectureship is supported
by a grant from the John P. McGovern
Foundation. The Foundation sought to
establish a lectureship that would
recognize eminent physicians and
scientists, both clinicians and
researchers, who have contributed
meritoriously to the advancement of
knowledge in the specialty of allergyimmunology. Lecturers receive the
prized John P. McGovern medallion,
created especially for the lectureship.
Dr. McGovern was a past president of
the College and a strong leader in the
field of patient care.
The annual Bela Schick lecture is
named in honor of one of medicine’s
most respected scientists. Bela Schick
was born in Hungary and attended
medical school in Austria. After serving
as Extraordinary Professor of Children’s
Diseases at the University of Vienna, he
immigrated to the United States in
1923. He was a pediatrician at Mt. Sinai
in New York for many years, loved by
his patients and respected by his fellows. Dr. Schick is best known for his
work with Clemens von Pirquet on
anaphylaxis and for the test he developed to assess immunity in diphtheria.
Daniel Goodman Lecture
Sunday, November 9, 11:30 am
Sidney Marcus Auditorium
Georgia World Congress Center
Probiotics in Prevention of Allergy
Alessandro Fiocchi, MD, FACAAI (SC)
Rome, Italy
The biennial Goodman Lecture is
supported by a grant from Dr. Daniel
Goodman. His purpose in establishing
this lectureship was to leave a legacy
to honor individuals who have demonstrated outstanding scholarship and
clinical abilities in the field of
allergy/immunology.
104
Bernard Berman
Memorial Lecture
Monday, November 10, 10:35 am
Sidney Marcus Auditorium
Georgia World Congress Center
Overview of Environmental
Assessment and Exposure Control
Jay M. Portnoy, MD, FACAAI
Kansas City, MO
The annual Bernard Berman Memorial
Lecture recognizes a kind, caring
clinician allergist with interests in the
various aspects of clinical allergy and a
passion for teaching. The Memorial
Lecture is a testament to Dr. Berman’s
caring nature, unique skills as a gifted
teacher and unselfish compassion for
his patients. He was a past president of
the College and one of the founders of
the American Board of Allergy and
Immunology.
Tribute to Our Past Presidents
Past Presidents
Bernard J. Efron, MD
French K. Hansel, MD
Harry L. Rogers, MD
Leon Unger, MD
Hal M. Davison, MD
George E. Rockwell, MD
Johnathan Forman, MD
John H. Mitchell, MD
Harold A. Abramson, MD
J. Warrick Thomas, MD
M. Murray Peshkin, MD
Homer E. Prince, MD
Lawrence J. Halpin, MD
Ethan Allan Brown, M.R.C.S.
Orval R. Withers, MD
Merle W. Moore, MD
Cecil M. Kohn, MD
Giles M. Koelsche, MD
Philip M. Gottlieb, MD
Mayer A. Green, MD
Morris A. Kaplan, MD
Boen Swinny, Sr., MD
Stanislaus H. Jaros, MD
M. Coleman Harris, MD
Lowell L. Henderson, MD
Howard G. Rapaport, MD
James E. Stroh, MD
John P. McGovern, MD
Johnny A. Blue, MD
Paul F. deGara, MD
Mason I. Lowance, MD
G. Frederick Hieber, MD
Alex S. Friedlaender, MD
Ralph Hale, MD
Boen Swinny, Jr., MD
Lamar B. Peacock, MD
Richard H. Jackson, MD
Wm. Sawyer Eisenstadt, MD
Robert J. Brennan, MD
Bernard A. Berman, MD
John L. Dewey, MD
Ben C. Eisenberg, MD
Lester W. Mittelstaedt, MD
Nathan Ernest Silbert, MD
Alexander McCausland, MD
Orville C. Thomas, MD
1942–43
1943–45
1945–46
1946–47
1947–48
1948–49
1949–50
1950–51
1951–52
1952–53
1953–54
1954–55
1955–56
1956–57
1957–58
1958–59
1959–60
1960–61
1961–62
1962–63
1963–64
1964–65
1964–67
1965–66
1966–67
1967–68
1967–68
1968–69
1968–69
1969–70
1969–70
1970–71
1970–71
1971–72
1971–72
1972–73
1972–73
1973–74
1973–74
1974–75
1974–75
1975–76
1975–76
1976–77
1976–77
1977–78
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
ACA
AACIA
ACA
ACA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
Gustav J. Beck, MD
1977–78
• Albert E. Hensel, Jr., MD
1978–79
Stanley L. Goldman, MD
1978–79
• T. Reed Maxson, MD
1979–80
William H. Wilson, MD
1979–80
• Solomon D. Klotz, MD
1980–81
• Walter R. MacLaren, MD
1980–81
Robert J. Dockhorn, MD
1981–82
• Warren J. Raymer, MD
1981–82
Gilbert D. Barkin, MD
1982–83
• Sidney Friedlaender, MD
1982–83
Rufus E. Lee, Jr., MD
1983–84
Burton M. Rudolph, MD
1983–84
• John G. Leonardy, MD
1984–85
• Albert G. Corrado, MD
1984–85
Charles H. Banov, MD
1985–86
Donald L. Unger, MD
1985–86
Peter B. Boggs, MD
1986–87
Donald C. McLean, MD
1986–87
• Robert J. Becker, MD
1987
• R. Faser Triplett, MD
1987–88
Donald W. Aaronson, MD, JD, MPH 1988–89
Dale B. Sparks, MD
1989–90
Edward J. O’Connell, MD
1990–91
Joseph A. Bellanti, MD
1991–92
• John C. Selner, MD
1992–93
• Robert T. Scanlon, MD
1993–94
Diane E. Schuller, MD
1994–95
Ira Finegold, MD
1995–96
Betty B. Wray, MD
1996–97
• Jean A. Chapman, MD
1997–98
Robert M. Miles, MD
1998-99
Don Q. Mitchell, MD
1999-00
Emil J. Bardana, Jr., MD
2000-01
Bobby Q. Lanier, MD
2001-02
William E. Berger, MD, MBA
2002-03
Michael S. Blaiss, MD
2003-04
Myron J. Zitt, MD
2004-05
William K. Dolen, MD
2005-06
Daniel Ein, MD
2006-07
Jay M. Portnoy, MD
2007-08
Richard G. Gower, MD
2008-09
Sami L. Bahna, MD, DrPH
2009-10
Dana V. Wallace, MD
2010-11
Stanley M. Fineman, MD, MBA
2011-12
Richard W. Weber, MD
2012-13
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
AACIA
ACA
ACAI
ACAI
ACAI
ACAI
ACAI
ACAI
ACAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
ACAAI
General Information
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
• Deceased
105
2014 Distinguished Fellows
ACAAI will award its “Distinguished Fellow” title to David A. Khan, MD, FACAAI and Todd A. Mahr, MD, FACAAI during
the Awards Ceremony, 7:00 pm, Saturday, in the International Ballroom Salons DE (Level M2 – North Tower) of the Omni
Hotel at CNN Center. At the same time, ACAAI will award its “International Distinguished Fellow” title to Mario SanchezBorges, MD and Tatiana Slavyanskaya, MD, PhD.
Distinguished Fellow Recipients
1971
John P. McGovern, MD
1972
M. Coleman Harris, MD
1973
Howard Rapaport, MD
1974
J. Warrick Thomas, MD
1975
William Browning, MD
Jerome Glaser, MD
French K. Hansel, MD
Merle W. Moore, MD
M. Murray Peshkin, MD
Leon Unger, MD
Orval R. Withers, MD
1976
Eloi Bauers, JD
Paul F. deGara, MD
John D. Gillaspie, MD
Giles A. Koelsche, MD
Stephen D. Lockey, MD
Homer E. Prince, MD
1977
Harold Abramson, MD
Bernard A. Berman, MD
Ethan Allan Brown, MD
Ben C. Eisenberg, MD
Sawyer Eisenstadt, MD
Philip M. Gottlieb, MD
Mayer A. Green, MD
Ralph Hale, MD
Lowell Henderson, MD
G. Frederick Hieber, MD
Lamar B. Peacock, MD
George E. Rockwell, MD
Nathan E. Silbert, MD
Boen Swinny, Sr., MD
1978
Susan C. Dees, MD
William C. Grater, MD
Frank Perlman, MD
Frederick Speer, MD
Peter B. Boggs, MD
Robert J. Brennan, MD
Lloyd V. Crawford, MD
Joel D. Teigland, MD
Gerald Vanderpool, MD
1979
Cecil Collins–Williams, MD
Meyer B. Marks, MD
Orville C. Thomas, MD
1988
Donald C. McLean, MD
Robert Moore, MD
Warren Richards, MD
1980
Albert E. Hensel, Jr., MD
Melvin Newman, MD
1989
Jean A. Chapman, MD
Bernard T. Fein, MD
R. Faser Triplett, MD
1981
Joseph A. Bellanti, MD
T. Reed Maxson, MD
1982
Robert J. Becker, MD
G. Everett Gaillard, MD
Solomon D. Klotz, MD
1983
Robert J. Dockhorn, MD
William T. Kniker, MD
1990
Donald Aaronson, MD
Martin J. Kaplan, MD
Betty B. Wray, MD
1991
Burton M. Rudolph, MD
Sheldon L. Spector, MD
Dale B. Sparks, MD
1984
Gilbert D. Barkin, MD
James C. Breneman, MD
1992
Emil J. Bardana, Jr., MD
Allan T. Luskin, MD
Edward O’Connell, MD
Warren Raymer, MD
1985
Joseph E. Ghory, MD
Rufus E. Lee, Jr., MD
Roland B. Scott, MD
1993
Herbert Mansmann, Jr., MD
Eli O. Meltzer, MD
R. Michael Sly, MD
1986
Robert Hamburger, MD
John G. Leonardy, MD
Harold S. Nelson, MD
1994
Arnold A. Gutman, MD
John C. Selner, MD
1987
Charles H. Banov, MD
1995
Hyman Chai, MD
Bob Q. Lanier, MD
Robert M. Miles, MD
Stuart L. Rusnak, MD
Robert T. Scanlon, MD
1996
Michael S. Blaiss, MD
Douglas S. Heiner, MD
Don Q. Mitchell, MD
Diane E. Schuller, MD
1997
Ira Finegold, MD
John M. O’Loughlin, MD
1998
Susan Rudd Bailey, MD
William E. Berger, MD
Alexander McCausland, MD
William W. Storms, MD
1999
Linda B. Ford, MD
Bettina C. Hilman, MD
Richard Nicklas, MD
2000
Stanley M. Fineman, MD
Lawrence S. Mihalas, MD
2001
William K. Dolen, MD
Jay Portnoy, MD
Nathan Segall, MD
2002
Phillip Lieberman, MD
Anthony Montanaro, MD
Suellyn S. Rossman, MD
2003
Charles J. Siegel, MD
Richard W. Weber, MD
2004
Sami L. Bahna, MD, DrPH
Lawrence DuBuske, MD
Jorge A. Quel, MD
2005
John Andrew Grant, MD
Mark T. O’Hollaren, MD
2006
Richard D. de Shazo, MD
Marianne Frieri, MD, PhD
2007
Ernest Charlesworth, MD
2008
John E. Moffitt, MD
2009
Michael B. Foggs, MD
Gailen D. Marshall, Jr., MD,
PhD
2010
Kathleen R. May, MD
James L. Sublett, MD
2011
Bryan L. Martin, DO
2012
Myron J. Zitt, MD
2013
Daniel Ein, MD
Richard G. Gower, MD
2014
David A. Khan, MD
Todd A. Mahr, MD
International Distinguished Fellow Recipients
1989
Jose Luis Cortes, MD
Angel Marchand, MD
1994
Julio Croce, MD
Moises Zebede, MD
1990
Felicidad Cua–Lim, MD
Jose Huerta Lopez, MD
1995
Charles K. Naspitz, MD
1991
Israel Glazer, MD
Samuel Malka, MD
1992
Sami Bahna, MD, DrPH
Attilio Boner, MD
Luisa Businco, MD
1993
Antero Palma–Carlos, MD
Sten Dreborg, MD
106
1996
Mario La Rosa, MD
Hugo E. Neffen, MD
1997
Giuliana Baldini, MD
Natalio Salmun, MD
1998
Giovanni Cavagni, MD
Cassim Motala, MD
1999
Sebastiano Guarnaccia, MD
João Ferreira Mello, MD
2000
Sergio Bonini, MD
2001
Anthony Frew, MD
Maurizio Miraglia
Del Giudice, MD
Marek Kowalski, MD
2002
Alessandro Fiocchi, MD
Constance Katerlaris, MD
2003
Helen Hei-ling Chan, MD
Pakit Vichyanond, MD
2004
Daniel Aguilar, MD
Kamal M. Hanna, MD
S.G.O. Johansson, MD, PhD
2005
Carlos Baena-Cagnani, MD
Todo A. Popov, MD
Paul van Cauwenberge, MD
2006
Ruby U. Pawankar, MD
Daphne Tsitoura, MD, PhD
2007
Ignacio Ansotegui, MD
Desiree L. LarenasLinnemann, MD
Noel Rodriguez Perez, MD
2010
Yin Jia, MD
Sang-Il Lee, MD, PhD
2011
Giovanni Pajno, MD
Fares Zatoun, MD
2012
Bee Wah Lee, MD
Revaz Sepiashvili, MD
2013
Sandra N. Gonzalez Diaz, MD,
PhD
2008
Alejandro Escobar-Gutierrez, MD 2014
Mario Sanchez-Borges, MD
Tatiana Slavyanskaya, MD, PhD
2009
G. Walter Canonica, MD
Yehia M. El-Gamal, MD, PhD
ACAAI Foundation
ACAAI Foundation “20K Club”
The following donors have met or exceeded their pledge of $20,000 to the ACAAI Foundation:
Nathan Segall, MD
David Bruce Engler, MD
General Information
Lawrence M. DuBuske, MD
ACAAI Foundation “10K Club”
The following donors have met or exceeded their pledge of $10,000 to the ACAAI Foundation:
Sami L. Bahna, MD, DrPH
Emil J. Bardana, Jr., MD
Joseph A. Bellanti, MD
Bradley E. Chipps, MD
Stanley M. Fineman, MD, MBA
Linda B. Ford, MD, AE-C
Richard Glen Gower, MD
John Andrew Grant, Jr., MD
Bobby Q. Lanier, MD
Phillip L. Lieberman, MD
Chao I. Lin, MD
Alnoor A. Malick, MD
Gailen D. Marshall, Jr., MD, PhD
Bryan Leslie Martin, DO
Kathleen R. May, MD
Don Quinton Mitchell, MD
Edward J. O’Connell, MD
James Lee Sublett, MD
Dana V. Wallace, MD
Richard W. Weber, MD
Betty B. Wray, MD
Alliance of the ACAAI
New England Society of Allergy
Texas Allergy, Asthma &
Immunology Society
ACAAI Foundation “5K Club”
The following donors have met or exceeded their pledge of $5,000 to the ACAAI Foundation:
Donald W. Aaronson, MD, JD, MPH
Suresh C. Anand, MD
Suresh Anne, MD
Eric S. Applebaum, MD
Robert J. Becker, MD
William E. Berger, MD, MBA
Michael S. Blaiss, MD
Larry Borish, MD
David Allen Brown, MD
Jean A. Chapman, MD
Ernest N. Charlesworth, MD
Susan H. Chua Apolinario, MD
James R. Claflin, MD
Joanne F. Domson, MD
Daniel Ein, MD
Andrew Cherner Engler, MD
John E. Erffmeyer, MD
Jafar Farnam, MD
Ira Finegold, MD
Luz Sison Fonacier, MD
Mary Brandt Hudelson, MD
Bobby Zachariah Joseph, MD
Martin J. Kaplan, MD
Roger M. Katz, MD
Kenneth Tongchul Kim, MD
Jerald W. Koepke, MD
Phillip Erwin Korenblat, MD
William R. Lumry, MD
Lyndon E. Mansfield, MD
Kevin Peter McGrath, MD
J. Allen Meadows, MD
Lawrence S. Mihalas, MD
Robert Milton Miles, MD
Mark W. Minor, MD
John Ellis Moffitt, MD
Anthony Montanaro, MD
David L. Morris, MD
Robert Alan Nathan, MD
Harold S. Nelson, MD
David Samuel Pearlman, MD
Hobert L. Pence, MD
Jay M. Portnoy, MD
Bruce Michael Prenner, MD
Gullapalli R. Krishna Rao, MD
Jeffrey Bryan Raub, MD
Russell R. Roby, MD
Anthony Robert Rooklin, MD
Diane E. Schuller, MD
John C. Selner, MD
Dennis Lee Spangler, MD
Dale B. Sparks, MD
Sheldon Laurence Spector, MD
Dexter Winn Walcott, MD
Myron Joseph Zitt, MD
IEINE
Whitehall-Robins
107
Anni6ve0rsthary
Alliance Program
The Hospitality Suite located in the Atrium Terrace (Atrium Terrace Level – South Tower) of the Omni
Hotel at CNN Center will be open for registered spouses and guests only during the following hours:
Friday – Monday, 8:00 – 10:30 am
The following presentations will take place in the Hospitality Suite and
are complimentary to registered spouses/guests and families:
Friday
Sunday
The History of Atlanta –
Margaret Mitchell & Gone With The Wind
Unusual Environmental Helpers
8:30 – 9:30 am
Once again we are pleased to revisit “Spotlighting our Own” by
having Bonnie Miles talk to us about how our environment
depends on as well as benefits from the activities of bats. These
amazing little creatures are decreasing in population and
Bonnie will emphasize the importance of their protection and
rehabilitation because preserving these tiny helpers will ultimately
affect all of us in a very big way. For all of those who value and
love nature, this presentation will be an educational and rewarding experience.
8:30 – 9:30 am
Led by an esteemed member of the Atlanta History Center and
Margaret Mitchell House family, this lecture will examine the personal legacy of Margaret Mitchell, a very distinguished Atlanta
Native, as well as the influence of her extraordinarily popular book
– Gone With The Wind.
Saturday
Comidas de America Sur
8:30 – 9:30 am
Beyond the realm of Mexico and its chiles, tacos and tamales
further south there is a world of other wonderful tastes. Chef
Ticha will delight you with an introduction to Latin American
cuisine. You will learn tips on preparing picadillos, platanos and
empenadas. And of course, what would a cooking program be
without a scrumptious dessert…this one you will love.
ACAAI KIDS – Zoo Atlanta Animal Encounters
9:30 – 10:30 am
Pine Room
A trained animal educator will present an exciting program using
live animals, biofacts like bones and fun activities to the kids to
create a connection to animals and conservation. Reptiles,
amphibians, mammals and insects galore!
Active Members of the Alliance
are invited to attend the Annual Business
Meeting and Luncheon
Sunday
12:30 – 3:00 pm
Location:
McCormick & Schmick’s
Centennial Room • One CNN Center
Fee $15 • Registration Required
During the luncheon, guests will be treated to a special
performance by the Atlanta Young Singers of Callanwolde.
The Alliance will be offering a notebook for sale that displays a
selection of photos from our recent Photography Contests on its
cover. Proceeds from your purchases will go to the Foundation. Be
sure to stop by one of our sales desks during the following hours:
Thursday, November 6:
Friday, November 7:
Saturday, November 8:
At all times:
108
3:00 – 6:00 pm near registration
7:00 – 9:00 am near registration
3:00 – 6:00 pm outside the Exhibit Hall
9:30 am – 1:30 pm outside the Exhibit Hall
7:30 – 9:00 pm at the Welcome Reception
In the Hospitality Suite
Fellows-in-Training
All Fellows-in-Training and are encouraged to participate in the following special activities designed to meet their unique
needs and interests. Friday’s FIT General Meeting includes the presentations and election of a Fellow-in-Training representative to the Board of Regents. Travel Grant Checks will be distributed at the FIT Welcome Reception. All of the activities
shown on this page, as well as plenary sessions and symposia, are complimentary.
Friday
Saturday
FIT Program
23rd Annual FIT Bowl Competition
3:30 – 5:30 pm
Rooms A311-312
Georgia World Congress Center
5:00 – 7:00 pm
Hall A-2
Georgia World Congress Center
Moderators:
Monica Bhagat, MD and Andrew Nickels, MD
Office Emergencies and Use of
SCIG/Omalizumab
Stanley M. Fineman, MD, MBA, FACAAI and
Virginia Rensel
1 2 3 4 5 6
Difficult Allergy and Immunology Cases
Donald W. Aaronson, MD, JD, FACAAI and
Gary N. Gross, MD, FACAAI
1 2 3 4 5 6
Awards Ceremony
NOT FOR
CREDIT
7:00 – 7:45 pm
International Ballroom Salons DE (Level M2 – North Tower)
Omni Hotel at CNN Center
President’s Welcome Reception
FIT General Meeting
NOT FOR
CREDIT
5:30 – 6:30 pm
Rooms A311-312
Georgia World Congress Center
FIT Welcome Reception
6:30 – 7:30 pm
Grand Ballroom Salons DE (Level M4 – North Tower)
Omni Hotel at CNN Center
NOT FOR
CREDIT
NOT FOR
CREDIT
7:45 – 9:00 pm
Grand Ballroom (Level M4 – North Tower)
Omni Hotel at CNN Center
Sunday
Doctors’ Job Fair
Supported by an independent educational grant from
Mylan Specialty L.P.
Supported by GREER®
Supported by Sanofi US
NOT FOR
CREDIT
12:30 – 3:30 pm
Hall A-1
Georgia World Congress Center
Residents for Allergy Program
A Special Program for Family Practice Residents
5:30 – 6:30 pm, Friday
Redwood Room (Level M1 – North Tower)
Omni Hotel at CNN Center
The Residents for Allergy Program is sponsored by the Foundation of the American College of Allergy, Asthma & Immunology. Its purpose is to provide Family Practice Residents with
information on new advances in allergy/immunology and how
to implement them when they have completed their residency.
The program will start with an orientation meeting.
Residents are also invited to the following events:
• Friday FIT Welcome Reception: 6:30 – 7:30 pm
(Grand Ballroom at the Omni Hotel)
• All Plenary Sessions and Symposia (Georgia World Congress
Center)
• Exhibit Hall (Georgia World Congress Center)
• FIT Bowl on Saturday: 5:00 – 7:00 pm (Hall A-2 in the Georgia
World Congress Center)
• Welcome Reception on Saturday: 7:45 – 9:00 pm
(Grand Ballroom at the Omni Hotel)
109
Fellows-in-Training
Upon completion of this session, participants should be able to:
identify important aspects of prescribing and dosing intravenous (IV)
and subcutaneous (SC) immunoglobulin replacement as well as
subcutaneous omalizumab therapy; manage adverse reactions to IV
and SC therapies in the clinical setting and manage anaphylaxis in the
allergy office setting; prepare for potential allergy/immunology office
emergencies; recognize and treat some of the most common but
difficult to diagnose allergic and immunologic diseases; broaden their
differentials for specific clinical patient presentations; consult key
subspecialists to aid in evaluation and management of difficult cases;
and describe various resources available regarding specialized
laboratory tests.
NOT FOR
CREDIT
Fellows-in-Training
Fellows-in-Training General Meeting Agenda
NOT FOR
CREDIT
5:30 – 6:30 pm, Friday • Rooms A311-312 • Georgia World Congress Center
ACAAI Alliance
Mrs. Margaret Quel
Alliance President
5:30 pm
Introduction and Welcome
Monica Bhagat, MD
Senior FIT Representative
5:35 pm
FIT Section Update
Andrew Nickels, MD
Junior FIT Representative
Candidate Speeches and Election of Junior
FIT Representative
5:45 pm
ACAAI Update
Michael B. Foggs, MD, FACAAI
President
6:00 pm
6:15 pm
Membership in the ACAAI
Curtis L. Hedberg, MD, FACAAI and
Kevin P. McGrath, MD, FACAAI
Co-Chairs, Membership Recruitment
Committee
Faculty Development
Bryan L. Martin, DO, FACAAI
ACGME/RRC and FITs
William K. Dolen, MD, FACAAI
JCAAI – Why It’s Important to Join
J. Allen Meadows, MD, FACAAI
JCAAI President
ABAI Certification
Stephen I. Wasserman, MD, FACAAI
President, The American Board of Allergy
and Immunology
Fellows-in-Training Awards
Clemens von Pirquet Awards
The ACAAI Alliance will present Clemens von Pirquet Awards to three Fellows-in-Training for their outstanding abstracts at
the Awards Ceremony, 7:00 pm, Saturday. The reciepients are:
The Alliance Memorial Award recipient is Dr. Jennifer Diaz, North Shore Long Island Jewish Health Care System, Great Neck,
NY, who will receive a $2,500 first place award for her abstract, “M1 Macrophages: A Potential Role in the Development of
Steroid Resistant Asthma in Obese Mice.”
The second place award of $1,500 will be presented to Dr. Caroline Kuo, UCLA Marion Davies Children's Center, Los
Angeles, CA, for her abstract, “Targeted Gene Therapy in the Treatment of X-Linked Hyper-IgM Syndrome.”
Dr. Alexei Gonzalez-Estrada, MD, Cleveland Clinic Foundation, Cleveland, OH, will receive a $1,000 third place award for his
abstract, “Popular on YouTube: A Critical Appraisal of the Educational Quality of Information Regarding Asthma.”
Young Faculty Support Awards
The Foundation of ACAAI will present two $50,000 Young Faculty Support Awards at the Awards Ceremony, 7:00 pm,
Saturday. The recipients of the awards are:
Sherry Farzan, MD, The Feinstein Institute for Medical Research, Manhasset, NY, who will conduct research on “The Role of
Glucocorticoid Receptor β in Steroid Insensitivity among Obese Atopic Asthmatics.”
Michael D. Keller, MD, Children’s National Health System, Division of Allergy and Immunology, Washington, DC, who will
conduct research on “Adoptive Immunotherapy for Treatment of Viral Infections in Primary Immunodeficiency Disorders.”
Supported by Merck
110
Travel Grant Recipients
Mitra Abaeian, MD
Kristyn Anthony, MD
Sean Brady, MD
Toronto, ON, Canada
McNeil Consumer Healthcare
New Orleans, LA
McNeil Consumer Healthcare
St. Louis, MO
Mylan Specialty L.P.
Pamella Abghari, MD
Ashish Asawa, MD
Kari Brown, MD
Detroit, MI
McNeil Consumer Healthcare
Galveston, TX
Genentech | Novartis
Cincinnati, OH
McNeil Consumer Healthcare
Julie Abraham, MD
Inessa Bachove, MD
Becky Buelow, MD
Cleveland, OH
McNeil Consumer Healthcare
Wilmington, DE
McNeil Consumer Healthcare
Milwaukee, WI
Genentech | Novartis
Rigoberto Acosta, MD
Michael C. Balduzzi, MD
Vanessa Bundy, MD
Shreveport, LA
Mylan Specialty L.P.
Tampa, FL
ACAAI Foundation
Los Angeles, CA
Mylan Specialty L.P.
Juan Adams, MD
Selene Bantz, MD
Jeana S. Bush, MD
Milwaukee, WI
ACAAI Foundation
New Haven, CT
Mylan Specialty L.P.
Augusta, GA
Drs. Charles and Betty Wray
Colleen Adkins, MD
Gillian Bassirpour, MD
Larisa Buyantseva, MD
Birmingham, AL
Genentech | Novartis
Detroit, MI
Genentech | Novartis
Hershey, PA
McNeil Consumer Healthcare
Vivek Agarwal, MD
Jenna Bergerson, MD
Amy CaJacob, MD
Denver, CO
Mylan Specialty L.P.
Chicago, IL
McNeil Consumer Healthcare
Birmingham, AL
Genentech | Novartis
Elias Akl, MD
Monica Bhagat, MD
Sonia Cajigal, MD
Richmond, VA
Genentech | Novartis
Philadelphia, PA
McNeil Consumer Healthcare
Detroit, MI
Mylan Specialty L.P.
Sohaib Aleem, MD
Humaa Bhatti, MD
Jennifer Camacho, MD
Iowa City, IA
McNeil Consumer Healthcare
Detroit, MI
McNeil Consumer Healthcare
New York, NY
Eastern Allergy Conference
Alexander Alvarez, MD
Sumit Bose, MD
Diego Antonio Carino Cartagena, MD
Richmond, VA
Genentech | Novartis
Chicago, IL
Mylan Specialty L.P.
Mexico City, DF, Mexico
Genentech | Novartis
William C. Anderson, III, MD
Varaz Bozoghlanian, MD
Carrie Caruthers, MD
Denver, CO
Mylan Specialty L.P.
Irvine, CA
Mylan Specialty L.P.
St. Louis, MO
Genentech | Novartis
Doerthe Adriana Andreae, MD
S. Claire Brabec, MD
Vanessa Y. Cavero, MD
New York, NY
Genentech | Novartis
Jackson, MS
David L. Moak, MD
Buffalo, NY
Mylan Specialty L.P.
ACAAI Thanks Its Travel Grant Sponsors
The Fellows-in-Training Section of ACAAI expresses its appreciation to the following institutions and physicians who
sponsored Fellows-in-Training Travel Grants this year:
Asthma & Allergy Proceedings
Eastern Allergy Conference
David L. Moak, MD
Scanlon Family Fund
Drs. Charles and Betty Wray
ALK, Inc.
Genentech | Novartis
McNeil Consumer Healthcare
Mylan Specialty L.P.
111
Travel Grants
The ACAAI Travel Grant Donors awarded travel grants to 223 Fellows-in-Training to attend the
2014 Annual Scientific Meeting. The travel grant recipients and their sponsors are shown below:
Travel Grant Recipients
The ACAAI Travel Grant Donors awarded travel grants to 223 Fellows-in-Training to attend the
2014 Annual Scientific Meeting. The travel grant recipients and their sponsors are shown below:
Sheva Chervinskiy, MD
Sharon Deol, MD
Jeffery Franklin, MD
Chapel Hill, NC
Mylan Specialty L.P.
Dallas, TX
Mylan Specialty L.P.
Atlanta, GA
McNeil Consumer Healthcare
Sergio E. Chiarella, MD
Jennifer Diaz, MD
James W. Fulton, MD
Chicago, IL
Mylan Specialty L.P.
Great Neck, NY
McNeil Consumer Healthcare
Denver, CO
Genentech | Novartis
Erica Chimienti, MD
Ashmi Doshi, MD
Stacey Galowitz, MD
Chicago, IL
Genentech | Novartis
La Jolla, CA
Genentech | Novartis
Wilmington, DE
Mylan Specialty L.P.
Melanie Chong, MD
Steven M. Draikiwicz, MD
Aries Caesar Gavino, MD
Mineola, NY
McNeil Consumer Healthcare
Newark, NJ
Mylan Specialty L.P.
Bellaire, TX
Genentech | Novartis
Kobkul Chotikanatis, MD
Cullen Dutmer, MD
Bob Geng, MD
Brooklyn, NY
McNeil Consumer Healthcare
Denver, CO
Genentech | Novartis
Los Angeles, CA
Genentech | Novartis
Amaziah Coleman, MD
Maureen Egan, MD
Kali Svarczkopf Gerace, MD
Madison, WI
Genentech | Novartis
New York, NY
McNeil Consumer Healthcare
Nashville, TN
McNeil Consumer Healthcare
Andrew Cooke, MD
Shelby Elenburg, MD
Asal Gharib, MD
Tampa, FL
Genentech | Novartis
Memphis, TN
Mylan Specialty L.P.
Irvine, CA
Genentech | Novartis
Samantha Melendez Coral, MD
Joseph Trent Ellenburg, MD
Parwinder Gill, MD
Mexico City, DF, Mexico
Mylan Specialty L.P.
Memphis, TN
McNeil Consumer Healthcare
Toronto, ON, Canada
Mylan Specialty L.P.
Gina Coscia, MD
Ezinma Ezealah, MD, MPH
Erica Glancy, MD
New York, NY
Mylan Specialty L.P.
Simpsonville, SC
Mylan Specialty L.P.
Cleveland, OH
Genentech | Novartis
Angelina Crans-Yoon, MD
Charles Feng, MD
Mudita Gogna, MD
Los Angeles, CA
Genentech | Novartis
Davis, CA
Genentech | Novartis
Pittsburgh, PA
McNeil Consumer Healthcare
Kara Crosby, MD
Nana S. Fenny, MD
Alexei Gonzalez-Estrada, MD
Buffalo, NY
ACAAI Foundation
Chicago, IL
McNeil Consumer Healthcare
Cleveland, OH
Genentech | Novartis
Miranda Curtiss, MD
Denisa Ferastraoaru, MD
Malika Gupta, MD
Birmingham, AL
McNeil Consumer Healthcare
Bronx, NY
Genentech | Novartis
Philadelphia, PA
McNeil Consumer Healthcare
Jasmeen Dara, MD
Jennifer E. Fergeson, MD
Mariam Hanna, MD
Bronx, NY
McNeil Consumer Healthcare
Tampa, FL
McNeil Consumer Healthcare
Oakville, ON
McNeil Consumer Healthcare
Jared Darveaux, MD
Juan Carlos Fernandez de Cordova
Aguirre, MD
Jill Hanson, MD
Madison, WI
McNeil Consumer Healthcare
Kathleen Dass, MD
Chicago, IL
McNeil Consumer Healthcare
Kristen Dazy, MD
San Diego, CA
McNeil Consumer Healthcare
112
Mexico City, DF, Mexico
McNeil Consumer Healthcare
Lindsay Finkas, MD
Denver, CO
McNeil Consumer Healthcare
Kansas City, MO
McNeil Consumer Healthcare
Heather Hartman, MD
Milwaukee, WI
Genentech | Novartis
Nicholas Hartog, MD
St. Louis, MO
Mylan Specialty L.P.
Travel Grant Recipients
Laura Helfner, MD
Brian Kelly, MD
Juhee Lee, MD
Great Neck, NY
McNeil Consumer Healthcare
Milwaukee, WI
Genentech | Novartis
Philadelphia, PA
McNeil Consumer Healthcare
Sarah Henrickson, MD
Erin Kempe, MD
Tricia Lee, MD
Philadelphia, PA
Mylan Specialty L.P.
Columbus, OH
Genentech | Novartis
New York, NY
Asthma and Allergy Proceedings
Hilda Hernandez Sanchez, MD
Yasmin Khan, MD
Christine Lee-Kim, MD
Monterrey, NL, Mexico
Genentech | Novartis
Nashville, TN
Mylan Specialty L.P.
Buffalo, NY
Genentech | Novartis
Claudia Hernandez-Ramirez, MD
Neha Kharod, MD
Zhenhong Li, MD
Mexico City, DF, Mexico
Genentech | Novartis
Buffalo, NY
Mylan Specialty L.P.
Albany, NY
Mylan Specialty L.P.
Darren Hirsch, MD
Amer Khojah, MD
Samantha Lin, MD
Great Neck, NY
Genentech | Novartis
Chicago, il
Genentech | Novartis
Hershey, PA
Genentech | Novartis
Alison L. Humphrey, MD
Jamie Kiehm, MD
Kevin Lindgren, MD
Kansas City, MO
Genentech | Novartis
Great Neck, NY
McNeil Consumer Healthcare
Chicago, IL
McNeil Consumer Healthcare
Muhammad Imran, MD
Julie Kim, MD
Stephanie Logsdon, MD
Kansas City, KS
McNeil Consumer Healthcare
Dallas, TX
McNeil Consumer Healthcare
Boston, MA
Eastern Allergy Conference
Parvez Islam, MD
Susan Kim, MD
Jeanne M. Lomas, MD
Roseville, CA
Mylan Specialty L.P.
Los Angeles, CA
Mylan Specialty L.P.
Rochester, NY
McNeil Consumer Healthcare
Junfang Jiao, MD
Anastasiya Kleva, MD
Margee Louisias, MD
St. Louis, MO
McNeil Consumer Healthcare
Great Neck, NY
Genentech | Novartis
Boston, MA
McNeil Consumer Healthcare
Qurat-Ul-Ain Kamili, MD
Michelle Korah-Sedgwick, MD
Yong Luo, MD
Houston, TX
Mylan Specialty L.P.
New Orleans, LA
McNeil Consumer Healthcare
Great Neck, NY
Mylan Specialty L.P.
Jennifer Kannan, MD
Robyn Kreiner, MD
Magdalena Molina Macip, MD
Cincinnati, OH
McNeil Consumer Healthcare
Bronx, NY
ACAAI Foundation
Mexico City, DF, Mexico
Mylan Specialty L.P.
Marilyn Karam, MD
Catherine Kubiak, MD
Paul J. Maglione, MD
Ann Arbor, MI
McNeil Consumer Healthcare
St. Petersburg, FL
Genentech | Novartis
New York, NY
Mylan Specialty L.P.
Irina Katayeva, MD
Caroline Kuo, MD
Shikha Mane, MD
Forrest Hills, NY
McNeil Consumer Healthcare
Los Angeles, CA
ACAAI Foundation
Shreveport, LA
Mylan Specialty L.P.
Anilkumar Katta, MD
Susanne LaBarba, MD
Ashish Mathur, MD
Burlington, MA
Mylan Specialty L.P.
Great Neck, NY
Mylan Specialty L.P.
Tucson, AZ
Genentech | Novartis
Theodore Kelbel, MD
Bruce J. Lanser, MD
Sara May, MD
Hershey, PA
Mylan Specialty L.P.
Denver, CO
Genentech | Novartis
Rochester, MN
Mylan Specialty L.P.
John Kelley, MD
Joyce Lee, MD
Jennifer McCracken, MD
Galveston, TX
McNeil Consumer Healthcare
Los Angeles, CA
McNeil Consumer Healthcare
Galveston, TX
McNeil Consumer Healthcare
Travel Grants
The ACAAI Travel Grant Donors awarded travel grants to 223 Fellows-in-Training to attend the
2014 Annual Scientific Meeting. The travel grant recipients and their sponsors are shown below:
113
Travel Grant Recipients
The ACAAI Travel Grant Donors awarded travel grants to 224 Fellows-in-Training to attend the
2014 Annual Scientific Meeting. The travel grant recipients and their sponsors are shown below:
Neha Mehrotra, MD
Iris Otani, MD
Whitney Rassbach, MD
Denver, CO
Mylan Specialty L.P.
Boston, MA
Genentech | Novartis
New York, NY
Mylan Specialty L.P.
Javier A. Mendez, MD
Pooja Oza, MD
Anupama Ravi, MD
San Juan, PR
McNeil Consumer Healthcare
Ann Arbor, MI
Mylan Specialty L.P.
Rochester, MN
Genentech | Novartis
Shari Montandon, MD
Thamiris V. Palacios, MD
Monica Reddy, MD
Pittsburgh, PA
Mylan Specialty L.P.
Charlottesville, VA
The Scanlon Family Fund
Denver, CO
McNeil Consumer Healthcare
Lindsey Moore, MD
Christopher Parrish, MD
Vinitha Reddy, MD
Jackson, MS
McNeil Consumer Healthcare
Los Angeles, CA
Genentech | Novartis
Hershey, PA
Mylan Specialty L.P.
Mahta Mortezavi, MD
Adesh Patel, MD
Jewmaull Reed, MD
New York, NY
McNeil Consumer Healthcare
Shreveport, LA
ALK, Inc.
Chicago, IL
McNeil Consumer Healthcare
Megan Motosue, MD
Bhavisha Patel, MD
Nasim Reedy, MD
Rochester, MN
McNeil Consumer Healthcare
Rochester, MN
Genentech | Novartis
St. Louis, MO
Mylan Specialty L.P.
Ahmad Ammor Mourad, MD
Heena Shah Patel, MD
Jennifer Regan, MD
Shreveport, LA
ALK, Inc.
New Orleans, LA
Genentech | Novartis
Chicago, IL
McNeil Consumer Healthcare
Vuong Nayima, MD
Kiran Patel, MD
Erin L. Reigh, MD
Birmingham, AL
Mylan Specialty L.P.
San Francisco, CA
McNeil Consumer Healthcare
St. Louis, MO
Genentech | Novartis
Adrianne Netterville, MD
Reenal Patel, MD
Manisha Relan, MD
New Orleans, LA
ALK, Inc.
Newark, NJ
Mylan Specialty L.P.
Buffalo, NY
McNeil Consumer Healthcare
Anthony Nguyen, MD
Shreya N. Patel, MD
Sudip Ringwala, MD
Atlanta, GA
Genentech | Novartis
Newark, NJ
Asthma & Allergy Proceedings
Plantation, FL
Mylan Specialty L.P.
Huyen-Tran Nguyen, MD
Andrew Pham, MD
Rahul Rishi, MD
Cincinnati, OH
McNeil Consumer Healthcare
Los Angeles, CA
Genentech | Novartis
Ft. Lauderdale, FL
Mylan Specialty L.P.
Andrew S. Nickels, MD
Chelle Pope, MD
Jonathan M. Rodrigues, MD
Rochester, MN
Genentech | Novartis
Jackson, MS
Genentech | Novartis
St. Louis, MO
McNeil Consumer Healthcare
Marco Nunez Velazquez, MD
Rebecca Pratt, MD
Hector Rodriguez, MD
Guadalupe, NL, Mexico
McNeil Consumer Healthcare
Hamilton, ON, Canada
Mylan Specialty L.P.
Memphis, TN
Genentech | Novartis
Jennifer Olivier, MD
Benjamin T. Prince, MD
Maristely Rodriguez-Roa, MD
New Orleans, LA
McNeil Consumer Healthcare
Chicago, IL
Genentech | Novartis
San Juan, PR
McNeil Consumer Healthcare
Jonathan Olsen, DO
Jaclyn Quirt, MD
Andrew Rorie, MD
Omaha, NE
McNeil Consumer Healthcare
Hamilton, ON Canada
McNeil Consumer Healthcare
Kansas City, KS
Genentech | Novartis
Roy Anthony Orden, MD
Qura Tul Ain Rashid, MD
Jaime Rosa, MD, PhD
Baltimore, MD
Mylan Specialty L.P.
Galveston, TX
Mylan Specialty L.P.
Stanford, CA
Mylan Specialty, L.P.
114
Travel Grant Recipients
Melanie Ruffner, MD, PhD
Aimee Speck, MD
Kara J. Wada, MD
Philadelphia, PA
McNeil Consumer Healthcare
Ann Arbor, MI
ALK, Inc.
Columbus, OH
McNeil Consumer Healthcare
Maryam Saifi, MD
Robert Sporter, MD
Jeremy D. Waldram, MD
Dallas, TX
McNeil Consumer Healthcare
Great Neck, NY
ACAAI Foundation
San Diego, CA
McNeil Consumer Healthcare
Nauman Salim, MD
Ryan Steele, DO
Shaan Waqar, MD
Tampa, FL
Mylan Specialty L.P.
Mineola, NY
Mylan Specialty L.P.
Great Neck, NY
Mylan Specialty L.P.
Eunice Sandoval, MD
Jessica L. Stern, MD
Kate Welch, MD
Mexico City, DF, Mexico
Mylan Specialty L.P.
Rochester, NY
McNeil Consumer Healthcare
New York, NY
McNeil Consumer Healthcare
Prathyusha Savjani, MD
Mark Stevens, MD
Karyn Winkler, MD
New Orleans, LA
ACAAI Foundation
Omaha, NE
McNeil Consumer Healthcare
Brooklyn, NY
McNeil Consumer Healthcare
Edith Schussler, MD
Kasey Strothman, MD
Anna Wolfson, MD
New York, NY
Genentech | Novartis
Columbus, OH
McNeil Consumer Healthcare
Boston, MA
Genentech | Novartis
Dimple Shah, MD
Von Ta, MD
Andrew K. Wong, MD
Denver, CO
Genentech | Novartis
San Diego, CA
Mylan Specialty L.P.
Los Angeles, CA
Genentech | Novartis
Nisha N. Shah, MD
Matt Tallar, MD
Lakiea Wright, MD
New Orleans, LA
McNeil Consumer Healthcare
Milwaukee, WI
McNeil Consumer Healthcare
Boston, MA
McNeil Consumer Healthcare
Amir Shahlaee, MD
Hana Tartibi, MD
Shuya Wu, MD
Augusta, GA
ACAAI Foundation
Shreveport, LA
Genentech | Novartis
Houston, TX
Mylan Specialty L.P.
Marissa Shams, MD
Jiah Shin Teh, MD
Idalia Vanessa Yanez-Perez, MD
Atlanta, GA
McNeil Consumer Healthcare
Philadelphia, PA
McNeil Consumer Healthcare
Monterrey, NL, Mexico
McNeil Consumer Healthcare
Mili Shum, MD
James Thompson, MD
Jose R. Zaragoza, MD
Greenwich, CT
McNeil Consumer Healthcare
Augusta, GA
Drs. Charles and Betty Wray
Hershey, PA
McNeil Consumer Healthcare
Sayantani Sindher, MD
Jennifer Toh, MD
Lan Zhou, MD
Philadelphia, PA
Mylan Specialty L.P.
Bronx, NY
McNeil Consumer Healthcare
Jackson, MS
McNeil Consumer Healthcare
Melissa Skupin, MD
James Tracy, MD
Detroit, MI
McNeil Consumer Healthcare
Plantation, FL
Genentech | Novartis
Maria A. Slack, MD
Karen T.S. Tuano, MD
Columbus, OH
McNeil Consumer Healthcare
Houston, TX
McNeil Consumer Healthcare
Shaila Smith, MD
Adam Updegraff, MD
Plantation, FL
ACAAI Foundation
Tampa, FL
ALK, Inc.
Kristin Sokol, MD
Ashvini Varadhi, MD
Galveston, TX
McNeil Consumer Healthcare
Chicago, IL
ACAAI Foundation
Travel Grants
The ACAAI Travel Grant Donors awarded travel grants to 224 Fellows-in-Training to attend the
2014 Annual Scientific Meeting. The travel grant recipients and their sponsors are shown below:
115
Saturday Product Theaters
NOT FOR
These are commercial presentations conducted by exhibiting companies in specially constructed theaters on the
CREDIT
exhibit floor. This year we will have two Product Theaters located in Hall A1 where a limited number of 25-minute
and 55-minute sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are nonCME forums organized by industry and designed to enhance your learning experience.
10:35 – 11:00 AM
FeNO: Let’s Clear the Air
Supported by Aerocrine
Presented by: Stanley M. Fineman, MD, MBA
The American Thoracic Society has published official guidelines on how FeNO measurements should be used and
interpreted in clinical practice. At this session, experts will review how they utilize FeNO measurements made with the
NIOX MINO® device to help assess and monitor their patients with asthma.
Also, visit Aerocrine at Booth #826
New Options in Allergy Immunotherapy: ORALAIR®
(Sweet Vernal, Orchard, Perennial Rye, Timothy, and
Kentucky Blue Grass Mixed Pollens Allergen Extract)
Tablet for Sublingual Use
Supported by GREER®
Presented by: Linda S. Cox, MD and Robert E. Esch, PhD
Oralair, a 5 grass mixed pollen allergy extract first approved in Europe in 2008, is now FDA-approved for immunotherapy for grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by a positive test for any of
the 5 grasses. This session will review Oralair clinical development, safety, and efficacy.
Also, visit GREER® at Booth #1129
12:35 – 1:30 PM
The Latest Information in Therapy for Asthma,
COPD, and Exercise-Induced Bronchospasm
Supported by Teva Respiratory
Presented by: Gregory W. Bensch, MD
This presentation will highlight the latest information in therapy for patients with asthma, COPD, and exercise-induced
bronchospasm (EIB). The under-recognition and under-treatment of EIB in America will be reviewed. The presentation
will then explore recent evidence about patients’ knowledge and tracking of medication in inhalers with a built-in
dose counter.
Also, visit Teva Respiratory at Booth #1001
Treatment of Symptomatic CIU
Despite H1 Antihistamines
Supported by Genentech | Novartis
Presented by: Dennis K. Ledford, MD
Genentech and Novartis will be hosting a non-CME product theater program presented by Dennis K. Ledford, MD on
the “Treatment of Symptomatic CIU Despite H1 Antihistamines". This program will be held on Sunday, November 9
from 12:35 pm – 1:30 pm in the Product Theater #2 at the Georgia World Congress Center, Hall A1.
Also, visit Genentech | Novartis at Booths #927, #415
116
Sunday Product Theaters
NOT FOR
These are commercial presentations conducted by exhibiting companies in specially constructed theaters on the
CREDIT
exhibit floor. This year we will have two Product Theaters located in Hall A1 where a limited number of 25-minute
and 55-minute sessions will be presented each day during the refreshment and lunch breaks. Product Theaters are nonCME forums organized by industry and designed to enhance your learning experience.
10:05 – 10:30 AM
Guiding the Future: The Latest in Alpha-1
Antitrypsin Deficiency
Supported by CSL Behring
Presented by: Timothy Craig, DO
Hear from Alpha-1 experts as it relates to the advancements in alpha-1 diagnostic tools and therapy updates.
Also, visit CSL Behring at Booth #1027
12:35 – 1:30 PM
Allergic Rhinitis: An Option for Pediatric and
Adult Patients
Supported by Merck
Presented by: Ray Davis, MD
Learning Objectives:
➢ Discuss clinical presentation of allergic rhinitis in pediatric and adult patients
➢ Review study design
➢ Review efficacy and safety data for a treatment option for appropriate patients with allergic rhinitis.
Also, visit Merck at Booth #1107
Supported by GREER®
Presented by: Linda S. Cox, MD, Anju T. Peters, MD, and Robert E. Esch, PhD
This session will review current published concepts on SLIT immunobiology. It will discuss product development,
clinical safety and efficacy of Oralair, an FDA-approved immunotherapy for treatment of grass-pollen induced allergic
rhinitis with or without conjunctivitis confirmed by a positive test for any of the 5 grasses contained in the product.
Also, visit GREER® at Booth #1129
117
Product Theaters
Sublingual Immunotherapy: Immunobiology of SLIT
and Development of ORALAIR® (Sweet Vernal, Orchard,
Perennial Rye, Timothy, and Kentucky Blue Grass Mixed
Pollens Allergen Extract) Tablet for Sublingual Use
Exhibits
Hall A-1 • Georgia World Congress Center
Exhibit Hours
3:00 pm – 6:00 pm, Friday
9:45 am – 4:00 pm, Saturday
9:45 am – 4:00 pm, Sunday
Aerocrine, Inc.
Booth 826
5151 McCrimmon Pkwy, Ste 260
Morrisville, NC 27560
Phone: (919) 518-3073
Website: www.aerocrine.com
Contact Name: Connie Williams
Contact Email: [email protected]
Booth 928
6201 South Freeway
Fort Worth, TX 76134-2099
Phone: (817) 551-4059
Fax: (817) 302-3733
Website: www.alcon.com
As the global leader in eye care, Alcon offers an extensive
breadth of products serving the full lifecycle of patient
needs across eye diseases, vision conditions and refractive
errors, as well as ear infections. For more information, visit
www.alcon.com.
ALK
Booth 1220
1700 Royston Ln
Round Rock, TX 70664
Phone: (800) 325-7354
Fax: (888) 329-2551
Website: www.alk.net/us
Contact Name: Sophia Chen
Contact Email: [email protected]
ALK is a research driven, global pharmaceutical company
focusing on allergy treatment, prevention and diagnosis. As
the world leader in allergy immunotherapy, a treatment
given to increase immunity to substances causing allergic
symptoms, ALK is devoted to improving the quality of life for
people and pets with allergies by creating products that
treat the cause of allergies. ALK is also committed to
supporting the business of allergy by providing diagnostic
tools, automation software and customized business,
technical and clinical consulting services.
118
Booth 715
2525 Dupont Dr
Irvine, CA 92612
Phone: (714) 246-4500
Fax: (714) 246-4971
Website: www.allergan.com
Aerocrine, a leader in fractional exhaled nitric oxide (FeNO)
technology, markets the NIOX MINO®. FeNO is a marker of
allergic airway inflammation. Routine FeNO measurements
using NIOX can guide inhaled corticosteroid dose
optimization to reduce asthma exacerbations by up to 50%.
FeNO levels should be evaluated as a complement to the
established clinical and laboratory assessment in asthma.
Visit Booth 826 and learn more about this simple 2-minute
test to help optimize asthma management.
Alcon Laboratories, Inc.
Allergan, Inc.
Allergan is a multi-specialty health care company
established more than 60 years ago with a commitment to
uncovering the best of science and helping people reach
their life’s potential. With approximately 11,400 employees
worldwide, we are committed to discovering new therapies
to treat unmet medical needs in eye care, neurosciences,
medical aesthetics, medical dermatology, breast aesthetics
and urology.
Allergy & Asthma Network
Booth 1320
8229 Boone Blvd Ste 260
Vienna, VA 22182
Phone: (703) 641-9595
Fax: (703) 288-5271
Website: www.aanma.org
Contact Name: Beth Gannett
Contact Email: [email protected]
Allergy & Asthma Network is dedicated to ending the
needless death and suffering due to asthma, allergies, and
related conditions through education, outreach and
advocacy. Stop by our booth to receive your free copy of
“Asthma Blues” a guideline based education tool for
patients.
Exhibits
Hall A-1 • Georgia World Congress Center
Booth 727
95 Pitman St
Providence, RI 02906
Phone: (401) 331-2510
Fax: (401) 331-0223
Website: www.allergyandasthmaproceedings.com
Contact Name: Ginny Loiselle
Contact Email: [email protected]
The Proceedings, together with American Journal of
Rhinology & Allergy and Allergy & Rhinology (open access)
are published by OceanSide Publications, Providence, RI.
Booth 1224
1620-D Satellite Blvd
Duluth, GA 30097
Phone: (800) 255-3749
Fax: (800) 395-9303
Website: www.allergycontrol.com
Contact Email: [email protected]
For almost 30 years, Allergy Control Products has been a
trusted source for helpful allergen avoidance information
and effective allergy relief products. We value our
relationship with ACAAI physicians and look forward to
seeing physicians who have supported us throughout the
years and to meeting new physicians who wish to learn
more about environmental controls and how they can
benefit patients.
Allergy Guardian
Booth 33
1045 SW Second Street
Oklahoma City, OK 73109
Phone: (800) 654-3971
Fax: (800) 811-3389
Website: www.allergylabs.com
Contact Email: [email protected]
The primary focus of Allergy & Asthma Proceedings is
directed to the publication of articles with the highest
degree of clinical relevance for the practicing
allergist/immunologist. Additionally, the Proceedings is
committed to medical education, having recently published
the teaching tool, Northwestern University A-I Syllabus for
Medical Students and Residents. Academically, the
Proceedings has established a 35 year reputation as a
National Library of Medicine/PubMed indexed journal with
print circulation at 5000 and impact factor of 3.35
Allergy Control Products
Allergy Laboratories, Inc.
Booth 815
9525 Monroe Road, Suite 100
Charlotte, NC 28270
Phone: (910) 704-8075
Contact Name: Anne Patrick
Contact Email: [email protected]
Welcome to Allergy Guardian! Please stop by booth #815 to
learn about our company, our staff and our new teaching
tools for your office. Our “Ready, Set, Guard!”™ Program will
assist your patients in “Taking Action Against Allergens” and
help identify the best allergen avoidance program for their
condition. Because Allergy Guardian is the manufacturer,
you can be assured your patients will receive the highest
quality products at unbeatable manufacturer direct prices!
Allergy Laboratories, Inc. is proud to be the oldest American
owned allergenic extract manufacturer. We produce a full
range of diagnostic and therapeutic allergens, as well as
sterile empty vials and pre-filled vials of allergenic extract
diluting solutions. We invite your inquires.
Allergy Partners
Booth 813
1978 Hendersonville Road, Suite 130
Asheville, NC 28803
Phone: (828) 277-1300
Fax: (828) 277-2499
Website: www.allergypartners.com
Contact Name: melody Interlicchia
Contact Email: [email protected]
Allergy Partners, P.A. is the nation’s largest allergy, asthma
and immunology practice. Our network of 47 main practice
locations spans 18 states and encompasses over 110 total
locations of care. We currently have 105 allergists, 20 midlevel providers and over 800 employees providing care to
more than 500,000 patients. As our reputation continues to
grow, we are committed to our vision and to bringing only
the best physicians and practices into our network.
Want to know more? Visit with us in booth 813 or contact
Melody Interlicchia: [email protected] or 828277-1300.
Allergychoices Inc
Booth 409
2800 National Drive Ste 100
Onalaska, WI 54650
Phone: (866) 793-1680
Fax: (608) 788-1730
Website: www.allergychoices.com
Contact Name: Michelle Montet
Contact Email: [email protected]
Allergychoices helps allergy specialists efficiently and
effectively integrate patient-specific sublingual
immunotherapy as a treatment option. Begin with a family
of protocols based on 45 years of clinical experience and
research, which is optimized for each patient’s safety,
comfort and efficacy, based on thorough diagnostics and
tailored treatment. We offer practices a broad range of
proven services and support tools – including pharmacy
services, diagnostic tools, staff and patient education,
research updates, marketing and compliance tools– into
your existing workflow so you can help more of your allergic
patients quickly and effectively. Learn how you can integrate
SLIT now. www.allergychoices.com/expandcare.
119
Exhibits
Allergy & Asthma Proceedings
Exhibits
Hall A-1 • Georgia World Congress Center
American Board of Allergy
& Immunology (ABAI)
Booth 1225
111 S Independence Mall E, Ste 701
Philadelphia, PA 19106-2515
Phone: (215) 592-9466
Fax: (215) 592-9411
Website: www.abai.org
Contact Name: Gina Capozzoli
Contact Email: [email protected]
The ABAI currently has 5,552 Diplomats who are boardcertified in Allergy and Immunology.
The American Partnership for Eosinophilic Disorders
(APFED) is a non-profit organization for those living with
eosinophilic esophagitis, eosinophilic gastroenteritis,
eosinophilic colitis, hypereosinophilic syndrome, and other
eosinophilic disorders. We are a resource for patients, their
families, physicians and the medical community. Our goals
are to increase awareness, educate patients and physicians,
increase funding for research and provide support for the
eosinophilic community. To become an APFED member, or
to make a tax-deductible donation, visit
http://www.apfed.org.
Asthma and Allergy Foundation
of America (AAFA)
Booth 1017
PO Box 198
Slinger, WI 53086
Phone: (608) 874-4044
Website: www.latexallergyresources.org
Contact Name: Sue Lockwood
Contact Email: [email protected]
American Latex Allergy Association (ALAA) is a national,
non-profit, 501(c) 3, educational and support
organization, founded in 1993. ALAA’s mission is to create
awareness of latex allergy through education, and to
provide support to allergists and to their patients who
have developed latex allergy. ALAA is one of the Lay
Organizations that works closely with ACAAI. Our website
www.latexallergyresources.org provides alternative product
lists, educational support, news and links. Follow us on
Facebook and Twitter. Stop by booth 1017 to learn about
our Latex Allergy 101 program and to see other educational
resources that are available. Including the new booklet,
Living with Latex Allergy.
120
Booth 817
PO Box 29545
Atlanta, GA 30359
Phone: (713) 493-7749
Website: www.APFED.org
The ABAI was established in 1971 as a Conjoint Board of the
ABIM and ABP. The internal medicine subspecialty existed
from 1936 – 1971 and the pediatric subspecialty existed
from 1944 – 1971. The ABAI is committed to working closely
with its parent boards to maintain the highest educational
and clinical standards in the specialty of allergy/
immunology.
American Latex Allergy
Association (ALAA)
American Partnership for Eosinophilic
Disorders (APFED)
Booth 829
8201 Corporate Drive #1000
Landover, MD 20785
Phone: (202) 466-7643
Fax: (202) 466-8940
Website: www.aafa.org
Contact Email: [email protected]
The Asthma and Allergy Foundation of America (AAFA) is
dedicated to improving the quality of life for people with
asthma and allergies by providing free patient education,
advocating on behalf of patients, and supporting ongoing
medical research in search of a cure. Kids with Food Allergies
(KFA), a division of AAFA, provides support for families with
food allergies. Please visit www.aafa.org for more
information.
Exhibits
Hall A-1 • Georgia World Congress Center
Booster Shot Media
Baxter Healthcare
Booth 709
One Baxter Pkwy
DF2-2E
Deerfield, IL 60015
Phone: (224) 948-2000
Website: www.baxter.com
Contact Name: Erika Hajdu
Contact Email: [email protected]
Baxter Healthcare Corporation, along with its subsidiaries,
develops, manufactures and markets healthcare products
that save and sustain the lives of people with hemophilia,
immune disorders, infectious diseases, kidney disease,
trauma, and other chronic and acute medical conditions.
As a global, diversified healthcare company, Baxter applies
a unique combination of expertise in medical devices,
pharmaceuticals and biotechnology to create healthcare
products that advance patient care worldwide.
Come visit Baxter’s BioTherapeutics booth, where our
specialists will be available to answer your questions about
Baxter products and our commitment to the fields of
immunology and neurology. For more information on
Baxter’s products and services, please visit
www.baxter.com.
Baxter Healthcare Corporation
Booth 615
One Baxter Way
Westlake Village, CA
Phone: (805) 372-3510
The BioTherapeutics Medical Affairs booth will be staffed by
Baxter Medical Affairs representatives who are able to
answer medical and scientific questions about Baxter’s
immune globulin products. For more information on
BioTherapeutics, please visit www.baxter.com.
Booth 914
PO Box 7452
Santa Monica, CA 90406
Phone: (909) 274-9254
Website: www.boostershotmedia.com
Contact Name: Gary Ashwal
Contact Email: [email protected]
Booster Shot Media creates patient education materials for
allergists and other healthcare providers. “Iggy and the
Inhalers” turns asthma medications into brave superheroes
and allergens into villainous monsters. Our animated videos,
comic-books, and trading cards empower children while
teaching them about asthma symptoms, triggers, and
medications. Come by our booth to hear about the latest
research on our materials! For grownups, our allergy and
asthma whiteboard videos explain disease, treatment, and
prevention with plain language and clear visuals. Boardcertified allergist Alex Thomas, MD and health
communication specialist Gary Ashwal design educational
materials to help save time and boost patient health.
Boston Scientific Corporation
Booth 621
300 Boston Scientific Way
Marlboro, MA 01752
Phone: (508) 683-6004
Fax: (508) 683-6004
Contact Name: Colleen Moore
Contact Email: [email protected]
Boston Scientific is committed to helping advance the
diagnosis and treatment of pulmonary diseases by focusing
on the development of less invasive devices and procedures.
We have developed the first device to treat adult patients
with severe asthma. Bronchial Thermoplasty (BT) delivered
by the Alair™ System is a safe outpatient procedure clinically
proven to provide long-lasting reduction in exacerbations.
79% of patients treated with BT had a significant
improvement in their asthma-related quality of life.
Exhibits
GOLD PARTNER
121
Exhibits
Hall A-1 • Georgia World Congress Center
Carestream
Booth 825
Chattem a Sanofi Company
Booth 1311
1765 The Exchange SE
Atlanta, GA 30339
Phone: (888) 477-4359
Website: www.carestream.com/ent-allergy
Contact Name: Dayna Davis
Contact Email: [email protected]
55 Corporate Dr
Bridgewater, NJ 08807
Phone: (800) 981-2491
Website: www.sanofi.us
Contact Name: Dawn Will
Contact Email: [email protected]
For more than 100 years, Carestream has delivered medical
imaging technology that improves your practice’s workflow
and bottom line. With over 4,000 point of-care CT system
placements, Carestream is dedicated to providing solutions
to improve patient care and treatment planning worldwide.
Chattem, Inc. is part of the Sanofi-Aventis Group. Sanofi U.S.
is an affiliate of Sanofi-Aventis, a leading global
pharmaceutical company that discovers, develops, and
distributes therapeutic solutions to improve lives.
CS 9300 System for Point-of-Care CT Imaging Designed for
Sinus and Temporal Bone Applications. For fast and accurate
diagnoses, choose the CS 9300: the point-of-care CT system
that is easy to implement and afford. Featuring a range of
fields of view and resolutions, the unit is ideal for visualizing
temporal bone and sinus structures–and all with less
radiation than conventional CT exams.
Coram CVS / Specialty Infusion Services Booth 1312
Cascade Survey Research
Booth 1322
C/o Kaz USA, Inc.
250 Turnpike Rd
Southboro, MA 01772
Phone: (775) 847-0796
Website: www.cascade-research.com
Cascade Survey Research conducts fast and easy Survey
Station touch screen computer based market research
intercept surveys at professional meetings and events. We
collect the valid and accurate data required for effective
development of marketing, sales, and new product
development strategies in dynamic markets.
Chandler Chicco Agency
Booth 523
450 West 15th Street, 7th Floor
New York, NY 10011
Phone: (212) 462-8721
Website: www.anaphylaxis101.com
Contact Email: [email protected]
Get Schooled in Anaphylaxis™: An Interactive Experience
Food allergies, a common cause of life-threatening allergic
reactions (anaphylaxis), are on the rise, especially in children,
therefore making anaphylaxis awareness in the school
setting critical. Visit the interactive exhibit to explore Get
Schooled in Anaphylaxis™, an initiative sponsored by Mylan
Specialty that helps those in the school setting be prepared
to respond should anaphylaxis occur. Learn how you can be
prepared at Anaphylaxis101.com.
122
555 17th St, Ste 1500
Denver, CO 80202
Phone: (303) 672-8612
Website: www.coramhc.com
Contact Name: Kristen Plante
Contact Email: [email protected]
Coram CVS/Specialty Infusion Services is a leading national
provider of specialty home infusion and pharmacy services
with more than 30 years of experience servicing the needs of
complex patients. With more than 85 locations including
over 65 ambulatory infusion suites across the country, Coram
offers both national presence and comprehensive local
coverage. Coram’s clinical staff is known in the industry for
providing an exceptional level of personalized care to
thousands of home and infusion suite IV patients every day.
Exhibits
Hall A-1 • Georgia World Congress Center
Crowell Systems
Booth 721
Dyax Corp.
Booth 921
4235 South Stream Blvd, #100
Charlotte, NC 28217-3535
Phone: (704) 665-2000
Fax: (704) 665-2080
Website: www.crowellsystems.com
Contact Name: Susan Burris
Contact Email: [email protected]
55 Network Dr
Burlington, MA 01803
Phone: (617) 225-2500
Fax: (617) 225-2501
Website: www.dyax.com
Contact Name: Brian Linder
Contact Email: [email protected]
MedFormix©Vue is designed specifically for allergists with
PM, Allergy-Specific EMR including tightly integrated Skin
Tests, Spirometry, Shot and Antigen Lab Modules. This
system increases functionality within the practice by
eliminating redundancy and improving patient care.
Dyax is a fully integrated biopharmaceutical company
focused on the discovery, development and
commercialization of novel biotherapeutics for unmet
medical needs. The Company discovered and developed
KALBITOR® (ecallantide) and is selling this product in the
United States for the treatment of acute attacks of hereditary
angioedema (HAE) in patients 12 years of age and older.
Dyax is also developing DX-2930, an investigational fully
human monoclonal antibody inhibitor of plasma kallikrein,
for the prevention of HAE attacks. DX-2930 is currently in a
Phase 1b clinical study in HAE patients. Both KALBITOR and
DX-2930 were identified using Dyax’s patented phage
display technology.
You will soon discover the multitude of benefits
MedFormix©Vue brings to you, your staff and patients. You
will have total control of your practice and should realize an
increase to your bottom line.
“Medformix allows for maximal integration of numerous
aspects of medical practice from patient scheduling, to care
delivery via both office visits and telephone triage, to coding
and billing, to facilitating patient follow up and recall visits.”
Marta Little, MD
Come see MedFormix©Vue in booth 721.
CSL Behring
Booth 1027
1020 First Ave
King of Prussia, PA 19406
Phone: (610) 878-4000
Website: www.cslbehring.com
CSL Behring is a global leader in plasma protein therapeutics.
The company manufactures safe and effective plasmaderived and recombinant therapies for treating coagulation
disorders, primary immune deficiencies, hereditary
angioedema and inherited respiratory disease, and
neurological disorders in certain markets. The company’s
products are also used in cardiac surgery, organ
transplantation, burn treatment and to prevent hemolytic
disease of the newborn. CSL Behring is a subsidiary of CSL
Limited (ASX:CSL), a biopharmaceutical company with
headquarters in Melbourne, Australia. For more information:
www.cslbehring-us.com.
Edge Medical Solutions
Booth 603
7257 NW 4th Blvd #252
Gainesville, FL 32607
Phone: (352) 870-6599
Website: www.edgemedsol.com
Contact Name: David Kratzer
Contact Email: [email protected]
Edge Medical Solutions, LLC is a specialty distribution
company focusing on cost effective solutions and products
used in the diagnosis, monitoring and treatment of
pulmonary disorders. We are proud to partner with leading
global manufacturers such as Medical Developments
International of Australia and are dedicated to providing
world class technology and products that significantly
enhance the lives of those afflicted with respiratory
conditions such as Allergies, Asthma and COPD. Edge
Medical Solutions, LLC also offers solutions for weight
management as well as sports fitness training and
assessment through scientifically validated technologies.
www.edgemedsol.com.
Exhibits
Using a totally redesigned GUI-type interface,
MedFormix©Vue is very appealing, extremely easy and fast
to use. The new portal by Ingage Patient completes the
solution by integrating fully for all doctors, staff and patients.
123
Exhibits
Hall A-1 • Georgia World Congress Center
Edge Pharmaceuticals, LLC
Booth 31
7264 NW 63rd Terrace
Parkland, FL 33067
Phone: (877) 580-3343
Fax: (877) 581-3343
Website: www.edgepharmaceuticals.com
Contact Email: [email protected]
Edge Pharmaceuticals specializes in:
•Sublingual (SLIT) metered dose dispensers
• Sublingual treatment material
• Allergy testing and treatment materials
• Specialty pharmacy compounding – e.g. anti-allergy
products
We look forward to meeting with you. Please stop by our
booth to see us.
ELSEVIER, INC.
Booth 1316
1600 JFK Blvd, Ste 1800
Philadelphia, PA 19103-2899
Phone: (215) 239-3722
Fax: (215) 239-3494
Website: www.elsevierhealth.com
Contact Name: Kim Pollock
Contact Email: [email protected]
Booth 811
Genentech, Inc
South San Francisco, CA 94080
Website: www.xolairpregnancyregistry.com
Founded more than 35 years ago, Genentech is a leading
biotechnology company that discovers, develops,
manufactures and commercializes medicines to treat
patients with serious or life-threatening medical conditions.
The company, a member of the Roche Group, has
headquarters in South San Francisco, California.
124
Booth 1330
7925 Jones Branch Drive, Suite 1100
McLean, VA 22102
Phone: (800) 929-4040
Fax: (703) 691-2713
Website: www.foodallergy.org
Contact Name: Michael Spigler
Contact Email: [email protected]
Food Allergy Research and Education (FARE) works on behalf
of the 15 million Americans with food allergies, including all
those at risk for life-threatening anaphylaxis. This potentially
deadly disease affects 1 in every 13 children in the U.S. FARE’s
mission is to find a cure for food allergies, and to keep
individuals with food allergies safe and included. FARE
invests in world-class research that advances treatment and
understanding of the disease, provides evidence-based
education and resources, undertakes advocacy at all levels of
government and increases awareness of food allergy as a
serious public health issue. Visit FARE at
www.foodallergy.org.
Forest Pharmaceuticals, Inc.
ELSEVIER is a leading publisher of health science
publications, advancing medicine by delivering superior
reference information and decision support tools to doctors,
nurses, health practitioners and students. With an extensive
media spectrum – print, online and handheld, we are able to
supply the information you need in the most convenient
format.
EXPECT Pregnancy Registry Study
Food Allergy Research and
Education (FARE)
Booth 714
909 Third Ave
New York, NY 10022
Phone: (800) 947-5227
Website: www.frx.com
Contact Email: [email protected]
Forest is a leading, fully integrated, specialty pharmaceutical
company largely focused on the United States market. The
Company markets a portfolio of branded drug products and
develops new medicines to treat patients suffering from
diseases principally in the following therapeutics areas:
central nervous system, cardiovascular, gastrointestinal,
respiratory, anti-infective, and cystic fibrosis. Our strategy of
acquiring product rights for development and
commercialization through licensing, collaborative
partnerships, and targeted mergers and acquisitions allows
us to take advantage of the attractive late-stage
development and commercial opportunities, thereby
managing the risks inherent in drug development.
Exhibits
Hall A-1 • Georgia World Congress Center
Greer Laboratories, Inc.
Genentech
Booth 927
1 DNA Way
South San Francisco, CA
Phone: (650) 238-8040
Considered the founder of the industry, Genentech, now a
member of the Roche Group has been delivering on the
promise of biotechnology for over 35 years.
At Genentech, we use human genetic information to
discover, develop, manufacture and commercialize
medicines to treat patients with serious or life-threatening
medical conditions. Today, we are among the world’s
leading biotech companies, with multiple products on the
market and a promising development pipeline.
Georgia Regents University PaCE
Booth 1321
919 15th Street FI Bldg., #1066
Augusta, GA 30912
Phone: (706) 721-2329
Fax: (706) 721-4642
Website: www.gru.edu/ce
Contact Name: Paula Owens
Contact Email: [email protected]
GlaxoSmithKline
7545 Hartman Industrial Way
Austell, GA 30168
Phone: (404) 921-5173
Website: www.gsk.com
Contact Name: Barak Bright
Contact Email: [email protected]
GlaxoSmithKline
Five Moore Drive
Research Triangle Park, NC 27709
Phone: (800) 366-8900
Website: www.gsk.com
GREER® is a leading developer and provider of allergy
immunotherapy products and services for treating humans
and animals. As part of its commitment to allergy
immunotherapy innovation, GREER’s clinical development
programs are focused on sublingual allergy immunotherapy
liquid (SAIL)™. GREER also markets ORALAIR®, a sublingual
allergy immunotherapy tablet with a mix of five grass
allergen extracts, in the United States through its partnership
with STALLERGENES. Sublingual immunotherapy is an
extension of GREER’s allergy immunotherapy products and
provides another treatment option for allergy specialists to
offer patients.
GREER was founded in 1904 and is located in Lenoir, North
Carolina. For more information, visit www.greerlabs.com.
HAE: Learn About It, Talk About It
Booth 702
Booth 1227
199 Water Street, Floor 14
New York City, NY 10038
Phone: (212) 257-6731
Website: www.letstalkhae.com
Contact Name: Michael Steier
Contact Email: [email protected]
HollisterStier Allergy
Booth 501
Booth 1129
639 Nuway Circle NE
Lenoir, NC 28645
Phone: (828) 754-5327
Fax: (828) 754-5320
Website: www.greerlabs.com
Contact Email: [email protected]
Booth 701
3525 N Regal St
Spokane, WA 99207
Phone: (509) 482-4974
Fax: (800) 752-6258
Website: www.hsallergy.com
Contact Name: Customer Service
Contact Email: [email protected]
Fed up with watching their families suffer from allergies, in
1921 chemist Guy Hollister and pathologist Robert Stier
came together to develop a treatment. Nearly a century later,
HollisterStier Allergy continues its mission to improve the
lives of allergy sufferers.
We manufacture a complete line of immunotherapy supplies
that give allergists the tools they need to provide
comprehensive allergy testing and treatment. HollisterStier
Allergy offers allergen extracts, positive and negative
controls, diagnostic devices, and sterile empty vials. In
addition, we continue to look for ways to improve the way
allergies are treated. This dedication has led to some unique
products, like our multiple skin test devices and our phenol
free antigens.
125
Exhibits
SILVER PARTNER
Exhibits
Hall A-1 • Georgia World Congress Center
Immune Deficiency Foundation
Booth 1319
40 W Chesapeake Ave, Ste 308
Towson, MD 21204-4803
Phone: (410) 321-6647
Fax: (877) 396-4525
Website: www.primaryimmune.org
Contact Email: [email protected]
Infinite Therapeutics
Meda Pharmaceuticals
Booth 627
68A Rt 125
Kingston, NH 03848
Phone: (603) 347-6006
Fax: (603) 642-9291
Website: www.infinitymassagechairs.com
Contact Email: [email protected]
Booth 509
265 Davidson Ave
Somerset, NJ 08873
Phone: (732) 564-2280
Website: www.meda.us
Contact Name: Jean Risimini
Contact Email: [email protected]
Meda Pharmaceuticals is a global specialty pharmaceutical
company that develops, markets, and promotes branded
prescription products in the respiratory, pain, women’s
health and men’s health therapeutic areas.
The Infinity IT-8800, COMPARABLE TO THE INADA™ for ½ the
price, offers state of the art roller foot reflexology, thigh and
hip massage, an amazing spinal decompression stretch,
sensors for customized targeted massage, lumbar heat and
music, endless luxury, ULTIMATE MASSAGE!
Kaz USA Inc.
GOLD PARTNER
Booth 1121
250 Turnpike Rd
Southboro, MA 01772
Phone: (508) 490-7214
Fax: (508) 480-0502
Website: www.kaz.com
Contact Email: [email protected]
Meditab Software, Inc.- Allergy EHR
Booth 620
333 Hegenberger Rd #800
Oakland, CA 94621
Phone: (510) 913-3969
Fax: (510) 259-9731
Website: www.allergyehr.com
Contact Name: Kunal Shah
Contact Email: [email protected]
GOLD PARTNER
Honeywell is the market leader in portable air purification
products, offering True Hepa permanent filtration providing
your patients with superior air cleaning products for over 25
years!
Merck
Lincoln Diagnostics, Inc.
Today’s Merck is a global healthcare leader working to help
the world be well. Merck is known as MSD outside the
United States and Canada. Through our prescription
medicines, vaccines, biologic therapies, and consumer care
and animal health products, we work with customers and
operate in more than 140 countries to deliver innovative
health solutions. We also demonstrate our commitment to
increasing access to healthcare through far-reaching
policies, programs and partnerships that donate and
deliver our products to the people who need them. For
more information, visit www.merck.com.
Booth 908
PO Box 1128
Decatur, IL 62526
Phone: (509) 537-1336
Fax: (217) 877-5645
Website: www.lincolndiagnostics.com
Contact Name: John J. Lenski, Jr.
Contact Email: [email protected]
Lincoln Diagnostics is displaying state-of-the-art, safetyengineered, allergy skin testing devices that meet all current
OSHA requirements - UniTest® PC and Multi-Test® PC (Pain
Control), Multi-Test® II, Multi-Test®, Duotip-Test® II and
Duotip-Test®. Please visit our exhibit to learn about the
economic value of using Lincoln devices and why they are
the most widely used and most extensively published on
devices available.
126
Booth 1107
One Merck Drive
Whitehouse Station, NJ 08889
Phone: (908) 423-1000
Website: www.merck.com
Exhibits
Hall A-1 • Georgia World Congress Center
Booth 916
803 Webster St
Lewiston, ME 04240
Phone: (800) 588-3381
Fax: (207) 786-7280
Website: www.mdspiro.com
Contact Name: Ann Therriault
Contact Email: [email protected]
Micro Direct Inc. is the primary source of sales, technical
support and service for all Micro Medical products. Our sales
and support staff has over 100 years of combined experience
in the medical equipment industry. Stop by our booth and
see our complete line today!
Booth 411
PO Box 786099
San Antonio, TX 78278-6099
Phone: (210) 696-8400
Fax: (210) 581-8719
Website: www.missionpharmacal.com
Contact Name: Dora Gignac
Contact Email: [email protected]
Mission Pharmacal Company is a privately held
Pharmaceutical company based in San Antonio, Texas. For
sixty-five years, the company has been dedicated to
identifying unmet health needs in the marketplace and
developing innovative prescription and over-the-counter
products to meet them.
Mission: Allergy, Inc.
Booth 1116
8359 Office Park Dr
Grand Blanc, MI 48439
Phone: (248) 434-0444
Website: www.modulemd.com
Contact Name: Jacqueline Otto
Contact Email: [email protected]
Micro Direct is pleased to offer Total Spirometry Solutions
with five models priced from $750 to $2,495, all designed to
meet your needs; and each with your choice of inexpensive
cardboard mouthpieces, one-way mouthpieces or full
protection pulmonary filters. Micro Direct also offers low cost
screening spirometers and inexpensive peak flow meters for
office and home use.
Mission Pharmacal Company
ModuleMD, LLC
Booth 1009
28 Hawleyville Rd
Hawleyville, CT 06440
Phone: (877) NOALLERGY (662-5537)
Website: www.missionallergy.com
Contact Name: Jeffrey Miller, MD
Leading allergists and allergy divisions recommend Mission:
Allergy for its scientific accuracy and highest quality products
for allergen avoidance. In addition to manufacturing our own
microfiber pillow and mattress encasings and comforters, we
distribute the full line of high-quality BlueAir air cleaners, and
recently introduced to the allergist community AD
RescueWear garments for wet-wrap therapy of atopic
dermatitis. Please stop by our booth to request your free
supply of our informative Allergy Self-Help Guide for
patients, and to view an unusual display of live Dust Mites.
For over 15 years, ModuleMD has been a leader in EHR Cloud
Technology solutions to Allergists. As an ONC-ACB certified
integrated EHR system for Meaningful Use Stage 2,
ModuleMD Wise™ delivers peak clinical, operational and
financial performance to Allergy Practices. ModuleMD
integrates an Allergy Module™ for skin testing and
immunotherapy practice needs. When you select ModuleMD
Wise™ for your practice, you receive more than just a product
or a service; you have a dedicated partner with an interest in
your practice’s success. In addition to technology, ModuleMD
offers billing and revenue management services, which
enhances ModuleMD’s leadership in the area of Practice
Management. Partner with ModuleMD for Allergy Practice
Management success. Solutions…not just software.
MotherToBaby
Booth 1314
9500 Gilman Dr, MC 0828
La Jolla, CA 92093
Phone: (877) 311-8972
Fax: (858) 246-1710
Website: www.pregnancystudies.org
Contact Name: Diana Johnson
Contact Email: [email protected]
PLATINUM PARTNER
Mylan Inc.
Booth 909
1000 Mylan Blvd
Cannonsburg, PA 15317
Phone: (724) 574-1800
Website: www.mylan.com
Contact Name: Kathleen Theiss
Mylan Specialty, a subsidiary of Mylan Inc., is a specialty
pharmaceutical company focused on the development,
manufacturing and marketing of prescription drug
products for the treatment of respiratory diseases, lifethreatening allergic reactions and psychiatric disorders. For
more information, please visit mylanspecialty.com.
Exhibits
Micro Direct, Inc.
127
Exhibits
Hall A-1 • Georgia World Congress Center
National Allergy Supply, Inc.
Booth 1231
1620-D Satellite Blvd
Duluth, GA 30097
Phone: (770) 495-3369
Fax: (800) 395-9303
Website: www.nationalallergy.com
Contact Email: [email protected]
Just like you, National Allergy believes that avoiding airborne
allergens can help improve patient outcomes. We are firmly
established as the leader in the allergen avoidance products
market having sold to hundreds of thousands of customers
through the referrals of thousands of doctors since our start
in 1988. Our colorful patient flyers are super easy to use as
compared to bulky catalogs and offer your patients a
generous discount on their first order with us. Our BedCare
barrier encasings are made in the USA and set the standard
for comfort, quality, and affordable allergen protection. See
for yourself by visiting our booth and we’ll be happy to give
you a FREE Standard Size Pillow encasing.
NeilMed Pharmaceuticals, Inc.
Booth 1308
601 Aviation Blvd
Santa Rosa, CA 95404
Phone: (707) 525-3784
Fax: (707) 525-3785
Website: www.neilmed.com
Contact Name: Ashly Guntz
Contact Email: [email protected]
The mission of the company is to create and maintain safe,
affordable and effective products to sustain long-term
growth and create drug free and effective nasal / sinus care
devices for millions of consumers worldwide. Please visit the
website www.neilmed.com for more details.
SILVER PARTNER
nSpire Health, Inc.
Booth 1120
1830 Lefthand Circle
Longmont, CO 80501
Phone: (800) 574-7374
Fax: (800) 574-7373
Website: www.nspirehealth.com
Contact Name: Kevin O’Connor
Contact Email: [email protected]
nSpire Health is the leading provider of diagnostic
respiratory care products and associated clinical trial
services. The company’s enterprise class products and
services including HDpft® Pulmonary Function Testing,
HDweb™ Respiratory PACS, KoKo® Spirometry, Pocket™ and
Piko® Home Monitoring products promise interoperability
while eliminating the variability traditionally associated with
PFT measurements, dramatically improving clinical trial and
patients’ outcomes while reducing the cost of care.
OSIA Medical
Booth 510
9690 S 300 West Floor 3
Sandy, UT 84070
Phone: (385) 275-2085
Website: www.osiamedical.com
Contact Name: Joshua Dees
Contact Email: [email protected]
OSIA Medical, produces health-management platforms
which improve personalized healthcare by enabling patients
to manage their condition while improving the
patient/doctor communication. AsthmaAlly, is a cloud-based
service using smartphones that connects patient condition
and environmental data with their physician. AsthmaAlly
correlates self-reported patient information with
environmental data including air quality, weather, and
pollen. This real-time, data is delivered to their medical team
providing insight into disease condition trends; thereby,
improving patient care.
Novartis Pharmaceuticals Corporation Booth 415
Perrigo Company
1 Health Plaza
East Hanover, NJ 07936
Phone: (888) NOW-NOVA
Website: www.novartis.com
490 Eastern Ave
Allegan, MI 49010
Phone: (269) 673-8451
Fax: (269) 673-9122
Novartis Pharmaceuticals is dedicated to discovering,
developing, manufacturing and marketing prescription
drugs that help meet our customers’ medical needs and
improve their quality of life. Please visit the Novartis exhibit
where our representatives will be available to discuss our
products.
Perrigo is among the top pharmaceutical companies in the
world and is the largest manufacturer of “store-brand” overthe-counter medicines for the nation’s leading retailers,
grocers, club stores and pharmacy chains. The company
produces an extensive portfolio of store-brand over-thecounter medications, nutritional supplements and infant
formula that compare to leading national-brands. What’s
more, Perrigo’s store-brand medicines meet or exceed FDA
quality standards, while offering consumers an average
savings of 36 percent over national-brands.
www.perrigo.com.
128
Booth 23
Exhibits
Hall A-1 • Georgia World Congress Center
Pharmaceutical Specialties, Inc.
Booth 617
1620 Industrial Dr NW
Rochester, MN 55901
Phone: (800) 325-8232
Fax: (507) 288-7603
Website: www.vanicream.com
Contact Name: Brian Leary
Contact Email: brianlpsico.com
Protein Sciences Corporation
Rabbit Air
Booth 716
125 N Raymond Ave, Ste 308
Pasadena, CA 91103
Phone: (888) 866-8862
Website: www.rabbitair.com
Contact Email: [email protected]
Rosch Visionary Systems, Inc.
Booth 726
1000 Research Pkwy
Meriden, CT 06450
Phone: (203) 686-0800
Fax: (203) 686-0268
Website: www.proteinsciences.com
Contact Name: Daniel Adams
Contact Email: [email protected]
Flublok® is Protein Sciences’ recently approved influenza
vaccine.
“[Flublok] approval represents a technological advance in the
manufacturing of an influenza vaccine,” said Karen Midthun,
M.D., director of the FDA’s Center for Biologics Evaluation and
Research.
Assistant Secretary Nicole Lurie, U.S. Department of Health
and Human Services stated that the approval of Flublok
“stands as one of the most significant improvements in flu
vaccine technology in the past 50 years.”
Booth 924
501 Howard Ave, Ste A204
Altoona, PA 16601
Phone: (800) 307-3320
Fax: (814) 941-1115
Website: www.roschvisionary.com
Contact Name: Lee Angela Johnson
Contact Email: [email protected]
Rosch Visionary Systems is the leading provider of allergy
software. Rosch Immunotherapy is our shot room
automation software, designed to safely and effectively
manage allergy extract mixing, injections and reactions. Not
only is our system lined with multiple safety features, but our
system complies with all new regulations involving the 2013
Compounding Allergenic Extract Rule.
Our newest addition, Rosch Skin Testing, electronically
records all prick and intradermal using the results to quickly
and easily build the patient’s immunotherapy prescription,
which is integrated with Rosch Immunotherapy.
The vaccine is made via a cutting edge, cell-based
technology that is very similar to that used to create cervical
cancer vaccines. The FDA has also referred to Flublok as
“Revolutionary”. Visit us at Booth 726.
Patient compliance is a must for a successful allergy practice.
Visionary Allergy Tracker (VAT) will remind patients when
they are due for their next injection via text, email, and push
notifications as well as tracking their immunotherapy history
via our state-of-the-art phone app.
PuraCap Pharmaceutical
Use the Rosch Allergy Software suite as a standalone system
or interface with your existing PM / EMR.
Booth 827
1001 Durham Ave.
South Plainfield, NJ 07080
Phone: (908) 941-5456
Website: www.epicpram-us.com
Contact Name: Elise Klein
Contact Email: [email protected]
Exhibits
EpiCeram® Controlled Release Skin Barrier Emulsion is a
ceramide-dominant emulsion for the treatment of atopic
dermatitis (Rx only). EpiCeram® is steroid-free, fragrance-free,
noncomedogenic, paraben-free, propylene glycol-free and
available in a 90g tube and a 225g airless pump. To learn
more about EpiCeram® and for full prescribing information,
please visit www.epiceram-us.com.
129
Exhibits
Hall A-1 • Georgia World Congress Center
GOLD PARTNER
SILVER PARTNER
Salix Pharmaceuticals, Inc.
Booth 401
8510 Colonnade Center Ave
Raleigh, NC 27615
Phone: (919) 862-1000
Fax: (919) 862-1095
Website: www.salix.com
Booth 900
300 Shire Way
Lexington, MA 02421
Phone: (617) 349-0200
Website: www.shire.com
Salix Pharmaceuticals, Inc., headquartered in Raleigh,
North Carolina, is a specialty pharmaceutical company
committed to advancing the treatment of many chronic
gastrointestinal disorders. For more than 20 years, we have
licensed, developed, and marketed innovated products to
provide healthcare professionals and patients with
effective solutions for the management of some of the
most chronic and debilitating conditions. Salix currently
markets its product line through dedicated, specialty sales
groups to U.S. healthcare providers in the areas of
gastroenterology, hepatology, colorectal surgery,
endocrinology, internal medicine, primary care, and
pediatric urology.
SILVER PARTNER
Sanofi US
Shire
Booth 1115
55 Corporate Dr
Bridgewater, NJ 08807
Phone: (800) 981-2491
Website: www.sanofi.us
Contact Name: Dawn Will
Contact Email: [email protected]
Sanofi, a global and diversified healthcare leader, discovers,
develops and distributes therapeutic solutions focused on
patients’ needs. Sanofi has core strengths in the field of
healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer
healthcare, emerging markets, animal health and the new
Genzyme.
Shire enables people with life-altering conditions to lead
better lives. Our strategy is to focus on developing and
marketing innovative specialty medicines to meet
significant unmet patient needs. We provide treatments in
Neuroscience, Rare Diseases, Gastrointestinal, and Internal
Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in
other targeted therapeutic areas, such as Ophthalmology.
SmartPractice Dermatology | Allergy
Booth 700
3400 E McDowell Rd
Phoenix, AZ 85008
Phone: (800) 878-3837
Website: www.smartpractice.com/dermatology
Contact Name: Kristine Schreiber
Contact Email: [email protected]
Our Dermatology | Allergy division exists because patients
deserve a diagnosis™. Developed over the past 10 years, our
multi-brand, multi-product Dermatology | Allergy division
focuses on providing innovative products to help diagnose
and treat patients with allergic contact dermatitis.
SmartPractice is the manufacturer and exclusive North
American distributor of T.R.U.E. TEST®, Finn Chambers®,
allergEAZE® chambers, Reveal & Conceal™, patchMap™,
patchTransport™ and patchProtect™. Through our
investments in technology, clinical science, and world-class
service, SmartPractice is committed to “all things contact
dermatitis”™ for physicians and patients.
www.smartpractice.com/dermatology
Solutionreach
Booth 508
2912 Executive Pkwy, Ste 300
Lehi, UT 84043
Phone: (801) 331-7114
Solutionreach is a cloud-based platform for revolutionizing
patient relationships and optimizing patient experience, with
a powerful array of tools to help providers easily acquire,
retain, educate and reactivate patients. Delivering the right
message, to the right patient, at the right time, makes every
patient the only patient.
130
Exhibits
Hall A-1 • Georgia World Congress Center
Booth 613
PO Box 3022
Fargo, ND 58102
Phone: (701) 282-2600
Fax: (701) 282-5325
Website: www.sunbutter.com
Contact Name: Juli Tubby
Contact Email: [email protected]
Teva Respiratory, LLC
Booth 607
84 Waterford Drive
Marlborough, MA 01752
Phone: (888) 394-7377
Website: www.sunovionprofile.com
Sunovion is a leading pharmaceutical company dedicated
to discovering, developing and commercializing
therapeutic products that advance the science of medicine
in the Psychiatry, Neurology and Respiratory disease areas
and improve the lives of patients and their families.
Sunovion, an indirect, wholly-owned subsidiary of
Sumitomo Dainippon Pharma Co., Ltd., is headquartered in
Marlborough, Mass. More information about Sunovion
Pharmaceuticals Inc. is available at www.sunovion.com.
41 Moores Road
Frazer, PA 19355
Phone: (816) 718-1624
Fax: (816) 578-4528
Website: www.tevapharmaceuticals.com
Contact Name: Econne Matthews
Contact Email: [email protected]
Stop by our booth to learn more about Qvar®
(beclomethasone dipropionate HFA)and ProAir HFA
(albuterol sulfate). Information, educational materials, and
resources to benefit your practice will be available.
The Mastocytosis Society
GOLD PARTNER
Teva Pharmaceuticals
Booth 1001
41 Moores Rd
Frazer, PA 19355
Phone: (888) 482-9522
Website: www.tevarespiratory.com
SunButter® is a completely peanut and tree nut free
alternative to peanut butter, not to mention healthy and
delicious! Please stop by booth #613 or visit
www.sunbutter.com/allergykits to receive a free sample and
give it a try!
Sunovion Pharmaceuticals, Inc.
DIAMOND PARTNER
Booth 728
Booth 521
PO Box 129
Hastings, NE 68902-0129
Phone: (952) 905-6778
Website: www.tmsforacure.org
Contact Name: Mishele Cunningham
Contact Email: [email protected]
Thermo Fisher Scientific
Booth 820
4169 Commercial Avenue
Portage, MI 49002
Phone: (800) 346-4364
Fax: (888) 243-5214
Website: www.isitallergy.com
As the immunodiagnostic experts within Thermo Fisher
Scientific, we work to dramatically improve the management
of allergy, asthma and autoimmune diseases. We do this by
providing healthcare professionals with superior diagnostic
technologies and clinical expertise. This results in better
healthcare and quality of life for millions of patients and their
families. For more information, visit www.isitallergy.com
US Hereditary Angioedema Association Booth 917
Seven Waterfront Plaza
500 Ala Moana Blvd
Honolulu, HI 96813
Phone: (866) 798-5598
Fax: (508) 432-0303
Website: www.haea.org
The US Hereditary Angioedema Association (HAEA) provides
a wide range of patient services, patient advocacy programs
and clinical research for this rare genetic blood disease. We
display information on HAE diagnosis and treatment as well
as on our Scientific Registry – Patient Driven Research for a
Cure.We also display important information on the opening
of the new US HAEA Angioedema Center at UC San Diego.
131
Exhibits
SunButter, LLC
Exhibits
Hall A-1 • Georgia World Congress Center
Viracor-IBT Laboratories
Booth 1221
1001 NW Technology Dr
Lee’s Summit, MO 64086
Phone: (800) 305-5198
Fax: (816) 347-0143
Website: www.viracoribt.com
Contact Name: Carol Smith
Contact Email: [email protected]
Vitalograph, Inc.
Booth 601
13310 W 99th St
Lenexa, KS 66215
Phone: (800) 255-6626
Fax: (913) 888-4259
Website: www.vitalograph.com
Contact Email: [email protected]
Vitalograph is a global leader in pulmonary diagnostic device
manufacturing and clinical trial professional services. Our
extensive respiratory range includes a variety of world class
spirometers, asthma monitors, COPD screeners, peak flow
meters, e-diaries and inhaler trainers. As we celebrate our
50th anniversary we are proud to introduce the latest version
of Spirotrac PC-based Spirometry Software and the new
Compact comprehensive desktop medical workstation,
offering advanced spirometry, pulse oximetry, ambulatory
blood pressure, ECG and more.
Well Amy, LLC
Booth 712
60 Lakeview Ave
Short Hills, NJ 07078
Phone: (973) 218-6152
Fax: (973) 218-6153
Website: www.wellamy.com
Contact Name: Amy Hull Brown
Contact Email: [email protected]
World Allergy Organization (WAO)
Booth 1021
555 E Wells St, Ste 1100
Milwaukee, WI 53202
Phone: (414) 276-1791
Fax: (414) 276-3349
Website: www.worldallergy.org
Contact Name: Amanda Hegg
Contact Email: [email protected]
The World Allergy Organization (WAO) is an international
umbrella organization whose members consist of 95 regional
and national allergology and clinical immunology societies
from around the world. By collaborating with member
societies, WAO provides direct educational outreach
programs, symposia and lectureships to members in nearly
100 countries around the globe. For your National Allergy
Society to become a WAO Member Society, you must
complete an application:
www.worldallergy.org/wao_societies/apply.php.
132
World Immunopathology
Organization
Booth 1125
4 Ostrovityanova Street
Moscow, 117513
Russia
Phone: +7 495 735 1414
Fax: +7 495 735 1441
Website: www.wipocis.org
Contact Name: Maya Khatamova
Contact Email: [email protected]
World Immunopathology Organization (WIPO) is non-profit
organization. The WIPO global mission is to promote through
education and research activities worldwide: basic and
clinical research in experimental and clinical immunology,
allergy and asthma, autoimmunity, immunodeficiency;
prevention and treatment of different manifestations of
immunopathology; immune-associated disorders.
Xoran Technologies, LLC
Booth 809
5210 South State Rd
Ann Arbor, MI 48108-7936
Phone: (734) 418-5168
Website: www.xorantech.com
Contact Name: Rachel Gajda
Contact Email: [email protected]
Hundreds of Allergy physicians have chosen to trust Xoran –
the market leader in medical point-of-care imaging. The
MiniCAT CT scanner provides the perfect solution for
increased convenience, immediate access to images and a
favorable return on investment for small and large practices
alike. Your patients will appreciate an enhanced level of care
from the scanner’s ultra-low radiation dose scanning
capability. Contact us today to find out how the MiniCAT can
work for you!
Exhibits
Hall A-1 • Georgia World Congress Center
Xtract Solutions
Booth 21
9495 SW Locust St, Ste E
Portland, OR 97223
Phone: (503) 379-0110
Fax: (503) 715-1378
Website: www.xtractsolutions.com
Contact Name: James Baker
Contact Email: [email protected]
Xtract Solutions is a market leader in Allergy Immunotherapy
Software. The Xtract Preparation System is an innovative
workflow solution for managing and compounding your
immunotherapy prescriptions, with its primary advantages
being efficiency, accomplished through our user friendly
touch screen interface and automated labeling, and safety,
obtained through barcode verification to help confirm a
patient vial is mixed accurately. Xtract’s Injection System
utilizes fingerprint and barcode verification to ensure
patients are getting their correct shots and our touch screen
dashboard allows for efficient patient management in the
shot room. Visit us today to see how we can add to your
practice’s productivity.
Yodle
Booth 1016
50 W 23 St, Ste 401
New York, NY 10010
Phone: (877) 276-5104
Website: www.yodle.com
Contact Name: Carolyn Volper
Contact Email: [email protected]
Exhibits
Yodle, a leader in local online marketing, empowers local
businesses to find and keep their customers simply and
profitably. Yodle offers all the online marketing essentials
that local businesses need through one easy-to-use,
affordable and automated platform, fully supported by a live
customer service team. Today, Yodle simplifies success for
45,000+ local businesses.
133
Index of Exhibits
Exhibits – Listed by Category
Allergy Extracts
Dietary Products
ALK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1220
Allergy Laboratories, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Greer Laboratories, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1129
HollisterStier Allergy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 701
SmartPractice Dermatology / Allergy . . . . . . . . . . . . . . . . . . . 700
Well Amy, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 712
Allergy Friendly Food
SunButter, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 613
Biotechnology
Genentech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 927
Educational Initiative
Chandler Chicco Agency . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 523
Environmental Products
Allergy Control Products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1224
Allergy Guardian . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 815
Kaz USA Inc./Honeywell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1121
Mission: Allergy, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1009
National Allergy Supply, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . 1231
Rabbit Air . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 716
Bronchial Thermoplasty
Boston Scientific Corporation. . . . . . . . . . . . . . . . . . . . . . . . . . . 621
Expect Registry Study
EXPECT Pregnancy Registry Study . . . . . . . . . . . . . . . . . . . . . . 811
Clinical Research Organization
Food Allergy Research and Education (FARE). . . . . . . . . . . 1330
Furniture
Infinite Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 627
Computer Hardware/Software
Crowell Systems. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 721
Meditab Software, Inc.- Allergy EHR. . . . . . . . . . . . . . . . . . . . . 620
Osia Medical . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 510
Rosch Visionary Systems, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . 924
Solutionreach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 508
Vitalograph, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 601
Xtract Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Health/Body Care
Pharmaceutical Specialties, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 617
Immunotherapy
Allergychoices Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 409
Market Research
Diagnostic Equipment
Cascade Survey Research. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
Carestream. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 825
Xoran Technologies, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 809
Marketing
Yodle . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1016
Diagnostic Testing
Edge Medical Solutions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 603
Lincoln Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 908
Thermo Fisher Scientific . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 820
Viracor-IBT Laboratories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1221
Medical Device
Aerocrine, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 826
Forest Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 714
Non-Profit Organization
World Immunopathology Organization . . . . . . . . . . . . . . . . 1125
134
Index of Exhibits
Exhibits – Listed by Category
Patient/Public Education
Physician Education
Allergy & Asthma Network . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1320
American Latex Allergy Association. . . . . . . . . . . . . . . . . . . . 1017
American Partnership for
Eosinophilic Disorders (APFED) . . . . . . . . . . . . . . . . . . . . . . . . . 817
Asthma and Allergy Foundation of America (AAFA) . . . . . 829
Booster Shot Media . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 914
Georgia Regents University PaCE . . . . . . . . . . . . . . . . . . . . . . 1321
HAE: Learn About It, Talk About It . . . . . . . . . . . . . . . . . . . . . 1227
Immune Deficiency Foundation . . . . . . . . . . . . . . . . . . . . . . . 1319
MotherToBaby . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1314
US Hereditary Angioedema Association. . . . . . . . . . . . . . . . . 917
World Allergy Organization (WAO). . . . . . . . . . . . . . . . . . . . . 1021
American Board of Allergy & Immunology (ABAI) . . . . . . 1225
The Mastocytosis Society . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 521
Physician Recruitment
Allergy Partners . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 813
Publications
Allergy & Asthma Proceedings. . . . . . . . . . . . . . . . . . . . . . . . . . 727
ELSEVIER, INC.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1316
Specialty Infusion Service
Coram CVS / Specialty Infusion Services . . . . . . . . . . . . . . . 1312
Pharmaceuticals
Spirometry
Micro Direct, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 916
NSpire Health, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1120
Technology
ModuleMD, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1116
Exhibits
Alcon Laboratories, Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 928
Allergan, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 715
Baxter Healthcare . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 709
Baxter Healthcare Corporation. . . . . . . . . . . . . . . . . . . . . . . . . . 615
Chattem a Sanofi Company . . . . . . . . . . . . . . . . . . . . . . . . . . . 1311
CSL Behring. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1027
Dyax Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 921
Edge Pharmaceuticals, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
GlaxoSmithKline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 702
GlaxoSmithKline. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 501
Meda Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 509
Merck. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1107
Mission Pharmacal Company . . . . . . . . . . . . . . . . . . . . . . . . . . . 411
Mylan Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 909
NeilMed Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 1308
Novartis Pharmaceuticals Corporation . . . . . . . . . . . . . . . . . . 415
Perrigo Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Protein Sciences Corporation . . . . . . . . . . . . . . . . . . . . . . . . . . . 726
PuraCap Pharmaceutical. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 827
Salix Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 401
Sanofi US . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1115
Shire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 900
Sunovion Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . 607
Teva Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728
Teva Respiratory, LLC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1001
135
Index of Exhibitors
Exhibitors – Listed by Booth
Booth 21. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Xtract Solutions
Booth 23 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Perrigo Company
Booth 31 . . . . . . . . . . . . . . . . . . . . . . . . Edge Pharmaceuticals, LLC
Booth 33 . . . . . . . . . . . . . . . . . . . . . . . . . . Allergy Laboratories, Inc.
Booth 401 . . . . . . . . . . . . . . . . . . . . . . . Salix Pharmaceuticals, Inc.
Booth 409 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allergychoices Inc
Booth 411 . . . . . . . . . . . . . . . . . . . . Mission Pharmacal Company
Booth 415 . . . . . . . . . . . Novartis Pharmaceuticals Corporation
Booth 501 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GlaxoSmithKline
Booth 508 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Solutionreach
Booth 509. . . . . . . . . . . . . . . . . . . . . . . . . . . Meda Pharmaceuticals
Booth 510. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Osia Medical
Booth 521 . . . . . . . . . . . . . . . . . . . . . . . . The Mastocytosis Society
Booth 523 . . . . . . . . . . . . . . . . . . . . . . . . . Chandler Chicco Agency
Booth 601 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Vitalograph, Inc.
Booth 603 . . . . . . . . . . . . . . . . . . . . . . . . . . Edge Medical Solutions
Booth 607 . . . . . . . . . . . . . . . . . . Sunovion Pharmaceuticals, Inc.
Booth 613 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SunButter, LLC
Booth 615 . . . . . . . . . . . . . . . . . . . Baxter Healthcare Corporation
Booth 617 . . . . . . . . . . . . . . . . . . Pharmaceutical Specialties, Inc.
Booth 620 . . . . . . . . . . . . . . Meditab Software, Inc.- Allergy EHR
Booth 621 . . . . . . . . . . . . . . . . . . . . Boston Scientific Corporation
Booth 627 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Infinite Therapeutics
Booth 700. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SmartPractice
Booth 701 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . HollisterStier Allergy
Booth 702 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . GlaxoSmithKline
Booth 709. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Baxter Healthcare
Booth 712 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Well Amy, LLC
Booth 714. . . . . . . . . . . . . . . . . . . . . . Forest Pharmaceuticals, Inc.
Booth 715 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allergan, Inc.
Booth 716 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Rabbit Air
Booth 721 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Crowell Systems
Booth 726 . . . . . . . . . . . . . . . . . . . . Protein Sciences Corporation
Booth 727 . . . . . . . . . . . . . . . . . . . Allergy & Asthma Proceedings
Booth 728 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Teva Pharmaceuticals
Booth 809 . . . . . . . . . . . . . . . . . . . . . . . . . Xoran Technologies, LLC
Booth 811 . . . . . . . . . . . . . . . EXPECT Pregnancy Registry Study
Booth 813 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allergy Partners
Booth 815. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Allergy Guardian
Booth 817 . . . . . . . . . . . . . . . . . . . . . . . . American Partnership for
Eosinophilic Disorders (APFED)
Booth 820 . . . . . . . . . . . . . . . . . . . . . . . . . Thermo Fisher Scientific
Booth 825 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Carestream
Booth 826 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Aerocrine, Inc.
136
Booth 827 . . . . . . . . . . . . . . . . . . . . . . . . . PuraCap Pharmaceutical
Booth 829 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Asthma and Allergy
Foundation of America (AAFA)
Booth 900 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Shire
Booth 908 . . . . . . . . . . . . . . . . . . . . . . . . . Lincoln Diagnostics, Inc.
Booth 909 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mylan Inc.
Booth 914. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booster Shot Media
Booth 916 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Micro Direct, Inc.
Booth 917 . . . . . . . . . . US Hereditary Angioedema Association
Booth 921 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dyax Corp.
Booth 924 . . . . . . . . . . . . . . . . . . . . Rosch Visionary Systems, Inc.
Booth 927 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Genentech
Booth 928 . . . . . . . . . . . . . . . . . . . . . . . . . . Alcon Laboratories, Inc.
Booth 1001 . . . . . . . . . . . . . . . . . . . . . . . . . . . Teva Respiratory, LLC
Booth 1009 . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mission: Allergy, Inc.
Booth 1016. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Yodle
Booth 1017 . . . . . . . . . . . . . American Latex Allergy Association
Booth 1021 . . . . . . . . . . . . . . World Allergy Organization (WAO)
Booth 1027 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . CSL Behring
Booth 1107 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Merck
Booth 1115 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sanofi US
Booth 1116 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ModuleMD, LLC
Booth 1120 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . nSpire Health, Inc.
Booth 1121. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Kaz USA Inc.
Booth 1125 . . . . . . . . . World Immunopathology Organization
Booth 1129 . . . . . . . . . . . . . . . . . . . . . . . . . Greer Laboratories, Inc.
Booth 1220 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ALK
Booth 1221 . . . . . . . . . . . . . . . . . . . . . . . . Viracor-IBT Laboratories
Booth 1224. . . . . . . . . . . . . . . . . . . . . . . . Allergy Control Products
Booth 1225. . . . . . . . . . . . . . . . . . . . American Board of Allergy &
Immunology (ABAI)
Booth 1227. . . . . . . . . . . . . . . HAE: Learn About It, Talk About It
Booth 1231 . . . . . . . . . . . . . . . . . . . . National Allergy Supply, Inc.
Booth 1308 . . . . . . . . . . . . . . . . . . NeilMed Pharmaceuticals, Inc.
Booth 1311. . . . . . . . . . . . . . . . . . . . . Chattem a Sanofi Company
Booth 1312 . . . . . . . . Coram CVS / Specialty Infusion Services
Booth 1314. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . MotherToBaby
Booth 1316 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ELSEVIER, INC.
Booth 1319 . . . . . . . . . . . . . . . . Immune Deficiency Foundation
Booth 1320. . . . . . . . . . . . . . . . . . . . . . Allergy & Asthma Network
Booth 1321 . . . . . . . . . . . . . . . Georgia Regents University PaCE
Booth 1322 . . . . . . . . . . . . . . . . . . . . . . . Cascade Survey Research
Booth 1330. . . . . . . . . . . . . . . . . . . . . . . . . . Food Allergy Research
and Education (FARE)
Index of Exhibitors
Aerocrine, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 826
Alcon Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 928
ALK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1220
Allergan, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 715
Allergy & Asthma Network. . . . . . . . . . . . . . . . . . . . . . Booth 1320
Allergy & Asthma Proceedings . . . . . . . . . . . . . . . . . . . Booth 727
Allergy Control Products. . . . . . . . . . . . . . . . . . . . . . . . Booth 1224
Allergy Guardian. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 815
Allergy Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 33
Allergy Partners . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 813
Allergychoices Inc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 409
American Board of Allergy &
Immunology (ABAI) . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1225
American Latex Allergy Association . . . . . . . . . . . . . Booth 1017
American Partnership for
Eosinophilic Disorders (APFED). . . . . . . . . . . . . . . . . . . Booth 817
Asthma and Allergy Foundation
of America (AAFA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 829
Baxter Healthcare Corporation . . . . . . . . . . . . . . . . . . . Booth 615
Baxter Healthcare. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 709
Booster Shot Media. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 914
Boston Scientific Corporation . . . . . . . . . . . . . . . . . . . . Booth 621
Carestream . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 825
Cascade Survey Research . . . . . . . . . . . . . . . . . . . . . . . Booth 1322
Chandler Chicco Agency . . . . . . . . . . . . . . . . . . . . . . . . . Booth 523
Chattem a Sanofi Company. . . . . . . . . . . . . . . . . . . . . Booth 1311
Coram CVS / Specialty Infusion Services . . . . . . . . Booth 1312
Crowell Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 721
CSL Behring . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1027
Dyax Corp. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 921
Edge Medical Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 603
Edge Pharmaceuticals, LLC . . . . . . . . . . . . . . . . . . . . . . . . Booth 31
ELSEVIER, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1316
EXPECT Pregnancy Registry Study . . . . . . . . . . . . . . . Booth 811
Food Allergy Research and Education (FARE) . . . . Booth 1330
Forest Pharmaceuticals, Inc.. . . . . . . . . . . . . . . . . . . . . . Booth 714
Genentech . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 927
Georgia Regents University PaCE . . . . . . . . . . . . . . . Booth 1321
GlaxoSmithKline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 501
GlaxoSmithKline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 702
Greer Laboratories, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1129
HAE: Learn About It, Talk About It. . . . . . . . . . . . . . . Booth 1227
HollisterStier Allergy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 701
Immune Deficiency Foundation . . . . . . . . . . . . . . . . Booth 1319
Infinite Therapeutics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 627
Kaz USA Inc.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1121
Lincoln Diagnostics, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . Booth 908
Meda Pharmaceuticals. . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 509
Meditab Software, Inc.- Allergy EHR . . . . . . . . . . . . . . Booth 620
Merck . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1107
Micro Direct, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 916
Mission Pharmacal Company . . . . . . . . . . . . . . . . . . . . Booth 411
Mission: Allergy, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1009
ModuleMD, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1116
MotherToBaby. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1314
Mylan Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 909
National Allergy Supply, Inc. . . . . . . . . . . . . . . . . . . . . Booth 1231
NeilMed Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . Booth 1308
Novartis Pharmaceuticals Corporation . . . . . . . . . . . Booth 415
nSpire Health, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1120
Osia Medical. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 510
Perrigo Company . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 23
Pharmaceutical Specialties, Inc. . . . . . . . . . . . . . . . . . . Booth 617
Protein Sciences Corporation . . . . . . . . . . . . . . . . . . . . Booth 726
PuraCap Pharmaceutical . . . . . . . . . . . . . . . . . . . . . . . . . Booth 827
Rabbit Air . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 716
Rosch Visionary Systems, Inc. . . . . . . . . . . . . . . . . . . . . Booth 924
Salix Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . . . . . . Booth 401
Sanofi US . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1115
Shire . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 900
SmartPractice. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 700
Solutionreach . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 508
SunButter, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 613
Sunovion Pharmaceuticals, Inc. . . . . . . . . . . . . . . . . . . Booth 607
Teva Pharmaceuticals . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 728
Teva Respiratory, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1001
The Mastocytosis Society . . . . . . . . . . . . . . . . . . . . . . . . Booth 521
Thermo Fisher Scientific . . . . . . . . . . . . . . . . . . . . . . . . . Booth 820
US Hereditary Angioedema Association . . . . . . . . . . Booth 917
Viracor-IBT Laboratories . . . . . . . . . . . . . . . . . . . . . . . . Booth 1221
Vitalograph, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 601
Well Amy, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 712
World Allergy Organization (WAO) . . . . . . . . . . . . . . Booth 1021
World Immunopathology Organization . . . . . . . . . Booth 1125
Xoran Technologies, LLC . . . . . . . . . . . . . . . . . . . . . . . . . Booth 809
Xtract Solutions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 21
Yodle. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Booth 1016
137
Exhibits
Exhibitors – Listed Alphabetically
Exhibit Hall Map
Hall A1 • Georgia World Congress Center
Seating
Seating
Product
Theater
Product
Theater
2
1
POSTERS
Seating
Doctors’
Job Fair
138
Seating
Maps
Georgia World Congress Center
Level 1
Exhibits
Posters
Doctors’ Job Fair
Product Theaters
E
TR
C
AN
EN
Level 3
Down to Exhibit Hall
& Hall A2
139
Georgia World Congress Center
Level 4
Registration
General
Session
140
Coat
Check
Speaker
Ready Room
Maps
Omni Hotel at CNN Center
South Tower – Atrium Terrace Level
PINE
FOYER
PINE
ATRIUM TERRACE
BIRCH
SPRUCE
ATRIUM
FOYER
M
AP
C
LE
M
B
FO
YE
R
AP
LE
A
141
Omni Hotel at CNN Center
North Tower – M1 Street Level
T TA
ST.
A
MAR
IE
DOGWOOD
ROOM
B
A
ELEVATORS
COTTONWOOD
ROOM
REDWOOD
ROOM
B
PRE-FUNCTION LOBBY
OUTDOOR TERRACE
INTERNATIONAL BLVD.
142
Maps
Omni Hotel at CNN Center
North Tower – M2 International Ballroom Level
C
B
D
E
F
INTERNATIONAL
BALLROOM
A
Exit to
Georgia World
Congress Center
CEILING HEIGHT: 8'-2 1/2"
MAGNOLIA
JUNIPER
CYPRESS
SYCAMORE
143
Omni Hotel at CNN Center
North Tower – M3 Meeting Level
3
F-1
FEC
LV-M2B
2
2
FEC
2
UPPER INTERNATIONAL BALLROOM
FEC
FEC
PANTRY
6
IF-403
FEC
FEC
HICKORY
CHESTNUT
FEC
PRE-FUNCTION
LOBBY
BEECHNUT
144
D
IF-313
WP2
WP1
WP2
WP1
B
IF-313
WALNUT
HAZELNUT
PECAN
Maps
Omni Hotel at CNN Center
North Tower – M4 Grand Ballroom Level
C
B
D1
D2
E
Grand
Ballroom
A
REGISTRATION
DESK
PRE-FUNCTION
LOBBY
145
European Academy of
Allergy and Clinical Immunology
6 – 10 June 2015
Barcelona, Spain
EAACI
E
AA Congress 2015
t
Abstrac n
sio
Submis e:
Deadlin r y
ua
15 Jan
2015
w
www.eaaci2015.com
w w.e aaci2015.com
#eaaci2015
BRIEF SUMMARY OF THE PRESCRIBING INFORMATION
FOR GRASTEK
WARNING: SEVERE ALLERGIC REACTIONS
• GRASTEK can cause life-threatening allergic reactions such
as anaphylaxis and severe laryngopharyngeal restriction.
• Do not administer GRASTEK to patients with severe,
unstable or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes
following the initial dose.
• Prescribe auto-injectable epinephrine, instruct and train
patients on its appropriate use, and instruct patients to
seek immediate medical care upon its use.
• GRASTEK may not be suitable for patients with certain
underlying medical conditions that may reduce their ability
to survive a serious allergic reaction.
• GRASTEK may not be suitable for patients who may be
unresponsive to epinephrine or inhaled bronchodilators,
such as those taking beta-blockers.
INDICATIONS AND USAGE
GRASTEK is an allergen extract indicated as immunotherapy for the
treatment of grass pollen-induced allergic rhinitis with or without
conjunctivitis confirmed by positive skin test or in vitro testing for pollenspecific IgE antibodies for Timothy grass or cross-reactive grass pollens.
GRASTEK is approved for use in persons 5 through 65 years of age.
GRASTEK is not indicated for the immediate relief of allergic symptoms.
DOSAGE AND ADMINISTRATION
For sublingual use only.
Dose
One GRASTEK tablet daily.
Administration
Administer the first dose of GRASTEK in a healthcare setting under the
supervision of a physician with experience in the diagnosis and treatment
of allergic diseases. After receiving the first dose of GRASTEK, observe
the patient for at least 30 minutes to monitor for signs or symptoms of a
severe systemic or a severe local allergic reaction. If the patient tolerates
the first dose, the patient may take subsequent doses at home.
Administer GRASTEK to children under adult supervision.
Take the tablet from the blister unit after carefully removing the foil
with dry hands.
Place the tablet immediately under the tongue. Allow it to remain
there until completely dissolved. Do not swallow for at least 1 minute.
Wash hands after handling the tablet.
Do not take the tablet with food or beverage. Food or beverage should
not be taken for the following 5 minutes after taking the tablet.
Initiate treatment at least 12 weeks before the expected onset of each
grass pollen season and continue treatment throughout the season.
For sustained effectiveness for one grass pollen season after cessation
of treatment, GRASTEK may be taken daily for three consecutive years
(including the intervals between the grass pollen seasons). The safety
and efficacy of initiating treatment in season have not been established.
Data regarding the safety of restarting treatment after missing a dose of
GRASTEK are limited. In the clinical trials, treatment interruptions for up
to seven days were allowed.
Prescribe auto-injectable epinephrine to patients prescribed GRASTEK and
instruct them in the proper use of emergency self-injection of epinephrine
[See Warnings and Precautions].
DOSAGE FORMS AND STRENGTHS
GRASTEK is available as 2800 Bioequivalent Allergy Unit (BAU) tablets that
are white to off-white, circular with a debossed round detail on one side.
CONTRAINDICATIONS
GRASTEK is contraindicated in patients with:
• Severe, unstable or uncontrolled asthma
• A history of any severe systemic allergic reaction
• A history of any severe local reaction after taking any sublingual
allergen immunotherapy
• A history of eosinophilic esophagitis
• Hypersensitivity to any of the inactive ingredients [gelatin, mannitol and
sodium hydroxide] contained in this product.
WARNINGS AND PRECAUTIONS
Severe Allergic Reactions
GRASTEK can cause systemic allergic reactions including anaphylaxis
which may be life-threatening. In addition, GRASTEK can cause severe
local reactions, including laryngopharyngeal swelling, which can
compromise breathing and be life-threatening. Educate patients to
recognize the signs and symptoms of these allergic reactions and instruct
them to seek immediate medical care and discontinue therapy should any
of these occur. Allergic reactions may require treatment with epinephrine.
[See Warnings and Precautions]
Administer the initial dose of GRASTEK in a healthcare setting under the
supervision of a physician with experience in the diagnosis and treatment
of allergic diseases and prepared to manage a life-threatening systemic
or local allergic reaction. Observe patients in the office for at least
30 minutes following the initial dose of GRASTEK.
Epinephrine
Prescribe auto-injectable epinephrine to patients receiving GRASTEK.
Instruct patients to recognize the signs and symptoms of a severe allergic
reaction and in the proper use of emergency auto-injectable epinephrine.
Instruct patients to seek immediate medical care upon use of autoinjectable epinephrine and to stop treatment with GRASTEK.
See the epinephrine package insert for complete information.
GRASTEK may not be suitable for patients with certain medical conditions
that may reduce the ability to survive a serious allergic reaction or
increase the risk of adverse reactions after epinephrine administration.
Examples of these medical conditions include but are not limited to:
markedly compromised lung function (either chronic or acute), unstable
angina, recent myocardial infarction, significant arrhythmia, and
uncontrolled hypertension.
GRASTEK may not be suitable for patients who are taking medications
that can potentiate or inhibit the effect of epinephrine. These medications
include:
Beta-adrenergic blockers: Patients taking beta-adrenergic blockers
may be unresponsive to the usual doses of epinephrine used to
treat serious systemic reactions, including anaphylaxis. Specifically,
beta-adrenergic blockers antagonize the cardiostimulating and
bronchodilating effects of epinephrine.
Alpha-adrenergic blockers, ergot alkaloids: Patients taking
alpha-adrenergic blockers may be unresponsive to the usual doses
of epinephrine used to treat serious systemic reactions, including
anaphylaxis. Specifically, alpha-adrenergic blockers antagonize the
vasoconstricting and hypertensive effects of epinephrine. Similarly,
ergot alkaloids may reverse the pressor effects of epinephrine.
Tricyclic antidepressants, levothyroxine sodium, monoamine
oxidase inhibitors and certain antihistamines: The adverse effects
of epinephrine may be potentiated in patients taking tricyclic
antidepressants, levothyroxine sodium, monoamine oxidase inhibitors,
and the antihistamines chlorpheniramine, and diphenhydramine.
Cardiac glycosides, diuretics: Patients who receive epinephrine while
taking cardiac glycosides or diuretics should be observed carefully for
the development of cardiac arrhythmias.
Upper Airway Compromise
GRASTEK can cause local reactions in the mouth or throat that could
compromise the upper airway [See Adverse Reactions]. Consider
discontinuation of GRASTEK in patients who experience persistent and
escalating adverse reactions in the mouth or throat.
Eosinophilic Esophagitis
Eosinophilic esophagitis has been reported in association with sublingual
tablet immunotherapy [See Contraindications and Adverse Reactions].
Discontinue GRASTEK and consider a diagnosis of eosinophilic esophagitis
in patients who experience severe or persistent gastro-esophageal
symptoms including dysphagia or chest pain.
Asthma
GRASTEK has not been studied in subjects with moderate or severe
asthma or any subjects who required daily medication to treat asthma.
Withhold immunotherapy with GRASTEK if the patient is experiencing
an acute asthma exacerbation. Reevaluate patients who have recurrent
asthma exacerbations and consider discontinuation of GRASTEK.
Concomitant Allergen Immunotherapy
GRASTEK has not been studied in subjects who are receiving concomitant
allergen immunotherapy. Concomitant dosing with other allergen
immunotherapy may increase the likelihood of local or systemic adverse
reactions to either subcutaneous or sublingual allergen immunotherapy.
Oral Inflammation
Stop treatment with GRASTEK to allow complete healing of the oral
cavity in patients with oral inflammation (e.g., oral lichen planus, mouth
ulcers or thrush) or oral wounds, such as those following oral surgery or
dental extraction.
ADVERSE REACTIONS
Adverse reactions reported in ≥5% of patients were: ear pruritus, oral
pruritus, tongue pruritus, mouth edema, and throat irritation.
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and may
not reflect the rates observed in clinical practice.
Adults
The safety data described below are based on 6 clinical trials which
randomized 3589 subjects 18 through 65 years of age with Timothy
grass pollen induced rhinitis with or without conjunctivitis, including
1669 subjects who were exposed to at least one dose of GRASTEK. Of
the subjects treated with GRASTEK, 25% had mild asthma and 80% were
sensitized to other allergens in addition to grass. The subject population
was 88% White, 7% African American, and 3% Asian. Subjects were 52%
male, and 88% of subjects were between 18 and 50 years of age. Subject
demographics in placebo-treated subjects were similar to the active group.
The most common adverse reactions reported in subjects treated with
GRASTEK were oral pruritus (26.7% vs 3.5% placebo), throat irritation
(22.6% vs 2.8%), ear pruritus (12.5% vs 1.1%) and mouth edema (11.1%
vs 0.8%). The percentage of subjects who discontinued from the clinical
trials because of an adverse reaction while exposed to GRASTEK or
placebo was 4.9% and 0.9%, respectively. The most common adverse
reactions that led to study discontinuation in subjects who were exposed
to GRASTEK were pharyngeal edema and oral pruritus.
Seven adult subjects (7/1669; 0.4%) who received GRASTEK experienced
treatment-related systemic allergic reactions that led to discontinuation
of GRASTEK in four out of the seven subjects.
• Five of the seven subjects had reactions on Day 1 of treatment with
GRASTEK. Symptoms included swelling of lips/mouth; oral/pharyngeal
itching; ear itching, sneezing, rhinorrhea, throat irritation, dysphonia,
dysphagia, chest discomfort, and rash. Three of the five subjects
received treatment with epinephrine and antihistamines, and one of the
three also received oral corticosteroids. One of the five subjects who
had a reaction on Day 1 of treatment with GRASTEK also had a reaction
on Day 2 of treatment with GRASTEK. Symptoms on Day 2 included oral
burning sensation; rhinorrhea; and throat irritation.
• One of the seven subjects had a reaction on Day 2 after tolerating
treatment with GRASTEK on Day 1. Symptoms included edema of the
lower lip, epigastric discomfort and dizziness.
• One of the seven subjects developed chest tightness and shortness of
breath on Day 42 of treatment with GRASTEK.
Adverse reactions reported in ≥1% of subjects treated with GRASTEK are
shown in Table 1.
Table 1: Adverse Reactions Reported in ≥1% of Adults Treated
with GRASTEK
Adverse Reaction
GRASTEK
(N=1669)
PLACEBO
(N=1645)
2.1%
1.3%
12.5%
1.1%
Nervous System Disorders
Headache
Ear and Labyrinth Disorders
Ear pruritus
Respiratory, Thoracic and Mediastinal Disorders
Throat irritation
22.6%
2.8%
Pharyngeal edema
3.4%
0.1%
Dry throat
1.7%
0.4%
Oropharyngeal pain
1.6%
1.0%
Nasal discomfort
1.6%
1.0%
Throat tightness
1.4%
0.2%
Dyspnea
1.1%
0.4%
Oral pruritus
26.7%
3.5%
Mouth edema
11.1%
0.8%
Paraesthesia oral
9.8%
2.0%
Tongue pruritus
5.7%
0.5%
Lip swelling
4.0%
0.2%
Swollen tongue
2.8%
0.1%
Dyspepsia
2.3%
0.1%
Hypoesthesia oral
2.3%
1.0%
Nausea
1.9%
0.6%
Oral discomfort
1.6%
0.3%
Oral mucosal erythema
1.5%
0.6%
Lip edema
1.3%
0.1%
Glossitis
1.3%
0.1%
Stomatitis
1.1%
0.3%
Gastrointestinal Disorders
Brief Summary of the Prescribing Information for GRASTEK continues
after advertisement.
Actual size.
YOU HAVE
THE POWER
IN A TABLET
GRASTEK® (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use is an allergen extract indicated
as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis
confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or
cross-reactive grass pollens. GRASTEK is approved for use in persons 5 through 65 years of age.
GRASTEK is not indicated for the immediate relief of allergic symptoms.
Selected Important Safety Information About GRASTEK
WARNING: SEVERE ALLERGIC REACTIONS
• GRASTEK can cause life-threatening allergic reactions such as anaphylaxis and severe
laryngopharyngeal restriction.
• Do not administer GRASTEK to patients with severe, unstable or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct
patients to seek immediate medical care upon its use.
• GRASTEK may not be suitable for patients with certain underlying medical conditions that may reduce
their ability to survive a serious allergic reaction.
• GRASTEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled
bronchodilators, such as those taking beta-blockers.
• GRASTEK is contraindicated in patients with: severe, unstable, or uncontrolled asthma; a history of any
severe systemic allergic reaction or severe local reaction after taking any sublingual allergen immunotherapy;
a history of eosinophilic esophagitis; or who are hypersensitive to any of the inactive ingredients in GRASTEK.
• GRASTEK can cause systemic allergic reactions including anaphylaxis which may be life-threatening and
severe local reactions, including laryngopharyngeal swelling, which can compromise breathing and be
life-threatening. Educate patients to recognize the signs and symptoms of these allergic reactions and
to use epinephrine as appropriate. Review the epinephrine package insert for complete information.
• Patients who have persistent and escalating adverse reactions in the mouth or throat should be considered
for discontinuation of GRASTEK.
Please see the adjacent Brief Summary of the Prescribing Information, including the Boxed Warning
about severe allergic reactions.
For appropriate patients who suffer during grass pollen season and decline allergy shots
A DIFFERENT APPROACH TO ALLERGY IMMUNOTHERAPY
THE FIRST AND ONLY sublingual immunotherapy tablet for patients as young as 5 years
DEMONSTRATED FIRST-SEASON EFFICACY IN 3 CLINICAL STUDIES
TWO WAYS TO TREAT
— PRE-/CO-SEASONAL: Start at least 12 weeks before each grass pollen season and continue
throughout the season
— YEAR-ROUND FOR SUSTAINED EFFECT: Prescribe GRASTEK daily for 3 consecutive years
for effectiveness through the next season (posttreatment), starting at least 12 weeks before the
first grass pollen season
Selected Important Safety Information About GRASTEK
• Eosinophilic esophagitis has been reported in association with sublingual immunotherapy.
Discontinue GRASTEK and consider a diagnosis of eosinophilic esophagitis in patients who
experience severe or persistent gastro-esophageal symptoms including dysphagia or chest pain.
• GRASTEK should be withheld if the patient is experiencing an acute asthma exacerbation. Reevaluate
patients who have recurrent asthma exacerbations and consider discontinuation of GRASTEK.
• Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic
adverse reactions to either subcutaneous or sublingual allergen immunotherapy.
• Stop GRASTEK to allow complete healing of the oral cavity in patients with oral inflammation or wounds,
such as those following oral surgery or dental extraction.
• In clinical studies, adverse reactions reported for ≥5% of patients 5 years of age and older
were ear pruritus, oral pruritus, tongue pruritus, mouth edema, and throat irritation.
• GRASTEK should be used during pregnancy only if clearly needed.
Learn more at hcp.grastek.com
Copyright © 2014 Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc. All rights reserved. RESP-1130956-0000 09/14
BRIEF SUMMARY OF THE PRESCRIBING INFORMATION FOR
GRASTEK® (Timothy Grass Pollen Allergen Extract) (continued)
Table 1: Adverse Reactions Reported in ≥1% of Adults
Treated with GRASTEK (continued)
Tongue disorder
1.1%
0.2%
Tongue edema
1.1%
0.4%
Glossodynia
1.0%
0.3%
Dysphagia
Palatal edema
1.0%
0.2%
1.0%
0.1%
Skin and Subcutaneous Tissue Disorders
Pruritus
2.4%
1.0%
Urticaria
1.7%
0.9%
General Disorders and Administration Site Conditions
Chest discomfort
1.6%
0.5%
Fatigue
1.4%
0.4%
Table 2: Adverse Reactions Reported in ≥1% of Pediatric
Subjects Treated with GRASTEK (continued)
Paraesthesia oral
5.4%
Oral mucosal erythema
4.9%
1.2%
0.9%
Lip pruritus
2.9%
0.2%
Swollen tongue
2.5%
0%
Dysphagia
2.0%
0%
Nausea
1.6%
0.5%
Oral discomfort
1.6%
0.2%
Stomatitis
1.3%
0%
Hypoesthesia oral
1.1%
0.2%
Manufactured by:
Catalent Pharma Solutions Limited, Blagrove,
Swindon, Wiltshire, SN5 8RU UK
Glossodynia
1.1%
0.2%
For patent information: www.merck.com/product/patent/home.html
0.2%
Copyright © 2014 Merck Sharp & Dohme Corp.,
a subsidiary of Merck & Co., Inc.
All rights reserved.
Skin and Subcutaneous Tissue Disorders
Urticaria
1.8%
General Disorders and Administration Site Conditions
Adverse reactions of interest that occurred in ≤1% of GRASTEK recipients
include abdominal pain and gastroesophageal reflux.
Pediatrics
Safety data are based on 3 clinical trials which randomized 881 subjects
between 5 and 17 years of age with grass pollen induced rhinitis with
or without conjunctivitis. Overall, 445 subjects received at least one
dose of GRASTEK. Of the subjects treated with GRASTEK, 31% had mild
asthma and 86% were sensitized to other allergens in addition to grass.
The subject population was 86% White, 7% African American and 3%
multi-racial. The majority (66%) of subjects were male. The mean age
of subjects was 11.7 years. Subject demographics in placebo-treated
subjects were similar to the active group.
The most common adverse reactions in pediatric subjects treated with
GRASTEK were oral pruritus (24.4% vs 2.1% placebo), throat irritation
(21.3% vs 2.5%) and mouth edema (9.8% vs 0.2%). The percentage
of subjects who discontinued from the clinical trials because of an
adverse reaction while exposed to GRASTEK or placebo was 6.3%
and 0.7%, respectively.
One pediatric subject (1/447; 0.2%) who received GRASTEK experienced
a treatment-related systemic allergic reaction consisting of lip
angioedema, slight dysphagia due to the sensation of a lump in the
throat, and intermittent cough which was of moderate intensity on
Day 1. The subject was treated with epinephrine, recovered, and was
discontinued from the trial.
Adverse reactions reported in ≥1% of subjects treated with GRASTEK are
shown in Table 2.
Table 2: Adverse Reactions Reported in ≥1% of Pediatric
Subjects Treated with GRASTEK
Adverse Reaction
GRASTEK
(N=447)
PLACEBO
(N=434)
3.4%
1.8%
7.2%
0.5%
3.4%
2.1%
Nervous System Disorders
Headache
Ear and Labyrinth Disorders
Ear pruritus
Eye Disorders
Eye pruritus
Respiratory, Thoracic and Mediastinal Disorders
Throat irritation
21.3%
2.5%
Oropharyngeal pain
4.0%
1.4%
Pharyngeal erythema
3.6%
0.7%
Pharyngeal edema
2.9%
0%
Cough
2.7%
1.2%
Dyspnea
2.0%
0.5%
Nasal discomfort
1.6%
0.9%
Nasal congestion
1.6%
0.5%
Sneezing
1.6%
0.7%
Oral pruritus
24.4%
2.1%
Mouth edema
9.8%
0.2%
Tongue pruritus
9.2%
0.9%
Lip swelling
7.2%
0.5%
Gastrointestinal Disorders
Geriatric Use
There is no clinical trial experience with GRASTEK in patients over
65 years of age.
Chest discomfort
2.0%
For more detailed information,
please read the Prescribing Information.
Rx only.
Manufactured for: Merck Sharp & Dohme Corp., a subsidiary of
Merck & Co., Inc., Whitehouse Station, NJ 08889, USA
uspi-mk7243-sb-1406r001
0.5%
Postmarketing Experience
Postmarketing Safety Studies
In European post-approval studies which included 1,666 patients
treated with GRASTEK (marketed under the name GRAZAX), reported
serious adverse reactions assessed as related to GRASTEK use included
anaphylactic reaction, asthma exacerbation, hoarseness, laryngitis, oral
ulceration, and ulcerative colitis exacerbation.
Spontaneous Postmarketing Reports
The following adverse reactions have been identified during post-approval
use of GRASTEK (marketed under the name GRAZAX in Europe). Because
these reactions are reported voluntarily from a population of uncertain
size, it is not always possible to reliably estimate their frequency or
establish a causal relationship to drug exposure. These include: altered
state of consciousness, anaphylactic shock, angioedema, asthma
exercise induced, chest pressure, diarrhea, difficulty speaking, dizziness,
drowsiness, eosinophilic esophagitis, erythema facial, face edema, forced
expiratory volume decreased, heart rate increased, heart rate irregular,
hyperventilation, hypotension, laryngeal discomfort, oral pain, oxygen
saturation decreased, peak expiratory flow rate decreased, pneumonia,
rash, respiratory distress, sensation of foreign body, status asthmaticus,
swelling of neck, throat pruritus, tremor, vital capacity decreased,
vomiting, and wheezing. Included in these reports was an adult male
with asthma who experienced anaphylactic shock within two minutes of
administration of GRASTEK. The patient experienced depressed level of
consciousness, hypotension, increased heart rate, wheezing, urticaria,
and face edema.
Eosinophilic esophagitis has been reported following treatment with
GRASTEK (marketed under the name GRAZAX). The clinical details
of some postmarketing reports are consistent with a drug-induced
effect, including at least one case with resolution of symptoms upon
discontinuation of GRASTEK, relapse after resuming GRASTEK and
resolution again after discontinuation of GRASTEK.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category B: Reproductive and developmental toxicity studies
performed in female mice have revealed no evidence of harm to the fetus
due to GRASTEK. In these studies, the effect of Timothy grass (Phleum
pratense) pollen allergen extract, the active component of GRASTEK,
on embryo-fetal development was evaluated. Mice were administered
approximately 460,000 BAU/kg/day of Timothy grass pollen allergen
extract by oral gavage on days 0 to 15 of gestation. A dose of 460,000
BAU/kg/day of Timothy grass pollen allergen extract corresponds to
approximately 8,200-fold a human dose on a BAU/kg/day basis. No adverse
effects on embryo-fetal development were observed. There are, however,
no adequate and well-controlled studies in pregnant women. Because
animal reproduction studies are not always predictive of human response,
GRASTEK should be used during pregnancy only if clearly needed.
Because systemic and local adverse reactions with immunotherapy may
be poorly tolerated during pregnancy, GRASTEK should be used during
pregnancy only if clearly needed.
Nursing Mothers
It is not known if GRASTEK is excreted in human milk. Because many
drugs are excreted in human milk, caution should be exercised when
GRASTEK is administered to a nursing woman.
Pediatric Use
Efficacy and safety of GRASTEK have been established in children and
adolescents 5 through 17 years of age.
The safety and efficacy in pediatric patients below 5 years of age have not
been established.
RESP-1130956-0000 09/14
ACAAI Future Meeting Dates
November 5-9, 2015
San Antonio, Texas
November 10-14, 2016
San Francisco, California
October 26-30, 2017
Boston, Massachusetts
November 15-19, 2018
Seattle, Washington
November 7-11, 2019
Houston, Texas
Plan to attend the
ACAAI 2015
Annual Scientific Meeting
San Antonio
November 5 – 9, 2015
Texas
151
Become a
Fellow NOW
@ acaai.org/
fellow
PLEASE JOIN US FOR A NON-CME CORPORATE FORUM DINNER PRESENTATION AT THE
2014 ACAAI ANNUAL SCIENTIFIC MEETING
Advances in Aerosol Therapy for
PATIENTS WITH ASTHMA
OR ALLERGIC RHINITIS
Friday, November 7, 2014 | 6:00 PM – 7:30 PM
Omni Hotel at CNN Center
International Ballroom, Salon D, Atlanta, Georgia
Chitra Dinakar, MD
Maeve O’Connor, MD
Professor of Pediatrics
University of Missouri-Kansas City
Faculty, Division of Allergy, Asthma
and Immunology
Children’s Mercy
Kansas City, Missouri
President
Allergy Asthma & Immunology Relief
AAIR of Charlotte
Charlotte, North Carolina
Nancy K. Ostrom, MD
Ellen R. Sher, MD
Co-Director
Allergy & Asthma Medical Group &
Research Center, A P.C.
Associate Clinical Professor
Department of Pediatrics, Division of
Allergy and Immunology
University of California, San Diego
San Diego, California
Medical Director
Atlantic Allergy, Asthma &
Immunology Associates of NJ
Ocean, New Jersey
Clinical Assistant Professor of Medicine
Drexel University College of Medicine
Philadelphia, Pennsylvania
A COMPLIMENTARY DINNER WILL BE SERVED
Sponsored by
© Teva Respiratory 2014
RESP-40577
When patients need to
break through nasal and
non-nasal allergy symptoms*
®
Start with ZYRTEC as your
foundation for fast†, effective relief
Register at
ZyrtecProfessional.com
for FREE ZYRTEC® samples
and education materials.
*
ZYRTEC® Allergy relieves sneezing, runny nose, itchy, watery eyes, and itchy nose or throat.
†
ZYRTEC® 10 mg starts working at hour 1.
©McNeil-PPC, Inc. 2014
ZYR-749964
11/14
Use only as directed.

Translation and cultural adaptation to Portuguese of

AGENDA-STW NUTRALL kick-off

Asthma: Room for improvement in management

The Harold S. Nelson Lectureship

ITCASS

VALIDATION OF FOOD ALLERGY DEFINITION Validation of the

2015 Show Information

STEPPING STONES NWO 2014 Booth Reg form

(Springdale) - October 2015 - Ozark Regional Arts and Crafts Show

Yard Sale.psf - Bay Creek Elementary School